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ABSTRACT OF DISSERTATION 
 
 
 
 
IN VIVO OXIDATIVE STRESS IN ALZHEIMER DISEASE BRAIN AND A MOUSE 
MODEL THEREOF: EFFECTS OF LIPID ASYMMETRY AND THE SINGLE METHIONINE 
RESIDUE OF AMYLOID-β PEPTIDE 
 
Studies presented in this dissertation were conducted to gain more insight into the role of 
phospholipid asymmetry and amyloid-β (Aβ)-induced oxidative stress in brain of subjects with 
amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD).  AD is a largely 
sporadic, age-associated neurodegenerative disorder clinically characterized by the vast, 
progressive loss of memory and cognition commonly in populations over the age of ~65 years, 
with the exception of those with familial AD, which develop AD symptoms as early as ~30 
years-old.  Neuropathologically, both AD and FAD can be characterized by synapse and 
neuronal cell loss in conjunction with accumulation of neurofibrillary tangles and senile plaques.  
Elevated levels of oxidative stress and damage to brain proteins, lipids, and nucleic acids are 
observed, as well.  Likewise, aMCI, arguably the earliest form of AD, displays many of these 
same clinical and pathological characteristics, with a few exceptions (e.g., no dementia) and to a 
lesser extent. 
Studies in this dissertation focused on the contributions of oxidative stress to the 
exposure of phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, how and 
when PtdSer asymmetric collapse contributes to the progression of aMCI, AD, and FAD, and the 
role played by methionine-35 (Met-35) of Aβ in oxidative stress and damage, as measured in a 
transgenic mouse model of Aβ pathology.  Normally, the PtdSer is sequestered to the cytosolic, 
inner-leaflet of the bilayer by the adenosine triphosphate (ATP)-dependent, membrane-bound 
translocase, flippase, which unidirectionally transports PtdSer inward against its concentration 
gradient.  Oxidative stress-induced modification of flippase and/or PtdSer, however, leads to 
prolonged extracellular exposure of PtdSer on the outer membrane leaflet, a known signal for 
both early apoptosis and selective recognition and mononuclear phagocytosis of dying cells.  
Within the inferior parietal lobule (IPL) of subjects with aMCI and AD, a significant collapse in 
PtdSer asymmetry was found in association with increased levels of both pro- and anti-apoptotic 
proteins, Bax, caspase-3, and Bcl-2.  Moreover, a significant collapse in PtdSer asymmetry was 
also found in whole brain of human double-mutant knock-in mouse models of Aβ pathology, 
together with significantly reduced Mg
2+
ATPase activity, representing flippase activity, and 
increased levels of pro-apoptotic caspase-3.  Significant PtdSer externalization corresponded to 
the age at which significant soluble Aβ(1-42) deposition occurs in this particular mouse model (9 
months), and not of plaque deposition (12 months), suggesting that elevated levels of Aβ(1-42),
together with increasing oxidative stress and apoptosis, may contribute to altered PtdSer 
membrane localization. 
Also in this dissertation, transgenic mice carrying Swedish and Indiana mutations on the 
human amyloid precursor protein (APPSw,In) and APPSw,In mice carrying a Met35Leu mutation on 
Aβ were derived to investigate the role of Met-35 in Aβ(1-42)-induced oxidative stress in vivo.  
Oxidative stress analyses revealed that Aβ-induced oxidative stress requires the presence of Met-
35, as all indices of oxidative damage (i.e., protein carbonylation, nitration, and protein-bound 4-
hydroxy-2-trans-nonenal [HNE]) in brain of Met35Leu mice were completely prevented.  
Moreover, immunohistochemical analyses indicated that the Met35Leu mutation influences 
plaque formation, as a clear reduction in Aβ-immunoreactive plaques in Met35Leu mice was 
found in conjunction with a significant increase in microglial activation.  In contrast, behavioral 
analyses suggested that spatial learning and memory was independent of Met-35 of Aβ, as 
Met35Leu mice demonstrated inferior water-maze performance compared to non-transgenic 
mice.   
Differential expression and redox proteomic analyses to pinpoint proteins significantly 
altered by the APPSw,In and Met35Leu mutations was performed, as well.  Expression proteomics 
showed significant increases and decreases in APPSw,In and Met35Leu mouse brain, respectively, 
in proteins involved in cell signaling, detoxification, structure, metabolism, molecular 
chaperoning, protein degradation, mitochondrial function, etc.  Redox proteomics found many of 
these same proteins to be oxidatively modified (i.e., protein carbonylation and nitration) in both 
APPSw,In and Met35Leu mouse brain, providing additional insights into the critical nature of 
Met-35 of Aβ for in vivo oxidative stress in a mammalian species brain, and strongly suggesting 
similar importance of Met-35 of Aβ(1-42) in brain of subjects with aMCI and AD.  Taken 
together, studies presented in this dissertation demonstrate the role of oxidative stress-induced 
alteration of PtdSer asymmetry and Met-35 in Aβ-induced oxidative stress in aMCI, AD, and 
FAD brain.   
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CHAPTER 1 
 
INTRODUCTION 
 
The studies presented in this dissertation were performed to gain greater insight into the 
role of lipid peroxidation, phospholipid asymmetry, and amyloid-β (Aβ)-induced oxidative stress 
in brain of subjects with amnestic mild cognitive impairment (aMCI), Alzheimer disease (AD), 
and familial AD (FAD).  These studies investigated the hypotheses that,  
 
1) PtdSer asymmetry is significantly lost in synaptosomal membranes of the inferior 
parietal lobule (IPL) of subjects with aMCI and AD, as well as lost as a function of 
age and oligomeric Aβ(1-42) levels in synaptosomes isolated from brain of mouse 
models of Aβ pathology commonly found in FAD brain.  
 
2) The methionine 35 residue (Met-35) of the Aβ peptide is critical for in vivo oxidative 
stress in brain of well-characterized PDAPP transgenic mouse models of Aβ 
pathology commonly found in FAD brain.   
 
As a largely sporadic, age-related neurodegenerative disorder, AD is pathologically 
characterized by the appearance of neurofibrillary tangles, senile plaques, elevated oxidative 
stress and damage to brain proteins, lipids, and nucleic acids, and the eventual loss of neurons 
and synapses in populations over the age of ~65 years.  In rare FAD cases, however, this 
distinctive pathology begins as early as ~30 years of age (Citron et al., 1992; Scheuner et al., 
1996; Sturchler-Pierrat et al., 1997; Wisniewski et al., 1998).  Unfortunately, the 
neuropathological effects of this debilitating disease inevitably result in a significant decline in 
cognitive function and eventual death, and are, to date, without a truly effective therapy.  
Therefore, since aMCI is considered a possible transition point between normal cognitive aging 
and probable AD (Petersen et al., 1999; Winblad et al., 2004) and displays similar pathology to 
AD and FAD, results reported in this dissertation may not only identify possible biomarkers of 
early AD pathology, but also elucidate unique characteristics of patients with aMCI that 
eventually develop full-onset AD.   
Oxidative stress, a hallmark of aMCI, AD, and FAD pathology, can be characterized as 
an imbalance between the levels of antioxidants and oxidants within the cell, and can be 
propagated by a variety of molecules, including reactive oxygen species (ROS), reactive nitrogen 
species (RNS), and even Aβ(1-42), a major component of senile plaques.  In particular, oxidative 
stress and damage can induce protein oxidation, lipid peroxidation, and pro-apoptotic events in 
aMCI, AD, and FAD brain, disrupting normal cellular homeostasis (Abdul et al., 2008; 
Butterfield, 1997; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; 2006b; 2006d; 
2007b; Castegna et al., 2004; Hensley et al., 1995; Keller et al., 2005; Lauderback et al., 2001; 
Lyras et al., 1997; Markesbery, 1997; Mohmmad Abdul and Butterfield, 2005; Mohmmad Abdul 
et al., 2006; Petersen et al., 1999; Smith et al., 1997; Varadarajan et al., 2000; Winblad et al., 
2004).  Studies in this dissertation focused on the contributions of the lipid peroxidation product 
4-hydroxy-2-trans-nonenal (HNE), apoptotic factor expression, and Aβ(1-42) to the exposure of 
the aminophospholipid phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, as 
well as the role played by methionine-35 (Met-35) of Aβ in oxidative stress and damage.  
Normally, PtdSer is sequestered to the cytosolic, inner-leaflet of the lipid bilayer by the 
adenosine triphosphate (ATP)-dependent, membrane-bound, aminophospholipid translocase, 
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flippase, which unidirectionally transports PtdSer inward against its concentration gradient 
(Bretscher, 1972; Daleke and Huestis, 1985; Daleke and Lyles, 2000; Op den Kamp, 1979; 
Rothman and Lenard, 1977; Seigneuret and Devaux, 1984).  Under oxidative stress conditions, 
however, modification of flippase and/or PtdSer by HNE leads to prolonged extracellular 
exposure of PtdSer onto the outer-leaflet of the cell membrane, a known signal for both early 
apoptosis and selective recognition and mononuclear phagocytosis of dying cells (Castegna et 
al., 2004; Fadok et al., 2001; 1992a; Kagan et al., 2003; Tyurina et al., 2004a; 2004b).   
Apoptosis is typically modulated by both pro- and anti-apoptotic members, and plays a 
crucial role in neuronal loss both in vitro and in vivo in AD (Cras et al., 1995; Honig and 
Rosenberg, 2000; Ott et al., 2007).  Unfortunately, however, little is known about apoptotic 
pathways in aMCI to date.  Oxidative stress and damage in aMCI, AD, and FAD brain can 
initiate apoptosis by activation of pro-apoptotic proteins, disruption of the electron transport 
chain, and subsequent release of cytochrome c from mitochondria (reviewed in Ott et al., 2007).  
Specifically, increased anti-apoptotic Bcl-2 protein expression in AD blocks PtdSer exposure and 
apoptotic cell death (Engidawork et al., 2001; Fabisiak et al., 1997; Kitamura et al., 1998b), 
while increasing pro-apoptotic Bax and caspase-3 levels in AD brain promote PtdSer asymmetric 
collapse and neuronal loss (Giannakopoulos et al., 1999; Nagy and Esiri, 1997; Su et al., 2001; 
Tortosa et al., 1998).  For example, PtdSer externalization and loss of flippase translocating 
activity can be found downstream of caspases-3 activation in non-neuronal cell types under 
oxidative stress conditions (Mandal et al., 2002; 2005; Martin et al., 1996; Vanags et al., 1996).  
Furthermore, toxic Aβ(1-42) oligomers can also initiate lipid peroxidation and pro-apoptotic 
signaling events during AD and FAD progression that contribute to PtdSer asymmetric collapse 
(Abdul et al., 2008; Butterfield, 2002; Butterfield and Lauderback, 2002; Butterfield et al., 
2002b; 2007a; Lambert et al., 1998; Lauderback et al., 2001; Schubert et al., 1995; Selkoe, 
2001b).  This dissertation provides evidence that PtdSer asymmetric collapse is an early indicator 
of neurodegenerative processes already well underway in AD brain, and may represent a 
potential biomarker of those patients with aMCI that eventually develop full-onset AD.   
In aMCI, AD, and FAD, it is the soluble, oligomeric form of the 42-mer, Aβ(1-42), that 
is considered to be the toxic Aβ species (Demuro et al., 2005; Drake et al., 2003a; Selkoe, 2008; 
Viola et al., 2008), as it can lead to elevated protein oxidation and lipid peroxidation, as indexed 
by elevated levels of protein carbonyls, protein-resident 3-nitrotyrosine (3-NT), and protein-
bound HNE (Ansari et al., 2006; Boyd-Kimball et al., 2004; Pappolla et al., 1999; Sultana et al., 
2005).  The oxidative and neurotoxic properties of Aβ(1-42) are suggested to be dependent on 
the formation of a sulfur (S)-centered, transient free radical on a single methionine residue at 
position 35 that leads to a catalytic chain reaction in the lipid bilayer which amplifies production 
of lipid peroxidation products, like HNE, as well as protein oxidation (Boyd-Kimball et al., 
2004; Butterfield and Boyd-Kimball, 2005; Kanski et al., 2002; Varadarajan et al., 2001; Yatin et 
al., 1999).  For example, in vitro substitution of the Met-35 S-atom with a norleucine (Nle) CH2 
group in human Aβ(1–42) abrogates the oxidative and neurotoxic effects of the resulting Aβ(1-
42) Met35Nle peptide, while maintaining similar length, hydrophobicity, and tendency to 
aggregate as native Aβ(1-42) (Butterfield and Boyd-Kimball, 2005; Varadarajan et al., 2001; 
Yatin et al., 1999).  Moreover, in Caenorhabditis elegans AD models, a Met35Cys substitution 
in human Aβ(1-42) prevents in vivo protein oxidation, while not affecting Aβ(1-42) 
accumulation and plaque deposition (Drake et al., 2003a; Yatin et al., 1999).  These results 
suggest that those mechanisms of oxidative stress that involve Met-35 of Aβ(1-42) apply both in 
vitro and in vivo.  This dissertation also provides evidence that blocking oxidative damage 
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induced by Met-35 of Aβ in brain of subjects with aMCI, AD, and FAD offers a highly focused 
therapeutic approach, in which to treat, slow progression of, or prevent aMCI, AD, and FAD.   
 
In summary, this dissertation addresses the following questions: 
1. Is PtdSer asymmetry significantly altered in the inferior parietal lobule (IPL) 
of subjects with aMCI and AD, in association with the activation and up-
regulation of pro- and anti-apoptotic proteins, Bcl-2, Bax, and caspase-3, 
respectively? 
2. Is PtdSer asymmetry significantly altered in brain of human double-mutant 
knock-in mouse models of Aβ pathology, and if so, at what age?  Do age-
related changes in PtdSer leaflet localization correlate with age-related 
increases in Aβ(1-42), activation and up-regulation of pro-apoptotic caspase-
3, and oxidative modification of Mg
2+
ATPase (i.e., flippase) enzymes? 
3. Is Met-35 of the Aβ peptide critical for in vivo Aβ(1-42)-induced oxidative 
stress and AD-related spatial memory deficits in APPSw,In (PDAPP) 
transgenic mouse models of Aβ pathology carrying a Met35Leu substitution 
on the Aβ peptide? 
4. Which proteins are differentially expressed and/or oxidatively modified (i.e., 
protein carbonylation and nitration) in brain of PDAPP transgenic mouse 
models of Aβ pathology? 
5. Which proteins are differentially expressed and/or oxidatively modified (i.e., 
protein carbonylation and nitration) in brain of PDAPP transgenic mouse 
models of Aβ pathology carrying a Met35Leu substitution on the Aβ 
peptide? 
6. Are there any commonalities and/or differences in protein expression and/or 
oxidative modification between PDAPP transgenic mouse models of Aβ 
pathology and PDAPP mice carrying a Met35Leu substitution on the Aβ 
peptide?  Can these commonalities/differences provide further insight into 
the progression of AD? 
 
 
 
 
 
 
 
 
 
Copyright © Miranda Lu Lange, 2010 
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CHAPTER 2 
BACKGROUND 
 
2.1  The Brain 
2.1.1  Neurons 
As part of the central nervous system (CNS), the brain is composed of nerve cells 
(neurons) and support cells, called glia.  In the brain, neurons are the basic structural elements 
mainly responsible for cellular communication and signaling.  A typical mammalian neuron is 
composed of a cell body (soma or perikaryon) containing the nucleus, dendrites (neurites) 
branching from the cell body, short processes which receive most neuronal input, and 
unilaterally extending axons, long processes also projecting from the cell body which carry most 
neuronal outputs (Fig. 2.1).  Neurons also contain many intracellular organelles commonly 
standard in most cells of the body, including microtubules, ribosomes, endoplasmic reticulum 
(ER), Golgi, mitochondria, and neurofilaments, which are exclusive to neurons.  Interestingly, 
mitochondria can travel on microtubules to and from presynaptic terminals to aid in 
neuromodulation and neurotransmission (section 2.1.3), with assistance of motor proteins, 
kinesin and dynesin (Siegel et al., 2006).  Most mammalian neurons are multi-polar, with several 
dendrites and axons (Fig. 2.2).  For example, bipolar neurons possess a single dendrite and axon 
arising from the cell body; these neurons are typically sensory neurons, like those involved in 
vision or olfaction [Fig. 2.2] (Blumenfeld, 2002).   
 Insulating the axons and their contents from the surrounding environment are specialized 
glial cells that form a thick covering or “sheath” composed of the lipid molecule myelin (i.e., 
myelin sheath) [Fig. 2.3]; oligodendrocytes form myelin sheaths in the CNS (section 2.1.2), 
while Schwann cells form this sheath in the periphery.  The short, exposed segments of axon 
between areas of oligodendrocyte-myelin sheath, called nodes of Ranvier, are concentrated with 
voltage-gated ion channels, comprising the sites at which electrical conduction can be initiated.  
For example, rapid inter-nodal conduction occurs via saltatory conduction (Blumenfeld, 2002).   
Those areas of the CNS that contain primarily myelinated axons are called white matter, due to 
their off-white color, while areas predominant with cell bodies are called gray matter, for their 
gray color (Blumenfeld, 2002).  In general, the majority of synaptic inter-neuronal 
communication occurs in the gray matter, whereas axons within the white matter transmit signals 
over greater distances (Blumenfeld, 2002). 
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Figure 2.1 
 
 
 
 
Figure 2.1 Basic structure of a neuron (image adapted from the Alzheimer's Disease 
Education and Referral Center). 
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Figure 2.2 
 
 
 
 
Figure 2.2 Basic structures of different neuronal cells. A) & B) Most mammalian 
neurons are multi-polar, with several dendrites and axons. C) Sensory neurons are 
typically bipolar, with a single dendrite and axon arising from the cell body (adapted 
from Lodish et al., 2000).  
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Figure 2.3 
 
 
 
Figure 2.3 Basic structure of an oligodendrocyte (adapted from Carlson, 2008). 
 
 
2.1.2  Neuroglia 
Neuroglia are some of the most abundant cell-types in the brain, including astrocytes, 
oligodendrocytes, and microglia, among others.  Astrocytes are unique, in that they possess 
many more processes than other neuroglia and often resemble stars, from which their name 
originates.  These cells have numerous gap junctions, abundant glycogen granules, few 
microtubules, and a smooth distribution of chromatin within the nucleolus (Blumenfeld, 2002).  
There are two major types of astrocytes: protoplasmic (Fig. 2.4a), the typical gray matter 
astrocytes co-localized to neuronal somata and dendritic processes; and fibrous (Fig. 2.4b), the 
typical white matter astrocytes co-localized with axon bundles and arterioles (Blumenfeld, 
2002).  However, it should be noted that protoplasmic astrocytes can be found in white matter, 
and fibrous astrocytes can also be found in gray matter.  The abundant processes of astrocytes 
form extensive, “knobby” contacts called end-feet with other astrocytes and neuroglia, neurons, 
endothelial cells, and capillaries, which is crucial for cell signaling and nutrient delivery (Fig. 
2.5).  They are also known for being particularly rich in intermediate filaments, especially the 
glial fibrillary acidic protein (GFAP), which is a marker of inflammation.  Astrocytes are 
extensively intertwined with neuronal cell bodies and processes, supporting structural integrity of 
synapses and providing the structural framework for neuronal migration during development.  
Like neurons, they also take up extracellular K
+
, take up and metabolize neurotransmitters such 
as γ-aminobutyric acid (GABA), glutamate, and norepinephrine, and have receptors for many 
extracellular ligands, including neurotrophins, cytokines, growth factors, etc. (Blumenfeld, 
2002).   
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Figure 2.4 
 
 
Figure 2.4 Types of astrocytes. 
 
 
 
Figure 2.5 
 
 
 
 
Figure 2.5 Astrocyte end-feet. The abundant processes of astrocytes form extensive, 
“knobby” contacts, called end-feet (yellow arrow), with other astrocytes and neuroglia, 
neurons, endothelial cells, and capillaries (white arrow), which is crucial for cell 
signaling and nutrient delivery (adapted from Simard et al., 2003). 
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Unlike astrocytes, oligodendrocytes have round or oval nuclei, relatively few processes, 
clumpy chromatin, no glycogen granules, few intermediate filaments, and an extensive 
microtubule network (Blumenfeld, 2002).  As mentioned above, the main function of 
oligodendrocytes is to wrap neuronal axons with myelin sheaths to facilitate propagation of 
action potentials (section 2.1.3) and saltatory conduction (Fig. 2.3).  Other markers 
distinguishing oligodendrocytes include myelin related proteins, such as myelin basic protein. 
Microglia comprise roughly 20% of the brain‟s glia.  These cells are rich in lysosomes, 
have triangular nuclei, a fewer processes than astrocytes [Fig. 2.6] (Blumenfeld, 2002).  
Microglia are considered the brain‟s immune cells, as they contain all the membrane features that 
are characteristic of immune and inflammatory cells.  For example, they express major 
histocompatibility complex (MHC) proteins (e.g., HLA-DR, CD45, and CD64) and contain 
receptors for many extracellular ligands, including neurotrophins, growth factors, cytokines, etc 
(Blumenfeld, 2002).  Reactive microglia, in particular, act as phagocytes, becoming activated by 
phenotypic changes induced by various stimuli, such as inflammation, then clearing away 
unnecessary or dead/dying cells.  Interestingly, microglial activation increases with age.  
 
Figure 2.6 
 
 
 
Figure 2.6 Microglia (adapted from neuroscienceassociates.com). 
 
 
2.1.3  Neurotransmission & Neuromodulation 
In general, the neuron‟s primary function is to transmit and receive information through 
nerve impulses generated by the sizeable influx of Na
+
 ions into the neuron; at rest, the neuron is 
characterized by a higher intracellular concentration of K
+
 ions than Na
+
 ions (Siegel et al., 
2006).  Thus, the neuronal resting potential (-70 mV) is maintained (and restored) primarily by 
Na
+
/K
+
ATPase pumps, but also by various Ca
2+
 pumps, Na
+
/Ca
2+
 exchangers, and voltage-gated 
ion channels that open or close in response to changes in the electrochemical gradient of the 
neuron (Siegel et al., 2006).  As the charge difference across the neuronal membrane approaches 
zero, the membrane becomes depolarized, closing Na
+
 influx channels, opening K
+
 efflux 
channels, and restoring the intracellular net negative charge difference (-70 mV) across the 
membrane (Fig. 2.7).   
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Figure 2.7 
 
 
Figure 2.7 Overview of an action potential. Generation of an action potential begins with 
the opening of Na
+
 ion channels allowing a large influx of Na
+
 ions into the neuron.  As 
the charge difference across the membrane approaches zero (becoming more positive), 
the neuron becomes depolarized, closing Na
+
 influx channels and opening K
+
 efflux 
channels.  As neurons become hyperpolarized by the sizeable efflux of positive ions, K
+
 
efflux channels close, and the neuron becomes re-polarized.  Because cells are rarely at 
equilibrium and permeable to several ions at once, the Goldman-Hodgkin-Katz voltage 
equation (inset, above graph) can be used to calculate the steady-state potential across the 
membrane (Eion), wherein the summation of permeant ion contributions is weighted 
according to their relative permeabilities (Pi) using both the intracellular (i) and 
extracellular (o) concentrations of that ion.  R, universal gas constant (8.314 J∙K
−1
∙mol
−1
); 
T, absolute temperature (K); F, Faraday constant (9.648×10
4
 C∙mol
−1
). 
 
 
Inter-neuronal communication, or neurotransmission, takes place at synapses, specialized 
regions at the end of axons and dendrites that usually carry signals from axon terminals of one 
neuron to dendrites of the next (Fig. 2.8).  However, information can be transmitted in reverse, 
from dendrites to axons, at axo-axonic and dendro-dendritic synapses (Blumenfeld, 2002).  A 
synapse consists of three parts: the pre-synaptic element of the transmitting neuron, the synaptic 
cleft, and the post-synaptic region of the receptive neuron (Fig. 2.8).  Owing to both the chemical 
and electrical nature of the neuron, transient voltage changes, called an action potential, occur 
when an electrochemical impulse rapidly travels through the axon and causes release of 
neurotransmitter or neuromodulatory molecules from the presynaptic terminal into the synaptic 
cleft (Blumenfeld, 2002).  Action potentials can travel rapidly throughout the length of one 
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neuron, facilitated by the thick myelin sheath which insulates these electrical impulses from the 
surrounding environment.   
 
Figure 2.8  
 
 
 
Figure 2.8 The synaptic cleft. After stimulation by the appropriate action potential, 
synaptic vesicles fuse with the pre-synaptic (transmitting) neuronal membrane, and the 
stored neurotransmitter molecules are released into the synaptic cleft.  Upon release, 
neurotransmitters diffuse to and bind receptors on the post-synaptic (receiving), or even 
sometimes the pre-synaptic, neuron giving rise to another excitatory or inhibitory action 
potential within the receiving neuron (adapted from Sadava et al., 2007). 
 
 
Neurotransmitters are surrounded by synaptic vesicles within the pre-synaptic cleft, 
which act as a reservoir of chemical stimuli.  After stimulation by the appropriate electrical 
impulse, the synaptic vesicle fuses with the cell membrane, with the help of specialized proteins, 
and the neurotransmitter molecules are released into the synaptic cleft (Fig. 2.8).  Upon release, 
neurotransmitters diffuse to and bind receptors on the post-synaptic region of the receiving 
neuron giving rise to another, either excitatory or inhibitory, action potential within the second 
neuron, completing the process of neurotransmission.  By and large, neurotransmitters either 
mediate rapid inter-neuronal communication via excitatory post-synaptic potentials (EPSPs) and 
inhibitory post-synaptic potentials (IPSPs), depending on the specific receptors present, or 
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positively or negatively modulate neuronal signaling over a slower timescale [neuromodulation] 
(Blumenfeld, 2002).  Thus, the action of certain neurotransmitters may change at the same or at 
different synapses when a mixture of receptor types are present (Blumenfeld, 2002).  
Furthermore, often multiple neurotransmitter types are released into a single synapse.  A brief 
summary of a few important neurotransmitter and neuromodulator molecules, including 
acetylcholine, glutamate, dopamine, serotonin, histamine, GABA, norepinephrine, and glycine 
can be found in Table 2.1. 
 
Table 2.1 Important neurotransmitter/neuromodulatory molecules. 
Name Receptor Subtypes Main Action(s) 
Glutamate 
AMPA/kainate Excitatory neurotransmission 
NMDA Modulation of synaptoplasticity 
Metabotropic Activation of second messenger systems 
GABA 
GABAA, GABAB Inhibitory neurotransmission 
GABAC Inhibitory neurotransmission 
Acetylcholine 
Nicotinic Muscle contraction and Autonomic 
functions 
Muscarinic Parasympathetic functions 
Muscarinic & 
Nicotinic subtypes 
Neuromodulation 
Norepinephrine α and β subtypes Sympathetic system functions 
Dopamine D1-5 Neuromodulation 
Serotonin 5-HTs Neuromodulation 
Histamine H1-3 Mainly excitatory  neuromodulation 
Glycine 
Glycine Inhibitory neurotransmission
*
 
MNDA Neuromodulatory 
Peptides Numerous Neuromodulation 
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; NMDA, N-methyl D-
aspartate; GABA, γ-aminobutyric acid; D, dopamine; 5-HT, 5-hydroxytryptamine; H, 
histamine; MNDA, methyl D-aspartate [distinct from NMDA] (adapted from Blumenfeld, 
2002). 
 
 
2.2  The Cell Membrane 
2.2.1  Overview:  Structure, Function, & Composition 
Like all cells, neurons are surrounded by a plasma membrane, which provides the cell 
with an extensive framework within which cellular components are ordered for effective 
interaction.  The plasma membrane is a bimolecular layer of amphipathic lipids interspersed with 
proteins, which thermodynamically favors an arrangement in which polar groups face the outer 
aqueous environment, and hydrophobic fatty acyl chains face inward toward each other [Fig. 2.9] 
(Karp, 2003).  Thus, the plasma membrane is also referred to as a lipid bilayer, composed of two 
continuous leaflets that face both extracellular and intracellular environs.  This important 
structure prevents unrestricted exchange of molecules, while also providing a means of 
intercellular and inter-organelle communication since they contain proteins which transport 
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substances from one side of the membrane to another, responding to external signals (i.e., signal 
transduction) and facilitating energy transduction, especially in mitochondria (Karp, 2003).   
 
Figure 2.9 
 
 
 
Figure 2.9 The lipid bilayer.  The plasma membrane, or lipid bilayer, is a bimolecular 
layer of amphipathic lipids interspersed with proteins, which thermodynamically favors 
an arrangement in which polar groups face the outer aqueous environment, and 
hydrophobic fatty acyl chains face inward toward each other. 
 
 
In general, the most abundant type of plasma membrane lipid is the phosphoglyceride or 
phospholipid, which contains a polar phosphate head group and two nonpolar hydrocarbon tails.  
What makes these diglycerides unique is the additional small, hydrophilic functional group 
attached to the phosphate, comprising the head group.  Typically, these groups are choline 
(forming phosphatidylcholine, PtdCho), ethanolamine (forming phosphatidylethanolamine, 
PtdEtn), serine (forming phosphatidylserine, PtdSer), or inositol (forming phosphatidylinositol, 
PtdIns), among others; whereas a phospholipid without the additional substitution is called 
phosphatidic acid (PtdOH), the precursor of all glycerolipids (Fig. 2.10).  Other, less abundant 
lipids within the membrane are sphingolipids and the sterol, cholesterol.  Sphingolipids are 
amphipathic sphingosine derivatives, in which the sphingosine is linked to a fatty acid through 
its amino group, forming a ceramide (Fig. 2.11).  The majority of sphingolipids within the 
membrane have additional groups esterified to the terminal alcohol of the sphingosine moiety.  
For example, sphingomyelin carries a phosphorylcholine substitution and is the only membrane 
lipid without a glycerol backbone, whereas glycosphingolipids contain a carbohydrate 
substitution (Fig. 2.11).  Interestingly, glycolipids are particularly rich within the nervous 
system; the myelin sheath contains a high content of the glycolipid galactocerebroside, formed 
by addition of galactose to ceramide (Fig. 2.11), as well as PtdCho, PtdEtn, and ceramide (Karp, 
2003; Siegel et al., 2006). 
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Figure 2.10 
 
 
 
Figure 2.10 Phospholipids. 
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Figure 2.11 
 
 
 
Figure 2.11 Sphingolipids. 
 
 
In contrast, cholesterol is much smaller than other membrane lipids and less amphipathic.  
These molecules orient themselves in each bilayer leaflet with the small, hydrophilic hydroxyl 
groups facing the membrane surface, while the rest of the structure is embedded within the 
bilayer (Fig. 2.12b).  These rigid sterols are composed of flat, hydrophobic rings that interfere 
with the movement of phospholipid hydrocarbon tails (Fig. 2.12a), adjusting the fluidity of each 
membrane as necessary to cope with changing body temperatures and allowing membrane 
proteins to assemble at particular sites within the membrane and form specialized structures, 
such as intracellular junctions and synapses (Karp, 2003; Siegel et al., 2006).  
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Figure 2.12 
 
 
 
 
 
Figure 2.12 Cholesterol. A) Cholesterol structure.  B) Orientation of cholesterol within 
the bilayer.  
 
 
2.2.2  Lipid Asymmetry 
Of particular relevance to this dissertation is the highly asymmetrical distribution of 
lipids within the inner- and outer-leaflets of the membrane bilayer.  Though the bilayer leaflets of 
different intracellular organelles tend to have markedly different lipid compositions, the cell 
membrane typically confines PtdCho, sphingomyelin, and glycosphingolipid species to the 
extracellular, outer-leaflet, while PtdSer, PtdEtn, and PtdIns are localized to the intracellular, 
inner-leaflet, thus, conferring very different physical and chemical properties to each leaflet of 
the bilayer.  Most membrane lipids are synthesized entirely within the ER, with the exception 
sphingomyelin, glycolipids, and some unique mitochondrial membrane lipids, and transported to 
the Golgi and/or plasma membrane as part of the membrane that encompasses transport vesicles 
(Karp, 2003).  Lipid asymmetry is first established in the ER where lipids and proteins are 
inserted into the two leaflets of the ER membrane, and is maintained as portions of this 
membrane move throughout the cell by budding and fusion from one compartment to another 
[Fig. 2.13] (Karp, 2003).  Thus, those proteins and lipids originally situated on the inner, luminal 
leaflet of the ER membrane are found on the luminal surface of transport vesicles and Golgi 
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cisternae, but the extracellular leaflet of the plasma membrane [Fig. 2.13] (Karp, 2003).  
Similarly, proteins and lipids situated on the outer, cytosolic leaflet of the ER membrane retain 
their orientation and are ultimately found on the intracellular leaflet of the cell membrane [Fig. 
2.13] (Karp, 2003). 
 
Figure 2.13 
 
 
Figure 2.13 Origination of lipid asymmetry.  Lipid asymmetry of the plasma membrane 
is first established in the endoplasmic reticulum (ER) bilayer, and is maintained as 
portions of this membrane move throughout the cell by vesicular budding and fusion 
(Karp, 2003).  As a result, proteins and lipids originally situated on the inner, luminal 
leaflet of the ER membrane (red circles) are found on the luminal surface of transport 
vesicles and Golgi cisternae, but the extracellular leaflet of the plasma membrane.  
Similarly, proteins and lipids situated on the outer, cytosolic leaflet of the ER membrane 
(green circles) retain their orientation and are ultimately found on the intracellular leaflet 
of the cell membrane (Karp, 2003). 
 
 
Unfortunately, this manner of lipid integration into the cell membrane results in a 
complete reversal of the proper asymmetrical distribution of lipids between leaflets that must be 
corrected.  Although phospholipids can diffuse laterally with relative ease, the transverse 
diffusion between leaflets is thermodynamically unfavorable, and therefore, more or less 
restricted (Karp, 2003).  To bypass this problem, integral membrane proteins which actively 
transport phospholipids inward and/or outward against their concentration gradients establish and 
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maintain the appropriate asymmetrical distribution of phospholipids within the bilayer (section 
2.2.3).  While the purpose of lipid asymmetry beyond structural organization is not entirely 
understood, it has been found that many membrane lipids act as receptors for certain ligands, 
initiate intra- and extracellular signal transduction events, and are involved in cell regulation and 
apoptosis.  For example, the function of membrane phosphoinositides is among the most well-
known, as they are intimately involved in membrane trafficking, maintenance of the 
cytoskeleton, cell death and survival, and regulation of ion channel activity (Karp, 2003; Siegel 
et al., 2006).  Cleavage of phosphoinositol-4,5-bisphosphate (PIP2) by phospholipases produces 
the second messengers diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3), which 
activate protein kinases and affect intracellular Ca
2+
 signaling (Karp, 2003; Siegel et al., 2006).  
Therefore, the localization of membrane lipids to a specific bilayer leaflet is of utmost 
importance to normal cell function.   
Germaine to this dissertation, however, is the leaflet localization of the 
aminophospholipid PtdSer.  Typically, PtdSer is concentrated on the cytosolic leaflet of the 
bilayer (Bretscher, 1972; Op den Kamp, 1979; Rothman and Lenard, 1977), due, in part, to its 
small, negatively charged head group and overall conical shape, which fits seamlessly into the 
inner-leaflet‟s negative radius of curvature [Fig. 2.14] (reviewed in Piomelli et al., 2007).  
Although the functional properties of PtdSer on the inner-leaflet of the membrane are, as of yet, 
unknown, it is thought that the net negative charge PtdSer carries at physiological pH makes it a 
candidate for binding positively charged lysine and arginine residues located within the 
membrane-spanning regions of integral membrane proteins (section 2.2.3).  By contrast, the 
appearance of PtdSer onto the outer-leaflet of the bilayer is better understood, as prolonged 
exposure of PtdSer to the extracellular milieu has been found not only to induce blood 
coagulation and signal the induction of early apoptosis (Fadok et al., 2001; 1992a; Kagan et al., 
2003; Tyurina et al., 2004a; 2004b), but is also crucial for membrane fusion events, such as 
endo- and exocytosis and selective recognition and mononuclear phagocytosis of target cells by 
macrophages and fibroblasts in the periphery or by microglia in the brain (Balasubramanian and 
Schroit, 2003; Devaux, 2000; Farge et al., 1999; Zwaal and Schroit, 1997; Zwaal et al., 1998).   
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Figure 2.14 
 
 
Figure 2.14 Plasma membrane radius of curvature.  Phosphatidylserine (PtdSer) is 
normally concentrated on the cytosolic leaflet of the lipid bilayer, due, in part, to its 
small, negatively charged head group and overall conical shape, which fits seamlessly 
into the inner-leaflet‟s negative radius of curvature.  In contrast, phosphatidylinositol 
(PtdIns),  is normally concentrated on the outer-leaflet of the lipid bilayer as a result of its 
large head group and inverted conical shape, which fits well into the outer-leaflet‟s 
positive radius of curvature (adapted from Piomelli et al., 2007).   
 
 
2.2.3  Membrane-Associated Proteins 
Plasma membranes typically contain hundreds of different proteins that are grouped by 
their relationship to the membrane.  Of these, the lipid-anchored and peripheral proteins are 
located entirely outside of the membrane, on either the intra- or extracellular side, but are 
associated with the bilayer in different ways; peripheral proteins associate with the membrane 
surface by non-covalent bonds, while lipid-anchored proteins are covalently linked to a lipid 
molecule situated within the bilayer [Fig. 2.15] (Karp, 2003).  The third group of membrane-
associated proteins is the integral or transmembrane proteins, which completely penetrate the 
bilayer, passing entirely through both leaflets.  Like the lipids that make up the bilayer, integral 
membrane proteins are amphipathic, with nonpolar α-helical domains spanning the hydrophobic 
intermembrane space.  While some transmembrane proteins have only one membrane spanning 
domain, others traverse the membrane multiple times.   
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Figure 2.15 
 
 
Figure 2.15 Membrane-associated proteins. 
 
 
As previously mentioned, it is integral membrane proteins that are actively involved in 
the maintenance of lipid asymmetry within the bilayer.  These phospholipid transporters are 
divided into three classes based on their direction of lipid transport: the non-energy dependent, 
relatively non-specific, bidirectional „scramblases‟; the energy-dependent, unidirectional 
„flippases‟ that move aminophospholipids to the inner-leaflet of the membrane; and the energy-
dependent, unidirectional „floppases‟ that transport sphingolipid and choline-containing 
phospholipids to the outer-leaflet of the bilayer.  Specifically, flippases are of interest to this 
dissertation due to their optimal specificity for PtdSer.  Flippases are members of the multiple 
membrane domain, Type 4 subfamily of P-type ATPases that unidirectionally transport one 
PtdSer or, to a lesser extent, one PtdEtn, inward against their concentration gradient for every 
one adenosine triphosphate (ATP) hydrolyzed by the enzyme (Beleznay et al., 1993; Daleke and 
Huestis, 1985; Daleke and Lyles, 2000; Seigneuret and Devaux, 1984).  PtdSer transport, 
however, is dependent on a number of variables, namely the lipid head group and glycerol 
backbone size and composition, enzyme sensitivity to Mg
2+
, and a critical cysteine residue of the 
flippase primary structure. 
Previous studies have shown that modification of the amine functional group of the 
PtdSer head group (Fig. 2.10) significantly inhibits lipid transport (Daleke et al., 1995; 
Drummond and Daleke, 1995; Morrot et al., 1989), with exception of N-methyl-PtdSer, which is 
transported well (Daleke et al., 1995), indicating that flippase likely requires a protonatable 
amine group.  In contrast, modification of the serine carboxy moiety of the head group does not 
appear to significantly affect transport, as evidenced by flippase‟s ability to transport both PtdSer 
and PtdEtn (Fig. 2.10), although PtdEtn transport is 10-fold slower (Daleke and Lyles, 2000).  
Flippase is also known to interact specifically with the DAG backbone [Fig. 2.10] (Morrot et al., 
1989), requiring acylation and proper stereochemistry of the glycerol backbone for effective 
transport (Daleke and Huestis, 1985; Daleke et al., 1995; Hall and Huestis, 1994; Martin and 
Pagano, 1987; Morrot et al., 1989).  Interestingly, however, the composition of the lipid fatty 
acyl chain does not appear to affect flippase translocation of PtdSer (Anzai et al., 1993; Daleke 
and Huestis, 1985; 1989; Loh and Huestis, 1993; Morrot et al., 1989; Tilley et al., 1986). 
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Flippase activity can be distinguished from other ATPases by its insensitivity to ionic 
substrates and selective inhibitors of ion-motive ATPases.  For example, flippase activity is 
insensitive to intra- and extracellular [Na
+
] and [K
+
], as well as to the Na
+
K
+
ATPase inhibitor, 
Ouabain (Seigneuret and Devaux, 1984), and is fully functional with selective depletion of 
intracellular Ca
2+
 (Bitbol et al., 1987; Daleke and Huestis, 1985).  However, flippase PtdSer 
transport is reversibly inhibited with depletion of the divalent cation Mg
2+
, indicating that 
flippase is a Mg
2+
ATPase (Bitbol et al., 1987; Daleke and Huestis, 1985).  Furthermore, flippase 
cannot be activated by extracellular ATP and is insensitive to externally applied proteases 
(Connor and Schroit, 1989; Martin and Pagano, 1987), indicating that residue(s) responsible for 
flippase activity are located within one of the transmembrane domains of this enzyme.  In 
particular, it is a cysteine residue of the primary structure of this enzyme that is most critical to 
its conformational structure and translocating ability (Connor and Schroit, 1988; 1990).  
2.3  Cellular Metabolism 
2.3.1  Overview 
 In general, metabolism can be defined as a series of thermodynamically interdependent 
chemical reactions that convert large molecules into smaller, more biologically useful forms.  
Metabolic pathways are classified as either catabolic, those reactions that breakdown larger 
molecules into smaller, more useful biomolecules, or anabolic, those reactions that require an 
input of energy to synthesize complex molecules from simpler starting materials (Berg et al., 
2007; Karp, 2003).  Extraction of energy from biofuels can be divided into three stages (Berg et 
al., 2007).  In the first stage, large food molecules are crudely degraded into smaller units by the 
process of digestion.  Proteins are broken down into their amino acids, carbohydrates into 
hexoses and pentoses (e.g., glucose), and fats into fatty acids and glycerol.  Digestion prepares 
food for fatty acid, amino acid, or carbohydrate metabolism (i.e., glycolysis), in the second stage 
of metabolic energy extraction.  Although only a small amount of ATP (i.e., energy) is generated 
in this stage, it is of utmost importance for membrane transporters, as well as other enzymes 
located within the cytosol.  The completion of the second phase of metabolism results in the 
production of a common metabolite, acetyl coenzyme A (CoA) [Fig. 2.16], that is transported 
into the mitochondria to begin the third and final phase of energy extraction.  Within the 
mitochondria ATP is produced from the complete oxidation of acetyl CoA, beginning with the 
tricarboxylic acid (TCA) cycle (also called the citric acid or Kreb‟s cycle) and finishing with 
oxidative phosphorylation. 
 
22 
 
Figure 2.16 
 
 
 
 
Figure 2.16 Structure of acetyl coenzyme A (CoA). 
 
 
2.3.2  Glycolysis 
The glycolytic break down of carbohydrates is common to virtually all cells, both 
prokaryotic and eukaryotic (Berg et al., 2007).  In eukaryotes, glycolysis occurs within the 
cytosol in three stages, beginning with the conversion of glucose to fructose-1,6-bisphosphate 
(Fig. 2.17).  The main purpose behind this first stage is to trap glucose within the cell and from it 
form a compound that is readily phosphorylated and cleaved into three-carbon units, which 
occurs at the beginning of stage 2 (Fig. 2.17).  The resultant three-carbon units are readily 
interconvertible, and ultimately oxidized to a net total of two pyruvates with concomitant net 
production of two ATP (Fig. 2.18) and two nicotinamide adenine dinucleotide (NADH) 
molecules (Fig. 2.19).  The entire process is completed in 10 linked anaerobic reactions within 
the cytosol, and pyruvate converted to acetyl CoA (Fig. 2.16) under aerobic conditions within the 
mitochondria  (Berg et al., 2007).  The production of pyruvate is physiologically important 
because it can be converted into the amino acids alanine, valine, and leucine (Fig. 2.21), and is a 
main source of acetyl CoA within the cell, over that produced by amino acid, fatty acid, and 
glycerol metabolism.   
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Figure 2.17 
 
 
 
 
Figure 2.17 Glycolysis.  In the stage one of glycolysis (steps 1-4), glucose is trapped in 
the cell, readily phosphorylated, then cleaved into two glyceraldehyde-3-phoshate (GAP) 
three-carbon units (only one shown).  In stage two (step 5), GAP is reversibly converted 
to dihydroxyacetone phosphate (DHAP) as needed by the cell.  In the third and final 
glycolytic stage (steps 6-10), one molecule of GAP is oxidized to one molecule of 
pyruvate with concomitant net production of two adenosine triphosphate (ATP) and one 
nicotinamide adenine dinucleotide (NADH) molecules.  Because stage one actually 
results in the production of two GAP molecules, stage three is completed twice (only 
shown once) for every one molecule of glucose glycolytically metabolized. PGI, 
phosphoglucose isomerase; PFK, phosphofructokinase; ADP, adenosine diphosphate; 
TPI, triose phosphate isomerase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
PEP, phosphoenolpyruvate. 
 
 
 
24 
 
Figure 2.18 
 
 
Figure 2.18 Structure of adenosine triphosphate (ATP). 
 
 
Figure 2.19 
 
 
 
Figure 2.19 Structure of nicotinamide adenine dinucleotide (NAD
+
/NADH). 
 
 
Interestingly, many studies have demonstrated that key glycolytic enzymes, such as 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase, aldolase, enolase, 
phosphoglycerate mutase, phosphoglycerate kinase, and hexokinase, are electrostatically bound 
to cell and organelle membranes of various cell types (Kant and Steck, 1973; Rogalski et al., 
1989; Tsai et al., 1982; Xu and Becker, 1998; Xu et al., 1995).  In fact, the glycolytic activity 
many of these membrane-bound glycolytic enzymes is directly affected by their interaction with 
these membranes (Galli et al., 1998; Kant and Steck, 1973; Rogalski et al., 1989; Tsai et al., 
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1982).  Some studies suggest that, although neither glycolysis nor oxidative phosphorylation 
alone is capable of sustaining cellular energy deficits, the primary source of ATP for membrane 
ion pumps, such as the Na
+
/K
+
-ATPase and Ca
2+
-ATPase, is glycolytic (Kauppinen et al., 1988; 
Mielke et al., 1996; Xu et al., 1995).  Moreover, glycolytic ATP has been shown to be more 
important for maintaining ER Ca
2+
 stores and inositol trisphosphate (IP3)-mediated Ca
2+
 
signaling than ATP produced from the electron transport chain (ETC) (Kahlert and Reiser, 2000; 
Kauppinen et al., 1988).  These studies suggest that the close proximity of glycolytic enzymes to 
other membrane-associated proteins would predispose the coupling of glycolysis to ion pump 
activity (Kahlert and Reiser, 2000; Xu et al., 1995), as well as account for the cell‟s glycolytic 
ATP preference (Weiss and Lamp, 1989; Xu et al., 1995).   
Furthermore, inhibition of any glycolytic enzyme would cause the cell to shift its reliance 
on glycolysis to the pentose phosphate shunt (section 2.3.5), which produces nicotinamide 
adenine dinucleotide phosphate (NADPH) in lieu of NADH.  This metabolic switch can be 
beneficial as some antioxidant enzymes require NADPH to detoxify the cell.  However, under 
pathological conditions this shift is often permanent, producing a hypometabolic environment 
that ultimately leads to cell death.  Therefore, because the brain is one of the greatest consumers 
of glucose, it is of utmost importance that glycolysis be maintained. 
2.3.3  The Tricarboxylic Acid (TCA) Cycle 
Following glycolysis, pyruvate is transported into the mitochondrial matrix and 
oxidatively decarboxylated by the pyruvate dehydrogenase complex to form acetyl CoA and 
NADH (Fig. 2.20), irreversibly linking glycolysis to the TCA cycle (Berg et al., 2007).  The 
acetyl units of acetyl CoA are then completely oxidized to CO2 in the TCA cycle (also called the 
citric acid or Kreb‟s cycle).  This cycle generates a net total of four high-energy electrons that are 
eventually utilized for the synthesis of ATP in the ETC (section 2.3.4.2).  The TCA cycle can be 
considered a “central metabolic hub” within the cell, as it is “the gateway to the aerobic 
metabolism of any molecule that can be transformed into an acetyl group or another component 
of the TCA cycle,” and is an important source of amino acids, nucleotide bases, and porphyrin 
(the organic component of hemes) [Fig. 2.21] (Berg et al., 2007).   
Overall, the TCA cycle begins with the condensing of a two-carbon acetyl group with the 
four-carbon oxoacetate to yield a six-carbon tricarboxylic acid (Fig. 2.21).  Following two 
successive oxidative decarboxylations, the six-carbon tricarboxylic acid releases two CO2 
molecules that yield high-energy electrons in the form of reduced energy carriers, NADH and 
flavin adenine dinucleotide (FADH2) [Fig. 2.22].  The four-carbon oxaloacetate is then 
regenerated, and can initiate another round of the cycle (Fig. 2.21).  Although the TCA cycle 
does not generate a large amount of ATP, it does produce a net two molecules of guanosine 
triphosphate (GTP) [Fig. 2.23], which are energetically equivalent to ATP, and two molecules 
each of the reduced energy carriers, NADH and FADH2, which yield 2.5 and 1.5 ATP molecules 
each, respectively, when oxidized by O2 in the ETC (Berg et al., 2007).   
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Figure 2.20 
 
 
 
Figure 2.20 Conversion of pyruvate to acetyl coenzyme A (CoA). 
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Figure 2.21 
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Figure 2.21 The tricarboxylic acid (TCA) cycle and amino acid synthesis. 
 
 
 
Figure 2.22 
 
 
 
Figure 2.22 Structure of flavin adenine dinucleotide (FAD/FADH2). 
 
 
 
Figure 2.23 
 
 
Figure 2.23 Structure of guanosine triphosphate (GTP). 
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2.3.4  Oxidative Phosphorylation 
2.3.4.1  Mitochondrial Structure 
Mitochondria are oval-shaped, semi-autonomous, intracellular organelles that contain 
their own DNA and RNA, as well as the ETC, TCA cycle, and enzymes of fatty acid oxidation.  
Interestingly, mitochondria are bounded by a double lipid membrane, where the outer membrane 
bilayer is generally smooth and faces the intracellular milieu, and the inner-membrane bilayer is 
folded into a series of internal ridges, called cristae (Berg et al., 2007).  Although the outer 
membrane is permeable to most small molecules and ions by way of multiple pore-forming 
porins (i.e., voltage-dependent anion channels [VDAC]), the inner membrane is essentially 
impermeable.  Access to the mitochondrial matrix is attained through a large family of integral 
membrane transporters, including the malate-aspartate and glycerol-3-phosphate shuttles, 
situated within the inner membrane that shuttle metabolites such as NADH, ATP, pyruvate, and 
citrate across the inner mitochondrial membrane (Berg et al., 2007). 
As a result of the double membrane, mitochondria have two compartments, the 
intermembrane space between the inner and outer bilayers, and the matrix, bounded solely by the 
inner membrane.  Compartmentalization of different molecules, proteins, and reactions allows 
mitochondria to effectively carry out a variety of cellular functions simultaneously.  For 
example, conversion of pyruvate to acetyl CoA, the TCA cycle, and fatty acid oxidation take 
place in the matrix, while oxidative phosphorylation takes place within the inner mitochondrial 
membrane.  Moreover, mitochondria are the major source of cellular ATP, since they possess the 
entire ETC, and are considered the “power-house” of the cell. 
2.3.4.2  The Electron Transport Chain (ETC) 
Oxidative phosphorylation is the process that couples the oxidation of biofuels in fatty 
acid, amino acid, and carbohydrate (i.e., glycolysis) metabolism and the TCA cycle to large-scale 
ATP synthesis within the cell.  ATP is formed from the transfer of electrons from NADH or 
FADH2 to reduce molecular O2 to water by a series of electron carriers situated within the inner 
mitochondrial membrane (Fig. 2.24).  The reduced energy carriers NADH and FADH2 each 
contain a pair of electrons with a high-energy transfer potential.  Flow of these electrons through 
the ETC liberates a large amount of free energy that leads to pumping of protons out of the 
matrix and into the intermembrane space, against their concentration gradient (Berg et al., 2007).  
Build-up of protons within the intermembrane space not only creates a pH gradient, but also a 
transmembrane electrical potential, created by the net positive charge of the unequally 
distributed protons (Berg et al., 2007).  Flow of these protons back into the mitochondrial matrix 
generates a proton-motive force that facilitates the synthesis ATP.  Overall, oxidative 
phosphorylation generates 26 of the 30 ATP molecules that are produced by the complete 
breakdown of one molecule of glucose, assuming transport of cytosolic NADH into the 
mitochondrial matrix is by the glycerol-3-phosphate shuttle.   
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Figure 2.24 
 
 
 
Figure 2.24 The electron transport chain (ETC).  The ETC is located within the inner 
mitochondrial membrane.  As Complex I, III, and IV pump protons (H
+
) out of the 
mitochondrial matrix and into the intermembrane space, Complex V pumps the 
heightened concentration of intermembrane H
+
 back into the matrix to facilitate 
production of adenosine triphosphate (ATP).  NAD
+
/NADH, nicotinamide adenine 
dinucleotide; FAD/FADH2, flavin adenine dinucleotide; Q, Coenzyme Q or ubiquinone; 
CytC, cytochrome c; ADP, adenosine diphosphate; e
-
, electron; I, NADH-Q 
oxidoreductase (Complex I); II, succinate-Q reductase (Complex II); III, Q-cytochrome c 
oxidoreductase (Complex III); IV, cytochrome c oxidase (Complex IV); V, ATP synthase 
[Complex V] (adapted from Kaplan, 2009). 
 
 
The conversion of the electrons into the proton-motive force is carried out by the 
electron-driven, transmembrane proton pumps of the ETC, NADH-Q oxidoreductase (Complex 
I), Q-cytochrome c oxidoreductase (Complex III), and cytochrome c oxidase (Complex IV) [Fig. 
2.24], which contain multiple oxidation–reduction centers, including quinines, flavins, iron-
sulfur clusters, hemes, and copper ions.  Complex II (succinate-Q reductase), on the other hand, 
does not pump electrons since it does not completely traverse the inner mitochondrial membrane, 
but instead converts FADH2 to FAD by transferring its electrons to Complex III (Fig. 2.24).  
Electrons are carried from Complex I and II to Complex III by the reduced form of coenzyme Q 
(or ubiquinone) [Fig. 2.24], a hydrophobic quinone that diffuses rapidly within the inner 
mitochondrial membrane (Fig. 2.25), while electrons from Complex III are carried to Complex 
IV by cytochrome c, a small soluble protein (Fig. 2.24).  The last of the proton pumping 
assemblies, Complex IV, catalyzes the transfer of four electrons from cytochrome c to molecular 
O2, the final electron acceptor of the ETC, which produces two molecules of water while 
pumping four protons out of the matrix.  Finally, ATP is synthesized by ATP synthase [or 
Complex V (Berg et al., 2007)], an ATP synthesizing assembly that is driven by the flow of 
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protons back into the mitochondrial matrix (i.e., the proton-motive force).  Interestingly, the role 
of the proton-motive force in ATP synthesis is not to form ATP but to facilitate its release from 
the synthase complex, as ATP synthase has been shown to readily convert adenosine diphosphate 
(ADP) to ATP in the absence of a proton gradient; proton flow through ATP synthase drives the 
rotational release of ATP from the catalytic site of the synthase enzyme (Berg et al., 2007). 
 
Figure 2.25 
 
 
 
Figure 2.25 Reduction of ubiquinone (Q).  Electrons are carried from Complex I and II to 
Complex III in the electron transport chain by the reduced form of coenzyme Q (or 
ubiquinone; Q), a hydrophobic quinone that diffuses rapidly within the inner 
mitochondrial membrane.  Q is a quinine derivative with a long hydrocarbon tail, whose 
chain length depends on the Q species (e.g., the commonly known dietary supplement 
CoQ10 has 10 hydrocarbon isoprene units).  In the fully oxidized state, Q has two keto 
groups.  The addition of one electron (e
-
) and one proton (H
+
) results in the formation of a 
semiquinone (QH
.
), while addition of a second e
-
 and H
+
 forms reduced Q, ubiquinol 
(QH2). 
 
 
2.3.5  The Pentose Phosphate Pathway (PPP) 
The PPP, or pentose phosphate shunt (PPS), provides an alternative pathway for the 
degradation of glucose within the cytoplasm, in which oxidation of glucose generates NADPH, 
the primary source of reductive biosynthesis within the cell (e.g., reduction of oxidized 
glutathione; section 2.4.6.1).  This pathway begins with the oxidative production of NADPH, 
followed by the non-oxidative interconversion of three-, four-, five-, six-, and seven-carbon 
phosphorylated sugars [Fig. 2.26] (Berg et al., 2007).  The PPP is also employed by cells to 
metabolize the dietary intake of five-carbon sugars, synthesize sugars required for nucleotide, 
fatty acid, cholesterol, and neurotransmitter biosynthesis, and to catabolize and synthesize 
typically uncommon four- and seven-carbon sugars (Berg et al., 2007).  Overall, the PPP 
generates 12 molecules of NADPH for each molecule of glucose-6-phosphate completely 
oxidized to CO2. 
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Figure 2.26  
 
 
 
Figure 2.26 The pentose phosphate pathway (PPP). The PPP, or pentose phosphate 
shunt, provides an alternative pathway for the degradation of glucose, since glucose can 
be readily converted to glucose-6-phosphate when necessary.  Phase one of this pathway 
begins with production of nicotinamide adenine dinucleotide phosphate (NADPH), 
followed by the formation of five-carbon sugars.  In phase two, 5-carbon sugars are 
interconverted to three-, four-, five-, six-, and seven-carbon sugars.  Overall, the PPP 
generates 12 molecules of NADPH for each molecule of glucose-6-phosphate completely 
oxidized to CO2 (only one cycle shown).  G-6-P DH, glucose-6-phosphate 
dehydrogenase; 6-PG DH, 6-phosphogluconate dehydrogenase. 
 
 
As stated above (see section 2.3.2), inhibition of glycolysis would cause a metabolic shift 
to the PPS, producing NADPH instead of NADH.  In the short-term this shift would benefit 
detoxification of the cell, however, a permanent shift would be detrimental considering the PPP 
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does not directly produce ATP, nor can NADPH be exploited by the ETC to yield ATP.  
Furthermore, although excess pentose sugars produced by the PPP can be converted into 
glycolytic intermediates, their interconversion is not substantial enough for the cell to completely 
bypass the glycolytic break-down of carbohydrates for prolonged periods of time.   
2.4  Oxidative Stress 
2.4.1  Overview 
 Oxidative stress can be characterized as an imbalance between the levels of antioxidants 
and oxidants within the cell caused by age, environmental stressors, or diseases which lead to a 
deficiency in endogenous antioxidants, the excess production of reactive oxygen (ROS) and/or 
reactive nitrogen species (RNS), or the reduced clearance of damaged proteins within the cell 
[Fig. 2.27] (Brown et al., 1997; Grune et al., 2004; Halliwell, 1991; 2006a; b; Harman, 1956; Liu 
and Mori, 1993).  In the brain, levels of oxidative stress have been shown to increase with age, 
inducing protein and nucleic acid oxidation, lipid peroxidation, and apoptosis, leading to loss of 
synapses and neurons, and declining cognition (Aruoma et al., 1991; Halliwell, 2006a; Halliwell 
and Aruoma, 1991; Sastre et al., 2000; Stadtman, 2006).  Oxidative modification of proteins and 
lipids by ROS and/or RNS, in turn, results in either the diminished, complete loss of, or toxic 
gain in protein function (Butterfield and Stadtman, 1997; Stadtman, 2006), thereby enhancing 
age- and disease-related brain dysfunction. 
 
Figure 2.27 
 
Figure 2.27 Oxidative stress. Oxidative stress can be characterized as an imbalance 
between the levels of antioxidants (AOX) and oxidants (reactive oxygen species 
[ROS]/reactive nitrogen species [RNS]) within the cell caused by depletion of AOX, 
excess production of ROS/RNS, or the reduced clearance of damaged proteins within the 
cell. 
 
 
2.4.2  Reactive Oxygen Species (ROS) 
ROS are moderate to highly destructive molecules that contain oxygen, but possess a 
higher reactivity than ground state O2; these molecules include both radical and non-radical 
species (Table 2.2).  In general, the majority of ROS found in the cell result from electron 
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leakage from the ETC within the mitochondria, which leads to production of the superoxide 
anion (O2
.-
) and hydrogen peroxide (H2O2) by partial reduction of molecular O2 (Adam-Vizi, 
2005; Berg et al., 2007; Miquel et al., 1980).  However, it should be noted that ROS can stem 
from other sources, such as environmental toxins, metal-catalyzed reactions, the ER, as well as 
many other enzymatic reactions and cellular processes [Fig. 2.28] (Adam-Vizi, 2005; Kamata 
and Hirata, 1999; Santos et al., 2009; Thomas and Aust, 1986).  Thus, because there is always a 
basal level of oxidative stress and damage to intracellular contents (Halliwell and Whiteman, 
2004), there are many systems and mechanisms the cell employs to scavenge ROS and protect 
cellular homeostasis, which are briefly discussed in the following section (section 2.4.6).  Yet, 
even though ROS are very reactive and potentially damaging, they are not without benefit.  
Extracellular secretion of pro-oxidants stimulates a variety of immune responses and recruits the 
phagocytic ingestion of damaged cells, bacteria, viruses, and other pathogens (reviewed in 
Martinon et al., 2009), while their intracellular secretion stimulates various cell signaling 
systems (reviewed in Kamata and Hirata, 1999).  Unfortunately, it is conditions which promote 
the excess production of ROS and RNS, with subsequent oxidative stress and damage that are the 
focus of this dissertation.  Below is a discussion of some prominent ROS; a more complete list of 
ROS can be found in Table 2.2. 
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Table 2.2 List of different free radical and non-radical reactive species produced during 
oxidative stress. 
 Free Radical Species Non-Radical Species 
ROS 
Superoxide (O2
.-
) 
ROS 
Hydrogen Peroxide (H2O2) 
Hydroxyl radical (
.
OH) Ozone (O3) 
Hydroperoxyl radical (HO2
.
) Ground-state Oxygen (O2) 
Carbonate radical anion (CO3
.-
) Organic peroxidases (ROOH) 
Carbon Dioxide radical anion (CO2
.-
) Peroxomonocarbonate (HOOCO2
-
) 
Peroxyl radical (RO2
.
) 
RCS 
Hypochlorous acid (HOCl) 
Alkoxyl radical (RO
.
) Nitryl Chloride (NO2Cl) 
RCS Atomic Chlorine (Cl*) 
Chlorine gas (Cl2) 
Chlorine Dioxide (ClO2) 
RBS Atomic Bromine (Br*) 
Bromine Chloride (BrCl)
†
 
Nitryl Chloride (NO2Cl)
‡
 
RNS 
Nitric Oxide radical (NO
.
) 
RBS 
Hypobromous acid (HOBr) 
Nitrogen Dioxide radical (NO2
.
) Bromine gas (Br2) 
Nitrate radical (NO3
.
) Bromine Chloride (BrCl)
†
 
  
RNS 
Nitrous acid (HNO2) 
Nitrosyl cation (NO
+
) 
Nitroxyl anion (NO
-
) 
Dinitrogen Tetroxide (N2O4) 
Dinitrogen Trioxide (N2O3) 
Peroxynitrite (ONOO
-
) 
Peroxynitrate (O2NOO
-
) 
Peroxynitrous acid (ONOOH) 
Nitronium cation (NO2
+
) 
Alkyl Peroxynitrite (ROONO) 
Alkyl Peroxynitrate (RO2ONO) 
Nitryl Chloride (NO2Cl)
‡
 
Peroxyacetyl Nitrate [CH3C(O)OONO2] 
ROS, reactive oxygen species; RCS, reactive chlorine species; RBS, reactive bromine species; RNS, 
reactive nitrogen species.  
†
Considered both RCS and RBS; 
‡
Considered both RCS and RNS (adapted 
from Halliwell, 2006a). 
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Figure 2.28 
 
 
 
Figure 2.28 Overview of reactive oxygen species (ROS) production in the cell. COX, 
cyclooxygenase; UV, ultraviolet; NOS, nitric oxide synthase; NADP
+
/NADPH, 
nicotinamide adenine dinucleotide phosphate; NAD
+
/NADH, nicotinamide adenine 
dinucleotide; SOD, superoxide dismutase; Q, ubiquinone or coenzyme Q; C, cytochrome 
C, I, Complex I; II, Complex II; III, Complex III; IV, Complex IV; GPx, glutathione 
peroxidase; GSH, glutathione; GSSG, oxidized glutathione; ATP, adenosine triphosphate 
(adapted from Kamata and Hirata, 1999). 
 
 
2.4.2.1  Superoxide (O2
.-
), Hydrogen Peroxide (H2O2), & Hydroxyl Radicals (
.
OH) 
As stated above (see section 2.4.2), O2
.-
 is a moderately reactive free radical species 
produced from the transfer of a single electron to molecular O2 (reaction 1), primarily at, but not 
limited to, Complexes I and IV of the ETC.   
 
  (reaction 1) 
 
O2
.-
 can also originate from other ETC complexes, the ER, and other enzymes, such as 
NADPH oxidase, lipoxygenase, cyclooxygenase (COX), cytochrome P450, xanthine oxidase, 
and UV-γ-irradiation, among others [Fig. 2.28] (Adam-Vizi, 2005; Kamata and Hirata, 1999; 
Santos et al., 2009).  Because O2
.-
 is a free radical, it has an inherently short half-life, being able 
to react with almost anything in close proximity.  For example, O2
.-
 can destroy the catalytic 
function of various enzymes by attacking the iron-sulfur clusters (Flint et al., 1993), cause 
protein oxidation and lipid peroxidation (sections 2.4.4 & 2.4.5), and create additional highly 
reactive free radical species which serve to amplify conditions of oxidative stress.  One 
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mechanism in which the cell is able to scavenge this free radical is through the 
disproportionation of O2
.-
 by manganese superoxide dismutase (MnSOD) in the mitochondrial 
matrix (Weisiger and Fridovich, 1973) or by Cu/ZnSOD in the mitochondrial intermembrane 
space and/or the cytosol, to form molecular O2 and H2O2 [reaction 2] (Fridovich, 1989; McCord 
and Fridovich, 1969).   
 
  (reaction 2) 
 
Unfortunately, H2O2, is itself, a potent non-radical oxidizing agent that can react with 
reduced metal ions, such as Cu
2+
 (reaction 3) and Fe
2+
 (reaction 4) [i.e., Fenton chemistry], to 
form highly reactive hydroxyl radicals [
.
OH] (Butterfield and Stadtman, 1997) if not quickly 
scavenged by other enzymes, such as peroxidases, reductases, and catalases, back into water 
(reviewed in Gilgun-Sherki et al., 2001).  Other significant sources of H2O2 in the cell are 
NADPH oxidase, xanthine oxidase, lysosomes, and monoamine oxidase, among other enzymatic 
processes [Fig. 2.28] (Kamata and Hirata, 1999; Santos et al., 2009), as well as from many other 
radical-radical recombination reactions. 
   
(reaction 3) 
  
(reaction 4) 
 
 
However, it is 
.
OH, produced from H2O2-induced Fenton chemistry and the reaction 
between O2
.-
 and H2O2 that is the most reactive ROS (reaction 5).   
 
      (reaction 5) 
 
Hydroxyl free radicals (
.
OH) inflict severe oxidative damage by reacting with almost any 
molecule it comes in contact with.  For example, 
.
OH can cause protein oxidation and lipid 
peroxidation through direct or indirect cleavage of the peptide backbone (section 2.4.4) and 
polyunsaturated fatty acids (PUFAs) [section 2.4.5], β-scission of amino acid side-chains 
(section 2.4.4), generation of protein-protein cross-linkages (sections 2.4.4 & 2.4.5), and 
generation of RNS (Butterfield and Stadtman, 1997; Stadtman, 2006). 
2.4.3  Reactive Nitrogen Species (RNS) 
Like ROS, RNS are moderate to highly reactive compounds that contain nitrogen and 
oxygen and include both radical and non-radical species (Table 2.2).  RNS are typically derived 
from nitric oxide (NO
.
), an abundant cell signaling molecule with both autocrine and paracrine 
activities.  In the CNS, NO
.
 production is associated with cognitive function, including the 
induction and maintenance of synaptic plasticity, as well as control of the sleep-wake cycle, 
appetite, body temperature, and neurosecretion (Guix et al., 2005; McCann, 1997; Rivier, 2001).  
Excess production of NO
.
, however, is toxic, especially to cells already consumed by oxidative 
stress.  Oxidation and/or reduction of NO
.
 by ROS, in turn, forms toxic RNS compounds that 
further cultivate oxidative damage to cells, termed nitrosative stress (Ridnour et al., 2004).  Thus, 
as with ROS, there exist certain endogenous antioxidant defense systems within the cell to 
scavenge RNS and protect cellular homeostasis, which are described below (section 2.4.6).  
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Although RNS have different reactivities from one another, their half-lives are generally longer 
than 
.
OH and O2
.-
 (Balazy and Nigam, 2003).  Below is a more detailed discussion of some of the 
most common RNS, with a more complete list located in Table 2.2. 
2.4.3.1  Nitric Oxide (NO
.
) 
As mentioned above, membrane-permeable NO
.
 is an abundant cell signaling molecule in 
the CNS associated with cognitive function.  However, the oxidation and/or reduction of NO
.
 by 
ROS forms toxic RNS compounds that cultivate oxidative damage, during nitrosative stress.  
Primarily, it is the NO
.
 synthase (NOS) family of enzymes that are responsible for synthesizing 
NO
.
, by catalyzing the conversion of L-arginine to L-citrulline with the cofactor NADPH and in 
the presence of O2 (Fig. 2.29).  This family of enzymes contains three isoforms, which can all be 
found in the brain: constitutively expressed, Ca
2+
-dependent neuronal NOS (nNOS), abundant in 
the cytoplasm of neurons, as well as astrocytes, cerebral blood vessels, and a few areas of the 
periphery (Bredt et al., 1991; Dawson and Snyder, 1994; De Giorgio et al., 1994; Guix et al., 
2005; Magee et al., 1996; Rodrigo et al., 1994; Toda et al., 2005; Vincent and Kimura, 1992); 
Ca
2+
-independent inducible NOS (iNOS), located in the cytosol of astrocytes and microglia 
following inflammation, viral infection, or trauma (Bredt, 1999; Calabrese et al., 2006), as well 
as in the periphery; and constitutively expressed, Ca
2+
-dependent endothelial NOS (eNOS), 
located within the plasma membrane of cerebral and peripheral endothelial cells wherein it 
regulates blood flow (Calabrese et al., 2006; Colasanti et al., 1998; Rajasekaran et al., 1998).  
 
Figure 2.29 
 
 
 
Figure 2.29 Formation of nitric oxide (NO.) from nitric oxide synthase (NOS).  
NADP
+
/NADPH, nicotinamide adenine dinucleotide phosphate. 
 
 
Interestingly, NO
.
 can be both neuroprotective and neurotoxic, depending on the 
oxidative state of the cell.  Because of their long half-lives, the reaction between NO
.
 and other 
free radicals (e.g., O2
.-
 and 
.
OH) “stabilizes” these radicals, essentially scavenging them from 
solution (Halliwell et al., 1999).  NO
.
, via N2O3, S-nitrosylates (section 2.4.4.2) pro-apoptotic 
caspase-3 and two subunits of the N-methyl-D-aspartate receptor (NMDAR), consequently, 
inhibiting caspase-3 and glutamate-induced NMDAR Ca
2+
 influx activity and reducing the levels 
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of cell death (reviewed in Calabrese et al., 2007a).  NO
.
 also activates the neuroprotective cyclic 
AMP-responsive element binding-protein (CREB) and Akt proteins via stimulation of the 
soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP)-protein kinase G 
(PKG) pathway (reviewed in Calabrese et al., 2007a).  Furthermore, NO
.
 induces production of 
biliveridin by heme oxygenase-1 (HO-1), which is a precursor to the powerful antioxidant and 
anti-nitrosative molecule, bilirubin [Fig. 2.30] (Kitamura et al., 1998a; Mancuso et al., 2003; 
Motterlini et al., 2002). 
 
Figure 2.30 
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Figure 2.30 Formation of bilirubin.  NO
.
 induces production of biliveridin by heme 
oxygenase-1 (HO-1), which is a precursor to the powerful antioxidant and anti-nitrosative  
molecule, bilirubin.  NADP
+
/NADPH, nicotinamide adenine dinucleotide phosphate. 
 
 
NO
.
 typically does not elicit neurotoxic effects unless produced in excess or within a cell 
in the pro-oxidant state, as is the case in many neurodegenerative disorders.  In a majority of 
these disorders, excess NO
.
 is produced by iNOS as a result of a pro-inflammatory response, or 
by nNOS due to excitotoxicity.  Under these conditions, NO
.
 mediates the nitrosylation of 
critical sulfur residues (i.e., S-nitrosylation) within proteins (section 2.4.4.2), inhibiting their 
activity.  For example, NO
.
 acutely and rapidly inhibits neuronal energy production in neurons as 
it pertains to both mitochondrial oxidative phosphorylation and glycolysis by S-nitrosylating a 
number of enzymes involved in both processes, including glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and enolase (Brorson et al., 1999; Calabrese et al., 2007a).  
Additionally, NO
.
 activates COX enzymes, which generate free radicals and pro-inflammatory 
prostaglandins (reviewed in Calabrese et al., 2007a).  Antioxidant defense systems within the cell 
scavenge RNS and their by-products, including GSH (section 2.4.6.1), redoxin enzymes, and 
other various peroxidases and sulfoxide reductases (Fang et al., 2002; Halliwell, 2006a).  
2.4.3.2  Peroxynitrite (ONOO
-
) & Nitrite Radicals (NO2
.
) 
NO
.
 indirectly elicits its cytotoxic effects by reacting with O2
.-
, a by-product of NOS 
activity, to form the potent RNS molecules, peroxynitrite (ONOO
-
) [reaction 6] and the nitrite 
radical (NO2
.
) [reaction 7] (Halliwell et al., 1999).   
 
  (reaction 7) 
 
The interaction between ONOO
-
 or NO2
.
 and a variety of cellular components results in 
destructive protein nitration and S-nitrosylation [section 2.4.4.2] (Guix et al., 2005; Halliwell et 
al., 1999; Keszler et al., 2010).  For example, nitration of either type of SOD disables their 
ability to scavenge ROS, resulting in an excess of intracellular H2O2 and an overall increase 
oxidative stress (Alvarez et al., 2004; Jackson et al., 1998).  Furthermore, the reaction between 
ONOO
-
 and CO2 can also produce NO2
.
 (reaction 8), as well as from many other radical-radical 
recombination reactions. 
 
(reaction 8) 
 
NO2
.
 can also be absorbed into the body through inhalation of indoor/outdoor air 
pollutants, such as car emissions, fossil fuels, cigarette smoke, etc. (Persinger et al., 2002).  
Studies have shown that even minimal exposure to NO2
.
 can result in long-term morphological 
changes resulting in inflammation and cellular injury (Moldeus, 1993), as this radical RNS, as 
well as others, leads to an increase in lipid peroxidation, especially in lung tissue (Persinger et 
al., 2002; Sagai et al., 1984).  During inflammation, NO2
.
 oxidation is mediated by peroxidases, 
such as eosinophil peroxidase and myeloperoxidase (Byun et al., 1999; Dedon and Tannenbaum, 
2004; Podrez et al., 1999; Wang et al., 1995a; Zhang et al., 2002).  
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2.4.4  Protein Oxidation 
As previously mentioned, increasing levels of oxidative stress in brain with age and/or 
disease pathogenesis induce protein and oxidation and lipid peroxidation events, which 
inevitably lead to neuronal cell death (Aruoma et al., 1991; Halliwell, 2006a; Halliwell and 
Aruoma, 1991; Sastre et al., 2000; Stadtman, 2006).  Post-translational oxidative modification of 
proteins by ROS and RNS results in diminished and/or complete loss of protein function, 
whereas oxidative modification of lipids results in the production of additional reactive 
nucleophilic species, amplifying the neurotoxic effects of ROS and RNS (Butterfield and 
Stadtman, 1997; Stadtman, 2006).  Examples of oxidative modifications include 
phosphorylation, glycosylation, carbonylation (section 2.4.4.1), nitration (section 2.4.4.2), and S-
nitrosylation (section 2.4.4.2). 
2.4.4.1  Protein Carbonylation 
Protein carbonylation of proteins is among the most common post-translational oxidative 
modifications, resulting from β-scission of amino acid side-chains (Fig. 2.31) and direct or 
indirect cleavage of the peptide backbone (Fig. 2.32) by ROS and RNS (Butterfield and 
Stadtman, 1997; Stadtman, 2006).  Although moderately carbonylated proteins can be degraded 
by the proteasome, those proteins that are heavily carbonylated often accumulate to form high-
molecular-weight aggregates that are resistant to proteolysis and can even inhibit proteasomal 
activity (reviewed in Dalle-Donne et al., 2006).  Interestingly, although this is the most abundant 
and common form of post-translational oxidative modification, there appears to be a form of 
selectivity to carbonylation, considering the relative amount of a protein does not dictate the 
degree of carbonylation, and many studies have shown that some proteins are more susceptible 
to carbonylation than others (Cabiscol et al., 2000; Choi et al., 2005; Dalle-Donne et al., 2006; 
Jana et al., 2002).  It has been proposed that such selectivity is likely due to protein structure 
since the presence of a transition metal binding-site appears to be a key feature in predicting the 
susceptibility of proteins to carbonylation (Stadtman, 1990; 2006).  Because protein 
carbonylation is an irreversible form of oxidative damage, immunochemical detection protein 
carbonyls (described in Chapter 3) is the most widely recognized way in which to index levels of 
global oxidative stress in a given tissue (Dalle-Donne et al., 2006; 2005; Levine et al., 1990). 
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Figure 2.31 
 
 
 
 
 
Figure 2.31 β-Scission of amino acid side-chains: Protein carbonyl formation (adapted 
from Stadtman, 2006). 
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Figure 2.32 
 
 
 
Figure 2.32 Oxidative cleavage of the peptide backbone.  I) α-Amidation.  II) Diamide 
formation (adapted from Stadtman, 2006). 
 
 
2.4.4.2  Protein Nitration & S-Nitrosylation 
As mentioned above, the interaction between RNS and a variety of cellular components 
results in destructive protein nitration and S-nitrosylation (Greenacre and Ischiropoulos, 2001; 
Guix et al., 2005; Halliwell et al., 1999).  ONOO
-
 can S-nitrosylate sulfur atoms on methionine 
and cysteine residues [Fig. 2.33] (Broillet, 1999), as well as nitrate tryptophan and tyrosine 
residues to form 3-nitrotyrosine (3-NT)-protein adducts (Fig. 2.34), which inhibit normal protein 
function (Alvarez and Radi, 2003; Greenacre and Ischiropoulos, 2001; Halliwell et al., 1999).  
Like protein carbonyls, immunochemical detection of 3-NT (described in Chapter 3) is a second 
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way in which to index the level of protein oxidation and overall oxidative stress in a given tissue 
(Greenacre and Ischiropoulos, 2001; Ischiropoulos, 1998; Ohshima et al., 1990). 
 
Figure 2.33 
 
 
 
Figure 2.33 Overall reaction of S-nitrosylation of sulfur containing amino acids.  
 
 
Figure 2.34 
 
 
 
Figure 2.34 3-Nitrotyrosine (3-NT) formation. 
 
 
2.4.5  Lipid Peroxidation 
Within the brain, lipids are most vulnerable to oxidation since this organ is particularly 
enriched with PUFAs.  The majority of lipid peroxidation events within the cell occur as a result 
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of free radical chain reactions, in which their allylic carbons are most susceptible, until quenched 
[reactions 9-12] (reviewed in Spiteller, 2001).   
 
 
 
(reactions 9 -12) 
 
Moreover, oxidative modification of lipids results in the production of additional reactive 
species, amplifying the neurotoxic effects of ROS and RNS (Butterfield and Stadtman, 1997; 
Stadtman, 2006).  Examples of lipid peroxidation products include malondialdehyde [MDA] 
(Esterbauer and Cheeseman, 1990; Esterbauer et al., 1991), 4-hydroxy-2-trans-nonenal [HNE] 
[section 2.4.5.1] (Esterbauer et al., 1991; Mattson et al., 1997; Waeg et al., 1996), conjugated 
fatty acids (Esterbauer and Zollner, 1989; Jira et al., 1996), isoprostanes (Morrow and Roberts, 
1997; Wang et al., 1995b), and products derived by addition of lipid peroxidation products to 
DNA and/or proteins (Burcham, 1998; Waeg et al., 1996). 
2.4.5.1  Protein-Bound 4-Hydroxy-2-Trans-Nonenal (HNE) 
Arachidonic acid, linoleic acid, and decosahexanoic acid are the main PUFAs that 
compose the hydrophobic, lipid phase of the neuronal plasma membrane.  Because of their 
extreme length, and therefore, high content of allylic carbons, oxidative cleavage of either PUFA 
generates a wide variety of highly reactive peroxidation products.  In particular, it is the β-
oxidation of the 11
th
 carbon of arachidonic acid that is of interest in this dissertation, due to its 
production of the highly reactive alkenal, HNE (Fig. 2.35).  Increased levels of HNE can cause 
disruption of Ca
2+
 homeostasis, membrane damage, and cell death by covalently modifying 
amino acid residues, such as lysine, histidine, and cysteine [Fig. 2.36] (Esterbauer et al., 1991; 
Schaur, 2003; Siems and Grune, 2003; Subramaniam et al., 1997).  Immunochemical detection 
of protein-bound HNE is a third way in which to index the level of protein oxidation and overall 
oxidative stress in a given tissue (Waeg et al., 1996). 
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Figure 2.35 
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Figure 2.35 Formation of 4-hydroxy-2-trans-nonenal (HNE) from arachidonic acid. 
 
 
Figure 2.36 
 
 
 
Figure 2.36 Formation of 4-hydroxy-2-trans-nonenal (HNE) adducts. Increased levels of 
HNE can cause protein oxidation and lipid peroxidation by covalently modifying 
(Michael addition) amino acid residues, such as lysine, histidine, and cysteine. 
 
 
2.4.6  Antioxidants 
As previously mentioned, because there is always a basal level of oxidative damage to 
intracellular contents (Halliwell and Whiteman, 2004), there are many endogenous antioxidant 
defense systems and mechanisms the cell employs to scavenge ROS and RNS and protect 
cellular homeostasis.  Unfortunately, these antioxidant defense systems become impaired with 
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age and neurodegenerative disease, since many antioxidant enzymes are redox sensitive and, 
therefore, easily oxidized (Mates et al., 1999).  Thus, recent surges in the research of exogenous 
antioxidant compounds as a therapeutic strategy to combat increasing oxidative stress and 
damage with age and disease progression has lead to increased dietary supplementation.   
Beyond the endogenous antioxidant systems and enzymes mentioned above (see sections 2.4.2 & 
2.4.3), this section will describe in detail the endogenous GSH system (section 2.4.6.1), as well 
as the exogenous, non-enzymatic low-molecular-weight molecules, γ-glutamylcysteine ethyl 
ester (GCEE) [section 2.4.6.2], vitamin E (section 2.4.6.3), vitamin C (section 2.4.6.4), α-lipoic 
acid (LA) [section 2.4.6.5].  Other dietary antioxidants that have been investigated for their 
neuroprotective effects in neurodegenerative disease include, but are not limited to, quercitin, 
coenzyme Q10, polyphenolic flavonoids (e.g., resveratrol and quercitin), curcumin, ferulic acid 
and ferulic acid ethyl ester (FAEE), and N-acetyl-L-cysteine (NAC). 
2.4.6.1  The Glutathione (GSH) System 
GSH is the most prevalent, endogenous, antioxidant in the brain as it can be found in 
millimolar concentrations within cells.  Thiol-containing GSH scavenges ROS and RNS, as well 
as nucleophilic compounds, using its reduced thiol group [i.e., S-glutathionylation] (reviewed in 
Dalle-Donne et al., 2009).  By reacting with ROS and RNS (i.e., S-nitrosylation), GSH is 
oxidized to produce GSSG by GSH peroxidase (GPx), then is recycled back to two GSH 
molecules by GSH reductase and NADPH (from the PPP; see section 2.3.5), effectively 
completing this detoxification cycle [Fig. 2.37] (Dalle-Donne et al., 2009; Keszler et al., 2010).  
GSH S-transferase (GST) catalyzed S-glutathionylation of nucleophilic compounds, like the lipid 
peroxidation product HNE, by GSH results in the production of GSH-S-protein conjugates that 
are effluxed from the cell by the multidrug resistance protein-1 (MRP-1) [Fig. 2.38] (Renes et 
al., 1999).  Interestingly, S-glutathionylation not only scavenges ROS and RNS, but also protects 
redox sensitive proteins, including glycolytic enzymes GAPDH and enolase  (reviewed in Dalle-
Donne et al., 2009), from oxidative modification since this type of post-translational 
modification is reversed by the thiol transferase, glutaredoxin [Fig. 2.38] (Chrestensen et al., 
2000).  Therefore, the ratio of GSSG to GSH is often used as a marker of redox thiol status and 
overall oxidative stress in the cell.  For example, a linear correlation between increased GSSG 
levels and cognitive status using the Mini-Mental Status Examination (MMSE) has been 
previously ascertained in Alzheimer disease patients (Lloret et al., 2009).   
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Figure 2.37 
 
 
 
 
Figure 2.37 Cycling of reduced and oxidized glutathione (GSH/GSSG).  By reacting with 
ROS and RNS, GSH is oxidized to GSSG by GSH peroxidase (GPx), then is recycled 
back to two GSH molecules by GSH reductase and nicotinamide adenine dinucleotide 
phosphate (NADPH/NADP
+
), effectively completing this detoxification cycle. 
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Figure 2.38 
 
 
 
Figure 2.38 Antioxidant cycling. NADP
+
/NADPH, nicotinamide adenine dinucleotide 
phosphate; R, protein; LOH, lipid hydroxide; LOOH, lipid hydroperoxide; LOO
.
, lipid 
peroxyl radical; GSH, reduced glutathione; GSSG, oxidized glutathione; Vit C, vitamin 
C; Vit E, vitamin E; S, sulfur; ATP, adenosine triphosphate; ADP, adenosine 
diphosphate; Pi, inorganic phosphate; MRP-1, multi-drug resistance protein-1; GST, 
glutathione-S-transferase; GPx, glutathione peroxidase; GR, glutathione reductase; GRx, 
glutaredoxin; Gly, glycine; Cys, cysteine; GCL, -glutamylcysteine ligase; -Glu-Cys; -
glutamylcysteine; GCEE, -glutamylcysteine ethyl ester (adapted from Fang et al., 2002). 
 
 
Unfortunately, the levels of GSH in the brain decrease as a function of age, as well as in a 
number of neurodegenerative diseases (Higuchi, 2004; Liu and Mori, 1993; Liu and Choi, 2000).  
Moreover, oxidative modification of GPx, GST, GSH reductase, and even MRP-1 often 
increases with brain aging and disease, increasing the levels of oxidative stress (Sultana et al., 
2004).  Thus, exogenous supplementation with GSH precursors in order to increase levels of 
GSH may be an effective way to protect against oxidative stress.  Although the glutamate and 
glycine components of GSH are naturally abundant in the brain, cysteine residues are limited.  
Therefore, much research has recently focused on increasing the levels of free cysteine for the 
biosynthesis of GSH. 
2.4.6.2  γ-Glutamylcysteine Ethyl Ester (GCEE) 
One highly effective way to increase biosynthesis of GSH is supplementation with GCEE 
[Fig. 2.39] (Anderson and Meister, 1983).  Because -glutamylcysteine formation is the rate-
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limiting step in GSH biosynthesis, due to the low level of free cysteines, supplementation with -
glutamylcysteine bypasses the feed-back inhibition loop of GSH on -glutamylcysteine ligase 
(GCL) [Fig. 2.38], which produces -glutamylcysteine, while attaching an ethyl ester group to 
the N–terminus of -glutamylcysteine allows this GSH precursor to readily traverse the blood-
brain barrier (BBB) and cell membranes (Drake et al., 2002; 2003b).  GCEE has been shown to 
increase brain and mitochondrial GSH levels, thereby protecting synaptosomes, neurons, and 
mitochondria against ONOO
-
 damage, protein oxidation and lipid peroxidation, and DNA 
fragmentation (Drake et al., 2002; 2003b; Reed et al., 2009).  In addition to increasing GSH 
levels, GCEE may also protect cells from oxidative stress and damage by directly reacting with 
ROS/RNS via its thiol-containing cysteine residue (Aluise et al., 2009; Hayashi et al., 1998). 
 
Figure 2.39 
 
 
 
Figure 2.39 Structure of γ-glutamylcysteine ethyl ester (GCEE). 
 
 
2.4.6.3  Vitamin E 
Vitamin E (i.e., tocopherol) [Fig. 2.40] is one of the most well-known phenolic 
compounds known to scavenge free radicals with its phenolic hydrogen-atom and is recycled 
through various pathways, including vitamin C, GSH, and theoredoxin [Fig. 2.38] (Kagan et al., 
1992).  This lipophilic compound can insert itself within the lipid bilayer and protect PUFAs 
from lipid peroxidation, as well as protect proteins from post-translational oxidative modification 
and prevent free radical formation (Topinka et al., 1989).  Vitamin E is a chain-breaking 
antioxidant and, therefore, disrupts free radical chain reactions associated with lipid peroxidation 
(reactions 9-12; see section 2.4.5).  Vitamin E originates from various food sources, mainly plant 
oils (e.g., corn and soybean), and consists of -, -, -, and -tocopherol isoforms.  However, 
vitamin E supplements often consist solely of -tocopherol, arguably the most biologically 
potent form of vitamin E. Unfortunately, studies focused only on the use of -tocopherol to 
prevent or slow cognitive decline and dementia have been inconsistent (Morris et al., 2005); 
thus, combining different isoforms may produce more effective results.  For instance, although 
both -tocopherol and -tocopherol have been shown to independently reduce cerebral ischemia-
induced brain damage when injected into rat brain (Mishima et al., 2003), -tocopherol displayed 
greater anti-inflammatory properties (Jiang and Ames, 2003) and was a major RNS scavenger 
(Morton et al., 2002; Williamson et al., 2002).  Moreover, other studies have shown that dietary 
supplementation with -tocopherol has been shown to decrease -tocopherol levels in plasma 
(Handelman et al., 1985).   
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Figure 2.40 
 
 
Figure 2.40 Structure of vitamin E. 
 
 
Vitamin E has been investigated for decades to determine its relationship to cognitive 
decline, and many have shown that levels of this vitamin decrease with age and dementia, 
correlating with memory loss (Butterfield et al., 2002a; Perkins et al., 1999).  However, while 
vitamin E supplementation does, in fact, increase vitamin E levels in the body and decrease 
susceptibility of lipoproteins to oxidation (Kontush et al., 2001), it is unclear whether vitamin E 
actually improves cognition.  Many studies with vitamin E alone or in combination with other 
vitamins and minerals have shown no association with dementia (Fillenbaum et al., 2005; Laurin 
et al., 2004; Luchsinger et al., 2003), while others have noted a correlation with improved 
cognitive performance (Chandra, 2001; Engelhart et al., 2002; Morris et al., 1998; Nourhashemi 
et al., 2000; Zandi et al., 2004).  A recent study by Lloret, et al. (2009) found that of Alzheimer‟s 
patients on high-dose vitamin E, only half maintained or improved cognitive skill, while the 
other half showed decreased cognition compared to controls (Lloret et al., 2009).  Their findings 
demonstrated that those patients displaying cognitive improvement on high-dose vitamin E had 
decreased oxidative stress, as measured by GSSG/GSH ratio and MDA levels (Lloret et al., 
2009).  It is possible that vitamin E is detrimental to individuals with already high levels of 
oxidative stress and do not show improvement with supplementation, since oxidized vitamin E 
can be reactive unless promptly recycled and reduced (Fig. 2.38).  Thus, supplementation of 
vitamin E in combination with other water-soluble antioxidant(s) capable of recycling vitamin E 
and increasing redox thiol status, such as inducing GCEE up-regulation, may have more 
consistent positive effects on cognition. 
2.4.6.4  Vitamin C 
Vitamin C (ascorbate) [Fig. 2.41] is a water-soluble molecule found in many citrus fruits, 
which also has the ability to protect against intracellular oxidative stress and damage alone, or by 
recycling vitamin E to its reduced form [Fig. 2.38] (Chan, 1993; Padh, 1990).  Beyond being a 
scavenger of ROS and RNS, vitamin C is necessary for normal brain functions as its oxidized 
form, dehydroascorbate (Fig. 2.41), can undergo irreversible hydrolysis and decarboxylation to 
produce certain components of the PPP (see section 2.3.5) or oxalic and threonic acid 
(Grunewald, 1993; Schreiber and Trojan, 1991).  In addition, vitamin C is thought to be involved 
in catecholamine synthesis and release, may be a critical cofactor for the dopamine β-
hydroxylase enzyme, and release of is highly associated with glutamatergic neuron activity, 
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primarily by glutamate-ascorbate heteroexchange across neuronal or glial membranes 
(Grunewald, 1993; Schreiber and Trojan, 1991).  Since humans cannot synthesize this vitamin 
naturally, it must be obtained from the diet (Chatterjee et al., 1975).  Vitamin C crosses the BBB 
as dehydroascorbate and is retained in brain tissue as ascorbic acid at concentrations 10-fold 
greater than that which is found in the plasma and serum (Agus et al., 1997; Frei et al., 1989; 
Rose and Bode, 1993; Schreiber and Trojan, 1991).  Thus, it is very likely that increasing the 
concentration of ascorbic acid, and therefore, dehydroascorbate, in the blood by dietary 
supplementation may also increase the concentration of vitamin C in the brain.  However, recent 
clinical trials investigating the use of vitamin C supplementation as a therapeutic strategy for 
certain neurodegenerative disorders have reported a lack of efficacy when administered alone, 
while supplementation in combination with vitamin E showed some benefit (reviewed in Gilgun-
Sherki et al., 2001).  Moreover, a study by Lee, et al. (2001) demonstrated that high doses of 
vitamin C mediate formation of genotoxins from lipid hydroperoxides and can cause DNA strand 
breaks (Lee et al., 2001). 
 
Figure 2.41 
 
 
 
Figure 2.41 Structure of vitamin C and dehydroascorbate. 
  
 
2.4.6.5  α-Lipoic Acid (LA) 
LA (i.e., thioctic acid) plays many roles as an antioxidant in neurodegenerative diseases 
and has been widely investigated for its neuroprotective effects.  Being readily available from 
dietary sources, LA is absorbed into the small intestines, and easily passes through the BBB 
(Seaton et al., 1996).  LA, as well as its reduced form, dihydrolipoic acid (DHLA), contains two 
sulfur atoms that are responsible for its antioxidant, anti-inflammatory, and metal ion chelation 
abilities [Fig. 2.42] (Packer et al., 1997).  LA has also been shown to have diverse 
pharmacological properties and is a cofactor in multi-enzyme complexes in the mitochondria, 
such as pyruvate dehydrogenase and -ketoglutarate dehydrogenase (Packer et al., 1997).  LA 
also interacts with other antioxidants such as GSH, ubiquinol, thioredoxin, vitamin C, and 
indirectly with vitamin E, regenerating their reduced forms [Fig. 2.43] (Kagan et al., 1992; Ou et 
al., 1995; Sen et al., 1997).  For example, dehydroascorbate is reactive if not readily reduced 
back to ascorbic acid in the brain; LA can inhibit dehydroascorbate-induced production of H2O2 
by Cu
+
 (Kagan et al., 1992).   
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DHLA may also play a role as a cofactor for choline acetyl transferase (ChAT) or reduce 
a vital cysteine residue that is required for enzyme activity, as it has been found to increase 
ChAT activity, whereas LA did not (Haugaard and Levin, 2000).  In mitochondria, the lipoamide 
dehydrogenase enzyme catalyzes reduction of free LA to DHLA, using NADH as a cofactor, 
whereas, in the cytosol, GSH reductase catalyzes this reduction, using NADPH as a cofactor 
(reviewed in Biewenga et al., 1997).  Therefore, when DHLA is derived from lipoamide 
dehydrogenase reduction of LA, the cell is able to draw on its pool of NADH molecules to 
promote antioxidant activity, in addition to its NADPH pools via GSH reductase, which are 
usually consumed during oxidative stress (reviewed in Biewenga et al., 1997). 
 
Figure 2.42 
 
 
 
Figure 2.42 Structure of α-lipoic acid and dihydrolipoic acid (DHLA). 
 
 
Figure 2.43 
 
 
 
Figure 2.43 Cycling of α-lipoic acid.  GSH, reduced glutathione; GSSG, oxidized 
glutathione; LOO
.
, lipid peroxyl radical; LOOH, lipid hydroperoxide; ROO
.
, alkyl 
peroxyl radical; ROOH, alkyl hydroperoxide (adapted from Butterfield et al., 2002a). 
 
 
Several studies in aged rats and canines have shown that diets rich in antioxidants, such 
as LA, have improved learning and reversed memory impairment, as well as decreased levels of 
certain markers of oxidative stress (Bickford et al., 2000; Christie et al., 2009; Farr et al., 2003; 
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Liu et al., 2002; Opii et al., 2008).  Aged rats fed LA were able to increase activity of 
mitochondrial enzymes isocitrate dehydrogenase, NADH dehydrogenase, succinate 
dehydrogenase, -ketoglutarate dehydrogenase, and cytochrome c oxidase (Arivazhagan et al., 
2001).  Other studies have shown that GSH levels and GCL activity decrease almost 50% with 
age, due, in part, to a 50% reduction in total and nuclear levels of NF-E2-related factor-2 [Nrf2] 
(Suh et al., 2004), which governs expression of GCL subunits through the antioxidant response 
element in DNA.  When aged rats were administered R-α-LA, levels of Nrf2 increased along 
with an increase of GCL levels and activity (Suh et al., 2004).  In addition, DHLA may aid GSH 
biosynthesis by reduction of cystine to cysteine (Packer et al., 1997).  Thus, demonstrating that 
LA influences GSH levels through direct regeneration, increasing the GSH precursor cysteine 
and transcription factors that regulate GSH synthesis.  Furthermore, recent clinical studies of 
Alzheimer disease patients demonstrated that administration of 600 mg/day of LA stabilized 
cognitive function as assessed by the MMSE and Alzheimer Disease Assessment Scale 
Cognitive Subscale scores (Hager et al., 2007).  Patients with mild dementia showed 
significantly delayed disease progression compared to untreated patients or patients on 
acetylcholine esterase inhibitors (Hager et al., 2007).   
2.5  Cell Death 
2.5.1  Apoptosis 
Apoptosis, or “programmed cell death,” is a process that removes cells that are no longer 
required or damaged beyond repair, and can be characterized by the overall shrinkage of cell 
volume, the loss of adhesion to neighboring cells, membrane blebbing, nuclear chromatin 
condensation and fragmentation, mitochondrial changes, activation of pro-apoptotic proteins, and 
exposure of PtdSer to the cell surface (see sections 2.2.2 & 2.5.2) followed by the rapid 
phagocytic engulfment of the apoptotic cell [Fig. 2.44] (Karp, 2003).  Apoptosis can be triggered 
by both external and internal stimuli, both of which can be divided into three distinct phases: 
initiation, when the cell responds to death stimuli; integration/decision, when the cell commits 
itself to destruction by activating caspases and mitochondrial death effectors – considered “the 
point of no return”; and execution/degradation, when the death sentence is carried out in full and 
the cell is engulfed by phagocytosis (Karp, 2003; Kroemer et al., 2007). 
Although apoptosis can be elicited in many ways, it is the extrinsic and intrinsic 
pathways that are most prominent.  The extrinsic pathway is stimulated by external stimuli, 
which trigger the ligand-induced activation of transmembrane death receptors at the cell surface.  
Thus, the extrinsic pathway of apoptosis is also known as the “death receptor pathway.”  
Namely, one of the most well known death stimuli is the tumor necrosis factor (TNF), which 
evokes an apoptotic response by binding the TNF death receptor, TNFR1(Karp, 2003; Kroemer 
et al., 2007).  Upon binding TNF, TNFR1undergoes a conformational change within its 
cytoplasmic death domain, which recruits and induces oligomerization of adapter molecules, 
such as the Fas-associated death domain-containing protein [FADD] (Karp, 2003; Kroemer et 
al., 2007).  Oligomerized FADD can then bind the initiator aspartate-specific cysteine proteases 
(caspases) -8 and -10, causing their dimerization and activation (Debatin and Krammer, 2004), 
which initiate intracellular apoptotic events by proteolytic cleavage and subsequent activation 
and/or deactivation of downstream components (Karp, 2003; Kroemer et al., 2007). 
The intrinsic pathway, on the other hand, is stimulated by any number of internal stimuli, 
such as irreparable genetic damage, high concentrations of cytosolic Ca
2+
 (i.e., Ca
2+
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excitotoxicity), or severe oxidative stress, which lead to the activation of pro-apoptotic 
cytoplasmic factors and significant changes to mitochondria [Fig. 2.45] (Karp, 2003).  The most 
well-known apoptotic factors activated in this pathway are members of the B-cell lymphoma 
type-2 (Bcl-2) family of pro- and anti-apoptotic proteins; examples of prominent pro-apoptotic 
members include Bax, Bad, and Bid, while prominent anti-apoptotic members include Bcl-XL, 
Bcl-W, and Bcl-2 (Karp, 2003).  Activation of both anti- and pro-apoptotic factors by internal 
death stimuli typically causes the translocation and insertion of these factors from the cytosol 
into the outer mitochondrial membrane.  At this point, several changes in mitochondrial structure 
occur, including the increased production of ROS and RNS, K
+
 channel activation, significant 
Ca
2+
 ion uptake, swelling, depolarization of membrane potential, increased membrane 
permeability, and finally, the release of intermembrane and matrix-resident proteins, such as 
cytochrome c, apoptosis inducing factor (AIF), Smac/DIABLO, Omi stress-regulated 
endoprotease/high temperature requirement protein A2 (Omi/HtrA2), and at least two DNA 
degrading enzymes (Kroemer et al., 2007; Siegel et al., 2006).  Thus, the intrinsic pathway is 
also called the “mitochondrial pathway” since apoptosis results from an intracellular cascade of 
events in which mitochondrial permeabilization plays a crucial role (Scaffidi et al., 1998).   
 
Figure 2.44  
 
 
 
 
Figure 2.44 Overview of apoptosis. Apoptosis can be characterized by the overall 
shrinkage of cell volume, the loss of adhesion to neighboring cells, membrane blebbing, 
nuclear chromatin condensation and fragmentation, mitochondrial changes, apoptotic 
body formation, and apoptotic body lysis if the apoptotic cell is not phagocytized first 
(adapted from Yau, 2009). 
 
57 
 
Figure 2.45 
 
 
 
Figure 2.45 Intrinsic apoptosis.  The intrinsic apoptotic pathway is stimulated by internal 
stimuli, such as irreparable genetic damage, excitotoxicity, or severe oxidative stress. 
Several changes in mitochondrial structure occur, creating three different pathways by 
which to amplify the apoptotic pathway, beginning with increased mitochondrial 
membrane permeability (MMP) and eventual release of intermembrane and matrix-
resident proteins, such as cytochrome c (CytC), apoptosis inducing factor (AIF), 
Smac/DIABLO, Omi stress-regulated endoprotease/high temperature requirement protein 
A2 (Omi/HtrA2), and the DNA degrading enzyme, endoprotease G (EndoG).  In path I, 
CytC promotes formation of the apoptosome with apoptosis protease activating factor 1 
(Apaf-1) and adenosine triphosphate (ATP/dATP) which causes proteolytic cleavage and 
subsequent activation of pro-caspase-9 (ProCas-9) to caspases-9 (Cas-9).  Active Cas-9 
catalyzes the proteolytic activation of the effector caspases, which translocate to the 
nucleus contributing to DNA fragmentation and chromatin condensation.  In path II, 
caspase-independent death effectors, AIF and EndoG, translocate into the nucleus, also 
contributing to DNA fragmentation and chromatin condensation.  In Path III, 
Smac/DIABLO and Omi/HtrA2 indirectly promote apoptosis by antagonizing members 
of the inhibitor of apoptosis protein (IAP) family.  Binding of IAPs by Smac/DIABLO 
and Omi/HtrA2 serves to promote apoptosis induced by activation of effector caspases 
from paths I and II (adapted from Kroemer et al., 2007).   
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Formation of permeability transition pores in the mitochondrial membrane (MPTP) 
results from the association of voltage-dependent anion channels (VDAC), adenine nucleotide 
translocators, cyclophilin D, peripheral benzodiazepine receptors, hexokinase, and creatine 
kinase, which is promoted by attachment of pro-apoptotic Bcl-2 family members and prevented 
by anti-apoptotic Bcl-2 proteins [Fig. 2.46] (Karp, 2003; Kroemer et al., 2007; Siegel et al., 
2006). Upon release, cytochrome c binds the cytosolic adapter molecule, apoptosis protease 
activating factor-1 (Apaf-1), initiating formation of the multi-protein complex, called the 
apoptosome, and caspase-dependent apoptosis, while Smac/DIABLO and Omi/HtrA2 bind and 
neutralize cytosolic inhibitors of apoptosis proteins (IAPs), initiating caspase-independent 
apoptosis [Fig. 2.45] (Kroemer et al., 2007; Siegel et al., 2006).  Multimerization and activation 
of initiator caspase-9 by the apoptosome, in turn, causes activation of executioner, or effector, 
caspases-3, -6, and -7 (Fuentes-Prior and Salvesen, 2004), which mediate proteolytic cleavage of 
specific substrates and complete the final phases of the cell‟s destruction.  Although most 
vertebrate cell death proceeds through the intrinsic apoptotic pathway (Green and Kroemer, 
2004), both extrinsic and intrinsic pathways ultimately converge via activation of the same 
executioner caspases (Karp, 2003).  Moreover, previous studies have shown a certain amount of 
cross-talk between these pathways (Krammer, 2000; Scaffidi et al., 1998). 
 
Figure 2.46 
 
 
Figure 2.46 The mitochondrial permeability transition pore (MPTP).  The MPTP is 
thought to be composed of multiple proteins, including the voltage-dependent anion 
channel (VDAC), adenine nucleotide translocase (ANT), hexokinase (HK), creatine 
kinase (CK), peripheral-type benzodiazepine receptor (PBR), and cyclophilin D (CypD).  
Both anti-apoptotic Bcl-2 and pro-apoptotic Bax modulate activity of the MPTP, through 
direct interactions with ANT and/or VDAC (adapted from Kroemer et al., 2007).   
 
 
In normal cells, apoptosis is critically involved in the maintenance of tissue homeostasis, 
and therefore, must be strictly controlled (Green and Kroemer, 2004).  Dysfunction of even one 
apoptotic event or protein could pathogenically disable apoptosis, contributing to oncogenesis 
and cancer, or lead to unwarranted apoptosis, causing substantial cell loss and disease (Kroemer 
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et al., 2007).  Excessive apoptosis occurs in a majority of neurodegenerative diseases, as there is 
a significant loss of neuronal tissue, especially in Alzheimer disease brain. 
2.5.2  Phagocytosis 
Completion of the apoptotic process is accomplished through phagocytic engulfment of 
late-stage apoptotic cells (Fig. 2.47), which prevents further damage to the environment 
surrounding the dying cell.  However, before final clearance, apoptotic cells must first expose a 
certain signal on their extracellular surface to attract phagocytes to the appropriate location.  The 
most well-known signal for apoptotic-cell clearance is the exposure of PtdSer onto the outer-
leaflet of the plasma membrane (see section 2.2.2), which is crucial for selective recognition and 
mononuclear phagocytosis of target cells by macrophages and fibroblasts in the periphery, or 
microglia in the brain (Fadok et al., 2001; 1992a; Kagan et al., 2003; Schroit et al., 1985).  
Several phagocytic receptors have been implicated in the recognition of PtdSer, including the 
lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), β2-glycoprotein I (β2GPI) 
receptor, αvβ3-vitronectin receptor, Mer receptor tyrosine kinase, and the PtdSer receptor (PSR), 
among others (Arur et al., 2003; Balasubramanian et al., 1997; Fadok et al., 2000; 1992b; 
Hanayama et al., 2002; Li et al., 2003; Sambrano and Steinberg, 1995; Savill et al., 1990; Scott 
et al., 2001). 
 
Figure 2.47 
 
 
 
Figure 2.47 Phagocytosis (image courtesy of the U.S. National Library of Medicine, 
www.nlm.nih.gov). 
 
 
Normally, the collapse of PtdSer asymmetry and subsequent phagocytosis is considered a 
process balancing the rate of cell death and cell division, in order to maintain cellular 
homeostasis.  However, under conditions of oxidative stress, for example, an abnormal amount 
of apoptosis and extracellular exposure of PtdSer is observed (Kagan et al., 2000; 2002; Martin 
60 
 
et al., 1995; Tyurina et al., 2004a; 2004b), such as in the Alzheimer disease brain, which is 
discussed in the following sections.  Chapters 4 and 5 of this dissertation will focus on the 
relationship between PtdSer exposure, apoptosis, and oxidative stress in Alzheimer disease brain. 
2.6  Alzheimer Disease (AD) 
AD is an age-associated, largely sporadic, neurodegenerative disorder clinically 
diagnosed by the vast, progressive loss of memory and cognition commonly in subjects over the 
age of 65 (Price et al., 1998).  Neuropathologically, this dementing disorder can be characterized 
by synapse and neuronal cell loss in conjunction with the appearance and accumulation of 
neurofibrillary tangles (NFTs) and senile (or neuritic) plaques (SPs), whose composition consists 
largely of amyloid-β peptide (1-42) [Aβ(1-42)] (section 2.6.2).  A hallmark of AD is wide-spread 
oxidative stress and damage to brain proteins, lipids, and nucleic acids [see section 2.4] 
(Aksenov et al., 2001; Butterfield, 2002; Butterfield et al., 2007a; Castegna et al., 2003; 2002a; 
Hensley et al., 1995; Lyras et al., 1997; Markesbery, 1999; Perluigi et al., 2009; Smith et al., 
1997; Sultana et al., 2006a; 2006b; Varadarajan et al., 2000), as well as increased production of 
reactive aldehydes, like HNE, within the lipid bilayer [see section 2.4.2] (Butterfield, 2002; 
Butterfield et al., 2002b; 2006c; Lauderback et al., 2001; Lovell et al., 2001; Markesbery and 
Lovell, 1998; Perluigi et al., 2009; Williams et al., 2006).  This dementing disorder was first 
described in 1907 by Alois Alzheimer from a patient experiencing rapid memory loss and 
disorientation.  Following post-mortem autopsy of the patient‟s brain, Alzheimer found a 
significant reduction in brain mass, especially the hippocampus, as well as a substantial amount 
of what are now known as NFTs and SPs by histopathological analyses (Fig. 2.48).  Because the 
hippocampus is primarily responsible for memory function and processing, and is often the first 
area of the brain to succumb to AD pathogenesis, it is not surprising that this disease affects 
cognition to such a devastating degree. 
 
Figure 2.48 
 
 
Figure 2.48 Alzheimer disease (AD) brain histopathology. Silver stains of A) senile 
plaques (SPs) and B) neurofibrillary tangles (NFTs). 
 
 
NFTs are composed of paired helical filaments of the hyperphosphorylated microtubule-
associated protein (MAP), tau, which is almost exclusively expressed in the brain (Brandt and 
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Lee, 1993).  Microtubules play an important role in various cellular functions, including mitosis, 
intracellular transport, and maintenance of cell shape.  MAPs, such as tau, aid microtubule 
assembly by nucleation.  Tau is particularly enriched in axons (Binder et al., 1985; Brion et al., 
1988; Kowall and Kosik, 1987; Trojanowski et al., 1989) and plays a major role in the 
development of axonal morphology (Caceres and Kosik, 1990; Caceres et al., 1991).  Routine 
phosphorylation of tau is necessary to its function in the control of microtubule assembly and 
stability, as well as intracellular axonal transport (Brandt and Lee, 1993; Cleveland et al., 1977; 
Weidemann et al., 1989); however, hyperphosphorylation of tau results in the formation and 
intracellular accumulation of neurotoxic NFTs [Fig. 2.49] (Butterfield et al., 2006d; 1986a; 
Grundke-Iqbal et al., 1986b; Iqbal et al., 2000; Roder et al., 1993).   
 
Figure 2.49 
 
 
 
Figure 2.49 Formation of neurofibrillary tangles (NFTs). NFTs are composed of paired 
helical filaments of the hyperphosphorylated microtubule-associated protein, tau.  In 
Alzheimer disease brain, NFTs accumulate into neurotoxic “clumps” or tangles (image 
courtesy of the Alzheimer's Disease Education and Referral Center). 
 
 
In rare cases, AD pathology can begin as early as ~30 years of age due to autosomal 
dominant missense mutations in the amyloid precursor protein (APP; chromosome 21) or 
presenilin (PS) genes 1 (chromosome 14) and/or 2 [chromosome 1] (Citron et al., 1992; 
Scheuner et al., 1996; Sturchler-Pierrat et al., 1997; Wisniewski et al., 1998), with a mutation in 
PS-1 being more aggressive.  APP is a transmembrane protein that functions in neuronal 
plasticity, long term potentiation, and memory loss (Turner et al., 2003).  However, APP is most 
well-known for its role in pathologic production of the cleavage product, Aβ.  Because 
presenilins are involved in APP processing (Selkoe et al., 1996), mutations in APP and PS-1 or 
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PS-2 result in the increased production of pathologic Aβ(1-40) and Aβ(1-42) [section 2.6.2] 
(Borchelt et al., 1997; Cai et al., 1993; Oyama et al., 1998; Scheuner et al., 1996).  Thus, 
missense mutations in PS-1 or PS-2 are gain-of-function.  Presenilins are a group of conserved 
integral membrane proteins that have been shown to interact with and proteolytically cleave a 
number of different proteins, including catenins (Georgakopoulos et al., 1999; Yu et al., 1998; 
Zhou et al., 1997), cadherins (Georgakopoulos et al., 1999), Notch receptors (Baumeister et al., 
1997; De Strooper et al., 1999; Struhl and Greenwald, 1999), APP proteins (Xia et al., 1997; 
1998), and γ-secretases.  Interestingly, PS-1 is known to participate in the γ-secretase-associated 
cleavage of APP into Aβ (section 2.6.2), either as part of a proteolytic complex with γ-secretase, 
as a diaspartyl cofactor for γ-secretase, or actually is the γ-secretase which cleaves APP directly 
(Naruse et al., 1998; Thinakaran et al., 1998; Wolfe et al., 1998; 1999a; 1999b; Xia et al., 1997).  
Hence, presenilins (PS-1 in particular) may play a crucial role in the proteolytic turnover of the 
transmembrane domains of a variety of single-pass integral membrane proteins, thus 
participating in a variety signal transduction events and possibly even mediating apoptosis 
(reviewed in Selkoe, 2001a). 
2.6.1  Mild Cognitive Impairment (MCI) 
MCI is considered a transition point between normal cognitive aging and probable AD 
(Petersen et al., 1999; Winblad et al., 2004), as this disease displays similar pathology to AD at 
its earliest stages, although to a much lesser extent.  Diagnostic criteria include a lack of 
dementia, but a slight cognitive deficit that has not significantly disturbed the subject‟s activities 
of daily living (Petersen et al., 1999).  There are two broad subtypes of MCI: amnestic MCI 
(aMCI), in which subjects exhibit significant memory impairment as per the diagnostic criteria of 
MCI; and non-amnestic MCI, in which subjects do not present a significant memory deficit 
(Economou et al., 2007; Petersen, 2004; Portet et al., 2005).  Hence, aMCI is arguably the 
earliest form of AD, and is, therefore, the subtype of interest to this dissertation.  Other brain 
functions, such as language, attention, and viseospatial skills may also be impaired in either MCI 
subtype.   
Pathologically, MCI brain shows mild degradation of the hippocampus, entorhinal cortex, 
sulci, and gyri, though not as pronounced as in AD brain [Fig. 2.50] (Barnes et al., 2007; 
Devanand et al., 2007; Du et al., 2001; 2004; Jack et al., 1999; Mevel et al., 2006; Mori, 2005).  
SPs and NFTs are significantly elevated in aMCI brain compared to normal age-matched control 
individuals, but their levels are significantly lower when compared to AD brain (Markesbery et 
al., 2006).  Interestingly, the rate of aMCI patient conversion to full-onset AD is ~10-15% per 
year (Maioli et al., 2007; Rozzini et al., 2007), although some aMCI individuals have been 
shown to revert to a normal clinical phenotype (Petersen, 2000).  Furthermore, aMCI brain has 
also been reported to have elevated levels of oxidative stress  (2006b; Butterfield et al., 2006c; 
2007b; Keller et al., 2005; Lovell and Markesbery, 2007; Markesbery and Lovell, 2007; 
Markesbery et al., 2005; Reed et al., 2008a; 2008b).   
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Figure 2.50 
 
 
 
Figure 2.50 Pathological effects of Alzheimer disease (AD) progression. Compared to a 
A) normal brain, B) mild cognitive impairment (MCI) brain shows mild degradation of 
the hippocampus, entorhinal cortex, sulci, and gyri, and moderate enlargement of the 
ventricles; although these features are not as pronounced as those found in AD brain 
(image adapted from the Alzheimer's Disease Education and Referral Center). 
 
 
2.6.2  The Amyloid-β (Aβ) Peptide 
As previously mentioned, Aβ is a proteolytic product of APP cleavage produced in large 
quantities during the progression of AD, eventually accumulating as the main component of SPs. 
In particular, cleavage of APP by both β-secretase (N-terminus) and γ-secretase (C-terminus) 
enzymes results in the formation of Aβ(1-40) and/or Aβ(1-42) [Fig. 2.51].  In particular, it is the 
longer, more hydrophobic Aβ(1-42) that is toxic in AD (Drake et al., 2003a; Lambert et al., 
1998; Mattson, 1997), as it is considerably more prone to oligomerization and subsequent fibril 
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formation than the more abundantly produced Aβ(1-40) (Burdick et al., 1992; Jarrett et al., 
1993).  Whereas Aβ(1-42) deposits as the main component of SPs, Aβ(1-40) deposits as the main 
component of soluble diffuse plaques.  Similar to ROS and RNS produced en masse in AD and 
aMCI brain, Aβ(1-42) oligomers have been shown to initiate direct lipid peroxidation and 
indirect protein oxidation events [Fig. 2.52] (Butterfield, 2002; Butterfield et al., 2007a; Lambert 
et al., 1998; Lauderback et al., 2001; Schubert et al., 1995; Selkoe, 2001b) by integrating into the 
membrane and/or binding to its surface (Hertel et al., 1997; Kayed et al., 2004; McLaurin and 
Chakrabartty, 1997) and  increasing bilayer permeability and conductance by altering its 
dielectric structure (Arispe and Doh, 2002; Demuro et al., 2005; Kayed et al., 2004; Muller et al., 
1995; Sokolov et al., 2006).   
 
Figure 2.51 
 
 
 
 
Figure 2.51 Formation of the amyloid-β (Aβ) peptide.  A) & B) Proteolytic cleavage of 
the membrane-bound amyloid precursor protein (APP) by β- and γ-secretases results in 
the production of Aβ.  C) Aβ(1-40) is the main component of soluble, diffuse plaques, 
while Aβ(1-42) is the main component of senile plaques.  Both Aβ(1-40) and Aβ(1-42) 
are produced in large quantities during the progression of Alzheimer disease (AD) [image 
courtesy of the Alzheimer's Disease Education and Referral Center]. 
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Figure 2.52 
 
 
 
Figure 2.52 The amyloid-β (Aβ)-induced oxidative stress hypothesis. Similar to reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) which are mass produced in 
Alzheimer disease and amnestic mild cognitive impairment, Aβ(1-42) oligomers have 
been shown to initiate direct lipid peroxidation and indirect protein oxidation events, 
leading to neuronal cell death.  APP, amyloid precursor protein (adapted from Butterfield 
et al., 2010). 
 
 
Aβ(1-42) readily inserts itself into the hydrophobic interior of the lipid bilayer by 
adopting an α-helical formation.  Previous studies from the Butterfield laboratory and others 
have shown that in vitro and in vivo Aβ(1-42) results in elevated protein oxidation and lipid 
peroxidation (Abdul et al., 2008; Boyd-Kimball et al., 2005b; Drake et al., 2003a; Mohmmad 
Abdul et al., 2006; Resende et al., 2008; Zhu et al., 2008), which has been linked to a single 
methionine residue at position 35 of Aβ (residue 631 of human APP) [Fig. 2.53].  Substitution of 
the Met-35 sulfur (S)-atom with a norleucine (Nle) CH2 group in human Aβ(1–42) abrogates the 
oxidative and neurotoxic effects of the resulting peptide in cultured neurons, while maintaining 
similar length, hydrophobicity, and tendency to aggregate as native human Aβ(1-42) [Fig. 2.53] 
(Boyd-Kimball et al., 2005b; Varadarajan et al., 2001; Yatin et al., 1999).  In Caenorhabditis 
elegans, substitution of the Met codon with a cysteine codon in DNA encoding human Aβ(1-42) 
prevents in vivo protein oxidation, while not affecting Aβ(1-42) accumulation and plaque 
deposition (Yatin et al., 1999).   
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Figure 2.53 
 
 
 
Figure 2.53 Amyloid-β (Aβ) amino acid sequence. Previous studies have shown that in 
vitro and in vivo Aβ(1-42) results in elevated levels of oxidative stress due to a single 
methionine residue at position 35 (Met-35; M) of Aβ.  Substitution of the Met-35 sulfur 
(S)-atom with a norleucine (Nle) CH2 group in human Aβ(1–42) abrogates the oxidative 
and neurotoxic effects of the resulting peptide in cultured neurons, while maintaining 
similar length, hydrophobicity, and tendency to aggregate as native human Aβ(1-42) 
(Boyd-Kimball et al., 2005b; Varadarajan et al., 2001; Yatin et al., 1999). In 
Caenorhabditis elegans, substitution of the Met-35 S-atom with a cysteine (C) thiol 
group in human Aβ(1-42) prevents in vivo oxidative stress (Yatin et al., 1999). 
 
 
It has been proposed that Aβ-induced oxidative stress is dependent on the formation of a 
S-centered, transient free radical on Met-35 (Boyd-Kimball et al., 2004; Butterfield and Boyd-
Kimball, 2005; Kanski et al., 2002; Varadarajan et al., 2001; Yatin et al., 1999).  According to 
the "i+4" rule of α-helices, a lone-pair of oxygen electrons from the backbone carbonyl of 
isoleucine 31 (Ile-31) is within Van Der Waals distance of the Met-35 S-atom (Fig. 2.54).  This 
has been confirmed by Nuclear Magnetic resonance [NMR] (Riek et al., 2001).  The electron-
withdrawing effect of the oxygen lone-pair redistributes the sulfur‟s electron-density (towards 
the oxygen), making the Met-35 S-atom more susceptible to a one-electron oxidation event 
which would create a sulfuranyl radical cation on Met-35 (Kanski et al., 2002).  A small amount 
of sulfuranyl radical on Aβ(1–42) can become greatly amplified by a series of chain reactions 
within the hydrophobic intermembrane space of the bilayer, initiated by abstraction of an allylic 
hydrogen (H)-atom from unsaturated fatty acyl chains of lipids by the sulfuranyl radical [Fig. 
2.55] (Varadarajan et al., 2001).  As long as allylic H-atoms are available, this Met-35-induced 
radical chain reaction can continuously produce lipid peroxidation products, such as HNE (see 
section 2.4.5.1), and oxidatively modify membrane proteins [Fig. 2.55b] (Lauderback et al., 
2001; Mark et al., 1997).  Because this chain reaction inevitably regenerates the reduced form of 
Met-35, which can again undergo one-electron oxidation, this process is considered catalytic 
(Fig. 2.55).  Consequently, oligomeric Aβ(1-42) could be a major contributor to the oxidative 
stress and damage observed in AD and aMCI brain.  
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Figure 2.54 
 
 
 
 
 
Figure 2.54 The interaction between isoleucine 31 (Ile-31) and methionine 35 (Met-35) 
of the amyloid-β (Aβ) peptide.  In order to integrate into the membrane, Aβ must be in an 
α-helical conformation.  Thus, according to the "i+4" rule of α-helices, a lone-pair of 
oxygen (O) electrons from the backbone carbonyl of Ile-31 is within Van Der Waals 
distance of the Met-35 sulfur (S)-atom.  The electron-withdrawing effect of the oxygen 
lone-pair redistributes the sulfur‟s electron-density (towards the oxygen), making the S-
atom more susceptible to a one-electron oxidation, which would create a sulfuranyl 
radical cation on Met-35 (Kanski et al., 2002).  Data were obtained from the RCSB 
protein data bank as entry code 1Z0Q.pdb, DOI: 10.2210/pdb1z0q/pdb.  This figure was 
drawn using the DeepView Swiss-PDB viewer program, version 4.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
Figure 2.55 
 
 
 
 
  
Figure 2.55 Proposed reaction mechanism of amyloid-β (Aβ)-induced oxidative stress. 
A) Following “priming” of the methionine 35 (Met-35) sulfur (S)-atom by the backbone 
carbonyl oxygen of isoleucine 31, the S-atom becomes susceptible to one-electron 
oxidation by any number of oxidants to form a sulfuranyl radical cation.  The sulfuranyl 
radical quickly abstracts an allylic hydrogen (H)-atom from the unsaturated fatty acyl 
chains of lipids within the bilayer.  Following H-atom abstraction, the radical 
protein/lipid product (R
.
) can B) proceed to react with other nearby proteins and lipids, 
while the A) extremely acidic Met-35 cationic compound (pKa -5) readily reacts with any 
base, including water, removing the acidic H-atom and reforming reduced Met-35 
(Varadarajan et al., 2001).  This process is catalytic since the newly reduced Met-35 can 
again undergo a one-electron oxidation. 
 
Copyright © Miranda Lu Lange, 2010 
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CHAPTER 3 
MATERIALS & METHODS 
 
3.1  Control, Mild Cognitive Impairment (MCI), & Alzheimer Disease (AD) Brain 
Frozen inferior parietal lobule (IPL) brain samples from subjects with amnestic mild 
cognitive impairment (aMCI; n=5), late-stage Alzheimer disease (AD; n=5), and age-matched 
controls (n=5) with post-mortem intervals (PMI) ranging from 2.8 h to 3.4 h were obtained from 
the University of Kentucky Rapid Autopsy Program of the Alzheimer Disease Clinical Center 
(UK ADC; Tables 3.1 & 3.2).  All AD patients exhibiting significant cognitive decline met the 
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer 
Disease and Related Disorders Association (NINCDS-ARDA) Workgroup criteria for clinical 
diagnosis of probable AD (McKhann et al., 1984) and also displayed progressive intellectual 
decline (Table 3.2).  All age-matched control subjects in both the aMCI and AD 
phosphatidylserine (PtdSer) asymmetry studies were without a history of dementia or other 
neurological disorders and underwent annual mental status testing and semi-annual physical and 
neurological exams as part of the UK ADC normal volunteer longitudinal aging study, and had 
test scores in the normal range (Tables 3.1 & 3.2).  Brain tissue and demographics used for the 
AD PtdSer asymmetry study were described previously (Butterfield et al., 2006c).  Additional 
demographic parameters of controls and subjects with aMCI and AD without personal identifiers 
were made available by the UK ADC and are provided in Tables 3.1 and 3.2. 
 
Table 3.1 Characteristics of control and amnestic mild cognitive 
impairment (aMCI) patients available from medical records. 
Parameters: 
Demographic Variables 
Control Subjects aMCI Subjects 
Number of subjects 5 5 
Gender (male/female) 2/3 2/3 
Age at death (yrs)
a
 82 ± 2.6 88 ± 1.5 
PMI (h)
a
 2.87 ± 1.14 3.125 ± 1.033 
Brain Weight (g)
a
 1260 ± 120 1120 ± 61 
Braak Stage I-II III-V 
a
(mean  ± S.D.); PMI, post-mortem interval. 
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Table 3.2 Characteristics of control and Alzheimer disease (AD) patients available 
from medical records. 
Parameters: 
Demographic Variables 
Control Subjects AD Subjects 
Number of subjects 5 5 
Gender (male/female) 3/2 3/2 
Age at death (yrs)
a
 87.0 ± 3.94 85.8 ± 6.02 
PMI (h)
a
 2.9 ± 0.70 3.4 ± 1.4 
MMSE; number of months 
prior to death test taken
a
 
28 ± 0.8; 6.6 ± 1.4 15.7 ± 2.6; 6.6 ± 1.4 
APOE genotype, if known (n) 3/3 (3) 3/4 (2) ND 
Cause of death 
surgery complications, 
cardiac failure; COPD 
surgery complications, 
cardiac failure; COPD 
a
(mean  ± S.D.);  AD, Alzheimer disease; PMI, post-mortem interval; MMSE, Mini-Mental 
State Examination; APOE, apolipoprotein E; ND, not determined; n, number of 
individuals; COPD, Chronic Obstructive Pulmonary disease (adapted from Sultana et al., 
2006b). 
 
 
3.2  Animal Procedures 
3.2.1  Post-Mortem Interval (PMI) Mice 
All procedures using mice for PMI studies were approved by the University of Kentucky 
Animal Care and Use Committee.  Six male FBV/N mice (Harlan Laboratories Inc., 
Indianapolis, IN) were euthanized with CO2 in a chamber until death and quickly placed in a 
Styrofoam
™
 box containing two 710 ml bottles of water at ~37 °C, in order to delay post-mortem 
cooling of the brain and more closely approximate the human brain cooling curve (Geddes et al., 
1986; Schwab et al., 1994).  After intervals of 2.8 h and 3.4 h, whole mouse brains, excluding 
cerebellum, were isolated and frozen at −80 °C until use.  These PMIs were chosen based on the 
minimum and maximum human brain PMIs obtained from the UK ADC found in Tables 3.1 and 
3.2.  Three additional mice were euthanized with CO2 in a chamber until death, and whole brain 
tissue was rapidly removed, excluding cerebellum, to represent a 0 h PMI (i.e., fresh samples).  
Synaptosomes from fresh 0 h (n=3) and thawed 2.8 h (n=3) and 3.4 h (n=3) mouse brain were 
processed simultaneously.  
3.2.2  APP/PS-1 Knock-In Mice 
The University of Kentucky Animal Care and Use Committee approved all procedures 
using APP/PS-1 mice.  All mice used in this study were male.  APP
NLh
/APP
NLh
 x PS-1
P264L
/PS-
1
P264L
 human double mutant knock-in mice were generated using Cre-loc
©
 knock-in technology 
(Cephalon Inc., Frazer, PA) to humanize the mouse Aβ sequence (NLh), and create a presenilin-1 
(PS-1) proline to leucine mutation on codon 264 [P264L] (Reaume et al., 1996; Siman et al., 
2000), thus, creating a mammalian model of amyloid-β (Aβ) pathology commonly found in 
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familial AD (FAD) that yields proper cleavage of the amyloid precursor protein (APP) in order 
to generate Aβ peptides (Flood et al., 2002).  Gene expression produced by crossing APP
NLh
 and 
PS-1
P264L
 knock-in mice is driven by endogenous promoters of both the APP and PS-1 genes.  
Therefore, expression is limited by replacement of these genes and not by expression of multiple 
transgenes (Anantharaman et al., 2006).  APP/PS-1 mice were maintained on a CD-1/129 
background.  Five age-groups for both wild-type (WT) and APP/PS-1 mice were used (1, 3, 6, 9, 
and 12 months-old) to examine Aβ pathology (n=5 for all age groups, except 1 month-old mice, 
n=23) and PtdSer asymmetry (n=5 for all age groups, except 6 month-old mice, n=8) with age.  
Whole brain tissue was isolated and frozen at -80 
o
C until use. 
3.2.3  PDAPP Transgenic Mice 
All studies using PDAPP transgenic mice were approved by the Institutional Animal Care 
and Use Committee (IACUC) of the Buck Institute for Age Research (Novato, CA), and carried 
out in the Buck Institute‟s Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC)-accredited vivarium.  All mice used in this study were male.  PDAPP(M631L) 
mice were derived directly in the C57BL/6J genetic background using the same approach as 
described previously (Galvan et al., 2006; Mucke et al., 2000).  Briefly, a mutation was 
introduced into the platelet-derived growth factor (PDGF) β-chain promoter-driven human APP 
minigene, carrying the Swedish (K670N and M671L) and Indiana (V717F) familial AD (FAD) 
mutations, that mutated methionine 631 (APP695 numbering) to leucine, generating 
PDAPP(M631L) transgenic (Tg) mice by direct injection into C57BL/6J embryos.  The PDGF β-
chain promoter-driven APPSw,In minigene and J20 line of PDAPP mice, without the M631L 
substitution, were developed and provided by Professor Lennart Mucke at the University of 
California (San Francisco, CA) as previously described (Mucke et al., 2000), and kept in their 
original C57BL/6J background.  Tg PDAPP(M631L) mice express the PDAPP(Sw,In,M631L) 
transgenes to levels 12.5% higher than those of the PDAPP(Sw,In) transgene in the J20 line.  All 
Tg lines were maintained by heterozygous crosses with C57BL/6J breeders (Jackson 
Laboratories, Bar Harbor, ME); thus, all Tg animals were heterozygous with respect to the 
transgene.  Non-transgenic (Non Tg) littermates from each Tg line, J20 and M631L, were used 
as controls in all studies related to PDAPP mice.   
Whole mouse brain tissue was extracted and frozen at -80 
o
C by the Bredesen laboratory 
at the Buck Institute for Age Research (Novato, CA) and one-half on each brain sent to the 
Butterfield laboratory at the University of Kentucky (Lexington, KY), where they remained at -
80 
o
C until used.  Experimental groups of animals were as follows: Tg PDAPP(J20) [n=10]; Tg 
PDAPP(M631L) [n=10]; Non Tg PDAPP (n=5); Non Tg M631L (n=5). 
3.3  Experimental Materials 
For all PtdSer asymmetry studies in this dissertation, synaptosomes were prepared from 
either whole mouse brain tissue or the IPL tissue from brain of subjects with AD and aMCI, as 
described below (section 3.4.1).  All other studies incorporated whole or half mouse brain tissue 
homogenate.  All chemicals, proteases, and antibodies used in all of the following experiments of 
this chapter were purchased from Sigma-Aldrich (St. Louis, MO) unless noted otherwise.  All 
Criterion precast polyacrylamide gels (1D and 2D), Tris/Glycine/Sodium dodecyl sulfate (TGS) 
and XT 2-(N-morpholino)ethanesulfonic acid (MES) electrophoresis running buffer, 
ReadyStrip
™
 immobilized pH gradient (IPG) strips, mineral oil, Precision Plus Protein
™
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standards, overlay agarose, SYPRO Ruby
®
 Protein Stain, and nitrocellulose membranes (0.45 
μm) were purchased from Bio-RAD (Hercules, CA). 
3.4  Sample Preparation 
3.4.1  Synaptosome Preparation 
Synaptosomes are commonly used in studies of the brain as a complete model of a 
functional synapse.  This rather simplistic model system contains a continuous plasma membrane 
with functional pumps and channels capable of ion exchange, readily responds to depolarization 
in either a Ca
2+
-dependent or Ca
2+
–independent manner, and retains subcellular organelles such 
as mitochondria.  Furthermore, aminophospholipid translocase activity has been demonstrated 
previously in synaptosomes (Zachowski and Gaudry-Talarmain, 1990).  Therefore, 
synaptosomes provide a reliable in vitro model of neuronal PtdSer asymmetry, among other 
synaptic processes (Whittaker, 1993).   
Synaptosome fractions from mouse and human brain were prepared as previously 
described (Mohmmad Abdul and Butterfield, 2005; Whittaker, 1959; 1968), with exceptions.  
Brain tissue was homogenized in a Wheaton glass homogenizer (~100 passes) and suspended in 
isolation buffer (0.32 M sucrose, 0.2 mM PMSF, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 4 
g/ml leupeptin, 4 g/ml pepstatin, 5 g/ml aprotinin, and 20 g/ml trypsin inhibitor; pH 7.4); 
from this initial homogenate, a small aliquot was reserved for protein expression studies 
described below (sections 3.7.1 & 3.8.1).  The homogenate was then centrifuged at 4000 rpm 
(1940 x g) in a Beckman J2-MI high-speed centrifuge (JA-20 rotor; Beckman-Coulter, Fullerton, 
CA) for 10 min at 0 
o
C and the supernatant (S1) decanted.  Due to the precious nature of human 
brain tissue and the small sample size of human IPL provided, this first pellet (P1) was saved 
during preparation of human synaptosomes, re-homogenized in isolation buffer, and again, 
centrifuged at 4000 rpm (1940 x g) in a Beckman J2-MI high-speed centrifuge (JA-20 rotor; 
Beckman-Coulter, Fullerton, CA) for 10 min at 0 
o
C in order to extract an optimal amount of 
crude synaptosomes.  Following centrifugation, this second pellet (P2) was discarded, while the 
new supernatant (S2) was mixed with S1.  It should be noted, however, that preservation of P1 
was not necessary in preparation of mouse synaptosomes, as a larger sample size was available 
(i.e., whole mouse brain) and a sufficient amount of crude synaptosomes was extracted after the 
initial centrifugation.   
In order to ultra-purify synaptosomes, the supernatant (S1, for mice; S1+S2, for human) 
was centrifuged at 14,800 rpm (25,400 x g) for 12 min at 0 
o
C.  The resulting pellet from both 
tissue types was mixed with 1 ml of cold isolation buffer and layered onto cold discontinuous 
sucrose gradients containing 10 ml each of 1.18 M (pH 8.5), 1.0 M (pH 8.0), and 0.85 M (pH 
8.0) sucrose, as well as 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES.  Gradients were 
centrifuged in a Beckman Optima L-90K ultracentrifuge (SW-28 rotor; Beckman-Coulter, 
Fullerton, CA) at 22,000 rpm (82,500 x g) for 1 h at 4 
o
C.  The resulting ultra-purified 
synaptosomes were removed from the 1.18/1.0 M sucrose interface and washed three times in 
Locke‟s buffer (0.15 M NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 3 mM NaHCO3, 5 mM 
glucose, 5 mM HEPES; pH 7.4) at 15,500 rpm (29,100 x g) for 12 min each at 0 
o
C in a Hettich 
Mikro 22 R microcentrifuge (Hettich, Beverly, MA).  Protein concentrations were determined 
according to the Pierce BCA method described below (section 3.5).  
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3.4.2  Whole & Half Brain Tissue Preparation 
Whole or one-half mouse brain samples were homogenized using a Wheaton glass 
homogenizer (~100 passes) in 1 ml of Media I buffer (0.32 M sucrose, 0.10 mM Tris-HCl [pH 
8.0], 0.10 mM MgCl2, 0.08 mM EDTA, 10 g/ml leupeptin, 0.5 g/ml pepstatin, and 11.5 g/ml 
aprotinin; pH 8.0).  Homogenates were vortexed to equilibrate, aliquotted into Eppendorf 
microcentrifuge tubes, and sonicated with a Fisher Scientific 550 Sonic Dismembrator (Fisher 
Scientific, Pittsburgh, PA) for 10 s at 20% power.  Protein concentrations were determined 
according to the Pierce BCA method described below (section 3.5).   
3.5  Bicinchoninic Acid (BCA) Protein Assay 
All protein concentrations in this dissertation were determined using the Pierce 
Bicinchoninic acid (BCA) Protein Assay (Pierce, Rockford, IL).  This method combines the 
Biuret reaction, used for detection of peptide bonds, with the colorimetric detection of the 
cuprous cation (Cu
+
) by BCA (Smith et al., 1985).  In this assay, proteins mediate the reduction 
of Cu
2+
 to Cu
+
 through amino acids, such as cysteine or cystine, tryptophan, and tyrosine, and 
peptide bonds in an alkaline environment (Smith et al., 1985; Wiechelman et al., 1988).  The 
reduced Cu
+
 subsequently forms a soluble chromophoric complex with two BCA molecules (Fig. 
3.1), turning the solution purple and exhibiting strong linear absorbance at a wavelength of 562 
nm (Smith et al., 1985).  In this colorimetric assay, the intensity of the purple color is directly 
proportional to the protein concentration; therefore, determination of the protein concentration 
can be calculated with the Beer-Lambert law (A=εlc), using bovine serum albumin (BSA) to 
develop a standard curve.  Duplicate samples (2–5 μl) are diluted to 100 μl in a clear polystyrene 
fluorescence assay plate (non-treated, non-sterile, flat-bottom; Evergreen Scientific, Los 
Angeles, CA) with a 49:1 mix of Peirce BCA reagents A and B (Pierce, Rockford, IL), 
respectively.  After incubation at 37 
o
C for 10 min, sample absorbance is determined using a 
BIO-TEK μ-Quant UV plate reader (562 nm) [BIO-TEK, Winooski, VT]. 
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Figure 3.1 
 
 
 
Figure 3.1 Bicinchoninic acid (BCA) protein assay.  Proteins mediate reduction of Cu
2+
 
to Cu
+
 via amino acids and peptide bonds.  Reduced Cu
+
 subsequently forms a purple 
chromophoric complex with two BCA molecules, which exhibits strong absorbance at 
562 nm.  Color intensity is directly proportional to protein concentration using the Beer-
Lambert law (A=εlc).   
 
 
3.6  Phosphatidylserine (PtdSer) Asymmetry Assays 
3.6.1  Annexin V (AV) Fluorescence 
This assay was conducted as described previously (Castegna et al., 2004; Kuypers et al., 
1996) to directly study externalization of PtdSer, with exceptions.  Synaptosome samples (200 
g) from human and mouse brain were covered and incubated for 5 min at 37 
o
C in Annexin 
binding buffer (ABB) [10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2; pH 7.4] and fluorescein 
isothiocyanate (FITC)-labeled AV  (Invitrogen Molecular Probes, Eugene, OR).  Samples were 
then washed twice with ABB at 14,000 rpm (23,700 x g) for 5 min at 4 
o
C in a Hettich Mikro 22 
R microcentrifuge (Hettich, Beverly, MA), and resuspended in ABB (200 l).  After 
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resuspension, samples were loaded in duplicate onto a Costar black polystyrene fluorescence 
assay plate (non-treated, non-sterile, flat-bottom; Corning Inc., Corning, NY) where residual 
fluorescence was measured in a Molecular Devices SpectraMAX Gemini fluorescence plate 
reader (Ex/Em: 494/518 nm) [Molecular Devices, Sunnyvale, CA].  Exposed PtdSer is detected 
through its high binding affinity for AV, a phospholipid binding-protein coupled with a FITC 
(Fig. 3.2) fluorescent tag, leading to increased fluorescence for samples in which the AV probe 
has bound outer-leaflet exposed PtdSer.   
 
Figure 3.2 
 
 
 
Figure 3.2 Structure of the fluorescein isothiocyanate (FITC) fluorescent probe.  FITC is 
a basic fluorescein molecule functionalized with an isothiocyanate reactive group (–
N=C=S) at one of two hydrogen atoms on the bottom ring of the structure, and is reactive 
towards primary amine groups on proteins, peptides, and other biomolecules.  When 
coupled with AV, this fluorophore provides the basis of PtdSer outer-leaflet detection in 
the AV assay (λEx/Em: 494/518 nm).   
 
 
3.6.2  NBD-PS Fluorescence 
This assay was used to indirectly study externalization of the membrane phospholipid, 
PtdSer.  Synaptosome fractions (200 μg) from human and mouse brain were prepared for NBD-
PS [1-palmitoyl-2-[6(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl-sn-glycero-3-
phosphoserine] (Avanti Polar Lipids, Alabaster, AL) fluorescent assay as previously described 
(Comfurius et al., 1996; McIntyre and Sleight, 1991), with exceptions.  This particular probe was 
chosen because flippase enzymes (which unidirectionally transport PtdSer inward against its 
concentration gradient) are most sensitive to head group structure and relatively insensitive to 
acyl chain composition (Daleke and Lyles, 2000); therefore, the fluorescent NBD group attached 
to the fatty acyl tail would not interfere with the translocating activity of flippase enzymes and 
maintain validity of results.  Samples were covered and incubated for 1 h at 37 
o
C with NBD-PS 
(2 μg/mg), a PtdSer with a fluorescent NBD group attached (Fig. 3.3a), then washed twice with 
Locke‟s buffer (pH 7.4) at 14,000 rpm (23,700 x g) for 5 min at 4 
o
C in a Hettich Mikro 22 R 
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microcentrifuge (Hettich, Beverly, MA).  After resuspension in Locke‟s buffer (200 l), samples 
were loaded in duplicate onto a Costar black polystyrene fluorescence assay plate (non-treated, 
non-sterile, flat-bottom; Corning Inc., Corning, NY) and treated with 7.5 mM sodium dithionite 
(Na2S2O4) to quench fluorescence by reduction of any exposed, NBD-labeled PtdSer (Fig. 3.3b).  
Loss of residual fluorescence was measured in a Molecular Devices SpectraMAX Gemini 
fluorescence plate reader (Ex/Em: 460/514 nm) [Molecular Devices, Sunnyvale, CA]. 
This assay leads to a decrease in measured fluorescence for samples in which the NBD-
PS probe has successfully integrated into the membrane bilayer and has been subsequently 
exposed onto the outer leaflet, where membrane impermeable S2O4
2-
 can chemically convert the 
fluorescent NBD group into a non-fluorescent, 7-amino derivative [Fig. 3.3b] (McIntyre and 
Sleight, 1991).  Extracellular exposure of NBD-PS is interpreted as a consequence of the cell‟s 
inability to maintain PtdSer asymmetry, as PtdSer is preferentially sequestered onto the inner-
leaflet of the bilayer in non-apoptotic cells.  This assay has the value-added characteristic of 
addressing potential concerns related to AV-associated probe access to the inner leaflet of an 
unstable system, possibly creating an incorrect interpretation of asymmetric collapse, since 
highly ionic S2O4
2-
 does not readily diffuse through the bilayer (McIntyre and Sleight, 1991).  On 
the other hand, although this method has been extensively tested, it should be noted that, as with 
all experimental techniques, the NBD-PS assay does have potential limitations.  For example, 
this assay is carried out under the assumption that exogenous NBD-PS acts relatively identical to 
endogenous PtdSer.  However, the ability of NBD-PS to efficiently integrate into the outer 
membrane leaflet during the 1 h pre-incubation period can vary from sample to sample; the rate 
at which NBD-PS integrates into the membrane may be faster in some cells and slower in others, 
depending on the inherent fluidity of each cell membrane to begin with. 
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Figure 3.3 
 
 
 
Figure 3.3 NBD-PS fluorescence assay.  A) NBD-PS structure. This NBD-PS probe was 
chosen because flippase enzymes (which unidirectionally transport PtdSer inward against 
its concentration gradient) are most sensitive to head group structure and relatively 
insensitive to acyl chain composition (Daleke and Lyles, 2000); therefore, the fluorescent 
NBD group attached to the fatty acyl tail would not interfere with the translocating 
activity of flippase enzymes. B) Na2S2O4 quenching of NBD-PS. The highly 
electronegative NO2 functional group of the NBD moiety delocalizes electrons located 
within the conjugated ring system to which it is attached.  Reduction of this NO2 group to 
NH2 (electron-donating) by the dithionite ion (S2O4
2-
) alters the electronic transitions of 
this NBD-analogue, thereby altering its fluorescence properties in quenching existing 
fluorescence [λEx/Em: 460/514 nm] (McIntyre and Sleight, 1991). 
 
 
3.6.3  Mg
2+
ATPase Activity 
Determination of Mg
2+
ATPase activity in human and mouse brain was employed to 
indirectly represent the activity of the adenosine triphosphate (ATP)-dependent, membrane-
bound enzyme flippase, as highly specific antibodies to flippase have not yet been obtained 
(Auland et al., 1994).  Although flippase is known to transport both PtdSer and 
phosphatidylethanolamine (PtdEtn) [Fig. 2.10] inward against their concentration gradients, 
PtdEtn transport is 10-fold slower (Daleke and Lyles, 2000).  This assay was completed 
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according to previous procedures (Castegna et al., 2004; Sadrzadeh et al., 1993), with few 
exceptions.  Synaptosome samples (7.5 μg) suspended in ATPase assay buffer (18 mM Histidine, 
18 mM Imidazole, 80 mM NaCl, 15 mM KCl, 3 mM MgCl2, 0.1 mM EGTA; pH 7.1) were 
covered and incubated with 0.1 mM of the Na
+
/K
+
ATPase inhibitor Ouabain in a clear 
polystyrene microtiter plate (non-treated, non-sterile, flat-bottom; Evergreen Scientific, Los 
Angeles, CA) for 10 min at 37 
o
C (100 μl total volume).  Next, 3 mM ATP was added to all 
sample wells, and plates were incubated for another 60 min at 37 
o
C.  The reaction was 
terminated by addition of 5% SDS (5 μl) and 125 μl of color reagent containing 0.36 g of 
ascorbic acid in 15 ml of molybdate acid solution (3.7 mM ammonium molybdate 
[(NH4)6Mo7O24 ∙ 4 H2O] and 0.43 M H2SO4 [Fisher Scientific, Pittsburgh, PA]), turning the 
solution blue in color.  Mg
2+
ATPase activity was measured with a BIO-TEK μ-Quant UV plate 
reader (810 nm) [BIO-TEK, Winooski, VT] as the net amount of inorganic phosphate (Pi) 
produced by functional Mg
2+
ATPase enzymes following incubation with and subsequent 
cleavage of ATP [Fig. 3.4] (Sadrzadeh et al., 1993).  Like the BCA assay described above (see 
section 3.5), the Mg
2+
ATPase assay for enzyme activity is colorimetric in nature, and therefore, 
the intensity of the blue color is directly proportional to Mg
2+
ATPase activity. 
 
Figure 3.4 
 
 
Figure 3.4 Hydrolysis of adenosine triphosphate (ATP).  Because Mg
2+
ATPase enzymes 
(e.g. flippase) are ATP-dependent, their activity can be measured (810 nm) as the net 
amount of inorganic phosphate (Pi) produced by hydrolyzing ATP to adenosine 
diphosphate (ADP).  Like the BCA assay (see section 3.5), the Mg
2+
ATPase assay is 
colorimetric, and therefore, the intensity of the blue color (i.e., Pi produced) is directly 
proportional to Mg
2+
ATPase activity (Sadrzadeh et al., 1993).   
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3.7  Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
3.7.1  One-Dimensional (1D)-Gel Electrophoresis  
1D-PAGE is performed to separate proteins into bands based on size, shape, and 
molecular weight.  Prior to 1D-PAGE separation, brain homogenates of known concentration are 
prepared by suspension in a sample loading buffer (0.5 M Tris [pH 6.8], 40% glycerol, 8% SDS, 
20% β-mercaptoethanol, 0.01% bromophenol blue), then heated at 95 °C for 5-10 min to ensure 
protein denaturation and quick-cooled on ice prior to gel loading.  Precision Plus Protein
™
 All 
Blue Standards (2.5 μl) are loaded in a separate lane to provide a reference marker for various 
molecular weights.  Although gel-type and running buffer vary by experiment, electrophoresis 
typically begins at 80 V for ~10 min to ensure proper protein stacking, and finishes at 120 V for 
~120 min in a Criterion Cell
™
 vertical electrophoresis buffer tank (Bio-RAD, Hercules, CA) at 
room temperature (RT), unless indicated otherwise; electrophoretic run-time is given as an 
approximation due to differences in voltage preference and/or gel composition and porosity. 
3.7.1.1  Bcl-2, Bax, & Caspase-3 Expression  
In human IPL studies of apoptotic protein expression levels, equal amounts of brain 
homogenate (75 μg) were loaded and separated using 12.5% Tris-HCl polyacrylamide gels and a 
1 X dilution of TGS running buffer.  For APP/PS-1 mouse studies, however, equal amounts of 
whole brain homogenate (75 μg) were loaded and  separated using Criterion XT precast 4-12% 
Bis-Tris linear gradient gels and a 1 X dilution of XT MES running buffer starting with 80 V for 
~10 min to ensure proper protein stacking, and finishing with 140 V for ~110 min.  Instead of 
SYPRO Ruby
®
 in-gel staining of proteins, gels were directly transferred onto Western blots as 
described below (sections 3.8.1.1 & 3.8.1.2). 
3.7.1.2  Pyruvate Kinase M2 (PK M2) & Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) 
Expression 
These gels were run to experimentally verify selected PD-Quest-identified significantly 
differentially expressed protein spots PK M2 and Pin-1 in PDAPP mouse brain.  For PK M2 
expression, equal amounts of half brain homogenates (75 μg) were loaded and separated with 
Criterion precast 8-16% linear gradient Tris-HCl polyacrylamide gels and a 1 X dilution of TGS 
running buffer at 80 V for ~10 min to ensure proper protein stacking, followed by a voltage 
increase to 120 V for ~120 min for the duration of electrophoresis.  Pin-1 expression gels were 
run as described for PK M2, but using Criterion XT precast 12% Bis-Tris polyacrylamide gels in 
a 1 X dilution of XT MES running buffer at 80 V for ~10 min and finishing at 140 V for ~110 
min instead of SYPRO Ruby
®
 in-gel staining of proteins, all gels were directly transferred onto 
Western blots as described below (section 3.8.1.3).   
3.7.1.3  Amyloid Precursor Protein (APP) Expression 
PDAPP mouse brain APP expression studies were conducted by the Bredesen laboratory 
at the Buck Institute for Age Research (Novato, CA).  PDAPP mouse brain lysates (75 μg) were 
added to NuPage sample buffer (Invitrogen, Carlsbad, CA) with β-mercaptoethanol and 
separated with a 7% Tris-Acetate NuPage gel (Invitrogen, Carlsbad, CA) using Tris-Acetate 
running buffer.  Electrophoresis began at 80 V for ~10 min, and finished at 120 V for ~120 min.  
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Instead of SYPRO Ruby
®
 in-gel staining of proteins, gels were directly transferred onto Western 
blots as described below (section 3.8.1.4). 
3.7.2  Isoelectric Focusing (IEF) 
IEF is a technique used to separate proteins according to their inherent isoelectric point 
(pI) [Fig. 3.5a,b], and is the first-dimension of separation for proteins in a 2D-separation process 
used for proteomic analyses.  In preparation for this first dimension of electrophoresis, mouse 
brain homogenates (200 μg) are first precipitated by addition of trichloroacetic acid (TCA) or 
acetone, depending on the oxidative modification to be examined: 
 
Figure 3.5 
 
 
 
Figure 3.5 Overview of Isoelectric focusing (IEF) and 2D-polyacrylamide gel 
electrophoresis (2D-PAGE).  A) & B) IEF separates proteins according to their inherent 
isoelectric point (pI), and is the first-dimension of separation for proteins in a 2D-
separation process used for proteomic analyses.  C) 2D-PAGE separates individual 
proteins into single detectable spots based on molecular migration rate (i.e., size/shape 
and molecular weight) after they are separated by pI using IEF.  MWM, molecular weight 
marker; IPG, immobilized pH gradient. 
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Protein Carbonyls:  Samples to be analyzed for protein carbonylation are first 
derivatized to 4 X the sample volume with 10 mM 2,4-dinitrophenylhydrazine (DNPH) 
[Chemicon International, Temecula, CA]  in 2 N HCl for 30 min at RT to form a protein-2,4-
dinitrophenylhydrazone (DNP) adduct wherever a free carbonyl group (excluding primary chain 
peptide bond carbonyls) is located on a protein (Fig. 3.6), followed by the precipitation of 
proteins by addition of ice-cold 100% TCA to obtain a final concentration of 15% TCA in 
solution, and incubated on ice for 10 min.   
 
Figure 3.6 
 
 
 
Figure 3.6 2,4-Dinitrophenylhydrazine (DNPH) reaction mechanism.  Protein 
carbonylation is a way in which to quantify levels of oxidative stress in a given sample.  
Samples to be analyzed for protein carbonylation are first derivatized with DNPH, 
forming a protein-2,4-dinitrophenylhydrazone (DNP) adduct wherever a free carbonyl 
group (excluding primary chain peptide bond carbonyls) is located on a protein.  This 
condensation, or addition-elimination, reaction results in the nucleophilic addition of the 
DNPH NH2 group to the carbonyl group of the protein, followed by removal of water.  
The resulting protein-DNP adduct forms a dark orange-brown color in solution. 
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Protein-Resident 3-Nitrotyrosine (3-NT):  Samples to be analyzed for protein-resident 
3-NT, however, do not undergo derivatization, nor are they TCA precipitated because the highly 
acidic environment created by TCA could potentially remove the NO2 functional group from 3-
NT (Fig. 2.34) causing an incorrect interpretation of results.  Therefore, these samples are 
acetone precipitated, according to the Pierce Acetone Precipitation of Proteins procedure (Pierce, 
Rockford, IL), with exceptions.  Briefly, proteins are precipitated by addition of -20 
o
C, 100% 
acetone to 4 X the sample volume and incubated for 60 min at -80 
o
C. 
 
Samples are then centrifuged at 14,000 rpm (23,700 x g) for 5 min at 4 
o
C in a Hettich 
Mikro 22 R microcentrifuge (Hettich, Beverly, MA).  The pellet was then resuspended in Wash 
buffer (1:1 [v/v] ethanol:ethyl acetate) and vortexed to equilibrate.  Centrifugation and washing 
of the pellet is repeated three additional times to ensure adequate removal of excess salts that 
may interfere with proper IEF of proteins.  After the final wash, the supernatant is removed and 
pellets are allowed to dry at RT for ~10 min under a flow hood to evaporate any remaining 
organic solvent.  After sufficient drying, pellets are continuously vortexed and rehydrated for 2 h 
at RT in 200 μl of Rehydration buffer (8 M urea [BioRAD, Hercules, CA], 2 M thiourea, 50 mM 
dithiothreitol [DTT; Bio-RAD, Hercules, CA], 2.0% [w/v] CHAPS, 0.2% Biolytes [Bio-RAD, 
Hercules, CA], bromophenol blue).  Following rehydration, samples are sonicated in a Fisher 
550 Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA) for 10 s at 20% power and applied 
(200 μl) to an 11 cm ReadyStrip
™
 IPG strip (pH 3-10).   
To begin the process of IEF, strips were actively rehydrated with and soaked in the 
sample solution for 1 h at 20 
o
C in a Protean IEF Cell (Bio-RAD, Hercules, CA) to allow the 
uptake of proteins into the gel portion of strips, then were covered with 2 ml of mineral oil to 
prevent sample evaporation throughout the IEF process.  Strips continued with active rehydration 
for 16-18 h at 50 V and 20 
o
C, then began IEF at a constant temperature of 20 
o
C and a 
progressively increasing voltage beginning at 300 V for 2 h linearly, 500 V for 2 h linearly, 1000 
V for 2 h linearly, 8000 V for 2 h linearly, and finishing at 8000 V for 10 h rapidly.  After 
completion of IEF, strips were stored at -80 
o
C for no more than 3 weeks, until the second 
dimension of electrophoresis was performed. 
3.7.3  Two-Dimensional (2D)-Gel Electrophoresis 
2D-PAGE is performed to separate individual proteins already separated by pI into single 
detectable protein spots based on molecular migration rate (i.e., size/shape and molecular 
weight) [Fig. 3.5c].  Subsequent to IEF, proteins (200 μg) contained within IPG strips were 
thawed and equilibrated for 10 min in Equilibration buffer A (50 mM Tris-HCl [pH 6.8], 6 M 
urea, 1% [w/v] SDS, 30% [v/v] glycerol, 0.5% DTT [Bio-RAD, Hercules, CA]) and then re-
equilibrated for 10 min in Equilibration buffer B (50 mM Tris-HCl [pH 6.8], 6 M urea, 1% [w/v] 
SDS, 30% [v/v] glycerol, 4.5% IA [Bio-RAD, Hercules, CA]).  All strips were rinsed in a 1 X 
dilution of TGS running buffer before being placed into a Criterion precast 8-16% linear gradient 
Tris-HCl linear gradient gels suitable for 11 cm IPG strips and a 1 X dilution of TGS running 
buffer.  Precision Plus Protein
™
 All Blue Standards (2.5 μl) are loaded in a separate single well 
to provide a reference marker for various molecular weights.  To ensure strips remain 
immobilized and in contact with the gel during electrophoresis, ~1.5 ml of overlay agarose (0.5% 
in 1 X TGS with bromophenol blue) was evenly distributed overtop the protein standard and IPG 
strip wells and allowed to set.  Lastly, electrophoresis is run at a constant 200 V for 65 min at RT 
in a Criterion Cell
™
 vertical electrophoresis buffer tank (Bio-RAD, Hercules, CA). 
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3.7.4  SYPRO Ruby
®
 In-Gel Protein Staining  
After 2D-PAGE, gels were either incubated in a fixing solution (7% [v/v] acetic acid, 
10% [v/v] methanol) for 20 min at RT or directly transferred onto a nitrocellulose membrane 
(0.45 μm) for Western blotting, as described below (section 3.8.2).  To fixed gels, ~50 ml of 
SYPRO Ruby
®
 Protein Gel Stain was added to stain proteins overnight on a gently rocking 
platform at RT to obtain linear and sensitive staining, then gels were de-stained overnight in ~50 
ml deionized water at RT.  Gels were scanned into Adobe Photoshop 6.0 with a Molecular 
Dynamics STORM Phosphoimager (Ex/Em: 470/618 nm) [Molecular Dynamics, Sunnyvale, 
CA] and analyzed via PD-Quest 2D-Analysis software (Bio-RAD, Hercules, CA), as described 
below (section 3.9), and stored at 4 
o
C in deionized water until needed for in-gel trypsin 
digestion. 
3.8  Western Blotting 
Western blotting is performed to detect either 1D- or 2D-PAGE-separated protein(s) of 
interest immunochemically on a nitrocellulose membrane in order to quantitate either protein 
expression levels and/or post-translational modifications (Fig. 3.7).  Following 1D- or 2D-
PAGE, proteins are transferred to a nitrocellulose membrane (0.45 μm) using a Bio-RAD Trans-
Blot Semi-dry Transfer Cell system (Bio-RAD, Hercules, CA) at 20 V for 2 h (Fig. 3.7).  
Membranes are then incubated in a blocking solution to prevent non-specific binding of 
antibodies used for immunochemical detection of protein(s) and/or modification(s) of interest, 
incubated with primary and secondary antibodies, and then developed either colorimetrically 
(Fig. 3.8a,b) or by chemifluorescence (Fig. 3.8a,c), as noted. 
 
Figure 3.7 
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Figure 3.7 Western blot protein transfer set-up.  Following 1D- or 2D-polyacrylamide 
gel electrophoresis (PAGE), proteins are transferred onto a nitrocellulose membrane 
(0.45 μm) using a Semi-dry Transfer Cell system.     
 
 
Figure 3.8 
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Figure 3.8 (cont.) 
 
 
 
 
 
Figure 3.8 Western blot detection of proteins. Western blotting is performed to detect 
either 1D- or 2D-polyacrylamide gel electrophoresis (PAGE)-separated protein(s) of 
interest immunochemically on a nitrocellulose membrane in order to quantitate either 
protein expression levels and/or post-translational modifications.  A) Overview of 
detection process.  A primary antibody binds the protein of interest on the membrane and 
is detected using a colorimetric or chemifluorescent probe attached to a secondary 
antibody.  B) Colorimetric development: BCIP/NBT. In this procedure, 5-Bromo-4-
chloro-3-indolyl phosphate dipotassium (BCIP) is hydrolyzed by the secondary antibody, 
alkaline phosphatase (ALP), forming a blue intermediate.  The intermediate is then 
oxidized by Nitrotetrazolium Blue chloride (NBT) to produce an insoluble dimer that 
exhibits an intense purple color wherever an ALP-linked protein is located on the 
nitrocellulose membrane. C) Chemifluorescent development: Lumigen PS-3. In this 
detection procedure, Lumigen PS-3 (i.e., luminol) is oxidized by a horseradish peroxidase 
(HRP)-linked secondary antibody in the presence of acridan to form an acridinium ester 
intermediate.  Interaction of this intermediate with a buffer peroxide creates an excited 
radical product that fluoresces at λEx/Em: 470/618 nm, wherever a HRP-linked protein is 
located on the nitrocellulose membrane. 
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3.8.1  Protein Expression Levels 
3.8.1.1  Bcl-2, Bax, & Caspase-3 Expression in Human Inferior Parietal Lobule (IPL) 
Membranes analyzed in human IPL studies were blocked with 5% non-fat dried milk in 
Wash Blot (a phosphate-buffered saline [PBS] solution containing 0.01% [w/v] NaN3, 0.04% 
[v/v] Tween-20, and 0.10 M NaCl) at 4 
o
C for 1 h.  After blocking, blots were incubated in their 
respective blocking solutions for 2 h at RT on a rocking platform with either mouse monoclonal 
anti-Bcl-2 (1:1000) [Stressgen Biotech, Ann Arbor, MI], rabbit polyclonal anti-Bax (1:1000) 
[Calbiochem, La Jolla, CA], or rabbit polyclonal anti-caspase-3 (1:2000) [Calbiochem, La Jolla, 
CA] primary antibodies using the mouse polyclonal anti-β-tubulin (1:8000) primary antibody as 
a loading control.  Blots were then rinsed three times at RT for 5 min each in Wash Blot and 
incubated with anti-mouse and anti-rabbit IgG alkaline phosphatase (1:3000) secondary 
antibodies in Wash Blot for 1 h at RT on a rocking platform.  Subsequent to secondary 
incubation, blots were rinsed again in Wash Blot three times for 10 min each at RT, then 
colorimetrically developed with a solution of 5-Bromo-4-chloro-3-indolyl phosphate dipotassium 
combined with Nitrotetrazolium Blue chloride (BCIP/NBT) in ALP buffer (0.1 M Tris [Bio-
RAD, Hercules, CA], 0.1 M NaCl, 5 mM MgCl2 ∙ 6 H2O; pH 9.5) [Fig. 3.8a,b].  After, blots 
were dried at RT overnight between KIMTECH Kimwipes (Kimberly-Clark, Roswell, GA), 
scanned with a Hewlett Packard ScanJet 3300C into Adobe Photoshop 6.0, and quantified using 
Scion Image software (PC version of Macintosh-compatible NIH Image software).  
3.8.1.2  Caspase-3 Expression in APP/PS-1 Mouse Brain 
Membranes analyzed in APP/PS-1 mouse studies were blocked with 3% BSA in Wash 
Blot, without NaN3, for 2 h at RT on a rocking platform.  Blots were then incubated in their 
respective blocking solutions with both rabbit polyclonal anti-caspase-3 (1:5000) [Calbiochem, 
La Jolla, CA] and mouse polyclonal anti-α-tubulin (1:8000) primary antibodies for 2 h at RT on 
a rocking platform; anti-α-tubulin was used as the loading control from which to normalize 
caspase-3 immunoreactivity.  It should be noted that both anti-caspase-3 and anti-α-tubulin 
primary antibodies were added simultaneously since each antibody was raised in a distinct 
animal host and is specific for a particular protein(s) whose molecular weight(s) do not overlap.  
Blots were then rinsed three times for 5 min each in Wash Blot at RT, without NaN3, and 
incubated for 1 h with Amersham ECL anti-mouse and anti-rabbit IgG horseradish peroxidase 
(HRP)-linked (1:8000) [GE Healthcare, Pittsburgh, PA] secondary antibodies at RT on a rocking 
platform.  Again, both secondary antibodies were added simultaneously as there is minimal 
cross-reactivity between mouse- and rabbit-specific antibodies, and the molecular weights of 
active and latent forms of caspase-3 and α-tubulin do not overlap.  Following incubation with 
secondary, blots were rinsed in Wash Blot, without NaN3, three times for 10 min each at RT on a 
rocking platform and developed chemifluorescently through addition of a 40:1 dilution of 
Amersham ECL-Plus Western blotting detection reagents A and B (GE Healthcare, Pittsburgh, 
PA), respectively (Fig. 3.8a,c).  After allowing blots to develop while covered for 5 min at RT, 
they were scanned on a Molecular Dynamics STORM Phosphoimager (Ex/Em: 470/618 nm) 
[Molecular Dynamics, Sunnyvale, CA] and quantified using the 1D-component of GE 
ImageQuant TL software (GE Healthcare, Pittsburgh, PA). 
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3.8.1.3  Pyruvate Kinase M2 (PK M2) & Peptidyl-Prolyl Cis-Trans Isomerase 1(Pin-1) 
Expression in PDAPP Mouse Brain 
All blots used in PDAPP PD-Quest verification studies were blocked with 3% BSA in 
Wash Blot, without NaN3, for 2 h at RT on a rocking platform.  Blots were then incubated for 2 h 
at RT in their respective blocking solutions with either rabbit polyclonal anti-PK M2 (N-term) 
[1:2000] (Abgent, San Diego, CA) or rabbit anti-Pin-1 (H-123) [1:2000] (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) primary antibodies, and rabbit polyclonal anti-actin 
(1:8000) primary antibody as the loading control for all blots, on a rocking platform.  It should 
be noted that, both the protein of interest and actin primary antibodies were added 
simultaneously as each antibody was either raised in a distinct animal host, and/or specific for  
particular proteins whose molecular weights did not overlap.  Blots were then rinsed three times 
for 5 min each at RT in Wash Blot, without NaN3, with subsequent incubation in a secondary 
antibody for 1 h at RT on a rocking platform.   
Secondary antibody incubation was conducted as follows:  PK M2 blots were incubated 
with only anti-rabbit IgG alkaline phosphatase (1:3000) secondary antibody; Pin-1 blots were 
incubated with only Amersham ECL anti-rabbit IgG HRP-linked (1:8000) [GE Healthcare, 
Pittsburgh, PA] secondary antibody.  Unbound, excess secondary antibody was rinsed from blots 
three times for 10 min each at RT with Wash Blot, without NaN3, on a rocking platform before 
development.  PK M2 blots were developed colorimetrically (Fig. 3.8a,b) as described above for 
human IPL (see section 3.8.1.1).  However, these blots were scanned into Adobe Photoshop 6.0 
with a Canon CanoScan 8800F scanner.  Pin-1 blots were developed chemifluorescently (Fig. 
3.8a,c) as described above for PDAPP mouse brain (see section 3.8.1.3).  Both PK M2 and Pin-1 
blots were quantified using the 1D-component of GE ImageQuant TL software (GE Healthcare, 
Pittsburgh, PA). 
 3.8.1.4  Amyloid Precursor Protein (APP) Expression in PDAPP Mouse Brain 
PDAPP mouse brain APP Western blot analysis was conducted by the Bredesen 
laboratory at the Buck Institute for Age Research (Novato, CA).  Membranes analyzed in 
PDAPP mouse studies were transferred to polyvinylidene difluoride (PVDF) membranes 
(Schleicher & Schuell, Dassel, Germany) and initially stained with SYPRO Ruby
®
 (Invitrogen, 
Carlsbad, CA) to verify transfer and equal loading.  Immunochemical detection of APP was 
completed as follows:  PDVF membranes were blocked with 5% non-fat milk at 4 °C overnight.  
The following day, membranes were first incubated with rabbit anti-APP (CT15) primary 
antibody (Soriano et al., 2001) in blocking solution for 1-2 h at RT on a rocking platform, rinsed 
with Wash Blot, without NaN3, then incubated with HRP-conjugated donkey anti-rabbit 
secondary antibodies (GE Healthcare, Pittsburgh, PA) for 1-2 h at RT on a rocking platform.  
Blots were developed chemifluorescently (Fig. 3.8a,c) as described above for APP/PS-1 studies 
(see section 3.8.1.2). 
3.8.2  Post-Translational Oxidative Modification (Redox Proteomics) 
Membranes analyzed for protein carbonylation or protein-resident 3-NT, two indices of 
oxidative stress, were blocked with 3% BSA in Wash Blot, without NaN3, for 2 h at RT, 
followed by a 2 h incubation with either a rabbit anti-DNP (1:150) [Millipore, Temecula, CA] or 
rabbit polyclonal anti-Nitrotyrosine (1:2000) primary antibody in their respective blocking 
solutions at RT on a rocking platform.  Blots were rinsed three times for 5 min each at RT in 
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Wash Blot, without NaN3, followed by a 1 h incubation with an anti-rabbit IgG alkaline 
phosphatase (1:3000) [Chemicon International, Temecula, CA] secondary antibody in Wash 
Blot, without NaN3, at RT on a rocking platform.  Blots were again washed in Wash Blot, 
without NaN3, five times for 5, 15, 15, 15, and 5 min each at RT on a rocking platform and 
developed colorimetrically with BCIP/NBT in ALP buffer (Fig. 3.8a,b) as described above for 
human IPL (see section 3.8.1.1).  After drying overnight between KIMTECH Kimwipes 
(Kimberly-Clark, Roswell, GA), blots were scanned into Adobe Photoshop 6.0 with a Canon 
CanoScan 8800F scanner and analyzed via PD-Quest 2D-Image Analysis Software 7.2.0 (Bio-
RAD, Hercules, CA), as described below (section 3.9). 
3.9  PD-Quest 7.2.0 Image & Statistical Analysis 
3.9.1  Differential Expression Proteomics 
Spot intensities from SYPRO Ruby
®
-stained 2D-gel images were quantified 
densitometrically after selecting a “master” gel from which to compare and normalize spots from 
all other gels [Tg and Non Tg or Tg PDAPP(J20) and Tg PDAPP(M631L)] according to the total 
spot density (Fig. 3.9).  Differential expression analysis between gels begins with manual 
matching of common spots that could be visualized among all gels, until a significant number of 
matched spots are obtained (≥20 spots).  Then, the PD-Quest software launches an automated 
matching analysis to define spot centers for each gel based on user-defined detection parameters 
of the “master” gel which identify a faint spot, the smallest spot, and the largest spot cluster.  If 
automated matching should fail to identify spots that are obvious to the naked-eye, those spot 
centers can be manually assigned. 
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Figure 3.9 
 
 
 
Figure 3.9 Overview of the proteomics process. After homogenization of tissue, a known 
concentration of sample is subjected to isoelectric focusing (IEF), to separate proteins 
based on isoelectric point (pI), followed by 2D-polyacrylamide gel electrophoresis 
(PAGE) separation of proteins based on molecular migration rate.  Western blotting is 
performed to identify samples with post-translational oxidative modifications, such as 
protein carbonyls or protein-resident 3-nitrotyrosine (3-NT).  After PD-Quest analysis, 
proteins of interest are excised from 2D-gels and subjected to trypsin digestion.  The final 
phase of this process is mass spectrometry and computational analysis of tryptic peptides 
for identification. 
 
 
In order to identify a significant difference in protein expression levels between Tg and 
Non Tg or Tg PDAPP(J20) and Tg PDAPP(M631L) gels, three analysis sets were created using 
the Analysis Set Manger software integrated into PD-Quest to calculate the number of pixels per 
protein spot.  Only those spots with significantly increased or decreased pixelation (i.e., levels of 
protein expression) between Tg and Non Tg or Tg PDAPP(J20) and Tg PDAPP(M631L) groups 
are considered for mass spectrometry identification.  Of these analysis sets, the Quantitative 
Analysis Set recognizes matched spots with 1.5-fold increases or decreases, while the Statistical 
Analysis Set compares matched spots using a Student‟s t-test at 95% confidence, with P<0.05 
considered significant.  Finally, those spots identified by the Boolean Analysis Set as 
overlapping spots from the Quantitative and Statistical sets, were selected for in-gel trypsin 
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digestion (section 3.10) and subsequent mass spectrometric analysis (section 3.11) described 
below.  
3.9.2  Redox Proteomics 
The immunoreactivity of carbonyl and 3-NT post-translational oxidative modifications 
on Western blot images was also quantified densitometrically, as blot spot intensity is 
normalized to the actual protein content as measured by the spot intensity of untransferred, 
SYPRO Ruby
®
-stained, 2D-expression gels [Fig. 3.9] (Desiderio et al., 2006).  Like 2D-
expression gels, carbonyl and 3-NT blots were first quantified densitometrically by selecting a 
“master” blot from which to compare and normalize spots from all other blots [Tg and Non Tg or 
Tg PDAPP(J20) and Tg PDAPP(M631L)] according to spot density.  After selection of a 
“master” blot for each oxidative modification group, differential carbonyl and 3-NT analysis of 
blots by PD-Quest software is identical to that described above (see section 3.9.1).  
However, because significantly modified protein spots on nitrocellulose membranes 
cannot be excised for mass spectrometric analysis, blots require an additional PD-Quest 
comparison to 2D-expression gels, which also ensures immunochemistry results are not due to 
differences in protein expression levels.  To make this comparison, a “High-Match Set” is 
created between the “master” gel and each “master” blot, and PD-Quest analysis between these 
matched sets is completed as described above (see section 3.9.1), with exceptions.  Instead of 
creating analysis sets, raw spot intensity values summarized in a Quantity Table Report are 
exported to a Microsoft Excel spreadsheet where the average intensity for a particular spot on 
each blot is normalized to the average intensity of the same spot on each gel to determine the 
specific protein carbonyl or 3-NT level for that spot.  Those spots with statistically significant 
increases or decreases in protein carbonyl or protein-resident 3-NT levels as calculated by a 
Student‟s t-test at 95% confidence (P<0.05 considered significant) were selected for in-gel 
trypsin digestion (section 3.10) and subsequent mass spectrometric analysis (section 3.11) 
described below. 
3.10  In-Gel Protein Digestion 
In-gel trypsin digestion of selected gel spots was performed as previously described 
(Thongboonkerd et al., 2002).  Protein spots identified as significantly changed from controls 
were excised from SYPRO Ruby
®
-stained 2D-gels with a clean, sterilized blade and transferred 
to Eppendorf microcentrifuge tubes.  Gel plugs were then washed with 0.1 M NH4HCO3 at RT 
for 15 min, followed by incubation with 100% acetonitrile at RT for 15 min.  After solvent 
removal, gel plugs were dried in their respective Eppendorf tubes under a flow hood at RT.  
Plugs were then incubated with for 45 min in 20 μl of 20 mM DTT (Bio-RAD, Hercules, CA) in 
0.1 M NH4HCO3 at 56 
o
C.  The DTT/NH4HCO3 solution was then removed and replaced with 20 
μl of 55 mM IA (Bio-RAD, Hercules, CA) in 0.1 M NH4HCO3, tubes covered with foil, and 
incubated with gentle agitation at RT for 30 min.  The excess IA solution was then removed and 
plugs incubated for 15 min with 200 μl of 50 mM NH4HCO3 at RT.  To the previous solution, 
200 μL of 100% acetonitrile was added and tubes incubated for 15 min at RT.  Subsequent to 
incubation, the solvent was removed, and the gel plugs dried for 30 min at RT under a flow 
hood.  Plugs were rehydrated with 20 ng/μl of modified trypsin (Promega, Madison, WI) in 50 
mM NH4HCO3 with the minimal volume to cover the gel plugs and placed in a shaking incubator 
overnight at 37 
o
C. 
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3.11  Mass Spectrometry (MS) 
Following in-gel digestion of protein spots of interest, salts and contaminants were 
removed from tryptic peptide solutions using C18 ZipTips (Sigma-Aldrich, St. Louis, MO), 
reconstituted to a volume of ~15 µL in a 50:50 water:acetonitrile solution containing 0.1% 
formic acid.  In the event sample volumes became greater than ~15 μl, excess solvent was 
removed using a rotary evaporator (Roto-Vap) set to 37 
o
C.  Tryptic peptide solutions were then 
analyzed with an automated NanoMate electrospray ionization (ESI) [Advion Biosciences, 
Ithaca, NY] Orbitrap XL MS platform (ThermoScientific, Waltham, MA) [Fig. 3.10] at the 
University of Kentucky-Louisville (Louisville, KY).  The Orbitrap MS was operated in a data-
dependent mode whereby the eight most intense parent ions measured in the Fourier transform 
(FT) at 60,000 resolution were selected for ion trap fragmentation with the following conditions:  
injection time 50 ms, 35% collision energy, MS/MS spectra were measured in the FT at 7500 
resolution, and dynamic exclusion was set for 120 s.  Each sample was acquired for a total of 
~2.5 min.  MS/MS spectra were searched against the International Protein Index (IPI) database 
using SEQUEST and results were filtered with the following criteria:  Xcorr > 1.5, 2.0, 2.5, 3.0 
for +1, +2, +3, and +4 charge states, respectively, Delta CN > 0.1, and P-value (protein and 
peptide) < 0.01.  IPI accession numbers were cross-correlated with SwissProt accession numbers 
for final protein identification.  It should be noted that proteins identified with a single peptide 
were kept for further analyses if multiple spectral counts (SC, number of observed MS/MS 
spectra) were observed in a single analysis or if the peptide was identified in a separate analysis 
and workup of the same protein spot. 
 
Figure 3.10 
 
 
Figure 3.10 Schematic diagram of Orbitrap XL mass spectrometer. ESI, Electrospray 
Ionization; HCD, High-energy C-trap Dissociation (adapted from thermo.com).  
 
 
3.12  Immunoprecipitation 
Protein samples (250 μg) were first incubated with a Lysing buffer (5 N NaCl, 1 M Tris-
HCl [pH 7.6], 0.5% NP-40, 4 g/ml leupeptin, 4 g/ml pepstatin, 5 g/ml aprotinin) for 30 min 
at 4 
o
C while continuously agitated, then pre-cleared for 1 h at 4 
o
C while continuously agitated 
with Protein G PLUS/Protein A agarose beads (Calbiochem, La Jolla, CA).  Prior to pre-clearing, 
agarose beads were pre-washed three times with Lysing buffer in a Hettich Mikro 22 R 
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microcentrifuge (Hettich, Beverly, MA) at 3000 rpm for 5 min each at 4 
o
C to remove any 
possible contaminants that would cause non-specific binding of antibodies used for Western blot 
analysis.  Following a 5 min centrifugation in a Hettich Mikro 22 R microcentrifuge (Hettich, 
Beverly, MA) at 3000 rpm, supernatants were transferred to clean Eppendorf microcentrifuge 
tubes, and incubated overnight at 4 
o
C in rabbit anti-Pin-1 (H-123) antibody (1:2000) [Santa 
Cruz Biotechnology Inc., Santa Cruz, CA] with continuous agitation.  The next day (~18 hrs), 
samples were incubated again for 1 h at 4 
o
C while continuously agitated with Protein G 
PLUS/Protein A agarose beads (Calbiochem, La Jolla, CA) that had been pre-washed three times 
with Lysing buffer in a Hettich Mikro 22 R microcentrifuge (Hettich, Beverly, MA) at 3000 rpm 
for 5 min each at 4 
o
C to remove any contaminants.  Subsequent to incubation, protein-associated 
agarose beads were washed five times in RIA buffer (5 N NaCl, 1 M Tris-HCl [pH 7.6], 1% NP-
40) in a Hettich Mikro 22 R microcentrifuge (Hettich, Beverly, MA) at 3000 rpm for 5 min each 
at 4 
o
C.  Following the final wash, beads were prepared for 1D-PAGE separation on Criterion 
XT precast 12% Bis-Tris polyacrylamide gels in a 1 X dilution of XT MES running buffer and 
Western blotted, as described above (see sections 3.7.1 & 3.8.2), using rabbit polyclonal anti-
Nitrotyrosine (1:2000) primary and Amersham ECL anti- rabbit IgG HRP-linked (1:8000) [GE 
Healthcare, Pittsburgh, PA] secondary antibodies, and developed chemifluorescently (Fig. 
3.8a,c; see section 3.8.1.2).  Blots were scanned on a Molecular Dynamics STORM 
Phosphoimager (Ex/Em: 470/618 nm) [Molecular Dynamics, Sunnyvale, CA], and quantified 
using the 1D-component of GE ImageQuant TL software (GE Healthcare, Pittsburgh, PA). 
3.13  Slot-Blot Analysis Oxidative Stress (Oxyblotting) 
3.13.1  Protein Carbonyls (PCO) 
Protein carbonyls are a marker of protein oxidation (see section 3.4.4.1) and were 
determined as previously described (Butterfield and Stadtman, 1997), with exceptions.  Mouse 
brain samples (5 μl) were derivatized at RT for 20 min in 5 μl of 12% SDS and 10 μl 10 mM 
DNPH [Chemicon International, Temecula, CA] in 2 N HCl to denature proteins and form a 
protein-DNP adduct wherever a free carbonyl group is located on a protein (excluding primary 
chain peptide bond carbonyls) [Fig. 3.6].  Samples were then neutralized with 7.5 μl of 
neutralization solution (2 M Tris in 30% [v/v] glycerol; Millipore, Temecula, CA), and 
derivatized samples (250 ng/well) were loaded in duplicate onto a nitrocellulose membrane (0.45 
μm) under vacuum pressure using a Bio-RAD slot-blot apparatus (Bio-RAD, Hercules, CA). 
Membranes were blocked with 3% BSA in Wash Blot, without NaN3, for 1.5 h at RT and 
incubated with a 1:100 dilution of rabbit polyclonal anti-DNP primary antibody (Chemicon 
International, Temecula, CA) in blocking solution for 2 h at RT on a rocking platform.  After 
primary incubation, blots were rinsed three times for 5 min each at RT in Wash Blot, without 
NaN3, and subsequently incubated with anti-rabbit IgG alkaline phosphatase secondary antibody 
(1:8000) in Wash Blot, without NaN3, for 1 h at RT on a rocking platform.  Blots were then 
washed three times for 5 min each at RT in Wash Blot, without NaN3, on a rocking platform and 
developed colorimetrically (Figs. 3.8a,b; 3.11a) as described for Western blotting above (see 
section 3.8).  Finally, blots were dried overnight at RT between KIMTECH Kimwipes 
(Kimberly-Clark, Roswell, GA), scanned with a Hewlett Packard ScanJet 3300C into Adobe 
Photoshop 6.0, and quantified using Scion Image software (PC version of Macintosh-compatible 
NIH Image software).  In order to create a negative control which demonstrates the specificity of 
the anti-DNPH primary antibody for carbonyl groups, derivatization of samples was done with a 
93 
 
25 mM solution of sodium borohydride (NaBH4) in 80% methanol for 30 min at RT in order to 
reduce protein carbonyls to alcohols in lieu of DNPH.  Negative control blots were blotted and 
developed the same as positive control, (i.e., DNPH-derivatized) blots; however, no anti-DNPH 
primary antibody was added to control the specificity of protein carbonyl immunoreactivity 
localization.  
 
Figure 3.11 
 
 
Figure 3.11 Representative slot-blot membranes.  A) Anti-dinitrophenylhydrazone 
(DNP) probed blot for detection of protein carbonyls (PCO).  B) Anti-3-nitrotyrosine (3-
NT) probed blot for detection of protein-resident 3-NT.  C) Anti-protein-bound-4-
hydroxy-2-trans-nonenal (HNE) probed blot for detection of protein-bound HNE.  A)-C) 
All samples loaded in duplicate, horizontally. 
 
 
3.13.2  Protein-Resident 3-Nitrotyroine (3-NT) 
Protein-resident 3-NT levels are used as another marker of oxidative damage (see section 
2.4.4.2), and were determined as previously described (Butterfield and Stadtman, 1997; 
Butterfield et al., 2007b), with few exceptions.  Mouse brain samples (5 μl) were incubated at RT 
for 20 min in 5 μl of 12% SDS and 10 μl of Laemmli buffer (0.125 M Tryzma base [pH 6.8], 4% 
[v/v] SDS, 20% [v/v] glycerol) and diluted with 7.5 μl PBS.  Samples (250 ng) were blotted in 
duplicate, developed colorimetrically (Figs. 3.8a,b; 3.11b) using rabbit polyclonal anti-3-
Nitrotyrosine primary (1:2000) and anti-rabbit IgG alkaline phosphatase secondary (1:8000) 
antibodies, and quantified as described for protein carbonyl blots above (see section 3.13.1).  In 
order to create a negative control which demonstrates the specificity of the anti-3-NT primary 
antibody for nitrated proteins, samples were pretreated with sodium dithionite (Na2S2O4) in order 
to reduce 3-NT residues to amines.  Negative control blots were developed the same as 
untreated, positive control blots.  
3.13.3  Protein-Bound 4-Hydroxy-2-Trans-Nonenal (HNE) 
Levels of protein-bound HNE are used as a marker of lipid peroxidation (see section 
2.4.5.1) and were determined as previously described (Lauderback et al., 2001), with exceptions.  
Mouse brain samples (5 μl) were incubated at RT for 20 min in 5 μl of 12% SDS and 10 μl of 
Laemmli buffer then diluted with 7.5 μl PBS.  Samples (250 ng) were blotted in duplicate, 
developed colorimetrically (Figs. 3.8a,b; 3.11c) using rabbit polyclonal anti-HNE primary 
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(1:2000) [Alpha Diagnostic International Inc., San Antonio, TX] and anti-rabbit IgG alkaline 
phosphatase secondary (1:8000) antibodies, and quantified as described for protein carbonyl 
blots above (see section 3.13.1).  In order to create a negative control which demonstrates the 
specificity of the anti-HNE primary antibody for protein-bound HNE, blots were developed with 
an anti-HNE primary antibody that was pre-absorbed with HNE. 
3.14  Two-Site (Sandwich) Enzyme-Linked Immunosorbant Assay (ELISA) 
The principle behind both ELISA assays used in this dissertation was to quantitate the 
amount of target protein in a given tissue sample using a standard double antibody approach 
combined with colorimetric detection at a wavelength of 450 nm.  A monoclonal antibody to the 
amino (NH2)-terminus of each Aβ sequence (the capture antibody) is pre-coated onto the wells of 
the microtiter strips to which brain homogenate is added, followed by incubation with a second 
monoclonal antibody specific for the carboxy (COOH)-terminus of each Aβ sequence (detection 
antibody).  Addition of an HRP-linked secondary antibody and a substrate solution produces a 
color change whose intensity is directly proportional to the concentration of monoclonal Aβ 
antibody present in the original specimen (Fig. 3.12). 
 
Figure 3.12 
 
 
 
Figure 3.12 Two-site enzyme-linked immunosorbant assay (ELISA).  ELISA is performed 
to quantify the amount of amyloid-β (Aβ) peptides, Aβ(1-40) and Aβ(1-42), using a 
standard double antibody approach combined with colorimetric detection at 450 nm.  The 
capture antibody is pre-absorbed to the microtiter plate and is specific for the NH2-
terminus of Aβ, while the detection antibody is added to detect the COOH-terminus of 
Aβ.  Following incubation with a horseradish peroxidase (HRP)-linked antibody, addition 
of a tetramethylbenzidine (TMB) substrate solution produces a color change whose 
intensity is directly proportional to the concentration of Aβ present. 
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3.14.1  Amyloid-β (Aβ) Peptide Levels in APP/PS-1 Mouse Brain 
In collaboration with Dr. M. Paul Murphy at the University of Kentucky Sanders-Brown 
Center on Aging and Department of Molecular and Cellular Biochemistry (Lexington, KY), the 
solubility of Aβ was measured by a standard three-step serial extraction of Aβ followed by two-
site (sandwich) ELISA, as described previously (Das et al., 2003; Gravina et al., 1995; 
McGowan et al., 2005; Murphy et al., 2007; Suzuki et al., 1994).  This ELISA procedure has 
been demonstrated to quantitatively extract Aβ from brain tissue, and an estimate of this value 
can be determined by adding the amount of the Aβ(1-40) and Aβ(1-42) in all extracts (Das et al., 
2003; Levites et al., 2006; McGowan et al., 2005; Murphy et al., 2007; Roher et al., 1986; 1993).  
APP/PS-1 mouse brain tissue was homogenized with a Polytron homogenizer in DEA buffer (50 
mM NaCl, 0.2% diethylamine; 150 mg/ml wet tissue weight) including a complete protease 
inhibitor cocktail.  Samples were centrifuged at 14,000 × g for 30 min at 4 °C, and the 
supernatant collected, while the pellet was re-extracted by sonication (10 × 0.5 s microtip pulses 
at 100 W) with a Fisher Model 500 Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA) in 
2% SDS.  After a second centrifugation at 14,000 × g for 30 min at RT, the supernatant was 
again collected and the remaining pellet extracted by sonication in 70% formic acid (FA).  The 
final extract was then centrifuged at 100,000 × g for 1 h in a Beckman OptimaMAX tabletop 
ultracentrifuge (TLA55 rotor; Beckman-Coulter, Fullerton, CA).  All sample extracts were stored 
at −80 °C until the time of ELISA assay.  
Thawed SDS-soluble fractions were diluted in AC buffer (0.02 M sodium phosphate 
buffer [pH 7.0], 0.4 M NaCl, 2 mM EDTA, 0.4% Block Ace [AbD Serotec, Raleigh, NC], 0.2% 
BSA, 0.05% CHAPS, 0.05% NaN3), while FA fractions were diluted (at least 1:1) in AC buffer 
following neutralization by 1:20 dilution in TP buffer (1 M Tris base, 0.5 M Na2HPO4).  Pilot 
studies were completed to empirically determine final sample dilutions.  Standard curves were 
prepared in the same buffer as APP/PS-1 samples using known concentrations of synthetic Aβ(1-
40) and Aβ(1-42); all standards and samples were performed at least in duplicate.  ELISA was 
completed with monoclonal Ab9 [specific for human Aβ(1–16)], monoclonal 13.1.1 [end-
specific for human Aβ40; anti-Aβ(35-40)], and monoclonal  21.3.1 [end-specific for human 
Aβ42; anti-Aβ(35-42)] antibodies.  Nunc MaxiSorp ELISA antibody coated plates (1 μg/well in 
PBS) [Thermo Fisher Scientific, Rochester, NY] were blocked with a solution of 2% Block Ace 
(AbD Serotec, Raleigh, NC) and 1% BSA in PBS overnight.  COOH-terminal antibodies were 
used for capture, to avoid an excess of one Aβ peptide from competing away the other, while 
HRP-conjugated Ab9 antibody was used as a detection antibody.  The lower limit of detection 
was approximately 5 pM, with a linear range of about two orders of magnitude (~20–2000 pM).  
After development with tetramethylbenzidine (TMB) reagent (Kirkegaard and Perry 
Laboratories; Gaithersburg, MD), plates were stopped with 6% o-phosphoric acid and read at 
450 nm using a Bio-TEK multi-well plate reader (Bio-TEK, Winooski, VT).  Aβ concentrations 
(pmol/g wet tissue) were calculated using Softmax software (Molecular Devices, Menlo Park, 
CA) by comparing APP/PS-1 sample absorbance with respective Aβ(1-40) and Aβ(1-42) 
standard curves. 
 3.14.2  Amyloid-β (Aβ) Peptide Levels in PDAPP Mouse Brain 
The unused half of PDAPP mouse brains was used to measure the levels of Aβ(1–40) and 
Aβ(1–42) by two-site, solid-phase sandwich ELISA at the Bredesen laboratory of the Buck 
Institute for Age research (Novato, CA), similar to the procedure described for APP/PS-1 
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samples above, with exceptions; Aβ(1–40) and Aβ(1–42) were determined according to the 
manufacturer‟s protocol (Invitrogen, Carlsbad, CA).  Briefly, frozen PDAPP mouse hemi-brains 
were weighed and homogenized in 8 X the samples mass with cold 50 mM Tris (pH 8.0) 
containing 5 M guanidine to achieve 100 mg brain/ml buffer.  Hemi-brain samples were kept on 
ice and sonicated several times until homogeneous in solution, as the buffer was added in stages.  
Homogenates were then rotated at RT for 3-5 h and stored at -20 
o
C until used for ELISA assay.   
For ELISA, homogenate samples were diluted 1:50 in the provided Diluent buffer (15 
mM NaN3) [Invitrogen, Carlsbad, CA] and that same amount of guanidine was also included in 
the standard curve.  ELISA was completed with plates pre-coated with a rabbit monoclonal anti-
Aβ(1-40) or Aβ(1-42) antibody [specific for the NH2-terminus of Aβ(1-40) or Aβ(1-42)] 
(Invitrogen, Carlsbad, CA), incubation with the rabbit monoclonal anti-Aβ(1-40) or anti-Aβ(1-
42) detection antibody [specific for the COOH-terminus of Aβ(1-40) or Aβ(1-42)] (Invitrogen, 
Carlsbad, CA), and incubation with the rabbit anti-IgG HRP secondary antibody (Invitrogen, 
Carlsbad, CA).  After removal of excess HRP-conjugated secondary antibody, a Stabilized 
Chromagen (TMB) substrate solution was added (Invitrogen, Carlsbad, CA), which is acted upon 
by the bound HRP-enzyme to produce a color change.  Microtiter plate absorbance was read at a 
wavelength of 450 nm using a Bio-TEK multi-well plate reader (Bio-TEK, Winooski, VT).  Aβ 
concentrations (pmol/g wet tissue) were calculated using Softmax software (Molecular Devices, 
Menlo Park, CA) by comparing PDAPP sample absorbance with respective Aβ(1-40) and Aβ(1-
42) standard curves. 
3.15  Immunohistochemistry 
Immunohistochemical staining of PDAPP mouse brains was carried out by the Bredesen 
laboratory at the Buck Institute for Age Research (Novato, CA) to fluorescently label Aβ and 
microglia.  Amyloid plaques, comprised mainly of Aβ proteins and microglia, were labeled and 
plaques counted in Non Tg PDAPP (n=6) and Tg PDAPP(M631L) mice (n=6) at 8 months of 
age.  Mice were anesthetized, perfused with saline, and a sagittal hemi-brain from each mouse 
was submersion-fixed in 2% paraformaldehyde.  The fixed brains were processed into paraffin 
and 10 μm coronal sections cut from the area where the hippocampus is readily apparent (bregma 
−2.18) and mounted on charged glass slides (Platinum line; Mercedes Medical, Sarasota, FL).  
Two slides were used for each antibody label for each individual mouse, two sections per slide.  
Both the anti-Aβ (6E10) and the anti-ionized Ca
2+
 binding protein-1 (Iba-1) antibodies require 
that antigen retrieval be performed in 10 mM sodium citrate (pH 6.0) for 5 min at 98 °C.  For 
mouse monoclonal 6E10, endogenous mouse IgG was blocked with chicken anti-mouse (Vector) 
at 1:200 for 1 h in TBST (20 mM Tris base, 137 mM NaCl [pH 7.8], 0.05% Tween-20).  
Blocking of nonspecific antibody binding and all antibody incubations were done in 5% normal 
donkey serum in TBST; and all washes were done in TBST.  Both primary antibodies were 
diluted to 1:500 and incubated overnight at 4 °C.  The secondary antibodies were anti-mouse and 
anti-rabbit AlexaFluor 488 raised in donkey (Invitrogen, Carlsbad, CA).  Labeled sections were 
viewed and imaged at 20 X and 40 X on a Nikon Eclipse E800 fluorescence microscope (Nikon 
Instruments Inc, Melville, NY) using the FITC filter and Nikon Act 1 software (Nikon 
Instruments Inc, Melville, NY).  Plaques were counted only from the molecular layer of the 
hippocampus within the granular cell layer of the CA regions and above the dentate gyrus.  
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3.16  Behavioral Analysis of PDAPP Mice 
Behavioral analysis of PDAPP mice was carried out the Bredesen laboratory at the Buck 
Institute for Age Research (Novato, CA), using the Morris water-maze procedure to test spatial 
memory (Morris, 1984).  According to this procedure, mice are placed into a large circular pool 
of water containing a platform hidden just beneath the surface of the water.  In addition, the 
water is opacified with a non-toxic agent to render the platform virtually invisible to mice, 
eliminating any local cues that would guide animal escape.  Animals are then forced to search for 
an escape from the water (i.e., the platform) by swimming in random search paths throughout the 
pool; cognitively normal mice quickly learn to swim directly towards the platform from any 
starting position around the entire circumference of the pool using spatial memory relative to 
distal cues.  Cognitively impaired mice, however, have degenerate spatial awareness and, 
therefore, take much longer to locate the platform, as they continue to search at random. 
All PDAPP animals had normal motor and visual skills as determined by sensorimotor 
tasks performed before testing.  All groups were assessed for swimming ability with a straight 
water alley (15 cm x 200 cm) containing a submerged (1 cm) 12×12 cm platform 2 days before 
water-maze testing.  All water-maze cognitive tests were performed in a 100 cm diameter tank 
filled with water opacified by the addition of non-toxic paint.  The water was kept at 24 ± 1 °C 
and surrounded by dark walls containing geometric designs that served as distal visual cues.  
During acquisition, each animal was subjected to 3-4 trials per day for 3 days, with a maximum 
of 60 s to find the submerged platform, with 10 min inter-trial intervals.  After 60 s, mice that did 
not find the escape platform were physically guided to it and allowed to remain on the platform 
for 30 s.  A probe trial was performed at the end of training, in which the platform was 
inaccessible.  The time taken by each mouse to locate the platform (latency), their path lengths 
and patterns, the percentage time spent floating and percentage time spent engaged in 
thigmotactic swim (swimming at a distance of ≤10 cm from the tank wall) were monitored.  
Animals were monitored daily and weights recorded weekly.  Performance in all tasks (latency 
to platform, distance swum, swim velocity, time spent in target quadrant, passes through target, 
and thigmotaxis) was recorded by a computer-based video tracking system (HVS Image Analysis 
VP-200, HVS Image, Hampton, UK).  Data were analyzed offline by using HVS Image software 
(HVS Image, Hampton, UK) and processed with Microsoft Excel. 
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CHAPTER 4 
LOSS OF PHOSPHOLIPID ASYMMETRY & ELEVATED BRAIN APOPTOTIC 
PROTEIN LEVELS IN SUBJECTS WITH AMNESTIC MILD COGNITIVE 
IMPAIRMENT & ALZHEIMER DISEASE 
 
4.1  Overview 
Normally, the aminophospholipid phosphatidylserine (PtdSer) is asymmetrically 
distributed on the cytosolic, inner-leaflet of the lipid bilayer of all cells, including neurons.  
However, during oxidative stress, PtdSer is exposed onto the extracellular, outer-leaflet, 
initiating the first stages of an apoptotic process.  PtdSer asymmetry is actively maintained by the 
adenosine triphosphate (ATP)-dependent, membrane-bound translocase flippase, whose function 
is inhibited if covalently bound by lipid peroxidation products, such as 4-hydroxy-2-trans-
nonenal (HNE) and 2-propen-1-al (acrolein), within the bilayer.   In addition, pro-apoptotic 
proteins Bax and caspase-3 have been implicated in the oxidative modification of flippase and/or 
PtdSer, resulting in PtdSer asymmetric collapse, while anti-apoptotic protein Bcl-2 has been 
found to prevent this process.  The present dissertation study investigated loss of PtdSer 
asymmetry in synaptosomes from brain of subjects with Alzheimer disease (AD) and amnestic 
mild cognitive impairment (aMCI), as well as levels of apoptotic factors Bcl-2, Bax, and 
caspase-3.  NBD-PS fluorescence and Western blot analysis suggest that PtdSer outer-leaflet 
exposure is significantly increased in aMCI and AD brain, contributing to the early elevation of 
pro- and anti-apoptotic proteins, and subsequent neuronal cell loss.  Verifying these results were 
not simply due to post-mortem interval (PMI) or freeze-thawing, NBD-PS fluorescence and 
Mg
2+
ATPase (i.e., flippase) activity assays performed on synaptosomes isolated from normal 
mice demonstrated no significant difference in PtdSer exposure as a function of PMI or freeze-
thawing.  Since aMCI is considered a possible transition point between normal cognitive aging 
and probable AD, and is reported to have increased levels of tissue oxidation, results of this 
dissertation study could mark the progression of patients with aMCI into AD.  This study also 
contributes to a model of apoptosis-specific oxidation of phospholipids consistent with the notion 
that PtdSer exposure is required for apoptotic-cell death. 
4.2  Introduction 
Beyond basic structural integrity, phospholipid asymmetry influences the activity of 
membrane receptors and transport proteins (reviewed in Paulusma and Oude Elferink, 2005), 
intra- and extra-cellular signal transduction pathways (Verkleij and Post, 2000), and cellular 
morphology via lipid-protein and protein-protein interactions (Balasubramanian and Schroit, 
2003; Lubin et al., 1981; Schlegel et al., 1985; Wali et al., 1987; Zwaal and Schroit, 1997).  
Therefore, the asymmetric distribution and localization of phospholipids in the cell membrane is 
of physiologic importance and must be actively maintained.  Because phospholipids that 
necessitate equilibration between the two bilayer leaflets do so at slow rates, active transport by 
integral membrane proteins, and, to some extent, vesicle fusion and pinching between 
membranes, is a means by which living cells accelerate this process (reviewed in Sprong et al., 
2001).  In particular, the aminophospholipid PtdSer (Fig. 2.10) is typically sequestered to the 
cytosolic, inner-leaflet of the cell membrane (Bretscher, 1972; Op den Kamp, 1979; Rothman 
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and Lenard, 1977), a distribution that is actively regulated by the ATP-dependent, membrane 
bound, aminophospholipid translocase, flippase, which unidirectionally transports PtdSer, and to 
a much lesser extent, phosphatidylethanolamine (PtdEtn), inward against its concentration 
gradient (Daleke and Huestis, 1985; Daleke and Lyles, 2000; Seigneuret and Devaux, 1984).  In 
the course of asymmetric collapse, however, PtdSer is exposed to the outer-leaflet of the 
membrane, which signals induction of early apoptosis, and is crucial for selective recognition 
and mononuclear phagocytosis of target cells by macrophages and fibroblasts in the periphery, or 
microglia in the brain [see section 2.5.2] (Castegna et al., 2004; Fadok et al., 2001; 1992a; Kagan 
et al., 2003; Tyurina et al., 2004a; 2004b). 
Under normal conditions, collapse of PtdSer asymmetry and subsequent phagocytosis is 
considered a process balancing the rate of cell death to that of cell division, in order to maintain 
cellular homeostasis.  However, previous studies have found an abnormal levels of 
aminophospholipids in AD brain (Prasad et al., 1998), likely due to oxidative stress and damage 
that is inherent to this devastating disease (Aksenov et al., 2001; Butterfield and Lauderback, 
2002; Butterfield et al., 2007a; Castegna et al., 2003; 2002a; Hensley et al., 1995; Lyras et al., 
1997; Markesbery, 1999; Perluigi et al., 2009; Smith et al., 1997; Sultana et al., 2006a; 2006b; 
Varadarajan et al., 2000).  Oxidative stress can lead to an increased production of lipid 
peroxidation products, HNE (Fig. 2.35) and acrolein, within the bilayer [see section 2.4.5] 
(Butterfield and Lauderback, 2002; Butterfield et al., 2002b; 2006c; Lauderback et al., 2001; 
Lovell et al., 2001; Markesbery and Lovell, 1998; Perluigi et al., 2009; Williams et al., 2006) 
that can diffuse from their formation sites and react via Michael addition with flippase, 
covalently binding a critical cysteine residue of its primary structure (Fig. 2.36), thereby causing 
irreversible PtdSer asymmetric collapse (Butterfield and Stadtman, 1997; Castegna et al., 2004; 
Daleke, 2003; Daleke and Lyles, 2000; Paulusma and Oude Elferink, 2005; Tyurina et al., 
2004b).  Moreover, oxidative modification of flippase and/or PtdSer by these reactive alkenals is 
also greatly elevated in the early apoptotic phenotype of mouse models of Aβ pathology 
(Butterfield and Lauderback, 2002; Castegna et al., 2004; Fadok et al., 1992a; Herrmann and 
Devaux, 1990; Kagan et al., 2000; 2003; Markesbery and Lovell, 1998; Mohmmad Abdul and 
Butterfield, 2005). 
Oxidative stress and damage in AD can also initiate apoptosis by disruption of the 
electron transport chain and subsequent release of cytochrome c from mitochondria [see sections 
2.3.4 & 2.5.1] (Ott et al., 2007), both known to play important in vitro and in vivo roles in AD 
neuronal loss (Cras et al., 1995; Honig and Rosenberg, 2000).  Apoptosis is typically modulated 
by both pro- and anti-apoptotic members of the B-cell lymphoma-2 (Bcl-2) family (Pellegrini 
and Strasser, 1999).  Specifically, anti-apoptotic Bcl-2 protein expression has been found 
significantly increased in AD temporal and frontal cortex, blocking PtdSer oxidation and 
apoptotic cell death, while promoting neuronal survival (Engidawork et al., 2001; Fabisiak et al., 
1997; Kitamura et al., 1998b); further indication that PtdSer is essential to the apoptotic process, 
as well as neuronal life and death.  A second Bcl-2 family member is the pro-apoptotic Bcl-2-
associated X protein (Bax), known to compete with Bcl-2, as both proteins can be found 
constitutively expressed in neurons of the central and peripheral nervous systems (Castren et al., 
1994; Oltvai et al., 1993).  Previous studies have shown that in many regions of AD brain such 
as the hippocampus, entorhinal cortex, and frontal and temporal cortices, Bax immunoreactivity 
is increased with the exception of dentate granule hippocampal cells (Giannakopoulos et al., 
1999; Nagy and Esiri, 1997; Tortosa et al., 1998).  Thus, similar to Bcl-2, Bax may also 
indirectly affect PtdSer asymmetry. 
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In addition, other apoptotic factors, such as the aspartate-specific cysteine proteases 
(caspases), which function in both cell disassembly (effectors) and in initiating disassembly in 
response to pro-apoptotic signals [initiators; see section 2.5.1] (Wolf and Green, 1999), may also 
serve to affect PtdSer asymmetry, as activated caspase-3 has been shown to be elevated in 
neurons and astrocytes in AD brain (Su et al., 2001).  Interestingly, PtdSer externalization can be 
found downstream of caspase-3 activation in some cell types under oxidative stress conditions 
(Mandal et al., 2002; Martin et al., 1996; Vanags et al., 1996); in non-neuronal cells, caspase-3 
activation is associated with loss of flippase translocase activity (Mandal et al., 2005).  
Unfortunately, not much is known about PtdSer asymmetry and apoptotic processes with 
respect to aMCI, arguably the earliest form of AD and considered a transition point between 
normal cognitive aging and probable AD (Petersen et al., 1999; Winblad et al., 2004).  Like AD, 
oxidative stress-induced protein and nucleic acid oxidation, lipid peroxidation, and apoptosis, 
leading to loss of synapses and neurons and declining brain function is prominent in aMCI 
(2006b; Butterfield et al., 2006c; 2007b; Keller et al., 2005; Lovell and Markesbery, 2007; 
Markesbery and Lovell, 2007; Markesbery et al., 2005; Reed et al., 2008a; 2008b).  Moreover, 
effector caspase-6 has been shown to be intimately linked to pathological hallmarks of AD in the 
hippocampus of persons with all stages of AD, including MCI and NCI [severely aged, but 
cognitively normal] (Albrecht et al., 2007).  Therefore, the purpose of this study was to 
investigate the hypothesis that PtdSer asymmetry is significantly lost in synaptosomal 
membranes of the inferior parietal lobule (IPL) of subjects with aMCI and AD, due, in part, to 
increased oxidative modification by lipid peroxidation products.  A sequela of this hypothesis is 
that outer-leaflet exposure of PtdSer may also be due to activation of pro-apoptotic proteins in 
aMCI and AD. 
4.3  Experimental Procedures 
All materials and methods used in this study are described in Chapter 3 of this 
dissertation.  Specifically, sections 3.1, 3.2.1, 3.3, 3.4.1, 3.5, 3.6, 3.7.1.1, and 3.8.1.1. 
4.3.1  Statistical Analysis 
All data presented as mean ± standard deviation (S.D.).  All statistical analyses were 
performed using a two-tailed Student's t-test, where P<0.05 was considered significantly 
different from controls. 
4.4  Results 
4.4.1  Detection of Phospholipid Asymmetry in Synaptosomes of Subjects with Amnestic 
Mild Cognitive Impairment (aMCI) & Alzheimer Disease (AD) by NBD-PS Assay 
NBD-PS fluorescence is an indirect method in which to study PtdSer asymmetric 
collapse in AD and aMCI synaptosomes compared to non-diseased, control individuals.  This 
method results in a fluorescence decrease for those samples in which the NBD-PS probe has 
successfully integrated into the bilayer, and has been subsequently exposed onto the outer-leaflet 
where the fluorescent NBD-moiety is quenched by membrane-impermeable sodium dithionite 
(Na2S2O4) [Fig. 3.3].  This technique has a value-added characteristic of addressing potential 
concerns with fluorescent probe access to the inner-leaflet of an unstable system, which would 
create an incorrect interpretation of asymmetric collapse, as highly ionic S2O4
2-
 does not readily 
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diffuse through the membrane (McIntyre and Sleight, 1991).  These results suggest significant 
PtdSer exposure in brain of subjects with aMCI (Fig. 4.1, **P<0.00001) and AD (Fig. 4.1, 
*P<0.0001) compared to respective controls. 
 
Figure 4.1 
 
 
 
Figure 4.1 NBD-PS assay in synaptosomes isolated from the inferior parietal lobule 
(IPL) of subjects with amnestic mild cognitive impairment (aMCI) and Alzheimer disease 
(AD). Phosphatidylserine (PtdSer) outer-leaflet exposure is measured as the percent 
decrease in fluorescence following Na2S2O4 quenching.  Results show a significant 
decrease in NBD-PS fluorescence in both aMCI and AD brain compared to controls, 
suggesting significant loss of PtdSer asymmetry in both diseases.  The control value was 
set to 100%, to which experimental values were compared.  These data, in arbitrary units 
on the ordinate axis, are presented as mean ± S.D.; AD, n=5, *P<0.0001; aMCI, n=5, 
**P<0.00001. 
 
 
4.4.2  Post-Mortem Interval (PMI) Studies in FVB/N Mouse Synaptosomes 
Post-mortem autopsy of patients from the University of Kentucky Rapid Autopsy 
Program of the Alzheimer Disease Clinical Center (UK ADC) usually occurs no more than four 
hours after death in order to preserve brain tissue from further oxidation and degradation (Tables 
3.1 & 3.2).  However, in the short time between death and tissue extraction, it is possible that 
significant alteration of tissue could occur influencing the present AD and aMCI IPL results.  
Moreover, during the freeze-thawing process of samples post-mortem, freeze-fracturing of the 
cell membrane could conceivably occur, potentially causing a significant collapse in PtdSer 
asymmetry that would artifactually alter fluorescence results.  Because PMI studies were focused 
on the effects of post-mortem intervals, in addition to freeze-thawing, 2.8 h and 3.5 h samples 
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obtained from normal FBV/N mice held at ~37 °C post-mortem were compared to fresh (0 h) 
samples as a control.   
4.4.2.1  NBD-PS Fluorescence in FBV/N Mouse Synaptosomes as a Function of Post-
Mortem Interval (PMI) 
NBD-PS fluorescence was conducted as described above for human AD and aMCI IPL 
(see section 4.4.1).  However, mouse synaptosomal NBD-PS data were not analyzed and 
presented as a percentage of control; rather, the average fluorescence signal of each sample set 
was measured, in arbitrary units, and compared to the average 0 h fluorescence signal.  NBD-PS 
results from these mouse synaptosomes suggest no significant PtdSer exposure difference 
between 0 h, 2.8 h, and 3.5 h samples (Fig. 4.2).  It should be noted, however, that during 
synaptosome preparation, one sample of the 2.8 h PMI was irretrievably lost, reducing the 
sample number to n=2 for that PMI.  Thus, these results suggest that significant changes 
observed in aMCI and AD synaptosomes were likely due to oxidative processes inherent in 
aMCI and AD pathology, and are not artifactual in nature.  
 
Figure 4.2 
 
 
Figure 4.2 Post-mortem interval (PMI) NBD-PS assay in synaptosomes isolated from 
brain of normal FVB/N mice.  Outer-leaflet exposure of phosphatidylserine (PtdSer) was 
measured as a decrease in NBD-PS fluorescence signal, compared to 0 h, after quenching 
with Na2S2O4.  Since samples were not compared as a percentage of control, negative 
values are not seen, but graphical interpretation is relatively the same.  Results show no 
significant difference in NBD-PS fluorescence from 0 h to 2.8 h and 3.5 h, suggesting 
results obtained from amnestic mild cognitive impairment (aMCI) and Alzheimer disease 
(AD) NBD-PS assay were resultant from disease progression and not PMI.  A 
fluorescence decrease, compared to 0 h, would denote an increased amount of PtdSer 
exposure.  Data shown in arbitrary fluorescence units on the ordinate axis as mean ± 
S.D.; 0 h, n=3; 2.8 h, n=2; 3.5 h, n=3. 
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4.4.2.2  Mg
2+
ATPase Activity in FBV/N Mouse Synaptosomes as a Function of Post-
Mortem Interval (PMI) 
Mg
2+
ATPase activity was used as an indirect assessment of ATP-dependent, membrane-
bound flippase activity, as highly specific antibodies to flippase have not yet been obtained 
(Auland et al., 1994).  Mg
2+
ATPase activity was performed by measurement of the net amount of 
inorganic phosphate (Pi) formed by functioning Mg
2+
ATPase enzymes within the membrane 
following the hydrolysis of exogenous ATP [Fig. 3.4] (Sadrzadeh et al., 1993).  Present results 
show decreased UV-absorbance (810 nm) in 2.8 h and 3.4 h PMI sample sets compared to 0 h 
PMI samples, denoting an overall decrease in membrane Mg
2+
ATPase activity with PMI that 
was not significant (Fig. 4.3).  This suggests that, although PMI does appear to affect 
Mg
2+
ATPase (i.e., flippase) activity, significant PtdSer asymmetric collapse as measured by 
NBD-PS fluorescence in aMCI and AD brains of PMIs up to 3.4 h was not merely a function of 
PMI, but of disease progression. 
 
Figure 4.3 
 
 
Figure 4.3 Mg
2+
ATPase activity assay in synaptosomes isolated from brain of normal 
FVB/N mice.  Mg
2+
ATPase activity was measured to represent flippase activity.  Results 
only show a significant decrease in enzyme activity from 0 h to 2.8 h, but not from 0 h to 
3.5 h, also suggesting that results obtained from amnestic mild cognitive impairment 
(aMCI) and Alzheimer disease (AD) NBD-PS assay were resultant from disease 
progression and not post-mortem interval (PMI).  Decreased ultraviolet (UV)-absorbance 
(810 nm) compared to 0 h denotes decreased Mg
2+
ATPase activity.  Data shown in 
arbitrary absorbance units on the ordinate axis as mean ± S.D.; 0 h, n=3; 2.8 h, n=2, 
*P<0.04; 3.5 h, n=3.  
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4.4.3 Apoptosis-Related Proteins in Amnestic Mild Cognitive Impairment (aMCI) & 
Alzheimer Disease (AD) Brain 
The following Western blot analyses were conducted in order to investigate the 
relationship between outer-leaflet exposure of PtdSer and activation and/or up-regulation of pro-
apoptotic proteins in aMCI and AD brain.  All apoptosis-related protein data were obtained in 
collaboration with visiting Ph.D. student, Giovanna Cenini (University of Kentucky, Lexington, 
KY). 
4.4.3.1  Bcl-2 levels in Amnestic Mild Cognitive Impairment (aMCI) & Alzheimer 
Disease (AD) Inferior Parietal Lobule (IPL) 
Expression of anti-apoptotic Bcl-2 (26 kDa) was measured by Western blot analysis in 
aMCI and AD IPL compared to non-diseased control subjects, using β-tubulin (50 kDa) as a 
loading control to normalize the amount of protein loaded in each well of the gel (Fig. 4.4a).  
Quantification of band intensities on Western blots showed Bcl-2 protein levels were 
significantly increased in both aMCI (Fig. 4.4b, *P<0.006) and AD (Fig. 4.4c, *P<0.04) brain, 
illustrating a dramatic increase in neuronal apoptotic activity, as early as aMCI, that the brain is 
attempting to combat with increasing levels of anti-apoptotic proteins, such as Bcl-2.  
 
Figure 4.4 
 
 
105 
 
Figure 4.4 Bcl-2 levels in brain from subjects with amnestic mild cognitive impairment 
(aMCI) and Alzheimer disease (AD). Bcl-2 levels were measured by 1D-
polyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western 
blot analysis.  A) Increased band intensity after normalization with β-tubulin represents 
an increase in the amount of Bcl-2 present. B) & C) Graphical analysis of control (C), 
aMCI (M), and AD band intensities, respectively.  Results demonstrate a significant 
increase in Bcl-2 expression levels in both aMCI and AD, suggesting initiation of an 
apoptotic process as early as aMCI.  The control value was set to 100%, to which 
experimental values were compared.  Data are shown in arbitrary units on the ordinate 
axis as mean ± S.D.; aMCI, n=3, *P<0.006; AD, n=3, *P<0.04.  Data obtained in 
collaboration with visiting Ph.D. student, Giovanna Cenini (University of Kentucky, 
Lexington, KY). 
 
 
4.4.3.2  Bax levels in Amnestic Mild Cognitive Impairment (aMCI) & Alzheimer 
Disease (AD) Inferior Parietal Lobule (IPL) 
Expression of pro-apoptotic Bax (21 kDa) in IPL was measured by Western blot analysis 
in brain of subjects with aMCI and AD compared to non-diseased control subjects, using β-
tubulin (50 kDa) as a loading control to normalize the amount of protein loaded in each well of 
the gel (Fig. 4.5a).  Western blot analysis shows Bax protein levels to be significantly increased 
in aMCI brain compared to controls (Fig. 4.5b, *P<0.03), but significantly decreased in AD (Fig. 
4.5c, *P<0.005).  In addition, the ratios of Bax to Bcl-2 in aMCI and AD were 2.38 and 0.23, 
respectively.  Like the Bcl-2 assay, these results also suggest a dramatic increase in neuronal 
apoptotic activity, beginning early in disease progression with aMCI.  Interestingly, however, 
Bax levels in AD brain do not follow this trend, in that decreased Bax levels, as well as Bax/Bcl-
2 ratios, suggest an increase in neuronal resistance to apoptosis with disease progression. 
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Figure 4.5 
 
 
 
Figure 4.5 Bax levels in brain from subjects with amnestic mild cognitive impairment 
(aMCI) and Alzheimer disease (AD). Bax levels were measured by 1D-polyacrylamide 
gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot analysis.  A) 
Increased band intensity after normalization with β-tubulin represents an increase in the 
amount of Bax present. B) & C) Graphical analysis of control (C), aMCI (M), and AD 
band intensities, respectively.  Results demonstrate a significant increase in Bax 
expression levels in aMCI and a significant decrease in AD, suggesting initiation of an 
apoptotic process as early as aMCI.  The control value was set to 100%, to which 
experimental values were compared.  Data are shown in arbitrary units on the ordinate 
axis as mean ± S.D.; aMCI, n=3, *P<0.03; AD, n=3, *P<0.005.  Data obtained in 
collaboration with visiting Ph.D. student, Giovanna Cenini (University of Kentucky, 
Lexington, KY). 
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4.4.3.3  Caspase-3 Levels in Amnestic Mild Cognitive Impairment (aMCI) & 
Alzheimer Disease (AD) Inferior Parietal Lobule (IPL) 
Pro-apoptotic caspase-3 is synthesized as an inactive, cytosolic precursor (36 kDa), 
which upon receiving an apoptotic signal, is activated and subsequently cleaved into two active 
subunits, p18 (20 kDa; amino acids 29-175) and p12 (18 kDa; amino acids 176-277).  The anti-
caspase-3 primary antibody was used to recognize and probe both inactive precursor and 
activated caspase-3 fragments on Western blots, while β-tubulin (50 kDa) was used to normalize 
(Fig. 4.6a).  Interestingly, only the band relative to the inactive caspase-3 precursor was 
recognized, while bands relative to either activated fragment were not detected (Fig. 4.6a).  
Quantification of procaspase-3 immunoreactivity on blots revealed a significant increase in the 
levels of this precursor in both aMCI (Fig 4.6b, *P<0.02) and AD (Fig. 4.6c, *P<0.04) compared 
to non-diseased control subjects, confirming both Bcl-2 and Bax results, which demonstrate 
escalating levels of neuronal apoptosis in aMCI and AD brain.  
 
Figure 4.6 
 
 
 
Figure 4.6 Caspase-3 levels in brain from subjects with amnestic mild cognitive 
impairment (aMCI) and Alzheimer disease (AD). Caspase-3 levels were measured by 
1D-polyacrylamide gel electrophoresis (1D-PAGE) [75 μg/lane] and subsequent 
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Western blot analysis.  A) Increased band intensity after normalization with β-tubulin 
represents an increase in the amount of procaspase-3 present. B) & C) Graphical 
analysis of control (C), aMCI (M), and AD band intensities, respectively.  Results 
demonstrate a significant increase in procaspase-3 expression levels in both aMCI and 
AD, suggesting initiation of an apoptotic process as early as aMCI.  The control value 
was set to 100%, to which experimental values were compared.  Data are shown in 
arbitrary units on the ordinate axis as mean ± S.D.; aMCI, n=3, *P<0.02; AD, n=3, 
*P<0.04.  Data obtained in collaboration with visiting Ph.D. student, Giovanna Cenini 
(University of Kentucky, Lexington, KY). 
 
 
4.5  Discussion 
The present dissertation study investigated synaptosomal PtdSer asymmetry and its 
relation to apoptotic protein expression levels by fluorescent assay and immunoblotting, in order 
to determine the role of apoptosis-specific oxidation of PtdSer and/or flippase in the progression 
of aMCI into AD.  Results obtained from the NBD-PS assay demonstrated a significant decrease 
in fluorescence in both aMCI and AD IPL brain samples compared to non-diseased control 
subjects (Fig. 4.1), which suggests that PtdSer outer-leaflet externalization may be an important 
contributor to neurodegeneration found in AD brain and, notably, a potential link to those 
patients with aMCI that eventually develop AD.  
An investigation into elevated exposure of PtdSer to the outer-leaflet of the membrane 
bilayer in aMCI and AD brain begins with oxidative stress and damage, predominant in the 
progression of both aMCI and AD disease states (Aksenov et al., 2001; Butterfield and 
Lauderback, 2002; Butterfield et al., 2002b; 2007a; 2006b; 2006c; 2007b; Castegna et al., 2003; 
2002a; Hensley et al., 1995; Keller et al., 2005; Lauderback et al., 2001; Lovell and Markesbery, 
2007; Lovell et al., 2001; Lyras et al., 1997; Markesbery, 1999; Markesbery and Lovell, 1998; 
2007; Markesbery et al., 2005; Perluigi et al., 2009; Reed et al., 2008a; 2008b; Smith et al., 
1997; Sultana et al., 2006a; 2006b; Varadarajan et al., 2000; Williams et al., 2006).  Oxidative 
stress contributes to the production of lipid peroxidation products, HNE (Fig. 2.35) and acrolein, 
within the bilayer of apoptotic cells that can interfere with PtdSer asymmetry by eliciting protein 
oxidation and lipid peroxidation via free radical mechanisms of their own (Butterfield and 
Lauderback, 2002; Butterfield et al., 2002b; 2006c; Castegna et al., 2004; Lauderback et al., 
2001; Lovell et al., 2001; Markesbery and Lovell, 1998; Mohmmad Abdul and Butterfield, 2005; 
Perluigi et al., 2009; Prasad et al., 1998; Williams et al., 2006).  In particular, these neurotoxic 
alkenals likely affect PtdSer asymmetry by diffusing from their formation sites and forming 
Michael adducts with the translocase flippase, covalently binding a critical cysteine residue of 
this transporter‟s primary structure [Fig. 2.36] (Butterfield and Stadtman, 1997; Castegna et al., 
2004; Daleke, 2003; Daleke and Lyles, 2000; Paulusma and Oude Elferink, 2005; Tyurina et al., 
2004b), establishing a definite relationship between asymmetric collapse and lipid peroxidation 
in AD. 
In addition, oxidative stress is also known to initiate apoptosis, which plays an important 
role in neuronal loss both in vitro and in vivo in AD (Cotman and Anderson, 1995; Cras et al., 
1995; Honig and Rosenberg, 2000; MacGibbon et al., 1997; Smale et al., 1995).  Unfortunately, 
however, not much is known about apoptotic pathways in aMCI to date.  Several previous 
studies have demonstrated increased anti-apoptotic Bcl-2 expression in the hippocampus and 
entorhinal cortex of AD brains (Satou et al., 1995; Su et al., 1996).  Congruent with these 
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studies, present Western blot results conducted in human IPL illustrate basal Bcl-2 levels to be 
significantly increased in AD (Fig. 4.4a,c), and for the first time, in aMCI brain (Fig. 4.4a,b).  
This up-regulation of anti-apoptotic Bcl-2 can be interpreted as a compensatory response elicited 
by neurons in an attempt to resist increasing apoptotic activity and eventual cell death in aMCI 
and AD brain.  Moreover, because apoptotic PtdSer externalization is reportedly blocked by Bcl-
2 (Fabisiak et al., 1997), it is likely this neuroprotective response is an attempt to prevent the 
oxidative modification of PtdSer and/or flippase and subsequent apoptotic-cell phagocytosis. 
Like Bcl-2, pro-apoptotic Bax protein levels are also significantly increased in aMCI 
brain (Fig. 4.5a,b), confirming a dramatic increase in apoptotic activity that neurons are actively 
trying to moderate.  In contrast, however, the present study demonstrated a significant decrease 
in Bax levels in AD IPL (Fig. 4.5a,c), although previous studies have shown increased Bax 
immunoreactivity in many regions of AD brain, such as the hippocampus, entorhinal cortex, and 
frontal and temporal cortices, with the exception of dentate granule hippocampal cells 
(Giannakopoulos et al., 1999; Nagy and Esiri, 1997; Tortosa et al., 1998).  It is possible that 
present results in human IPL suggest a dynamic involvement of Bax in the earliest stages of AD 
in this particular brain region that is attenuated later in disease progression due to a relative 
neuronal resistance to apoptosis.  For instance, pro-apoptotic Bax is known to compete with Bcl-
2 as increased levels of Bax can induce cell death, while increased levels of Bcl-2 prevent it 
(Oltvai et al., 1993).  Evidence supporting the notion that the pro-apoptotic system in AD IPL is 
progressively neutralized by the anti-apoptotic system is demonstrated by the higher levels of 
Bcl-2 found in AD IPL compared to aMCI IPL (Figs. 4.4; 4.5).   
Additionally, latent and active caspase-3 immunoreactivity was investigated in this 
dissertation study because of their critical involvement in PtdSer externalization and apoptosis 
(Mandal et al., 2002; Nicholson, 1999).  While the antibody used in this study should have 
recognized both precursor and active fragments of caspase-3 if present in aMCI and/or AD IPL, 
only a signal correlating to increased procaspase-3 levels was detected by Western blot in both 
aMCI and AD samples (Fig. 4.6).  Although activated caspase-3 fragments, p18 and p12, are 
found only in cells undergoing apoptosis (Nicholson et al., 1995), present results do not 
necessarily indicate a lack of apoptosis in either aMCI or AD IPL brain, but rather they suggest 
that levels of key components of the apoptotic system are altered and may be the initial cause of 
neuronal loss.  Unfortunately, the relative contribution of apoptosis to neuronal cell loss in AD 
brain is difficult to assess due to the chronic nature of the process.  While some neurons exhibit 
morphological features of apoptosis, many degenerating neurons do not, indicating apoptosis is 
not the only mechanism of neurodegeneration in AD (Su et al., 1994), or even aMCI.  Detection 
of increased procaspase-3 in the current study is congruent with previous studies showing loss of 
flippase translocase activity and subsequent PtdSer externalization downstream of caspase-3 up-
regulation and activation under oxidative stress conditions (Mandal et al., 2002; 2005; Martin et 
al., 1996; Nicholson, 1999; Vanags et al., 1996).  These studies demonstrate that excessive outer-
leaflet exposure of PtdSer in erythrocytes, as well as loss of flippase activity, can be blocked by 
pretreatment with a caspase-3 inhibitor prior to oxidation (Mandal et al., 2002).  Such findings 
imply PtdSer oxidation and subsequent exposure is an intrinsic feature of the apoptotic process 
due to flippase inactivation (Kagan et al., 2002).  
Apart from the factors described above, other considerations could conceivably 
contribute to the loss of PtdSer asymmetry observed in aMCI and AD IPL in the current study.  
For example, flippase has a known sensitivity to the cellular influx of Ca
2+
, in that its 
translocating activity is significantly affected at [Ca
2+
]i of 0.2 μM or higher (Bitbol et al., 1987; 
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Daleke, 2003).  Furthermore, HNE and acrolein can also disrupt Ca
2+
 homeostasis, again 
interfering with PtdSer asymmetry by eliciting protein oxidation and lipid peroxidation on their 
own (Castegna et al., 2004; Mohmmad Abdul and Butterfield, 2005).  However, it is unlikely 
that elevated Ca
2+
 is the chief contributor to asymmetric collapse as previous studies indicate that 
in the presence of BAPTA AM (a Ca
2+
 chelator), acrolein can still induce significant loss of 
flippase activity and PtdSer externalization (Castegna et al., 2004).  In addition to intracellular 
Ca
2+
 levels, PtdSer asymmetry can also be affected by oxidative stress-induced changes in 
membrane cholesterol, elevated levels of amyloid-β peptide (Aβ), and aging (Lopez-Revuelta et 
al., 2007; Wood et al., 2003; 2002). 
Cholesterol is a physiochemical modulator of the lipid bilayer (Fig. 2.12) that affects 
multiple membrane functions (see section 2.2), including its susceptibility to oxidative stress 
(Lopez-Revuelta et al., 2007), control of Aβ synthesis, and interactions between Aβ and neuronal 
membranes (Eckert et al., 2003).  A previous study by Lopez-Revuelta et al. (2007) suggests that 
cholesterol depletion promotes oxidative stress-induced externalization of PtdSer associated with 
significant inhibition of flippase activity and increased uptake of altered cells by macrophages in 
the periphery (Lopez-Revuelta et al., 2007).  Moreover, diminishing membrane cholesterol levels 
could contribute to oxidative stress and neurodegeneration induced by increased production of 
small, soluble aggregates of Aβ(1-42) that elicit their neurotoxic effects by inserting into the 
bilayer [Fig. 2.52] (Butterfield et al., 2007a; Drake et al., 2003a; Kanski et al., 2002; Klein, 
2006; Lambert et al., 1998; Schubert et al., 1995; Selkoe, 2001b).  PtdSer asymmetric collapse 
has been reported to be caused by Aβ(1-42), a process that can be inhibited by antioxidants [see 
section 2.2.4.6] (Mohmmad Abdul and Butterfield, 2005).  Thus, cholesterol asymmetry and 
Aβ(1-42)-induced oxidative stress could also contribute to the loss of PtdSer asymmetry 
observed in aMCI and AD brain in the present study.  However, it is important to note that 
although many different parameters may contribute to PtdSer asymmetric collapse in AD and 
aMCI brain, all studies converge on the notion that oxidative-inactivation of flippase is a central 
cause.  
Results reported in this dissertation study represent the first investigation of aMCI PtdSer 
asymmetry and its relation to apoptotic-factor expression to date, and are consistent with the 
concept that oxidative modification of PtdSer and/or flippase occurred in the IPL of subjects with 
aMCI and AD causing the collapse of PtdSer inner-leaflet asymmetry and eventual neuronal cell 
death.  These findings also suggest that oxidative stress not only increases the production of lipid 
peroxidation products, HNE and acrolein in the bilayer, but also levels of pro- and anti-apoptotic 
proteins that affect PtdSer asymmetry, thereby causing neuronal death as early as aMCI.  By 
looking at both disease stages, we can conclude that PtdSer outer-leaflet exposure is an important 
link to those patients with aMCI that eventually develop full-onset AD, in accordance with the 
model of apoptosis-specific oxidation of phospholipids that confirms PtdSer exposure is required 
for apoptotic-cell phagocytosis in aMCI and AD brain.  Furthermore, it is crucial that flippase 
activity be highly maintained in order to prevent premature PtdSer exposure, early apoptosis, and 
subsequent neurodegeneration.  Once flippase-specific antibodies become available, we will be 
able to directly examine this particular translocase apart from similar integral membrane 
transporters, as well as its response to oxidation phenomena apart from PtdSer. 
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CHAPTER 5 
AGE-RELATED LOSS OF PHOSPHOLIPID ASYMMETRY IN APP
NLh
/APP
NLh
 x PS-
1
P264L
/PS-1
P264L
 HUMAN DOUBLE KNOCK-IN MICE:  RELEVANCE TO ALZHEIMER 
DISEASE 
 
5.1  Overview 
Using brain from APP
NLh
/APP
NLh
 x PS-1
P246L
/PS-1
P246L
 human double knock-in (APP/PS-
1) mice, this dissertation study examined whether phosphatidylserine (PtdSer) asymmetry is 
significantly altered in an age-dependent manner due to oxidative stress, toxic amyloid-β peptide 
(1-42) [Aβ(1-42)] oligomer production, and/or apoptosis.  Annexin V (AV) and NBD-PS 
fluorescent assays examined PtdSer exposure with age in synaptosomes of wild-type (WT) and 
APP/PS-1 mice, while Mg
2+
ATPase activity was determined in order to correlate PtdSer 
asymmetry changes with activity of flippase, the adenosine triphosphate (ATP)-dependent, 
membrane-bound PtdSer translocase.  AV and NBD-PS assays both demonstrated significant 
PtdSer exposure beginning at 9 months of age compared to 1 month-old WT controls, a trend 
that was augmented in APP/PS-1 synaptosomes.  Decreasing Mg
2+
ATPase activity confirmed 
that the age-related exposure of PtdSer to the outer-leaflet of the lipid membrane is likely due to 
declining flippase activity, which is more prominent in APP/PS-1 brain.  Two-site (sandwich) 
enzyme-linked immunosorbant assay (ELISA) on sodium dodecyl sulfate (SDS)- and formic 
acid (FA)-soluble APP/PS-1 brain fractions was completed in order to compare levels of soluble 
and insoluble Aβ(1-40) and Aβ(1-42) with age-related trends exhibited in AV, NBD-PS, and 
Mg
2+
ATPase assays.  ELISA assay revealed a significant increase in both SDS- and FA-soluble 
Aβ(1-40) and Aβ(1-42) with age, consistent with PtdSer and flippase assay trends.  Finally, the 
levels of both latent and active forms of caspase-3 were measured by Western blot to further 
examine the relationship between PtdSer exposure and pro-apoptotic factor expression, as PtdSer 
exposure is known to be affected by caspase-3.  Western blot analysis revealed an increase in 
both active fragments of caspase-3 with age, while levels of procaspase-3 gradually decreased.  
These results are discussed with relevance to loss of PtdSer asymmetry and consequent 
neurotoxicity in Alzheimer disease (AD) brain. 
5.2  Introduction 
AD is a largely sporadic, age-associated neurodegenerative disorder that can be 
pathologically characterized by the appearance of neurofibrillary tangles and neuritic plaques, 
elevated oxidative stress and damage to brain proteins, lipids, and nucleic acids, and eventual 
synapse and neuronal cell loss, all of which culminate into progressive cognitive decline (see 
section 2.6).  However, in rare cases this disease can be inherited as familial AD (FAD), which is 
caused by autosomal dominant mutations in the amyloid precursor protein [APP] (Goate et al., 
1991) or presenilin (PS) genes 1 and/or 2 (Citron et al., 1992; Cruts et al., 1998; Scheuner et al., 
1996; Sturchler-Pierrat et al., 1997), a mutation in PS-1 being more aggressive.  FAD produces 
the same clinical and pathological consequences as sporadic forms of AD, but at a much earlier 
age of onset [~30 years old] (Citron et al., 1992; Scheuner et al., 1996; Sturchler-Pierrat et al., 
1997; Wisniewski et al., 1998).  Because presenilins are involved in APP processing (Selkoe et 
al., 1996), mutations in APP and PS-1 or PS-2 result in the increased production of pathologic 
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amyloid-β peptides (1-40) [Aβ(1-40)] and (1-42) [Aβ(1-42)] (Figs. 2.51; 2.53) (Borchelt et al., 
1997; Cai et al., 1993; Oyama et al., 1998; Scheuner et al., 1996).  In particular, it is the longer, 
more hydrophobic Aβ(1-42) that is toxic in AD (Drake et al., 2003a; Lambert et al., 1998; 
Mattson, 1997), as it is considerably more prone to oligomerization and subsequent fibril 
formation than the more abundantly produced Aβ(1-40) (Burdick et al., 1992; Jarrett et al., 
1993), and represents the main component of neuritic plaques [see section 2.6.2] (Selkoe, 2001b; 
Wirths et al., 2006). 
Oxidative stress-induced lipid peroxidation in AD and FAD disrupts cellular homeostasis 
by interfering with a variety of processes (Butterfield and Lauderback, 2002; Lauderback et al., 
2001), such as phospholipid asymmetry in the cell membrane (Castegna et al., 2004; Mohmmad 
Abdul and Butterfield, 2005).  In particular, the aminophospholipid PtdSer (Fig. 2.10) is 
normally sequestered to the cytosolic, inner-leaflet of the lipid bilayer (Bretscher, 1972; Op den 
Kamp, 1979; Rothman and Lenard, 1977) by the ATP-dependent, membrane bound, 
aminophospholipid translocase, flippase, which unidirectionally transports PtdSer, and to a lesser 
extent, phosphatidylethanolamine (PtdEtn), inward against its concentration gradient (Daleke 
and Huestis, 1985; Daleke and Lyles, 2000; Seigneuret and Devaux, 1984).  However, collapse 
of PtdSer asymmetry can be induced by lipid peroxidation products, 4-hydroxy-2-trans-nonenal 
(HNE) [Fig. 2.36] and/or 2-propen-1-al [acrolein] (Butterfield et al., 2006c; Lauderback et al., 
2001; Lovell et al., 2001; Markesbery and Lovell, 1998), within the bilayer that expose PtdSer to 
the outer-leaflet, signaling the first stages of an apoptotic process and for selective recognition 
and mononuclear phagocytosis of dying cells [see section 2.5] (Castegna et al., 2004; Fadok et 
al., 2001; 1992a; Kagan et al., 2003; Tyurina et al., 2004a; 2004b). 
In the same way, toxic Aβ(1-42) oligomers can also initiate lipid peroxidation events 
during AD and FAD progression (Butterfield et al., 2007a; Kanski et al., 2002; Lambert et al., 
1998; Schubert et al., 1995; Selkoe, 2001b; Wirths et al., 2006) by integrating into the membrane 
and/or binding to its surface (Hertel et al., 1997; Kayed et al., 2004; McLaurin and Chakrabartty, 
1997) and being stabilized by the very phospholipids that comprise the majority of the membrane 
itself [Fig. 2.52] (Johansson et al., 2007b; Martins et al., 2008).  For example, Aβ(1-42)-induced 
lipid peroxidation can disrupt phosphatidylinositol-4,5-bisphosphate metabolism (Berman et al., 
2008), increase bilayer conductance by altering its dielectric structure (Sokolov et al., 2006), and 
increase bilayer permeability (Arispe and Doh, 2002; Demuro et al., 2005; Kayed et al., 2004; 
Muller et al., 1995).  Consequently, oligomeric Aβ(1-42) could be a major contributor to the 
oxidative stress and damage observed in AD and FAD by augmenting lipid peroxidation events, 
indexed by elevated levels of HNE and acrolein, and disrupting PtdSer distribution (Figs. 2.52; 
2.54; 2.55). 
Aβ(1-42)-induced oxidative stress can also elevate the levels of apoptosis and neuronal 
cell death by increasing pro-apoptotic factor expression, including the aspartate-specific cysteine 
protease, caspase-3.  Specifically, elevated levels of activated caspase-3 immunoreactivity have 
been found in neurons and astrocytes of subjects with AD (Su et al., 2001).  In addition, PtdSer 
outer-leaflet externalization and loss of flippase translocating activity has been found to occur 
downstream of caspase-3 activation in erythrocytes undergoing oxidative stress (Mandal et al., 
2002; 2005; Martin et al., 1996; Vanags et al., 1996).  Thus, it can be concluded that PtdSer 
extracellular exposure could be the result of one or more factors in AD and FAD brain either 
working alone or in concert to negatively affect cellular homeostasis. 
The present dissertation study investigated PtdSer asymmetry in brain of APP
NLh
/APP
NLh
 
x PS-1
P246L
/PS-1
P246L
 human double mutant knock-in mice (APP/PS-1) that are known to deposit 
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Aβ(1-42) in an age-dependent manner beginning at 9 months, with neuritic plaques developing at 
12 months (Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).  Synaptosomes 
prepared from brain isolated from wild-type (WT) and APP/PS-1 mice were examined in an age-
dependent manner using AV and NBD-PS fluorescent assays to test the hypothesis that PtdSer 
asymmetry is significantly altered in the brain of this mouse model of Aβ pathology, together 
with age-related increases in Aβ(1-42).  Two-site sandwich ELISA on SDS- and FA-soluble 
brain fractions of APP/PS-1 mice was conducted in order to correlate soluble and insoluble 
Aβ(1-40) and Aβ(1-42) levels with possible age-related trends ascertained from AV and NBD-
PS fluorescent assays.  In addition, Mg
2+
ATPase activity was determined to compare any 
changes observed in PtdSer asymmetry with flippase activity, while Western blotting was 
employed to investigate how PtdSer asymmetry and flippase activity are affected by the levels of 
latent and active forms of pro-apoptotic caspase-3.   
5.3  Experimental Procedures 
All materials and methods used in this study are described in Chapter 3 of this 
dissertation.  Specifically, sections 3.2.2, 3.3-3.6, 3.7.1.1, 3.8.1.2, and 3.14.1. 
5.3.1  Statistical Analysis 
All data in this dissertation study are presented as mean ± standard error of the means 
(S.E.M.) and analyzed via GraphPad Prism 5.0 software for Windows (San Diego, CA).  In one-
variable experiments, one-way analysis of the variants (ANOVA) was used to determine the 
effect(s) of WT mouse age on PtdSer asymmetry, Mg
2+
ATPase activity, and caspase-3 levels 
followed by a Tukey post-hoc analysis to evaluate the significance of differences between group 
means.  In two-variable experiments, two-way ANOVA was used to determine the effect(s) of 
age and WT or APP/PS-1 genotype on PtdSer asymmetry, Mg
2+
ATPase activity, and caspase-3 
levels followed by Bonferroni's post-hoc analysis to evaluate the significance of differences 
between group means.  P<0.05 was considered significant for all studies. 
5.4  Results  
5.4.1  Sodium Dodecyl Sulfate (SDS)-Soluble Aβ(1-40) & Aβ(1-42) Levels as a Function 
of Age in APP/PS-1 Mouse Brain  
Two-site sandwich ELISA analysis of SDS-soluble Aβ(1-40) and Aβ(1-42) levels was 
obtained in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, KY).  
Brain from 3, 6, 9, and 12 month-old APP/PS-1 mice were compared to brains from 1 month-old 
APP/PS-1 mice as a control, as these APP/PS-1 mice are known to have significantly more 
Aβ(1-40) and Aβ(1-42) than WT mice at all ages (Anantharaman et al., 2006; Murphy et al., 
2007; Reaume et al., 1996; Siman et al., 2000).  Current results demonstrate a significant age-
dependent increase in both SDS-soluble Aβ(1-40) and Aβ(1-42) that begins at 1 month-old, 
although values are masked by y-axis scaling (Fig. 5.1).  The age-related increase in Aβ(1-40) 
and Aβ(1-42) levels can be observed to begin at 3 months of age, although not significant, (Fig. 
5.1), and continues to rise 500-fold in Aβ(1-40) and 300-fold in Aβ(1-42) at 12 months of age 
relative to 1 month-old mice [Fig. 5.1a, Aβ(1-40), ***P<0.001; Fig. 5.1b, Aβ(1-42), 
***P<0.001].  Moreover, the levels of Aβ(1-40) are slightly higher than Aβ(1-42) at all ages, 
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consistent with the fact that Aβ(1-40) is produced in greater abundance (Burdick et al., 1992; 
Jarrett et al., 1993). 
 
Figure 5.1 
 
 
 
Figure 5.1 Soluble amyloid-β (Aβ) load in sodium dodecyl sulfate (SDS)-fractions of 
aging APP/PS-1 mouse brain.  Soluble Aβ(1-40) and Aβ(1-42) levels in brain from 1, 3, 
6, 9, and 12 month-old APP/PS-1 mice were quantified (pmol/g wet tissue) by enzyme-
linked immunosorbant assay (ELISA).  Results demonstrate a significant age-dependent 
increase in soluble A) Aβ(1-40) and B) Aβ(1-42) compared to respective 1 month-old 
APP/PS-1 controls, which suggests soluble, toxic Aβ species induce early oxidative stress 
and subsequent PtdSer outer-leaflet exposure.  A) & B) Data are presented as mean ± 
S.E.M. and significance assessed by one-way ANOVA followed by a Tukey post-hoc 
analysis; ***P<0.001.  1 month-old, n=23; 3, 6, 9, and 12 months-old, n=5.  Data 
obtained in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, 
KY). 
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5.4.2  Formic Acid (FA)-Soluble Aβ(1-40) & Aβ(1-42) Levels as a Function of Age in 
APP/PS-1 Mouse Brain  
Two-site sandwich ELISA analysis of FA-soluble Aβ(1-40) and Aβ(1-42) levels was 
obtained in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, KY).  
Brain from 3, 6, 9, and 12 month-old APP/PS-1 mice were compared to brains from 1 month-old 
APP/PS-1 mice as a control, as WT mice do not produce significant amounts of insoluble Aβ(1-
40) or Aβ(1-42) at any age (Anantharaman et al., 2006; Murphy et al., 2007; Reaume et al., 
1996; Siman et al., 2000).  These results demonstrate an age-dependent increase in FA-soluble 
Aβ(1-40) and Aβ(1-42) [Fig. 5.2] compared to 1 month-old APP/PS-1 control mice, that begins 
at 3 months-old for Aβ(1-42) [Fig. 5.2b], although not significantly.  Levels of insoluble Aβ(1-
42) continue to rise significantly 100-fold at 12 months of age (Fig. 5.2b, **P<0.01), while 
insoluble Aβ(1-40) levels do not begin this age-related increase until 6 months of age (Fig. 5.2a).  
Most notably, the amount of FA-soluble Aβ(1-42) is at all ages greater than that of Aβ(1-40), 
which can be attributed to Aβ(1-42) being considerably more prone to and faster at 
oligomerization and subsequent fibril formation than the more abundantly produced Aβ(1-40) 
(Burdick et al., 1992; Jarrett et al., 1993).    
 
Figure 5.2 
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Figure 5.2 Insoluble amyloid-β (Aβ) load in formic acid (FA)-fractions of aging APP/PS-
1 mouse brain.  Insoluble Aβ(1-40) and Aβ(1-42) levels in brain from 1, 3, 6, 9, and 12 
month-old APP/PS-1 mice were quantified (pmol/g wet tissue) by enzyme-linked 
immunosorbant assay (ELISA).  Results demonstrate a significant age-dependent 
increase in insoluble A) Aβ(1-40) and B) Aβ(1-42) compared to respective 1 month-old 
APP/PS-1 controls, suggesting that soluble Aβ is most likely associated with the 
observed age-dependent collapse in phosphatidylserine (PtdSer) asymmetry, and not the 
insoluble, plaque-deposited species.  A) & B) Data are presented as mean ± S.E.M. and 
significance assessed by one-way ANOVA followed by a Tukey post-hoc analysis; 
*P<0.05, **P<0.01.  1 month-old, n=23; 3, 6, 9, and 12 months-old, n=5.  Data obtained 
in collaboration with Dr. M. Paul Murphy (University of Kentucky, Lexington, KY). 
 
 
5.4.3  Annexin V (AV) Fluorescence in Synaptosomes from Brain of Wild-Type (WT) & 
APP/PS-1 Mice 
In order to assess the effects of normal brain aging on PtdSer outer-leaflet exposure, 
synaptosomes extracted from whole brain of 1 month-old WT mice were used as a control to 
compare synaptosomes isolated from whole brain of 6, 9, and 12 month-old WT mice.  Present 
results demonstrate a significant age-related increase in AV fluorescence beginning at 6 months-
old (Fig. 5.3a, *P<0.05), an increase that remains significant as mice age to 9 and 12 months-old 
(Fig. 5.3a, 9 months-old, ***P<0.001; 12 months-old, **P<0.01) and are consistent with the 
well-known increase in brain oxidative stress with age that leads to neuronal cell death 
(Butterfield and Stadtman, 1997; Harman, 1956). 
To assess effects of normal brain aging and genotype, AV-associated fluorescence in 
synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 mice was analyzed relative to that 
of 1 month-old WT mice as a control (Fig. 5.3b).  AV fluorescence was found to be significantly 
increased at 9 and 12 months of age in brain of APP/PS-1 mice compared to 1 month-old WT 
controls (Fig. 5.3b, 9 & 12 months-old, ***P<0.001).  Additionally, there was a significant 
increase in 9 and 12 month-old APP/PS-1 AV fluorescence compared to their respective 9 and 
12 month-old, age-matched WT mice (Fig. 5.3b, 9 month-old, 
§§
P<0.01; 12 month-old, 
§§§
P<0.001), demonstrating that the APP/PS-1 knock-in genotype affects PtdSer exposure 
significantly more than normal aging alone at these ages.  Interestingly, both WT and APP/PS-1 
mice exhibited an age-related AV fluorescence increase from 6 to 9 months-old, which was 
significantly more prominent in APP/PS-1 mice (Fig. 5.3a, 
§
P<0.05; Fig. 5.3b, 
§§§
P<0.001), 
directly correlating with significant Aβ(1-42) aggregation reported to begin at 9 months of age in 
this particular mouse model of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996; 
Siman et al., 2000).   
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Figure 5.3 
 
 
 
Figure 5.3 Annexin V (AV) binding assay in synaptosomes from wild-type (WT) and 
APP/PS-1 mice.  Synaptosomes isolated from 1, 6, 9, and 12 month-old WT and APP/PS-
1 mice were treated with the Annexin V FITC (AV).  A) Phosphatidylserine (PtdSer) 
outer-leaflet exposure for each WT age-group is presented as a percentage of 1 month-old 
WT control.  Results demonstrate a significant increase in AV fluorescence beginning at 
6 months that continues to increase with age.  Percent control values are presented as 
mean ± S.E.M. and significance assessed by one-way ANOVA followed by a Tukey 
post-hoc analysis; 
§,
*P<0.05, **P<0.01, ***P<0.001.  1, 9, and 12 month age groups, 
n=5; 6 month-old, n=8.  B) PtdSer outer-leaflet exposure for each WT and APP/PS-1 
age-group is presented as a percentage of 1 month-old WT control.  Results demonstrate 
a dramatic age-dependent increase in AV fluorescence in both WT and APP/PS-1 mice 
from 6 to 9 months that continues to increase with age.  However, this increase is more 
prominent in APP/PS-1 mice, suggesting that increasing oxidative stress, Aβ load, and/or 
apoptosis may cause significantly more PtdSer exposure than normal brain aging.  A) & 
B) Percent control values are presented as mean ± S.E.M. and significance assessed by 
two-way ANOVA followed by Bonferroni's post-hoc analysis; 
§,
*P<0.05, 
§§,
**P<0.01, 
§§§,
***P<0.001.  1, 9, and 12 month age groups, n=5; 6 month-old, n=8.   
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5.4.4  NBD-PS Fluorescence in Synaptosomes from Brain of Wild-Type (WT) & 
APP/PS-1 Mice 
In order to assess the effects of normal brain aging on PtdSer outer-leaflet exposure, 
synaptosomes extracted from whole brain of 1 month-old WT mice were used as a control to 
compare synaptosomes isolated from whole brain of 6, 9, and 12 month-old WT mice.  NBD-PS 
fluorescence was a second method employed to examine the effect of age on PtdSer asymmetry 
in synaptosomes and confirm results obtained from AV assay.  Loss of NBD-PS fluorescence is 
observed if the exogenous NBD-PS probe has successfully integrated into the membrane and has 
been exposed onto the outer bilayer leaflet where membrane-impermeable sodium dithionite 
(Na2S2O4) chemically quenches fluorescence [Fig. 3.3] (McIntyre and Sleight, 1991).  The value 
of this technique is that it addresses potential concerns with fluorescent probe access to the inner-
leaflet of an unstable system, creating incorrect interpretation of asymmetric collapse, since 
highly ionic S2O4
2-
 does not readily diffuse through the bilayer (McIntyre and Sleight, 1991).  In 
order to avoid graphical results showing negative, downward-facing bar graphs, data were 
analyzed as a percentage of control values set to 100%, yielding a graphical presentation more 
familiar to biochemical assays.  Like AV studies, results show a significant decrease in NBD-PS 
fluorescence beginning at 9 months (Fig. 5.4a, ***P<0.001) that remains significant to 12 
months of age (Fig. 5.4a, ***P<0.001), again consistent with the well-known increase in brain 
oxidative stress with age that can lead to neuronal cell death (Butterfield and Stadtman, 1997; 
Harman, 1956). 
To assess the effects of normal brain aging and genotype in WT and APP/PS-1 mice, 
NBD-PS fluorescence in synaptosomes isolated from brain of 1, 6, 9, and 12 month-old WT and 
APP/PS-1 mice was analyzed relative to that of 1 month-old WT mice as a control (Fig. 5.4b).  
NBD-PS fluorescence was significantly lost at 9 and 12 months-old in brain from APP/PS-1 
mice compared to 1month-old WT control brain (Fig. 5.4b, 9 & 12 months-old, ***P<0.001).  
Additionally, there was a significant decrease in 12 month-old APP/PS-1 fluorescence compared 
to age-matched, 12 month-old WT mice (Fig. 5.4b, 
§§
P<0.01), which also illustrates that the 
APP/PS-1 knock-in genotype has a significantly greater affect on PtdSer externalization than 
normal aging alone at these ages. 
Also confirming results obtained from AV fluorescence assay described above, both WT 
and APP/PS-1 mice exhibited a significant age-related decrease in NBD-PS fluorescence from 6 
to 9 months of age (Fig. 5.4a,b, WT & APP/PS-1, 
§§§
P<0.001) that is more prominent in 
APP/PS-1 mice.  These results directly correlate with significant Aβ(1-42) aggregation that is 
reported to begin at 9 months of age in this particular mouse model of Aβ pathology 
(Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).  Moreover, there was 
significantly greater maintenance of PtdSer asymmetry in brain from 1 and 6 month-old APP/PS-
1 mice compared to 1 month-old WT controls (Fig. 5.4b, 1 month-old, 
†††
P<0.001; 6 months-old, 
†
P<0.05), suggesting that the APP/PS-1 mouse brain attempts to counter elevated oxidative stress 
associated with Aβ(1-42) that develops at these early ages (Abdul et al., 2008). 
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Figure 5.4 
 
 
 
Figure 5.4 NBD-PS assay in synaptosomes from wild-type (WT) and APP/PS-1 mice.  
Synaptosomes isolated from 1, 6, 9, and 12 month-old WT and APP/PS-1 mice were 
treated with the fluorescent phospholipid NBD-PS and quenched with Na2S2O4.  A) 
Phosphatidylserine (PtdSer) outer-leaflet exposure for each WT age-group is presented as 
a percentage of 1 month-old WT mice as a control.  Results demonstrate a significant 
decrease in NBD-PS fluorescence from 6 to 9 months that continues to decrease with age.  
Percent control values are presented as mean ± S.E.M. and significance assessed by one-
way ANOVA followed by a Tukey post-hoc analysis; 
§§§,
***P<0.001.  1, 9, and 12 
month age groups, n=5; 6 month-old, n=8.  B) PtdSer outer-leaflet exposure for each WT 
and APP/PS-1 age-group is presented as a percentage of 1 month-old WT control.  
Results demonstrate an age-dependent decrease in NBD-PS fluorescence in both WT and 
APP/PS-1 mice from 6 to 9 months-old.  However, this decrease is more prominent in 
APP/PS-1 mice, suggesting that increasing oxidative stress, Aβ load, and/or apoptosis 
may cause significantly more PtdSer exposure than normal brain aging.  Conversely, at 1 
and 6 months of age there was a significant increase in APP/PS-1 NBD-PS fluorescence, 
suggesting less PtdSer exposure at these ages compared to age-matched WT controls.  A) 
& B) Percent control values are presented as mean ± S.E.M. and significance assessed by 
two-way ANOVA followed by Bonferroni's post-hoc analysis; Significant decrease: 
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§§
P<0.01, 
§§§,
***P<0.001; Significant increase: 
†
P<0.05, 
†††
P<0.001.  1, 9, and 12 month 
age groups, n=5; 6 month-old, n=8.  
 
 
5.4.5  Mg
2+
ATPase Activity in Synaptosomes from Brain of Wild-Type (WT) & 
APP/PS-1 Mice 
Mg
2+
ATPase activity was measured as an indirect representation of the activity of the 
ATP-dependent, membrane-bound PtdSer translocase, flippase, as highly specific antibodies to 
flippase have not yet been obtained (Auland et al., 1994).  Mg
2+
ATPase activity was measured 
by UV-absorbance (810 nm) as the net amount of inorganic phosphate (Pi) formed by 
functioning Mg
2+
ATPase enzymes within the membrane (Sadrzadeh et al., 1993).  The effect of 
normal brain aging on Mg
2+
ATPase activity was assessed by comparison of 6, 9, and 12 month-
old whole brain-extracted synaptosomes to those isolated from 1 month-old WT mice as a 
control.  These results demonstrate a significant age-dependent decrease in enzyme activity 
beginning at 9 months-old (Fig. 5.6a, *P<0.05), a decrease that becomes even more significant at 
12 months of age (Fig. 5.5a, **P<0.01) compared to 1 month-old WT controls.  Together with 
AV and NBD-PS studies described above, Mg
2+
ATPase results are also congruent with previous 
reports of increasing oxidative stress in brain due to normal aging processes (Butterfield and 
Stadtman, 1997; Harman, 1956). 
The effect of normal brain aging with respect to genotype in WT and APP/PS-1 mice on 
Mg
2+
ATPase activity was assessed by comparison of synaptosomes extracted from  1, 6, 9, and 
12 month-old WT and APP/PS-1 mice to that of 1 month-old WT mice as a control (Fig. 5.5b).   
Similar to WT aging trends, APP/PS-1 mice show a significant decrease in Mg
2+
ATPase activity 
starting at 9 months-old (Fig. 5.5a, **P<0.01) that becomes even more significant at 12 months 
of age (Fig. 5.5b, ***P<0.001) compared to 1 month-old WT controls.  Additionally, there was a 
significant decrease in 12 month-old APP/PS-1 mouse enzyme activity compared to 12 month-
old WT mice (Fig. 5.5b, 
§§§
P<0.001), illustrating that the APP/PS-1 genotype significantly 
affects the activity of all Mg
2+
ATPase enzymes, including flippase, to a greater extent than 
normal aging alone.   
Notably, APP/PS-1 mice exhibit a significant age-related decrease in Mg
2+
ATPase 
activity from 6 to 9 months and 9 to 12 months-old (Fig. 5.5b, 6 to 9 months-old, 
§§§
P<0.001; 9 
to 12 months-old, 
§§
P<0.01) that is absent in WT mice (Fig. 5.5a), which directly correlates to 
the significant aggregation of Aβ(1-42) that is reported to begin at 9 months of age in this mouse 
model of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).  
However, this trend is contrasted by either greater maintenance or enrichment of Mg
2+
ATPases 
in the lipid bilayer from 1 to 6 months-old in APP/PS-1 mice (Fig. 5.5b, 
†
P<0.05), a trend that is 
also significant between 6 month-old WT and age-matched 6 month-old APP/PS-1 mice (Fig. 
5.5b, 
†††
P<0.001).  Consistent with both AV and NBD-PS fluorescence, this particular trend 
reinforces the notion that young APP/PS-1 mouse brain is attempting to protect itself from an 
increasingly oxidative environment associated with Aβ(1-42) (Abdul et al., 2008). 
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Figure 5.5 
 
 
 
Figure 5.5 Mg
2+
ATPase activity in synaptosomes from wild-type (WT) and APP/PS-1 
mice.  Mg
2+
ATPase activity from 1, 6, 9, and 12 month-old WT and APP/PS-1 mice was 
measured to represent flippase activity.  Decreased UV-absorbance (810 nm) denotes 
decreased Mg
2+
ATPase (i.e., flippase) activity.  A) Mg
2+
ATPase activity for each WT 
age-group is presented as a percentage of 1 month-old WT mice as a control.  Results 
demonstrate a significant decrease in Mg
2+
ATPase activity beginning at 9 months that 
continues to decrease with age.  Percent control values are presented as mean ± S.E.M. 
and significance assessed by one-way ANOVA followed by a Tukey post-hoc analysis; 
§,
*P<0.05, **P<0.01.  1, 9, and 12 month age groups, n=5; 6 month-old, n=8.  B) 
Mg
2+
ATPase activity for each WT and APP/PS-1 age-group is presented as a percentage 
of 1 month-old WT mice as a control.  Results demonstrate an age-dependent decrease in 
Mg
2+
ATPase activity in both WT and APP/PS-1 mice from 6 to 9 months-old.  However, 
this decrease is more prominent in APP/PS-1 mice at 12 months-old, suggesting that 
increasing oxidative stress, amyloid-β (Aβ) load, and/or apoptosis may cause 
significantly more damage to transmembrane proteins, thus affecting PtdSer asymmetry.  
Conversely, from 1 to 6 months-old there was a significant increase enzyme activity in 
APP/PS-1 brain, suggesting significant protection or up-regulation of Mg
2+
ATPases at 
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these ages compared to age-matched WT mice.  A) & B) Percent control values are 
presented as mean ± S.E.M. and significance assessed by two-way ANOVA followed by 
Bonferroni's post-hoc analysis; Significant decrease: *P<0.05, 
§§,
**P<0.01, 
§§§,
***P<0.001; Significant increase: 
†
P<0.05, 
†††
P<0.001.  1, 9, and 12 month age 
groups, n=5; 6 month-old, n=8.  
 
 
5.4.6  Caspase-3 Levels in Brain of Wild-Type (WT) & APP/PS-1 Mice 
Pro-apoptotic caspase-3 is synthesized as an inactive, cytosolic precursor (36 kDa), that is 
cleaved into two active fragments, p18 (20 kDa; amino acids 29-175) and p12 (18 kDa; amino 
acids 176-277) upon activation by apoptotic stimuli.  The anti-caspase-3 primary antibody used 
in this study was chosen for its ability to recognize all three forms of caspase-3 on Western blots, 
while α-tubulin (50 kDa) was used as a loading control to normalize the amount of protein 
loaded in each well of the gel and transferred to blots (Figs. 5.6a; 5.7a; 5.8a).  In order to 
examine the effect of normal aging on the levels of latent and active forms of casepase-3, whole 
brain homogenate from 6, 9, and 12 month-old WT mice was blotted and analyzed with respect 
to 1 month-old WT mice as a control (Figs. 5.6-5.8).  Results demonstrate that procaspase-3 
levels steadily decrease with age (Fig. 5.6a,b), becoming significant at 12 months-old (Fig. 5.6b, 
*P<0.05) compared to 1 month-old WT controls.  This age-related decrease in procaspase-3 
levels was mirrored in brain from 1, 6, 9, and 12 month-old APP/PS-1 mice compared to 1 
month-old WT controls, emulating trends detected with NBD-PS fluorescence, in that, there is a 
large increase in 6 month-old APP/PS-1 procaspase-3 levels, although not significant, followed 
by steadily decreasing procaspase-3 levels with age (Fig. 5.6c).     
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Figure 5.6 
 
 
 
Figure 5.6 Procaspase-3 levels in brain from wild-type (WT) and APP/PS-1 mice.  
Procaspase-3 levels were measured by 1D-polyacrylamide gel electrophoresis (1D-
PAGE; 75 μg/lane) and subsequent Western blot analysis in 1, 6, 9, and 12 month-old 
WT and APP/PS-1 (HO) mice to correlate decreasing flippase activity with levels of pro-
apoptotic factor expression.  A) Increased band intensity after normalization with α-
tubulin represents an increase in the amount of procaspase-3 present.  n=5 for all age-
groups, however only representative bands from n=3 independent samples are shown.  B) 
Graphical analysis of WT mouse band intensities at each age compared to 1 month-old 
WT mice as a control demonstrates a gradual decrease in procaspase-3 levels with age 
that becomes significant at 12 months-old.  Percent control values are presented as mean 
± S.E.M. and significance assessed by one-way ANOVA followed by a Tukey post-hoc 
analysis; *P<0.05; n=5 for all age-groups.  C) Graphical analysis of WT and APP/PS-1 
band intensities at each age compared to 1 month-old WT controls show that APP/PS-1 
mice also present a decrease in procaspase-3 levels, becoming significant at 12 months-
old.  However, like NBD-PS & Mg
2+
ATPase data, there is an obvious increase in 6 
month-old APP/PS-1 procaspase-3 levels, although not significant, suggesting a possible 
increase in apoptotic processes at this early age compared to WT mice.  Percent control 
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values are presented as mean ± S.E.M. and significance assessed by two-way ANOVA 
followed by Bonferroni's post-hoc analysis; *P<0.05, 
§§,
**P<0.01; n=5 for all age-groups.  
 
 
In contrast, immunoblot analysis of the active-fragment p18 in 6, 9, and 12 month-old 
WT mice compared to 1 month-old WT controls shows a tendency for levels of this fragment to 
increase with age, becoming significant at 9 months-old (Fig. 5.7b, **P<0.01).  This age-related 
trend is also reflected in brain of 1, 6, 9, and 12 month-old APP/PS-1 mice compared to 1 month-
old WT animals as a control, where a significant increase in p18 levels appear at 9 months-old 
(Fig. 5.7c, ***P<0.001) and remaining significantly increased through 12 months of age (Fig. 
5.7c, ***P<0.001).  Moreover, there was a significant increase in both 9 and 12 month-old 
APP/PS-1 p18 levels compared to respective age-matched, 9 and 12 month WT brain (Fig. 5.7c, 
9 & 12 months-old, 
§
P<0.05), suggesting that the APP/PS-1 knock-in genotype causes 
significantly more neuronal apoptosis than normal aging alone in this particular mouse model of 
Aβ pathology.  Finally, the significant increase in p18 levels from 6 to 9 months-old in brain of 
APP/PS-1 mice (Fig. 5.7c, 
§
P<0.05) correlates with significant aggregation of Aβ(1-42) that is 
reported to begin at 9 months-old in this APP/PS-1 mouse (Anantharaman et al., 2006; Reaume 
et al., 1996; Siman et al., 2000).   
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Figure 5.7 
 
 
Figure 5.7 Active p18 fragment caspase-3 levels in brain from wild-type (WT) and 
APP/PS-1 mice.  Active caspase-3 fragment p18 (20 kDa) levels were measured by 1D-
polyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot 
analysis in 1, 6, 9, and 12 month-old WT and APP/PS-1 (HO) mice to correlate 
decreasing flippase activity with levels of pro-apoptotic factor expression.  A) Increased 
band intensity after normalization with α-tubulin represents an increase in the amount of 
the p18 caspase-3 fragment present. n=5 for all age-groups, however only representative 
bands from n=3 independent samples are shown.  B) Graphical analysis of WT mouse 
band intensities at each age compared to 1 month-old WT mice as a control demonstrates 
a gradual increase in p18 levels with age that becomes significant at 9 months.  Percent 
control values are presented as mean ± S.E.M. and significance assessed by one-way 
ANOVA followed by a Tukey post-hoc analysis; **P<0.01; n=5 for all age-groups.  C) 
Graphical analysis of WT and APP/PS-1 band intensities at each age compared to 1 
month-old WT controls shows that levels of p18 in APP/PS-1 brain also significantly 
increase from 6 to 9 months-old.  However, this age-related increase is more prominent in 
APP/PS-1 mice, suggesting that increasing oxidative stress and/or amyloid-β (Aβ) load 
may cause significantly more apoptosis than normal brain aging.  Percent control values 
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are presented as mean ± S.EM. and significance assessed by two-way ANOVA followed 
by Bonferroni's post-hoc analysis; 
§,
*P<0.05, **P<0.01, ***P<0.001; n=5 for all age-
groups. 
 
 
Interestingly, the p12 active fragment of caspase-3 appears to follow a remarkably 
different expression trend altogether, in that there is not an observable age-related increase or 
decrease in p12 levels in either WT or APP/PS-1 mice (Fig. 5.8).  Instead, both WT and APP/PS-
1 mice demonstrate a significant increase in p12 levels at 9 months of age (Fig. 5.8b, WT, 
**P<0.01; Fig. 5.8c, APP/PS-1, *P<0.05) compared to 1 month-old WT controls that disappears 
as WT and APP/PS-1 mice age from 9 to 12 months-old (Fig. 5.8b, WT, 
§§§
P<0.001; Fig. 5.8c, 
APP/PS-1, 
§
P,0.05).  However, it is of note that the present results do show a significant increase 
in pro-apoptotic p12 levels at the age when significant aggregation of Aβ(1-42) is reported to 
occur (i.e., 9 months) in brain of this particular mouse model of Aβ pathology (Anantharaman et 
al., 2006; Reaume et al., 1996; Siman et al., 2000). 
 
Figure 5.8 
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Figure 5.8 Active p12 fragment caspase-3 levels in brain from wild-type (WT) and 
APP/PS-1 mice.  Active caspase-3 fragment, p12 (18 kDa) levels were measured by 1D-
polyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot 
analysis in 1, 6, 9, and 12 month-old WT and APP/PS-1 (HO) mice to correlate 
decreasing flippase activity with levels of pro-apoptotic factor expression.  A) Increased 
band intensity after normalization with α-tubulin represents an increase in the amount of 
the p12 caspase-3 fragment present.  n=5 for all age-groups, however only representative 
bands from n=3 independent samples are shown.  B) Graphical analysis of WT mouse 
band intensities at each age compared to 1 month-old WT mice as a control demonstrates 
a gradual increase in p12 levels with age that becomes significant at 9 months-old.  
Percent control values are presented as mean ± S.E.M. and significance assessed by one-
way ANOVA followed by a Tukey post-hoc analysis; **P<0.01, 
§§§
P<0.001; n=5 for all 
age-groups.  C) Graphical analysis of WT and APP/PS-1 band intensities at each age 
compared to 1 month-old WT controls shows that levels of p12 in APP/PS-1 brain also 
significantly increase from 6 to 9 months-old.  However, this age-related increase is more 
prominent in APP/PS-1 mice, suggesting that increasing oxidative stress and/or amyloid-
β (Aβ) load may cause significantly more apoptosis than normal brain aging.  Percent 
control values are presented as mean ± S.E.M. and significance assessed by two-way 
ANOVA followed by Bonferroni's post-hoc analysis; 
§,
*P<0.05, **P<0.01, ***P<0.001; 
n=5 for all age-groups. 
 
 
5.5  Discussion 
AV and NBD-PS fluorescence analyses of synaptosomes from age-matched WT and 
APP/PS-1 mice confirm the hypothesis that PtdSer asymmetry is significantly altered in brain of 
this mouse model of Aβ pathology beginning at 9 months, in parallel with significant Aβ(1-42) 
aggregation and oxidative stress (Abdul et al., 2008; Anantharaman et al., 2006; Mohmmad 
Abdul et al., 2006; Reaume et al., 1996; Siman et al., 2000).  Both WT and APP/PS-1 mice 
follow a similar age-dependent trend in PtdSer outer-leaflet exposure, which suggests a 
significant collapse in PtdSer asymmetry as a function of age (Figs. 5.3; 5.4).  However, the key 
difference between the loss of PtdSer asymmetry found in WT mice and APP/PS-1 mice is the 
trend from 6 to 12 months of age, where the age-related increase in AV fluorescence, and 
decrease in NBD-PS fluorescence, from 6 to 12 months-old is greater in APP/PS-1 mice (Figs. 
5.3; 5.4), demonstrating that even though outer-leaflet exposure of PtdSer becomes increasingly 
apparent with age, the degree of exposure is augmented in APP/PS-1 brain.   
Furthermore, results from AV, NBD-PS, and ELISA assays illustrate that significant 
PtdSer externalization corresponds to the age at which significant Aβ aggregation occurs (9 
months; Figs. 5.1; 5.3; 5.4), and not of plaque deposition (12 months; Figs. 5.2-5.4).  This 
finding, along with previous studies of Aβ levels in APP/PS-1 mice (Anantharaman et al., 2006; 
Mohmmad Abdul et al., 2006; Murphy et al., 2007; Siman et al., 2000), suggests that elevated 
levels of SDS-soluble, oligomeric Aβ(1-42), together with increasing oxidative stress and 
damage (Abdul et al., 2008; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; Kanski 
et al., 2002; LaFontaine et al., 2002), in APP/PS-1 brain may contribute to altered PtdSer plasma 
membrane localization beyond the effects of normal brain aging.  
It is apparent from the significant rise in NBD-PS fluorescence in 1 and 6 month-old 
APP/PS-1 mice (Fig. 5.4) that PtdSer externalization is an important dynamic in the ongoing 
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neurodegeneration found in AD and FAD brain prior to significant Aβ aggregation or plaque 
deposition, possibly representing a stage of toxic Aβ(1-42) oligomer formation.  Consistent with 
this notion, previous studies of 6 month-old Tg2576 mice expressing APP mutations similar to 
this study (Hsiao et al., 1996) reveal that neuropathological changes and memory impairment 
occur long before Aβ plaque deposition, correlating with levels of various soluble Aβ oligomers 
(Hsia et al., 1999; Lesne et al., 2006; Mucke et al., 2000; Westerman et al., 2002).  Moreover, 
APP/PS-1 mice have been shown to have accumulated soluble Aβ as early as 1 day-old 
(Mohmmad Abdul et al., 2006), while current ELISA results demonstrate a visible increase in 
SDS-soluble Aβ(1-42) from 1 to 3 months-old that continues to escalate significantly with age 
(Fig. 5.1b), in parallel to increasing oxidative stress levels previously measured in this same 
APP/PS-1 mouse (Abdul et al., 2008).  At these young ages, it is reasonable to speculate that the 
APP/PS-1 mouse brain has up-regulated various neuroprotective systems (see section 2.4.6) that 
have yet to be overcome by oxidative stress and damage induced, in part, by toxic Aβ(1-42) 
oligomers.  Such an up-regulation of a cellular stress response is a well-known course of action 
which can be employed by neuronal cells to combat damage (Calabrese et al., 2007b; Poon et al., 
2004), and is consistent with the enrichment of PtdSer to the inner-leaflet of the plasma 
membrane from 1 to 6 months-old (Fig. 5.4).   
Initiation of a cell stress response involves the up-regulation of antioxidants and various 
proteins that may be involved in maintenance of PtdSer asymmetry, including flippase, which is 
represented by increasing Mg
2+
ATPase activity at 6 months of age in APP/PS-1 mouse brain 
(Fig. 5.5).  Current results suggest that during both WT and APP/PS-1 mouse brain aging, 
oxidative stress intensifies beyond the capacity of the stress response (Abdul et al., 2008), 
damaging flippase‟s translocating ability, and resulting in the age-dependent collapse in PtdSer 
asymmetry, from 6 to 12 months-old (Figs. 5.3-5.5).  Flippase activity is dependent on a critical 
cysteine residue within its primary structure (Daleke, 2003; Daleke and Lyles, 2000; Paulusma 
and Oude Elferink, 2005).  Oxidative stress induces production of reactive alkenals, HNE (Fig. 
2.35) and acrolein, within the bilayer that diffuse rapidly from their formation sites (Butterfield 
and Stadtman, 1997; Butterfield et al., 2006c; Lovell et al., 2001; Markesbery and Lovell, 1998) 
and form Michael adducts with cysteine residues, inhibiting flippase activity [Fig. 2.36] (Abdul 
et al., 2008; Castegna et al., 2004; Daleke, 2003; Daleke and Lyles, 2000; Lauderback et al., 
2001; Paulusma and Oude Elferink, 2005; Tyurina et al., 2004a). 
In addition to HNE and acrolein, Aβ(1-42) oligomers that continually form throughout 
AD and FAD progression can also initiate lipid peroxidation events [see section 2.6.2] 
(Butterfield, 2002; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; Kanski et al., 
2002; Schubert et al., 1995), either by penetrating the lipid membrane and/or binding to its 
surface (Fig. 2.52).  Either interaction is possible since Aβ(1-42) peptides are both hydrophobic 
and inherently attracted to negatively charged phospholipid head-groups, such as PtdSer [Fig. 
2.10] (McLaurin and Chakrabartty, 1997).  Depending on the avenue of association, oligomers 
can have a Ca
2+
 mobilizing effect through direct interaction with membrane receptors (Demuro 
et al., 2005; Snyder et al., 2005), destabilize membrane structure by increasing its permeability 
and fluidity (Demuro et al., 2005; Kayed et al., 2004; Muller et al., 1995; Sokolov et al., 2006), 
and induce oxidative stress leading to dysregulation of mitochondria and subsequent apoptosis 
[Figs. 2.52; 2.54; 2.55] (Butterfield, 2002; Butterfield and Lauderback, 2002; Butterfield et al., 
2007a; Drake et al., 2003a; Kanski et al., 2002; Lambert et al., 1998; Mattson, 2004; Schubert et 
al., 1995).  Thus, extensive oxidative stress, in addition to mounting Aβ(1-42) levels with age in 
brains of APP/PS-1 mice, could be significant enough to overwhelm initial neuroprotective stress 
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responses by 9 months-old and cause significant loss of PtdSer asymmetry beyond that of the 
normal aged brain (Figs. 5.1; 5.3-5.5). 
Ca
2+
 mobilization, whether Aβ(1-42)- and/or alkenal-induced, is noteworthy since 
flippase possesses a known sensitivity towards the influx of Ca
2+
 at concentrations of 0.2 μM and 
higher (Bitbol et al., 1987; Castegna et al., 2004; Daleke, 2003; Mohmmad Abdul and 
Butterfield, 2005).  However, prior studies with both in vitro and in vivo systems demonstrate 
that Ca
2+
 dysregulation is not the chief contributor to PtdSer asymmetric collapse, but rather, a 
secondary effect of oxidation events or other membrane alterations that lead to a detrimental  
influx of Ca
2+
 influx (Castegna et al., 2004; Mohmmad Abdul and Butterfield, 2005).  Therefore, 
plasma membrane structural integrity with respect to cholesterol is also considered important. 
The stability and structural integrity of the lipid membrane is generally attributed to 
cholesterol, whose rigid structure allows it to integrate between phospholipid head-groups and 
modulate membrane fluidity (Fig. 2.12).  This physiochemical membrane modulator can affect 
many bilayer functions (see section 2.2), including its susceptibility to oxidative stress (Lopez-
Revuelta et al., 2007), control of Aβ synthesis, and interactions between Aβ and neuronal 
membranes (Eckert et al., 2003).  For example, previous studies with APP/PS-1 mice indicate 
that brain Aβ(1-42) levels correlate inversely with declining membrane cholesterol levels 
(George et al., 2004; Wirths et al., 2006).  Another study by Arispe and Doh (2002) 
demonstrated that enrichment of PC12 cells with exogenous cholesterol (i.e. reducing fluidity) 
made them resistant to the cytotoxic action of soluble Aβ peptides, while reducing membrane 
cholesterol (i.e. increasing fluidity) made cells more vulnerable (Arispe and Doh, 2002).  
Furthermore, cholesterol depletion can stimulate an increase in lipid peroxidation (Lopez-
Revuelta et al., 2005), resulting in significant PtdSer externalization associated with significantly 
decreased flippase activity and increased uptake of altered cells by macrophages in the periphery 
(Lopez-Revuelta et al., 2007).  Taken en masse, this research suggests increased membrane 
fluidity due to cholesterol reduction would provide soluble Aβ(1-42) oligomers the opportunity 
to adversely affect PtdSer leaflet distribution and integral membrane protein (e.g. flippase) 
function. 
A third way in which soluble oligomers can lead to the age-related loss of synaptosomal 
PtdSer asymmetry in APP/PS-1 mice is by inducing the up-regulation of pro-apoptotic factor 
expression, as outer-leaflet exposure of PtdSer is a well-known signal of the initial stages of 
apoptosis [see section 2.5] (Fadok et al., 1992a; Kagan et al., 2003; Paulusma and Oude Elferink, 
2005; Tyurina et al., 2004a).  Most notably, PtdSer externalization is reported downstream of 
caspase-3 activation under oxidative stress conditions in some cell types (Mandal et al., 2002; 
Martin et al., 1996; Nicholson, 1999; Vanags et al., 1996); in studies of erythrocytes, caspase-3 
activation is also associated with loss of flippase PtdSer translocase activity (Mandal et al., 
2005).  Current Western blot analysis of both precursor and active caspase-3 levels confirm that 
apoptosis is an ongoing process in brain of APP/PS-1 mice as early as 1 month-old, as indicated 
by the presence of the p18 and p12 active fragments of caspase-3 (Figs. 5.7; 5.8), found only in 
apoptotic cells (Nicholson et al., 1995).  Furthermore, the increasing p18 and p12 
immunoreactivity beginning at 9 months is also consistent with AV, NBD-PS, and Mg
2+
ATPase 
assay results, which all show significant changes occurring between the ages of 6 and 9 months-
old, emphasizing the importance of this time point in disease progression in brain of this 
genotypic mouse model of Aβ pathology.  It is interesting to note, however, that procaspase-3 
levels steadily decrease as both WT and APP/PS-1 mice age, though more significantly in 
APP/PS-1 brain (Fig. 5.6).  Considering the steady increase in oxidative stress, Aβ(1-42) 
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pathology, and apoptosis in APP/PS-1 mouse brain, the observed inverse relationship is most 
likely due to the increased activation and cleavage of procaspase-3 into p18 and p12 active 
fragments with disease progression.  
Lastly, it should be noted that among other enzymes that could conceivably affect PtdSer 
asymmetry, phospholipase A2 (PLA2), known to be altered in AD (Chalbot et al., 2009; Moses et 
al., 2006), could contribute to exposure of PtdSer to the external leaflet in synaptosomes from 
APP/PS-1 mice.  However, previous studies of PLA2 from snake venom do not lead to 
significant exposure of PtdSer in synaptosomal membranes (Ghassemi and Rosenberg, 1992).  
Hence, though PLA2 may play a role in what we observed in this study, the likelihood of such a 
role is small. 
The current dissertation results are consistent with the notion that PtdSer exposure to the 
outer bilayer leaflet indicates not only mounting oxidative stress and Aβ pathology in FAD and 
AD, but also apoptosis at its earliest stages.  Results reported in Chapter 4 of this dissertation 
observing loss of PtdSer asymmetry in brain from subjects with aMCI and AD associated with 
increased caspase-3 levels, along with a previous study in collaboration with the Butterfield 
laboratory reporting a significant increase in oxidative stress beginning at 1 month-old in this 
same APP/PS-1 mouse model (Abdul et al., 2008) support this notion.  The significant inner-
leaflet enrichment of PtdSer at 1 and 6 months-old perhaps signifies an already well-advanced 
cell stress response, while the diminution of inner-leaflet PtdSer levels from 6 to 9 months 
suggests the elicited stress response was effectively overcome by harsh conditions generated 
during disease progression in this mouse model of Aβ pathology.  In summary, this study 
represents the first age-dependent investigation of PtdSer asymmetry in a mouse model of Aβ 
pathology by addressing how loss of PtdSer asymmetry may relate to pro-apoptotic factor 
expression and toxic Aβ(1-42) accumulation. 
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CHAPTER 6 
IN VIVO OXIDATIVE STRESS IN BRAIN OF ALZHEIMER DISEASE TRANSGENIC 
MICE: REQUIREMENT FOR METHIONINE 35 IN AMYLOID-β PEPTIDE OF APP 
 
6.1  Overview 
Numerous studies have demonstrated oxidative damage in the central nervous system in 
both subjects with and animal models of Alzheimer disease (AD) amyoid-β (Aβ) pathology.  In 
this dissertation study, PDAPP transgenic (Tg) mice carrying Swedish and Indiana mutations in 
the human amyloid precursor protein (APP) [Tg PDAPP(J20)] were used as an in vivo Aβ 
pathology commonly found in familial AD (FAD) brain.  In addition, genetically and age-
matched PDAPP mice carrying a methionine to leucine substitution at residue 35 (Met35Leu) on 
the Aβ peptide (residue 631 in human APP numbering) [Tg PDAPP(M631L)] were created to 
investigate the in vivo role of Met-35 in Aβ-induced oxidative stress.  Slot-blot measures of 
oxidative stress, indexed by levels of protein carbonyls, protein-resident 3-nitrotyrosine (3-NT), 
and protein-bound 4-hydroxy-2-trans-nonenal (HNE), demonstrate that Aβ-induced oxidative 
stress requires the presence of Met-35, as all indices of oxidative damage in brain of Tg 
PDAPP(M631L) mice were completely prevented.  Two-site enzyme-linked immunosorbant 
assay (ELISA) demonstrated no significant differences in the levels of APP, Aβ(1–42), and 
Aβ(1–40), or the ratio Aβ(1–42)/Aβ(1–40), suggesting that the loss of oxidative stress in vivo in 
the brain of Tg PDAPP(M631L) mice was solely due to the Met35Leu (i.e., M631L) 
substitution.  However, immunohistochemical analysis showed a marked reduction in Aβ-
immunoreactive plaques in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, but a 
significant increase in small punctuate areas of non-plaque immunoreactivity and microglial 
activation.  Contrasting slot-blot results, which suggested the requirement of Met-35 for 
oxidative damage, behavioral analysis demonstrated no significant improvement in spatial 
learning and memory in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  This is 
the first in vivo study to demonstrate the requirement for Met-35 of Aβ for oxidative stress in 
brain of a mammalian model of Aβ pathology.  However, in this specific Tg mouse model, 
oxidative stress is neither required nor sufficient for memory abnormalities. 
6.2  Introduction 
Previous studies have demonstrated elevated levels of oxidative stress and damage in 
brain of subjects with AD and amnestic mild cognitive impairment (aMCI), arguably the earliest 
form of AD (Butterfield, 1997; Butterfield et al., 2007a; 2006b; 2006c; 2007b; Hensley et al., 
1995; Keller et al., 2005; Lyras et al., 1997; Markesbery, 1997; Petersen et al., 1999; Smith et al., 
1997; Varadarajan et al., 2000; Winblad et al., 2004).  Proteomic analyses of human AD and 
aMCI brain have identified numerous dysfunctional, oxidatively modified proteins consistent 
with known biochemical, pathological, and clinical alterations in both conditions [see section 
2.6] (Butterfield et al., 2007a; 2006b; Reed et al., 2008a; 2008b; Sultana et al., 2007a; 2007b; 
2006b; 2006c). 
In brain of subjects with AD and aMCI, it is the soluble, oligomeric 42-mer of the Aβ 
peptide [Aβ(1-42)] that is considered to be the toxic Aβ species [see section 2.6.2] (Demuro et 
al., 2005; Drake et al., 2003a; Viola et al., 2008), leading to a dramatic decline in learning and 
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memory (Selkoe, 2008; Walsh et al., 2002).  Previous studies have shown that the addition of 
exogenous Aβ(1-42) to neurons in vitro results in elevated protein oxidation and lipid 
peroxidation, as indexed by elevated levels of protein carbonyls (see section 2.4.4.1; Figs. 2.31; 
2.32), protein-resident 3-NT (see section 2.4.4.2; Fig. 2.34), and protein-bound HNE (see section 
2.4.5.1; Figs. 2.35; 2.36), each of which is blocked by antioxidants [see section 2.4.6] (Ansari et 
al., 2006; Boyd-Kimball et al., 2004; Pappolla et al., 1999; Sultana et al., 2005).  Moreover, 
previous in vivo studies demonstrated that human Aβ(1-42) in Caenorhabditis elegans [C. 
elegans] (Drake et al., 2003a) or in rodent brain (Abdul et al., 2008; Boyd-Kimball et al., 2005b; 
Mohmmad Abdul et al., 2006; Resende et al., 2008; Zhu et al., 2008) also leads to oxidative 
stress and damage. 
Both Aβ(1-42) and Aβ(1-40) contain a single methionine residue at position 35 
(corresponding to residue 631 of human APP) [Fig. 2.53] that has been linked to the oxidative 
stress-inducing and neurotoxic properties of this peptide (Fig. 2.52).  The Butterfield laboratory 
has suggested that oxidative stress associated with toxic Aβ(1-42) is dependent on the formation 
of a sulfur (S)-centered, transient free radical on Met-35 that leads to both protein oxidation and 
lipid peroxidation in neurons [Figs. 2.54; 2.55] (Boyd-Kimball et al., 2004; Butterfield and 
Boyd-Kimball, 2005; Kanski et al., 2002; Varadarajan et al., 2001; Yatin et al., 1999).  For 
example, substitution of norleucine (Nle) for Met (replacing the Met S-atom with a CH2 group; 
Fig. 2.53) in human Aβ(1–42) abrogates the oxidative and neurotoxic effects of the resulting 
Aβ(1-42) M35Nle peptide in cultured neurons, while maintaining similar length, hydrophobicity, 
and tendency to aggregate as native human Aβ(1-42), even though this substitution does not 
prevent fibril formation (Butterfield and Boyd-Kimball, 2005; Varadarajan et al., 2001; Yatin et 
al., 1999).  Likewise, in C. elegans, the expression of human Aβ(1-42) is also associated with 
oxidative stress and damage (Drake et al., 2003a; Yatin et al., 1999); however, substitution of the 
Met codon with a cysteine (Cys) codon (Fig. 2.53) in DNA encoding human Aβ(1-42) prevents 
in vivo protein oxidation, while not affecting Aβ(1-42) accumulation or plaque deposition (Yatin 
et al., 1999).  These results suggest that those mechanisms of oxidative stress that involve Met-
35 of Aβ(1-42) apply both in vitro and in vivo, but do not involve deposition of the peptide. 
The present dissertation study investigated the hypothesis that Met-35 of Aβ(1-42) is 
critical for in vivo Aβ(1-42)-induced oxidative stress and in AD-related spatial memory deficits 
in a well-characterized transgenic mouse model of Aβ pathology.  Transgenic (Tg) mice carrying 
human APP mutations corresponding to the Swedish and Indiana (APPSw,In) familial forms of 
AD [Tg PDAPP(J20)] were derived, which show Aβ accumulation, plaque formation, and 
memory deficits (Galvan et al., 2006; Hsia et al., 1999; Mucke et al., 2000).  In addition, 
genetically and age-matched Tg PDAPP mice carrying an additional M631L mutation 
substituting a Leu for Met at residue 35 of Aβ [Tg PDAPP(M631L)] were also created to test the 
hypothesis.  Since Nle does not have a naturally occurring codon, Leu [-CH(CH3)2] was chosen 
for its similar length and hydrophobicity to Met (Fig. 2.53).  We then compared the degree of 
oxidative damage in brain of Tg PDAPP(J20) mouse models of Aβ pathology with Tg 
PDAPP(M631L) mice, as well as age-matched wild-type (WT) controls.   
6.3  Experimental Procedures 
All materials and methods used in this study are described in Chapter 3 of this 
dissertation.  Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, 3.7.1.3, 3.8.1.4, 3.13, 3.14.2, 3.15, and 
3.16.  
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6.3.1  Statistical Analysis 
All slot-blot (Oxyblot) and ELISA analyses in this dissertation study are presented as 
mean ± standard error of the means (S.E.M.) using a two-tailed Student‟s t-test, where P<0.05 
was considered significantly different.  All ELISA, 1D-polyacrylamide gel electrophoresis (1D-
PAGE), immunohistochemical, and behavioral analyses were performed by our collaborators at 
the Buck Institute for Age Research (Novato, CA) using GraphPad Prism software (San Diego, 
CA).  In two-variable experiments, as when scoring performance of different genotypes across 
several days of training, repeated measures, two-way analysis of the variants (ANOVA) followed 
by Bonferroni‟s post-hoc tests were used to evaluate the significance of differences between 
group means.  When analyzing one-variable experiments with more than two groups, as when 
scoring retention across genotypes in probe trials, significance of differences between means was 
evaluated using one-way ANOVA followed by Dunnet‟s multiple comparison post-hoc test 
using the Non Tg PDAPP and Tg PDAPP(M631L) as control groups in separate analyses.  The 
significance of differences in means between two different groups were further evaluated with 
Student‟s t-test, where P<0.05 was considered significant.  Pearson correlation coefficients 
between variables were calculated with regression analyses using GraphPad Prism software (San 
Diego, CA). 
6.4  Results 
PDAPP mice were created in collaboration with Professor Lennart Mucke at the 
University of California (San Francisco, CA), while M631L mice were created by our 
collaborators at the Buck Institute for Age Research (Novato, CA).  Many lines of 
PDAPP(M631L) were produced (>10) to derive two with high-level APP expression similar to 
that of Tg PDAPP(J20) mice, in order to form an accurate comparison.  Measures of Aβ(1–40) 
and Aβ(1–42) are shown for the two highest expressing lines, A1058 and A1059.  However, 
because the A1058 line was closest to Tg PDAPP(J20) mice in APP expression, it was used for 
all other studies reported in this study. 
6.4.1  Indices of Oxidative Stress 
Compared to Non Tg PDAPP littermates, brains isolated from Tg PDAPP(J20) mice 
displayed elevated indices of oxidative stress (Fig. 6.1).  Oxyblot (slot-blot) results demonstrate a 
significant increase in protein carbonyls (Fig. 6.1a, *P<0.003), protein-resident 3-NT (Fig. 6.1b, 
*P<0.002), and protein-bound HNE (Fig. 6.1c, *P<0.02) in brain from Tg PDAPP(J20) mice 
compared to age-matched Non Tg PDAPP littermates.  In addition, pre-treatment of Tg 
PDAPP(J20) brain samples with NaBH4, to determine the specificity of the marker for protein 
carbonyls by reducing carbonyls the alcohols preventing covalent attachment of 2,4-
dinitrophenylhydrazine (DNPH) [see section 3.13.1], prevented staining by the anti-
dinitrophenylhydrazone (DNP) primary antibody (Fig. 6.2), in marked contrast to Tg 
PDAPP(J20) samples derivatized with DNPH.  This result confirms previous reports from the 
Butterfield laboratory of the same finding (Aksenov et al., 2001; Sultana et al., 2006b).  In 
contrast, the Met35Leu substitution in brain of Tg PDAPP(M631L) completely abrogated the 
elevation in all three parameters of oxidative stress compared to Tg PDAPP(J20) mice (Fig. 6.1). 
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Figure 6.1 
 
 
 
Figure 6.1 Oxidative modification of brain in transgenic (Tg) and non-transgenic (Non 
Tg) mice: Role of Met-35 of amyloid-β (Aβ).  A)  Protein oxidation as indexed by protein 
carbonylation.  Results show a significant increase in the levels of protein carbonyls in 
Tg PDAPP(J20) mice (n=10) compared to age-matched Non Tg PDAPP controls (n=5).  
Tg PDAPP(M631L) mice (n=10) did not show a significant increase in protein carbonyls 
compared to respective Non Tg M631L controls (n=5), but did, however, have 
significantly reduced protein carbonyl levels compared to age-matched Tg PDAPP(J20) 
mice.  Non Tg control values were set to 100% to which Tg values were compared.  Data 
are presented as mean ± S.E.M. *P<0.003; **P<0.0004.  B)  Lipid peroxidation as 
indexed by protein-bound 4-hydroxy-2-trans-nonenal (HNE).  Results show a significant 
increase in the levels of protein-bound HNE in Tg PDAPP(J20) mice (n=10) compared to 
age-matched Non Tg PDAPP controls (n=5).  Tg PDAPP(M631L) mice (n=10), 
however, did not show a significant change in protein-bound HNE compared to Non Tg 
M631L controls (n=5).  Moreover, there were significantly reduced levels of protein-
bound HNE in Tg PDAPP(M631L) mice compared to age-matched Tg PDAPP(J20) 
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mice.  Non Tg control values were set to 100%, to which Tg values were compared.  Data 
are presented as mean ± S.E.M.  *P<0.02; **P<0.04.  C)  Protein oxidation as indexed by 
protein-resident 3-nitrotyrosine (3-NT).  In agreement with both protein carbonyl and 
protein-bound HNE blots, a significant increase in Tg PDAPP(J20) [n=10] 3-NT levels 
was found compared to age-matched Non Tg PDAPP controls (n=5), while Tg 
PDAPP(M631L) [n=10] 3-NT levels did not significantly change compared to Non Tg 
M631L controls (n=5).  However, there was a significant reduction in Tg 
PDAPP(M631L) 3-NT levels compared to age-matched Tg PDAPP(J20) mice.  Non Tg 
control values were set to 100%, to which Tg values were compared.  Data are presented 
as mean ± S.E.M.  *P<0.002; **P<0.0001. 
 
 
Figure 6.2 
 
 
 
Figure 6.2 Specificity assay for protein carbonyls. Duplicate brain samples from Tg 
PDAPP(J20) mice (n=2) were subjected to Oxyblot analysis of protein carbonyls with 
(right) and without (left) NaBH4 pre-treatment, a strong reducing agent that reduces 
carbonyls to alcohols (Aksenov et al., 2001; Sultana et al., 2006b).  Results clearly show 
that pre-treatment with NaBH4 abrogates binding and subsequent staining with the anti-
dinitrophenylhydrazone (DNP) primary antibody, demonstrating this assay‟s specificity 
for protein carbonyls. 
 
 
6.4.2  Amyloid Precursor Protein (APP) Expression, Amyoid-β (Aβ) production, & the 
Aβ(1-42)/Aβ(1-40) Ratio 
To ensure that Oxyblot results were not due to a difference in APP expression or 
accumulation of Aβ(1–42) or Aβ(1–40), our collaborators at the Buck Institute for Age Research 
(Novato, CA) compared the levels of APP by Western blot, while levels of both Aβ peptides 
were determined by two-site sandwich ELISA.  Western blot analysis of APP expression 
demonstrated that the A1058 line of Tg PDAPP(M631L) mice expressed APP to similar levels as 
Tg PDAPP(J20) mice (Fig. 6.3a), and therefore, the A1058 line of mice were chosen for all 
analyses described in this dissertation study.  ELISA assay demonstrated no significant 
differences in production of either Aβ(1–40) or Aβ(1–42) in brains of Tg PDAPP(M631L) mice 
compared to Tg PDAPP(J20) mice (Fig. 6.3b,c), whereas the ratio of Aβ(1–42) to Aβ(1–40) was 
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slightly elevated, although not significantly, in the brains of the Tg PDAPP(M631L) mice 
compared to Tg PDAPP(J20) mice (Fig. 6.3d).  As no significant differences were found in APP 
expression, Aβ(1–40) or Aβ(1–42) production, or the ratio of  Aβ(1–42)/Aβ(1–40) between Tg 
PDAPP(J20) and Tg PDAPP(M631L)A1058 mice, it was concluded that Oxyblot results were 
solely a consequence of the Met35Leu transgene, and not a difference in APP expression or 
accumulation of Aβ(1–42) or Aβ(1–40). 
 
Figure 6.3 
 
 
 
Figure 6.3 Amyloid precursor protein (APP) expression and amyloid-β (Aβ) production.  
Many lines of PDAPP(M631L) were produced to derive two with a high-level of APP 
expression similar to that of Tg PDAPP(J20) mice, to form an accurate comparison.  
Western blot and enzyme-linked immunosorbant assay (ELISA) analyses demonstrate 
that the PDAPP(M631L)A1058 line of mice A) express APP and B) produce Aβ(1-40) 
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and C) Aβ (1-42) to similar levels as PDAPP(J20) mice.  Therefore, A1058 Tg mice were 
used for all other studies reported.  D) The ratio of Aβ(1–42)/Aβ(1–40) between Tg 
PDAPP(J20) and Tg PDAPP(M631L)A1058 mice. B)-D) Data are presented as mean ± 
S.E.M.  Data obtained by our collaborators at the Buck Institute for Age Research 
(Novato, CA).   
 
 
6.4.3  Immunohistochemistry 
Plaque load in PDAPP mice was determined by our collaborators at the Buck Institute for 
Age Research (Novato, CA) by anti-Aβ (6E10) immunohistochemistry, while microglial 
activation was determined by anti-ionized Ca
2+
 binding-protein-1 (Iba-1) immunostaining.  In the 
molecular layer of the hippocampus, just superior to the dentate gyrus, anti-Aβ (6E10) staining 
showed marked reduction in the size and abundance of Aβ-immunoreactive plaques in Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice (Fig. 6.4a,b).  However, there was a 
clear increase in punctate 6E10 labeling in Tg PDAPP(M631L) mice associated with increased 
Iba-1 staining for microglial activation, not observed in Tg PDAPP(J20) mice (Fig. 6.4c,d).  
Instead, Tg PDAPP(J20) mice showed amoeboid phagocytic microglia surrounding plaques.  
Punctate labeling in Tg PDAPP(M631L) mice was even more marked in the corpus callosum and 
white matter tracts lateral to the hippocampus and surrounding the thalamus, associated with a 
proportionately greater microglial response (Fig. 6.4e,g).  Tg PDAPP(J20) mice, again, did not 
exhibit punctate staining, but instead showed phagocytic microglia surrounding plaques (Fig. 
6.4f,h).  Thus, these results suggest that Met-35 may be involved in Aβ plaque formation, as well 
as oxidative stress. 
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Figure 6.4 
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Figure 6.4 Immunohistochemical staining of amyloid plaques and microglia.  Coronal, 
paraformaldehyde-fixed, paraffin-embedded brain sections were labeled with anti-
amyloid-β (Aβ) [6E10] and ionized Ca
2+
 binding-protein-1 (Iba-1), a marker for 
microglia, antibodies.  In the molecular layer of the hippocampus, just superior to the 
dentate gyrus, 6E10 staining showed marked reduction in the size and abundance of Aβ-
immunoreactive plaques in A) Tg PDAPP(M631L) mice vs. B) Tg PDAPP(J20) mice.  
A) & B) 6E10 images at 10 X original magnification.  However, there was an increase in 
punctate 6E10 labeling in C) Tg PDAPP(M631L) mice associated with increased Iba-1 
staining for microglial activation, not observed in D) Tg PDAPP(J20) mice.  Instead, Tg 
PDAPP(J20) mice showed amoeboid phagocytic microglia surrounding plaques.  E) 
Punctate labeling in Tg PDAPP(M631L) mice was even more marked in the corpus 
callosum and G) white matter tracts lateral to the hippocampus and surrounding the 
thalamus, associated with a proportionately greater microglial response.  F) Tg 
PDAPP(J20) mice, again, did not exhibit punctate staining, but instead H) showed 
phagocytic microglia surrounding plaques.  C)-H) Iba-1 images at 20 X original 
magnification.  Data obtained by our collaborators at the Buck Institute for Age Research 
(Novato, CA).   
 
 
6.4.4  Behavioral Measures 
Before beginning behavioral analyses, our collaborators at the Buck Institute for Age 
Research (Novato, CA) evaluated PDAPP mice to ensure that their visual and somatic motor 
systems were intact and that they were capable of swimming.  None of the mice evaluated in this 
study displayed any problems completing these preliminary tests. 
In the Morris water-maze behavioral analyses (Morris, 1984), two indices were 
examined:  the latency index, which reflects the time necessary to find a hidden escape platform 
and is a measure of visuospatial learning; and the number of passes mice made over the original 
position of the platform after it was removed, which measures memory retention.  The latency 
index is characteristically abnormal in AD Tg mouse models, as well as other mice with 
hippocampal dysfunction.  The M631L mutation in Tg PDAPP(M631L) mice showed no 
improvement over Tg PDAPP(J20) mice in latency index, as their performances were 
indistinguishable from one another (Fig. 6.5a).  However, both Tg PDAPP(J20) and Tg 
PDAPP(M631L) mouse performance was significantly impaired with respect to Non Tg PDAPP 
mice as a control [Fig. 6.5a, Tg PDAPP(J20), 
#
P<0.01; Tg PDAPP(M631L), *P<0.01; Non Tg 
M631L, ^P<0.05].  Tg PDAPP(M631L) mice also showed significantly increased floating 
behavior with respect to all other groups (which were not significantly different from each other) 
that may reflect helplessness associated with memory dysfunction [Fig. 6.5b, *P<0.001,  
#
P<0.01, and ^P<0.001, with respect to Non Tg PDAPP, Non Tg M631L, and Tg PDAPP(J20) 
mice, respectively]. Interestingly, the percentage of time spent floating increased significantly as 
a function of day number during training for Tg PDAPP(J20), Tg PDAPP(M631L), and Non Tg 
M631L mice compared to Non Tg PDAPP controls, as well [Fig. 6.5b, *P<0.0001 for all 
groups].   
As described previously (Galvan et al., 2008; 2006; Saganich et al., 2006), Tg 
PDAPP(J20) mice showed a significant reduction in the number of passes over the former 
platform position (target) compared to Non Tg littermates (Fig. 6.5c, *P<0.05).  Similar to the 
latency index, Tg PDAPP(M631L) mice showed no significant difference between Tg 
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PDAPP(J20) and Non Tg M631L mice, suggesting that the M631L mutation did not improve 
memory retention (Fig. 6.5c). 
 
Figure 6.5 
 
 
 
Figure 6.5 Morris water-maze behavioral assessment of PDAPP mice: Effect of the 
M631L mutation.  A)  Latency index spatial training. Mean latencies to reach a hidden 
platform were significantly different for Tg PDAPP(J20) [n=10, 
#
P<0.01], Tg 
PDAPP(M631L) [n=10, *P<0.01], and Non Tg M631L [n=5, ^P<0.05] groups with 
respect to Non Tg PDAPP mice (n=5) as a control.  Data are presented as mean ± S.E.M. 
Data calculated by two-way ANOVA with Bonferroni's post-hoc test applied to a 
significant effect of genotype F(3,78)=7.05, P=0.0013. B) Floating. Percentage time 
spent floating increased significantly as a function of day number during training 
[***P<0.0001 for all groups; F(3,78)=40.14].  Tg PDAPP(M631L) mice (n=10) spent a 
significantly larger percentage of trial time floating than all other groups (which were not 
significantly different from each other) [*P<0.001, 
#
P<0.01, and ^P<0.001 with respect to 
Non Tg PDAPP (n=5), Non Tg M631L (n=5), and Tg PDAPP(J20) mice (n=10), 
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respectively].  Data are presented as mean ± S.E.M.  Data calculated by two-way 
ANOVA with Bonferroni's post-hoc test applied to a significant effect of genotype 
F(3,78)=9.22, P=0.0003.  “Floaters” were excluded from all other analyses.  C) Probe 
trial.  Retention of the former platform site was impaired in Tg PDAPP(J20) mice with 
respect to the Non Tg PDAPP littermates [*P<0.05; Dunnet's multiple comparison test 
applied to a significant effect of genotype P=0.03; one-way ANOVA].  No significant 
difference was observed for the comparison between Non Tg M631L or Tg PDAPP(J20) 
mice and Tg PDAPP(M631L).  Data are presented as mean ± S.E.M.  Data obtained by 
our collaborators at the Buck Institute for Age Research (Novato, CA).   
 
 
6.5  Discussion 
This dissertation study represents the first in vivo study to demonstrate the requirement of 
the Met-35 residue of human Aβ for AD-associated oxidative stress in brain of a mammalian 
model of Aβ pathology.  Substitution of Met with Leu at residue 631 of human mutant APPSw,In 
(corresponding to residue 35 of Aβ peptide) was shown to completely abrogate oxidative stress 
induced by Aβ(1-42) when Met-35 was present (Fig. 6.1).  Furthermore, differential expression 
of APP, as well as ELISA-analyzed levels of Aβ(1-40) and Aβ(1-42), was shown not to be the 
cause of diminished oxidative stress indices in brains of Tg PDAPP(M631L) mice (Fig. 6.4).  
However, the Met35Leu mutation was shown to influence plaque formation, as Tg 
PDAPP(M631L) mice displayed a reduction in 6E10 immunoreactive plaques (Fig. 6.5), and an 
increase in  non-plaque, punctate staining accompanied by a microglial response (Iba-1 staining) 
[Fig. 6.5].  These findings suggest that Met-35 may be involved in the Aβ plaque formation 
characteristic of Aβ, and are consistent with the notion that any non-specific or compensatory 
changes secondary to the presence of a human transgene are unlikely to be responsible for the 
lack of oxidative stress in brain isolated from Tg PDAPP(M631L) mice.   
In general, methionine has important cellular functions, such as shielding the active sites 
of enzymes against oxidation (Stadtman, 2004), promotion of α-helical secondary structure of 
proteins (Vogt, 1995), aiding activity of certain repair or chaperone proteins (Bose-Basu et al., 
2004), and participation in the maintenance of redox status of cells (Schoneich, 2002).  Within 
the Aβ peptide, current studies indicate that Met-35 plays a crucial role in the oxidative stress 
and damage associated with AD.  In a study by Varadarajan, et al., (2001), it was suggested that 
Aβ(1–42)-induced oxidative stress in neurons is carried out via catalytic processes [see section 
2.6.2] (Varadarajan et al., 2001).  They demonstrated that a small amount of Met-S-centered free 
radical on Aβ(1–42) can be greatly amplified, as a chain reaction produced in the lipid phase of 
the cell membrane initiated by abstraction of allylic hydrogen (H)-atoms from unsaturated acyl 
chains of lipids by the S-centered radical cation (i.e., sulfuranyl radical) on Met-35 [Figs. 2.54; 
2.55] (Varadarajan et al., 2001).  This chain reaction can continue as long as there are allylic H-
atoms available and continuously produce lipid peroxidation products, such as HNE [Fig. 2.35] 
(Lauderback et al., 2001; Mark et al., 1997).  This lipid peroxidation product can, in turn, react 
via Michael addition with Cys, histidine (His), and lysine (Lys) residues of proteins causing 
dramatic changes in structure [Fig. 2.36] (Subramaniam et al., 1997) and function (Esterbauer et 
al., 1991; Lauderback et al., 2001; Sayre et al., 1997).  When the sulfuranyl radical formed on 
Met-35 of Aβ(1–42) abstracts an allylic H-atom from an unsaturated fatty acyl chain, it forms an 
extremely acidic compound with a pKa of −5 (Fig. 2.55).  Hence, any base, including water, can 
remove the H
+
-atom from this acid, reforming the reduced S-atom on Met-35.  Because the 
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newly reduced Met-35 can, again, undergo a one-electron oxidation to form a sulfuranyl free 
radical, this process is considered to be catalytic (Fig. 2.55).  
The notion proposed by the Butterfield laboratory, that a one-electron oxidation of Met-
35 of Aβ(1–42) forms a sulfuranyl free radical that leads to lipid peroxidation and protein 
oxidation in neurons in the brain of subjects with AD and aMCI (Butterfield and Boyd-Kimball, 
2005; Kanski et al., 2002; Varadarajan et al., 2001), has been supported by other laboratories 
(Crouch et al., 2006; Gomez-Balderas et al., 2005; Kadlcik et al., 2004).  Recently, however, a 
study by Maiti, et al. (2010) found a different result, demonstrating that substitution of Met-35 
with a valine (Val) actually increases the toxicity of the resulting Aβ(M35V) peptide (Maiti et 
al., 2010).  However, it should be noted that this study was conducted with synthetic Aβ 
peptides, using an amino acid that is slightly longer than Met, which could alter the reactive 
properties of the resultant Aβ(Met35Val) peptide.  On the other hand, considering the 
aggregation properties of Aβ are strongly related to its toxicity, the current study has yet to 
investigate the effects of the Met35Leu substitution on Aβ aggregation.   
In agreement with the notion proposed by the Butterfield group, pulse radiolysis studies 
conducted by Kadlcik, et al. (2004) revealed a S-centered free radical on Aβ(1–40), but not on 
the peptide with the non-toxic, reverse sequence, Aβ(40–1) (Kadlcik et al., 2004).  Moreover, 
studies conducted by the Butterfield laboratory showing a lack of neurotoxicity, protein 
oxidation, and lipid peroxidation in brain cells exposed to Aβ(1–42) when Met-35 was 
substituted with Nle (Varadarajan et al., 2001; Yatin et al., 1999) or Cys [Fig. 2.53]  (Yatin et al., 
1999) have also been confirmed by others (Clementi et al., 2006; Dai et al., 2007; Murray et al., 
2005).  These studies suggested that Cu
2+
 was weakly bound to Met-35 of Aβ(1–42), consistent 
with an earlier hypothesis proposed by the Butterfield laboratory (Butterfield and Boyd-Kimball, 
2005), and with the results of studies with the divalent cation chelator clioquinol  (Cherny et al., 
2001; Huang et al., 1999).   
 
Figure 6.6 
 
 
 
Figure 6.6 Structure of the divalent cation chelator, Clioquinol.  
 
 
Clioquinol has been shown to dissolve plaques from Tg mice containing human mutant 
APP (Cherny et al., 2001), even though the dissociation constant (KD) of Cu
2+
 for clioquinol 
reportedly was nine orders of magnitude greater than that for Aβ(1–42) (Huang et al., 1999).  
Hence, Butterfield and Boyd-Kimball (2005) suggested that a weakly bound Cu
2+
 ion on Met-35 
of Aβ(1-42) could account for the one-electron oxidation of the Met-35, together with 
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simultaneous reduction of Cu
2+
 to Cu
+
, which is capable of undergoing Fenton-type chemistry to 
produce highly reactive free radicals (see section 2.4.3.1; reaction 3), and the data showing 
weakly bound Cu
2+
 could be easily removed from Met-35 by cliquinol; whereas it is unlikely 
that clioquinol could remove Cu
2+
 bound to His-6, -13, and -14 of Aβ(1–42) with a KD in the 
attomolar range (Butterfield and Boyd-Kimball, 2005).   
Indeed, oxidative stress has been demonstrated in the brain of another transgenic mouse 
model of AD Aβ pathology (Smith et al., 1997), as well as a double knock-in mouse model of 
Aβ pathology (Abdul et al., 2008).  Although some have questioned the relevance of oxidative 
stress associated with Aβ(1–42) in vivo (Nunomura et al., 2007), it is clear from the present 
dissertation study that Aβ(1–42)-induced oxidative stress does not occur in mouse brain in vivo if 
Met-35 of Aβ(1–42) is absent.  The importance of the current dissertation study is that results 
establish unequivocally the critical nature of Met-35 of Aβ(1-42) for in vivo oxidative stress in a 
mammalian species brain, strongly suggesting similar importance of Met-35 of Aβ(1-42) in brain 
of subjects with aMCI and AD.  Although genetic manipulation of Met-35 of Aβ(1-42) in 
humans is currently not possible, our results point to clinical translational possibilities for 
therapy to potentially treat, slow progression of, or prevent aMCI and AD.  Specifically, 
blocking oxidative damage dependent on Met-35 of Aβ(1-42) in brain of subjects with aMCI and 
AD offers a highly focused therapeutic approach, and studies to test this notion are in progress.  
In contrast to the clear role of Met-35 of Aβ(1–42) in oxidative damage demonstrated 
above, spatial learning and memory in Tg PDAPP(M631L) mice did not show a dependence on 
Met-35 of Aβ.  In behavioral analyses employing the Morris water-maze, neither the latency 
period nor the number of times Tg PDAPP(M631L) mice swam over the platform site differed 
significantly from that of the Tg PDAPP(J20) mice (Fig. 6.5).  Thus, it can be concluded that 
Met-35 and its associated oxidative damage are not required for the spatial memory loss that is 
characteristic of this particular mouse model of Aβ pathology and human AD.  However, it 
should be noted that it is possible that we have, to date, missed a behavioral effect of the M631L 
substitution, since mice were only analyzed for behavior and indices of oxidative stress at 9 
months-old, meaning that at earlier or later stages of life, differences in behavior, if present, 
would have been missed by the present studies.  The notion that later behavioral deficits might 
be mollified by the M631L substitution is compatible with recently published studies showing 
that Tg PDAPP(D664A) mice begin to show Morris water-maze abnormalities at 13 months-old 
that are not present at earlier ages (Galvan et al., 2008).  Although it is not clear that this 
behavioral trend is a result of oxidative damage, Tg PDAPP(D664A) mice do indeed show such 
damage (Galvan et al., 2008).  Thus further studies are needed to assess Tg mice with both the 
D664A and M631L substitutions, to determine whether they resist the trend toward deterioration 
in Morris water-maze performance with age. 
Finally, 6E10 immunoreactive Aβ deposits in the brains of Tg PDAPP(M631L) mice 
revealed marked differences from the frank plaque deposits found in Tg PDAPP(J20) mice (Fig. 
6.4).  Moreover, there is evidence of microglial activation in Tg PDAPP(M631L) mice (Fig. 6.4).  
Therefore, it is conceivable that increased microglial activation in Tg PDAPP(M631L) mice 
influenced behavior, potentially contributing to the lack of behavioral improvement relative to 
Tg PDAPP(J20) mice. 
In contrast to memory deficits apparently unaffected by the M631L substitution, the 
Met35Cys substitution in Aβ(1–42) in AD models (Fig. 2.53), in which human Aβ(1–42) was 
expressed in muscle [as opposed to full-length APP in neurons], abrogated this worm‟s paralytic 
phenotype without changing deposition of the modified peptide (Yatin et al., 1999).  
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Additionally, another study of aged beagle dogs (whose Aβ sequence is identical to that of 
humans) fed a high antioxidant diet and given a program of behavioral enrichment showed 
decreased oxidative stress in brain, improved learning and memory, and decreased levels of 
Aβ(1–42) (Opii et al., 2008).  Although the fundamental differences of these previous studies 
make direct comparisons to the current studies difficult (e.g., the comparison of mutant APP 
expression in mouse brain to Aβ expression in nematode muscle may, in fact, prove to be futile), 
such comparisons may nonetheless offer some clues into AD pathogenesis and strategies for 
future studies.  For example, the M631L mouse model employed full-length APP with familial 
AD-associated mutations, whereas the nematode model only expressed the Aβ peptide.  Thus, 
the lack of improvement in the mouse model may have been due to other, non-Aβ peptides 
derived from APP, such as sAPPβ, Jcasp, and C31, all of which have been implicated in aspects 
of the AD phenotype (Galvan et al., 2006; Lu et al., 2000; Madeira et al., 2005; Nikolaev et al., 
2009).  Moreover, mouse, dog, and nematode data are all compatible with the notion that 
multiple mechanisms are involved in AD pathogenesis, such that the threshold mechanism is 
likely to differ from model to model.  If this proves to be the case, then results obtained from 
these different systems argue that it will be critical to test potential new therapeutics in more than 
one system, and ultimately it will be crucial to determine which model or combination of models 
provides the greatest predictive value for human AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Miranda Lu Lange, 2010 
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CHAPTER 7 
DIFFERENTIAL EXPRESSION & REDOX PROTEOMICS ANALYSES OF AN 
ALZHEIMER DISEASE TRANSGENIC MOUSE MODEL: EFFECTS OF AMYLOID-β 
PEPTIDE OF APP 
 
7.1  Overview 
Amyloid-β peptide (Aβ)-induced oxidative stress has been demonstrated to play a key 
pathological role in brain from subjects with and animal models of Alzheimer disease (AD) Aβ 
pathology.  Results from Chapter 6 of this dissertation report elevated levels of oxidative damage 
in brain of PDAPP transgenic (Tg) mice carrying Swedish and Indiana mutations in the human 
amyloid precursor protein (APP) [Tg PDAPP(J20)], as indicated by increased levels of protein 
carbonyls, protein-resident 3-nitrotyrosine (3-NT), and protein-bound 4-hydroxy-2-trans-nonenal 
(HNE) compared to non-transgenic (Non Tg) littermate control mice.  This oxidative damage 
was found to be dependent upon the methionine 35 residue (Met-35) of the Aβ peptide.  Because 
further insight into the molecular pathways affected in this in vivo Tg model of familial AD 
(FAD) Aβ pathology may be gained by proteomics-based studies, 2D-gel expression proteomics 
was performed to compare any differences in brain protein levels of Tg PDAPP(J20) mice with 
Non Tg PDAPP littermate controls.  Based on these studies, eight proteins were identified as 
significantly up-regulated in Tg PDAPP(J20) mice relative to Non Tg PDAPP controls, many, of 
which, have been previously identified as differentially expressed in in vitro and in vivo models 
of Aβ pathology and subjects with AD and amnestic mild cognititve impairment (aMCI):  
calcineurin subunit B type 1,  GDP-dissociation inhibitor 1, F-actin capping protein subunit β, 
T-complex protein 1 subunit  A (TCP-1A), -enolase, peptidyl-prolyl cis-trans isomerase 1 
(Pin-1), ATP synthase, subunit  (mitochondrial), and peroxiredoxin-1.  Redox proteomics 
analyses identified three significantly oxidatively-modified proteins:  dihydropyrimidinase-
related protein 2 (Drp-2) with significantly increased levels of protein carbonylation and 
phosphatidylethanolamine-binding protein 1 (PEBP-1) and Pin-1 with significantly decreased 
levels of 3-NT in Tg PDAPP(J20) mice relative to Non Tg PDAPP controls.  In addition, 
Western blotting and immunoprecipitation analyses were used to validate spots identified as 
significantly differentially expressed or oxidatively modified by PD-Quest image analysis.         
7.2  Introduction 
AD is an age-related neurodegenerative disorder that is pathologically manifested by 
deposition of senile plaques (SPs), accumulation of neurofibrillary tangles (NFTs), and 
subsequent synapse and neuronal cell loss (see section 2.6).  Familial cases of AD have been 
linked primarily to autosomal dominant mutations in APP (Goate et al., 1991), presenilin-1 (PS-
1) and/or presenilin-2 (PS-2) genes (Citron et al., 1992; Cruts et al., 1998; Scheuner et al., 1996; 
Sturchler-Pierrat et al., 1997).  Additionally, oxidative stress has been implicated in the 
pathogenesis of AD (Butterfield and Lauderback, 2002; Butterfield et al., 2006c; Good et al., 
1996; Markesbery, 1997; Smith et al., 1997; 1994).  SPs are largely composed of the Aβ(1-42) 
peptide, generated by β- and -secretase cleavage of the APP protein (see section 2.6.2; Fig. 
2.51).  Although APP is known to produce Aβ(1-40) in higher abundance (Burdick et al., 1992; 
Jarrett et al., 1993), it is Aβ(1-42) that is considered to be the more toxic peptide in model 
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systems of AD (Boyd-Kimball et al., 2005a; 2005b; 2005c; Butterfield and Boyd-Kimball, 2004; 
Drake et al., 2003a; Lambert et al., 1998; Mattson, 1997; Mohmmad Abdul et al., 2004; 2006).  
In FAD, mutations close to the β- and γ-secretase cleavage sites are thought to lead to increased 
levels of Aβ.  Although Aβ peptides can exist as monomers, oligomers, fibrils, or aggregates, it 
is the soluble, oligomeric form of Aβ(1-42) that is believed to be the most toxic Aβ species in 
AD brain (Demuro et al., 2005; Drake et al., 2003a; Selkoe, 2008; Viola et al., 2008).  The major 
consequences of this toxicity are the observed cognitive losses in learning and memory (Selkoe, 
2008; Walsh et al., 2002).  The Butterfield laboratory, as well as others, have provided 
considerable evidence that Aβ(1-42) induces oxidative stress in AD and various AD model 
systems  (Abdul et al., 2008; Ansari et al., 2006; Boyd-Kimball et al., 2004; 2005b; Drake et al., 
2003a; Mohmmad Abdul et al., 2006; Pappolla et al., 1999; Resende et al., 2008; Sultana et al., 
2005; Zhu et al., 2008). 
In Chapter 6 of this dissertation, increased levels of three indices of oxidative stress (i.e., 
protein carbonyls, protein-resident 3-NT, and protein-bound HNE) in brain Tg PDAPP(J20) 
were reported compared to that of Non Tg PDAPP control mice.  Tg PDAPP(J20) mice carry 
mutations in human APP corresponding to the Swedish (K670N and M671L) and Indiana 
(V717F) familial forms of AD (APPSw,In), which are expressed behind a platelet-derived growth 
factor (PDGF) β-chain promoter (Galvan et al., 2006; Mucke et al., 2000).  Tg PDAPP(J20) mice 
display many aspects of AD pathology, such as Aβ accumulation, neuritic plaque (i.e., SP) 
formation, and memory deficits (Galvan et al., 2006; Mucke et al., 2000), but not NFTs.  
Therefore, the oxidative stress and damage found in Tg PDAPP(J20) mice can be directly 
correlated with these pathological hallmarks. 
This dissertation study iinvestigated the hypothesis that specific biochemical pathways 
are altered in Tg PDAPP(J20) mouse models of Aβ pathology.  Alterations of brain proteins 
from brain of Tg PDAPP(J20) mice in comparison to Non Tg PDAPP littermate controls were 
identified following 2D-polyacrylamide gel electrophoresis (2D-PAGE) separation and 
employing mass spectrometry (MS) and database searching techniques.  Redox proteomic 
experiments also were performed to identify brain proteins with significant differences in 
oxidative modification in Tg PDAPP(J20) mice as measured by protein carbonyls and 3-NT.  
SEQUEST and PD-Quest image analysis results were validated using 1D-Western blotting and 
immunoprecipitation analyses of Pin-1.  Overall, the findings from these proteomics studies 
enhance the understanding of altered pathways in AD and provide potential targets for AD 
prevention and treatment that warrant further investigation. 
7.3  Experimental Procedures 
All materials and methods used in this study are described in Chapter 3 of this 
dissertation.  Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, and 3.7-3.12.  
7.3.1  Statistical Analysis 
All data are presented as mean ± standard deviation (S.D.) or mean ± standard error of 
the means (S.E.M.), as noted.  Statistical analyses were performed using a two-tailed Student‟s t-
test, wherein P<0.05 was considered significant for differential expression fold-change values 
and oxidative modification levels.  Protein and peptide identifications obtained with the 
SEQUEST search algorithm with a P-value<0.01 were considered statistically significant.  To 
further validate PD-Quest and SEQUEST identifications of significantly different spots, the 
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location of protein spots on the 2D-gels were manually checked to ensure they were near the 
expected molecular weight (MW) and isoelectric point (pI) values based on SwissProt database 
information.   
7.4  Results 
7.4.1  Differential Expression Proteomics 
Differential expression proteomics analysis of proteins isolated from brains of Tg 
PDAPP(J20) and Non Tg PDAPP control mice using a 2D-PAGE approach was conducted.  
Effects inherently present in Tg PDAPP(J20) mouse brain as a result of the APPSw,In transgene 
can be realized through this analysis.  A total of eight protein spots were identified as being 
significantly up-regulated in Tg PDAPP(J20) mice compared to Non Tg PDAPP controls.  
Examples of 2D-gel images from these analyses can be found in Figure 7.1.  Tryptic digestion 
and MS analysis was completed on excised protein spots; Table 7.1 provides a list of the 
corresponding protein spot identifications, the number of peptide sequences and spectral counts 
(SC; the number of MS/MS events observed that meet SEQUEST filter criteria), MW, pI, fold-
change levels, and P-values associated with each protein identified.  Half of the proteins were 
identified with more than one single peptide and several SC (Table 7.1); for proteins identified 
with only a single peptide, more than one SC was observed and/or the protein was identified in 
other MS experiments of that protein spot.  I am confident in the identification of these proteins 
based on the low P-values associated with the SEQUEST identifications (i.e., P2.00e
-04
).  In 
addition, the location of protein spots visually align with their anticipated MW and pI values on 
the 2D-gels. 
 
Figure 7.1 
 
A)  Non Tg PDAPP 
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Figure 7.1 (cont.) 
 
B)  Tg PDAPP(J20) 
 
 
Figure 7.1 Representative 2D-gel images of proteins isolated from Tg PDAPP(J20) and 
Non Tg PDAPP mouse brain.  Significantly up-regulated protein spots in A) Non Tg 
PDAPP and B) Tg PDAPP(J20) mouse brain are labeled with protein identifications 
obtained from nanospray electrospray ionization (ESI)-MS/MS analyses. TCP-1α, T-
complex protein 1 subunit  A; GDP,  GDP-dissociation inhibitor 1; F-actin, F-actin 
capping protein, subunit β; Pin-1, peptidyl-prolyl cis-trans isomerase 1; ATP, adenosine 
triphosphate. 
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Table 7.1 List of proteins with differential levels in Tg PDAPP(J20) mice relative to 
Non Tg PDAPP controls.  
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
Fold-
Changec 
P-valued 
F-actin capping protein, 
subunit β 
P47757 30.61 5.62 1(2) 5.00e-06 49.6 ↑ 0.0064 
T-complex protein 1, 
subunit α A (TCP-1αA) 
P11984 60.30 5.70 1(2) 2.00e-07 47.9 ↑ 0.00069 
Peroxiredoxin-1 P35700 22.16 8.20 1(2) 2.00e-04 30.4 ↑ 0.0023 
ATP synthase, subunit α, 
mitohondrial 
Q03265 59.72 9.53 5(10) 8.00e-07 12.2 ↑ 5.1e-06 
Peptidyl-prolyl cis-trans 
isomerase 1 (Pin-1) 
P17742 18.30 7.97 1(3) 1.00e-05 3.09 ↑ 0.0047 
ρ GDP-dissociation 
inhibitor 1 
Q99PT1 23.39 4.96 3(13) 5.00e-09 2.62 ↑ 0.033 
Calcineurin, subunit B, 
Type 1 
Q63810 19.29 4.49 3(10) 3.00e-10 2.47 ↑ 0.014 
α-Enolase P17182 47.11 6.38 5(9) 8.00e-13 1.88 ↑ 0.039 
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.  
The total number of MS/MS spectral counts (SC) is indicated in ( ). 
b
The probability of an incorrect identification associated with each protein identification 
using the SEQUEST search alogorithm. 
c
The fold-change in spot density from Tg PDAPP(J20) mice compared to Non Tg PDAPP 
controls.  The arrow indicates the direction of change. 
d
The P-value associated with fold-change
c
 calculated using a Student‟s t-test.  n=10 for Tg 
PDAPP(J20), n=5 for Non Tg PDAPP. 
pI, isoelectric point; MW, molecular weight. 
 
 
Half of the brain proteins detected as significantly up-regulated in Tg PDAPP(J20) mice 
had fold-change levels greater than 10-fold compared to Non Tg PDAPP mice (Table 7.1), 
including F-actin capping protein, subunit β (49.6-fold, *P<0.006), TCP-1A (48-fold, 
*P<0.0007), peroxiredoxin-1 (30.4-fold, *P<0.002), and ATP synthase, subunit , 
mitochondrial (12.2-fold, *P<5.09e-06).  Other significantly up-regulated proteins in Tg 
PDAPP(J20) mice are Pin-1 (3.09-fold, *P<0.005),  GDP-dissociation inhibitor 1 (2.62-fold, 
*P<0.032), calcineurin, subunit B, Type 1 (2.47-fold, *P<0.013), and -enolase (1.88-fold, 
*P<0.038) [Table 7.1].          
7.4.2  Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) Western Blot Spot Validation  
Western blot analysis shows that the lanes corresponding to Pin-1 (18 kDa) and the loading 
control, actin (42 kDa; used as a loading control to normalize the amount of protein loaded in 
each well of the gel), levels agree with their expected positions based on MW (Fig. 7.2a).  The 
histogram based on lane intensity shows a ~15% significant increase (*P<0.04) in the level of 
Pin-1 levels in the brains of Tg PDAPP(J20) mice relative to Non Tg PDAPP littermate controls 
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(Fig. 7.2b).  These results are consistent with the expression proteomics analyses described 
above, though not duplicating the magnitude, in Tg PDAPP(J20) mice.     
 
Figure 7.2 
 
 
 
Figure 7.2 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) levels in brain of transgenic 
(Tg) and non-transgenic (Non Tg) mice.  Pin-1 and actin levels were measured by 1D-
polyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot 
analysis in 9 month-old Tg PDAPP(J20) [Tg] and Non Tg PDAPP [NTg] control mice.  
A)  Increased band intensity after normalization with actin represents an increase in the 
amount of Pin-1 present.  n=5 for both Tg and NTg groups, however only representative 
bands from n=3 independent samples are shown.  B) Graphical representation of data 
shown in A) demonstrates a significant increase in the levels of Pin-1 in Tg PDAPP(J20) 
mice compared to Non Tg PDAPP littermate controls.  Percent control values are 
presented as mean ± S.E.M.; *P<0.04. 
 
 
7.4.3  Redox Proteomics 
Utilizing previously established redox proteomics approaches for the detection of protein 
carbonyls and 3-NT (Butterfield and Sultana, 2008; Sultana et al., 2006b), three proteins were 
identified to be significantly carbonylated or nitrated in brain of Tg PDAPP(J20) mice relative to 
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Non Tg PDAPP controls (Table 7.2).  A significant increase in Drp-2 protein carbonylation was 
found in brain of Tg PDAPP(J20) mice in comparison to Non Tg PDAPP controls (*P<0.046; 
Fig. 7.3), while a significant decrease in protein-resident 3-NT was found for PEBP-1 
(*P<0.022; Fig. 7.4) and Pin-1 (*P<0.049; Fig. 7.5) in Tg PDAPP(J20) mice relative to their Non 
Tg PDAPP littermates (Table 7.2).  These results, as well as the aforementioned expression 
proteomics results, will be discussed in detail below (section 7.5) with respect to protein 
function(s) and how the detected changes may be implicated in AD etiology.  
 
Table 7.2 List of oxidatively modified proteins in Tg PDAPP(J20) mice relative to Non 
Tg PDAPP controls.  
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
% 
Control 
(NTg)c 
P-valued 
Protein Carbonyls:        
Dihydropyrimidinase-
related protein-2 
(Drp-2) 
O08553 62.24 5.93 6(17) 4.00e-11 6510 ↑ 0.046 
3-NT:        
Phosphatidylethanolamine-
binding protein 1 (PEBP-1) 
P70296 20.82 5.07 2(4) 3.00e-07 27.4 ↓ 0.023 
Peptidyl-prolyl cis-trans 
isomerase 1 (Pin-1) 
P17742 18.30 7.97 1(6) 3.00e-04 19.1 ↓ 0.049 
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.  The 
total number of MS/MS spectral counts (SC) is indicated in ( ). 
b
The probability of an incorrect identification associated with each protein identification using the 
SEQUEST search alogorithm. 
c
Percent oxidation in Tg PDAPP(J20) mice compared to Non Tg (NTg) PDAPP controls (oxidative 
level arbitrarily set to 100%). 
d
The P-value associated with % Control (NTg)
c
 calculated using a Student‟s t-test.  n=10 for Tg 
PDAPP(J20); n=5 for Non Tg PDAPP. 
pI, isoelectric point; MW, molecular weight. 
 
 
Figure 7.3 
 
A)  Non Tg PDAPP  B)  Tg PDAPP(J20) 
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Figure 7.3 Representative 2D-Western blot image corresponding to carbonylated 
dihydropyrimidinase-related protein 2 (Drp-2).  These images show a clear increase in 
protein carbonylated Drp-2 in B) Tg PDAPP(J20) mice compared to A) Non Tg PDAPP 
controls [images have been zoomed in to this spot].  Proteins were probed with an anti-
dinitrophenylhydrazone (DNP) antibody, as described in Chapter 3.   
 
 
Figure 7.4 
 
A)  Non Tg PDAPP           B)  Tg PDAPP(J20) 
 
   
 
 
 
 
 
 
 
 
 
Figure 7.4 Representative 2D-Western blot image corresponding to nitrated 
phosphatidylethanolamine-binding protein 1 (PEBP-1).  These images show a clear 
decrease in 3-nitrotyrosine (3-NT)-modified PEBP-1 in B) Tg PDAPP(J20) mice 
compared to A) Non Tg PDAPP controls [images have been zoomed in to this spot].  
Proteins were probed with an anti-3-NT antibody, as described in Chapter 3.   
 
 
Figure 7.5 
 
A)  Non Tg PDAPP         B)  Tg PDAPP(J20) 
 
    
 
 
Figure 7.5 Representative 2D-Western blot image corresponding to nitrated peptidyl-
prolyl cis-trans isomerase 1 (Pin-1).  These images show a clear decrease in 3-
nitrotyrosine (3-NT)-modified Pin-1 in B) Tg PDAPP(J20) mice compared to A) Non Tg 
PDAPP controls [images have been zoomed in to this spot].  Proteins were probed with 
an anti-3-NT antibody, as described in Chapter 3.   
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7.4.4  Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) Immunoprecipitation  
Immunoprecipitation validation was performed for Pin-1 as a representative confirmation 
of those brain proteins identified as significantly oxidatively modified by SEQUEST and PD-
Quest image analyses.  Western blot analysis shows that lanes corresponding to Pin-1 (18 kDa) 
are indeed nitrated (Fig. 7.6a), while the histogram representing the average lane intensity for 
both Tg and Non Tg mice shows a significant decrease in the level of nitrated Pin-1 in Tg 
PDAPP(J20) mice compared to Non Tg PDAPP controls (*P<0.02; Fig. 7.6b).  These results are 
consistent with the redox proteomics analyses described above, in which Pin-1 was identified as 
being significantly less nitrated in Tg PDAPP(J20) mice compared to Non Tg PDAPP controls 
(19.1%; Table 7.2). 
 
Figure 7.6 
 
 
 
Figure 7.6 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) nitration levels in brain of Tg 
PDAPP(J20) and Non Tg PDAPP mice.  Following immunoprecipitation, Pin-1 nitration 
was measured by 1D-polyacrylamide gel electrophoresis (1D-PAGE; 75 μg/lane) and 
Western blot analysis of 9 month-old Tg PDAPP(J20) [Tg] and Non Tg PDAPP [NTg] 
control mice.  A)  Increased band intensity represents an increase in the amount of 3-
nitrotyrosine (3-NT)-modified Pin-1 present.  n=5 for both Tg and NTg groups, however 
only representative bands from n=3 independent samples are shown.  B) Graphical 
representation of data shown in A) demonstrates a significant decrease in Pin-1 nitration 
levels in Tg PDAPP(J20) mice compared to Non Tg PDAPP littermate controls.  Percent 
control values are presented as mean ± S.E.M.; *P<0.02. 
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7.5  Discussion 
The J20 line of PDAPP mice used in the current dissertation study was 9 months-old, 
corresponding to the age at which pathological and behavioral characteristics that mimic those 
encountered in subjects with AD occur.  Previous studies have demonstrated that Tg 
PDAPP(J20) mice have age-related progressive accumulation of Aβ, SP formation, and cognitive 
decline associated with AD disease progression (Galvan et al., 2006; Hsia et al., 1999; Mucke et 
al., 2000).  Current studies measured changes in the brain proteomes of Tg PDAPP(J20) mice 
compared to Non Tg PDAPP littermate control mice using 2D-PAGE and MS/MS techniques.  
Eight proteins were found to be significantly up-regulated in Tg PDAPP(J20) mice relative to 
Non Tg PDAPP controls, including calcineurin, subunit B, Type 1,  GDP-dissociation inhibitor 
1, F-actin-capping protein, subunit β, TCP-1A, -enolase, Pin-1, ATP synthase, subunit  
(mitochondrial), and peroxiredoxin-1 (Table 7.1).  In accordance with results reported in Chapter 
6 of this dissertation, which show significant changes in the global levels of protein oxidation 
and lipid peroxidation in Tg PDAPP(J20) mice compared to Non Tg PDAPP controls, current 
redox proteomics results show a significant increase in Drp-2 carbonylation, and a significant 
decrease in PEBP-1 and Pin-1 nitration in Tg PDAPP(J20) mice compared to Non Tg PDAPP 
controls (Table 7.2).  The biochemical functions of proteins identified with altered levels or 
oxidative modification include energy dysfunction, metabolism alterations, calcium signaling, 
antioxidant defense, neuritic/structural abnormalities, cell-cycle/signaling, lipid abnormalities, 
and cholinergic dysfunction.  The relevance of increased levels of and/or differential oxidative 
modification of these proteins in Tg PDAPP(J20) mice is discussed below with regards to 
specific biochemical pathways and their significance in AD. 
 
Table 7.3 List of proteins with differential levels and oxidative modifications in Tg 
PDAPP(J20) mice relative to Non Tg PDAPP mice and their cellular functions.  
Current 
Alteration 
Protein Cellular Function(s) 
↑ Expression α-Enolase Energy Metabolism 
↑ Expression ATP synthase, subunit α, mitochondrial Energy Metabolism 
↑ Expression Peroxiredoxin-1 Antioxidant 
↑ Expression T-complex protein 1, subunit α A (TCP-1αA) 
Molecular Chaperone; 
Structural Integrity 
↑ Expression F-actin capping protein, subunit β Structural Protein 
↑ Carbonylation Dihydropyrimidinase-related protein 2 (Drp-2) Structural Protein 
↑ Expression ρ GDP-dissociation inhibitor 1 Cell Signaling 
↑ Expression; 
↓ Nitration 
Peptidyl-prolyl cis-trans isomerase (Pin-1) Cell Signaling; Cell-Cycle 
↓ Nitration 
Phosphatidylethanolamine-binding protein 1  
(PEBP-1) 
Cell Signaling, 
Proliferation, & Migration; 
Cholinergic System 
↑ Expression Calcineurin, subunit B, Type 1 
Ca
2+
 Signaling & 
Regulation 
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7.5.1  Energy Dysfunction & Metabolic Alterations 
Cellular metabolism, particularly cerebral glucose uptake, is known to be altered in the 
brains of patients with AD and amnestic mild cognititve impairment (aMCI) [Fig. 7.7] (Watson 
and Craft, 2004).  In this study, a significant increase in the levels of α-enolase and ATP 
synthase, subunit α (mitochondrial), in Tg PDAPP(J20) mice was observed.  α-Enolase is a 
glycolytic enzyme responsible for catalyzing the conversion of 2-phosphoglycerate into 
phosphoenolpyruvate in the final stages of glycolysis (Table 7.3; see section 2.3.2; Fig. 2.17).  
The up-regulation of α-enolase in brain of Tg PDAPP(J20) mice suggests an increased need for 
adenosine triphosphate (ATP; i.e., energy) production, in which the catabolic breakdown of 
glucose is of utmost importance, congruent with previous reports indicating hypometabolism to 
be a predominant pathological feature in AD brain (Mielke et al., 1996).  Hypometabolism has 
been associated with the oxidative-inactivation of several glycolytic enzymes, including enolase 
(Butterfield et al., 2006b; Castegna et al., 2002a; Sultana et al., 2007b).  Because the brain is one 
of the greatest consumers of glucose, hypometabolism can cause the up-regulation of glycolytic 
enzymes in an effort to combat the mounting energy deficit (Mielke et al., 1996).  Furthermore, 
key glycolytic enzymes, including enolase, have been shown to be electrostatically bound to cell 
and organelle membranes (Kant and Steck, 1973; Rogalski et al., 1989; Tsai et al., 1982; Xu and 
Becker, 1998; Xu et al., 1995), making glycolytically produced ATP the primary energy source 
for membrane ion pumps, such as the Na
+
/K
+
-ATPase and Ca
2+
-ATPase [see section 2.3.2] 
(Kauppinen et al., 1988; Mielke et al., 1996; Xu et al., 1995).   
 
Figure 7.7 
 
 
 
Figure 7.7 Cerebral glucose uptake. Positron Emission Tomography (PET) scans of 
altered glucose metabolism in normal, mild cognitive impairment (MCI), and Alzheimer 
disease (AD) brains.  Altered cellular metabolism, particularly cerebral glucose uptake, is 
altered as early as MCI, and becomes significantly decreased in AD brain (image 
courtesy of the Alzheimer's Disease Education and Referral Center).   
 
 
Although the glycolytic function of enolase does not directly produce ATP or the reduced 
energy carrier nicotinamide adenine dinucleotide (NADH), up-regulation of -enolase in the 
brain of Tg PDAPP(J20) mice suggests there may be an increased need for glycolytic ATP 
production.  Increased levels of -enolase have also been reported in proteomic studies of brain 
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from subjects with AD and MCI, arguably the earliest form of AD [see section 2.6.1] (Castegna 
et al., 2002a; Sultana et al., 2007b).  Also, increased oxidative modification of -enolase as 
indexed by protein carbonyls, 3-NT, and HNE has been reported in the brains of subjects with 
AD and AD model systems (Castegna et al., 2003; 2002a; 2002b).  Because oxidative 
modification of proteins generally leads to a loss of function (Butterfield and Stadtman, 1997), 
-enolase modification may result in impaired ATP production.  Current results are consistent 
with Positron Emission Tomography (PET) studies in AD and MCI brains that show altered 
glucose metabolism (Watson and Craft, 2004).  Moreover, α-enolase has other pro-survival 
functions, including activation of ERK 1/2 and induction of plasmin (via plasminogen), a 
degradation product, of which, is Aβ (Ledesma et al., 2000; Tucker et al., 2000a; 2000b; Van 
Nostrand and Porter, 1999).  Hence, conceivably up-regulation of α-enolase may be an attempt 
by the brain of Tg PDAPP(J20) mice to evoke enolase-related pro-survival pathways in view of 
induced Aβ(1-42) and subsequent oxidative stress observed. 
ATP synthase, subunit  (mitochondrial), is a part of the ATP synthase complex, an inner 
mitochondrial membrane integrated enzyme involved in the production of ATP during oxidative 
phosphorylation (Table 7.3; see section 2.3.4).  Mitochondrial dysfunction has been linked to AD 
pathogenesis (Blass et al., 2002; Bubber et al., 2005).  In advanced stages of AD, ATP synthase 
activity is reportedly decreased in AD brain (Schagger and Ohm, 1995), in addition to being 
oxidatively modified.  As noted, the age of Tg PDAPP(J20) mice used in these studies was 9 
months, an age at which significant Aβ accumulation and plaque deposition is present in the 
brains (Galvan et al., 2006; Mucke et al., 2000; Shankar et al., 2009).  Thus, both -enolase and 
ATP synthase, subunit α (mitochondrial), up-regulation may represent an early attempt to 
prevent lowered levels of ATP production that will inevitably occur with increased Aβ 
accumulation and SP formation, signatures of advanced stages of AD.  
7.5.2  Calcium Signaling 
Dysregulation of Ca
2+
 homeostasis has been linked to brain aging (Foster et al., 2001) 
and to AD (Mattson and Chan, 2001).  Calcineurin is a highly expressed, heterodimeric 
Ca
2+
/calmodulin-dependent serine (Ser)/threonine (Thr) protein phosphatase (also known as 
PP2B) important in Ca
2+
 signaling in the brain [Table 7.3] (Goto et al., 1986; Klee et al., 1998).  
Calcineurin consists of both a calmodulin binding subunit, calcineurin A (61 kDa), and a Ca
2+
 
binding subunit, calcineurin B [19 kDa] (Aitken et al., 1984; Hemenway and Heitman, 1999; 
Merat and Cheung, 1987).  Unfortunately, studies of calcineurin expression and activity in AD 
brain and various AD models to date have been somewhat contradictory.  For example, one 
study reported that calcineurin had reduced basal activity in AD frontal cortex (Lian et al., 2001), 
while studies of cortical cells treated with exogenous Aβ(25-35) and Aβ(1-40) showed an 
increase in calcineurin activity with protein levels being unaffected (Agostinho et al., 2008).  
However, in a study of primary neuronal cultures treated with exogenous Aβ, the levels of 
calcineurin were reduced (Celsi et al., 2007).  It is possible that previous studies vary drastically 
due to experimental design, in that in vitro systems do not necessarily always replicate what is 
observed in vivo.  Moreover, consistency may be found if each calcineurin subunit were 
investigated individually.  
For example, a study by Hata, et al. (2001) showed that the calcineurin subunit B is one 
of the most up-regulated genes in AD hippocampus (Hata et al., 2001).  Furthermore, the current 
dissertation study observed an increased level of calcineurin, subunit B, Type 1, in vivo in brain 
of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls.  Consistent with this 
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observation, a study by Norris, et al. (2005) reported significant over-expression of calcineurin in 
hypertrophic astrocytes that surround SP in the brains of APP/PS-1 double transgenic mice 
(Norris et al., 2005), which has also been reported in the hippocampus of patients with MCI and 
AD (Abdul et al., 2009).  Overall, increased levels of calcineurin in the present PDAPP mouse 
model of Aβ pathology are consistent with alterations in glutamate release, neuroinflammation, 
synaptic plasticity, cell survival, and cognitively related changes in behavior.        
7.5.3  Antioxidant Defense 
 Peroxiredoxin-1 is an antioxidant enzyme (Table 7.3) that catalyzes the reduction of 
peroxynitrite (ONOO
-
), hydrogen peroxide (H2O2), and alkyl hydroperoxides (ROOH) [see 
sections 2.4.2 & 2.4.3] (Peshenko and Shichi, 2001).  Thus, this enzyme is important to the cell‟s 
defense against reactive oxygen (ROS) and nitrogen (RNS) species.  Peroxiredoxin-1 is an 
abundant intracellular protein shown to be significantly up-regulated in brain of Tg PDAPP(J20) 
mice, relative to Non Tg PDAPP control mice, in the current dissertation study.  Such an 
increase in the levels of this antioxidant enzyme may represent a response to Aβ accumulation 
and plaque deposition and subsequent increases in ROS and RNS in the mouse brain.  In AD, 
peroxiredoxins, including peroxiredoxin-2 and -6, have been found oxidatively modified, which 
likely results in an increase in the levels of protein nitration (Reed et al., 2008b; Sultana et al., 
2006a).  In the present J20 mouse model of Aβ pathology, it appears that prior to SP formation 
(i.e., at 9 months) there are increased attempts at brain detoxification, considering Chapter 6 of 
this dissertation reports increased indices of oxidative stress (i.e., protein carbonyls, 3-NT, and 
HNE).  This notion is consistent with proteomic studies that report increased levels of 
peroxiredoxin-1 in the brains of AD subjects (Kim et al., 2001).            
7.5.4  Neuritic Abnormalities & Structural Integrity 
Cell structural integrity is known to be altered in AD, especially considering the wide-
spread loss of synaptic plasticity and neurons found in AD brain (Butterfield et al., 2006c).  The 
current study found the F-actin-capping protein, subunit β, to be significantly up-regulated in 
brains of Tg PDAPP(J20) mice.  This particular protein is highly involved in cellular structural 
integrity, as it binds to the end of filamentous actin polymers, regulating filament number and 
length [Table 7.3] (Weeds and Maciver, 1993).  Actin is also involved in cytoskeletal network 
integrity and intracellular locomotion (Weeds and Maciver, 1993).  Increased levels of F-actin 
capping protein, subunit β, are consistent with the notion of increased intracellular 
molecule/organelle movement, which may be evidence for the cell‟s increased effort to maintain 
structural integrity and locomotion in the presence of Aβ accumulation and plaque deposition 
that could be affecting these pathways in brain of Tg PDAPP(J20) mice.  
TCP-1A is a part of the TCP-1 family that is involved in molecular chaperoning, is an 
initiator of microtubule growth (Brown et al., 1996), and is necessary for maintaining normal 
actin and tubulin function [Table 7.3] (Chen et al., 1994; Gupta, 1995; Ursic et al., 1994).  
Because actin and tubulin are major TCP-1 substrates, an increase in TCP-1A would require an 
increase in actin and actin-related proteins, like the F-acting-capping protein.  The TCP-1 ε unit 
was reported as having decreased levels in the parietal cortex and brains of subjects with AD 
(Schuller et al., 2001; Yoo et al., 2001).  The significant increase in TCP-1A levels that was 
found in the present investigation further supports the notion that in the presence of Aβ deposits 
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and oxidative stress at 9 months of age, cytoskeletal structural integrity is not yet compromised 
in this particular Tg mouse model of Aβ pathology.      
Consistent with reports of oxidative modification of Drp-2 in AD brain (Castegna et al., 
2002a; Sultana et al., 2006b), the current study also demonstrates an increase in Drp-2 protein 
carbonylation in brains of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls.  Drp-2 is 
involved in axonal and dendritic outgrowth, through regulation of the protein collapsing, and in 
neuronal repair (Hamajima et al., 1996; Kato et al., 1998).  Thus, Drp-2 is important for 
maintaining synaptic plasticity in the brain (Table 7.3).  Oxidative modification of Drp-2 in Tg 
PDAPP(J20) mice could lead to shortened neuritic connections, such as observed in AD 
(Coleman and Flood, 1987), and is consistent with the substantial loss of learning and memory 
endemic in this dementing disorder.  Significant Drp-2 oxidative modification and consequent 
dysfunction is consistent with behavioral changes in Tg PDAPP(J20) mice, which demonstrate 
significant memory deficits (Galvan et al., 2006; Hsia et al., 1999; Mucke et al., 2000).   
7.5.5  Lipid Abnormalities & Cholinergic Dysfunction 
PEBP-1 is a precursor of the hippocampal cholinergic neurostimulating peptide (HCNP), 
a signaling transduction peptide which regulates choline acetyltransferase (ChAT) function 
(Table 7.3).  Alterations to ChAT lead to reduced levels of acetylcholine, a neurotransmitter that 
is necessary for regulating normal neurotransmission [see section 2.1.3; Table 2.1] (Ojika, 1998).  
The present study reports a significant decrease in 3-NT levels associated with PEBP-1 in brains 
of Tg PDAPP(J20) mice relative to Non Tg PDAPP controls.  This result is somewhat 
unexpected as PEBP-1 (also known as neuropolypeptide h3 and Raf-kinase inhibitor protein 
[RIP]) has been previously reported as being significantly nitrated and HNE-modified (Castegna 
et al., 2003; Reed et al., 2008a; 2008b), together with a decrease in PEBP-1 mRNA expression in 
AD brain (Maki et al., 2002).  In addition, PEBP-1 has been previously shown to have 20% 
greater expression in the hippocampus of subjects with AD (Chen et al., 2006) and is believed to 
be a potential calpain substrate leading to proteasome dysfunction.  Furthermore, because PEBP-
1 is known to bind the inner-leaflet sequestered, membrane lipid, phosphatidylethanolamine, an 
increase in PEBP-1 nitration in AD brain may contribute to disruption of lipid asymmetry in AD 
and aMCI (see Chapters 4 & 5), leading to increased levels of apoptosis and poor 
neurotransmission due to reduced acetylcholine levels.   
Conversely, lower levels of 3-NT-modified PEBP-1 that were found in the current study 
may indicate that acetylcholine levels and lipid asymmetry are not yet significantly disturbed at 
this stage of AD/FAD pathology (i.e., 9 months-old) in these animals.  Hence, under this 
scenario, altered acetylcholine levels and lipid abnormalities could be a result of more advanced 
plaque formation that occurs in later stages of AD and FAD.  Finally, current results suggest that 
Tg PDAPP(J20) mice at 9 months of age may not yet have experienced significant (if any) 
proteasomal dysfunction.  Taken together, it appears that specific biochemical changes observed 
in AD and FAD may occur later in disease progression in Tg PDAPP(J20) mice despite the 
presence of significant Aβ(1-42) accumulation, plaque deposition, and oxidative stress.        
7.5.6  Cell Signaling, Cell-Cycle, Tau Phosphorylation, & Amyloid-β (Aβ) Production 
Pin-1 belongs to the family of peptidyl-prolyl isomerase enzymes (PPIases) and acts as a 
regulatory protein by binding to and isomerizing a proline residue on the C-terminal side of a 
phosphorylated Ser/Thr moiety (pSer/pThr) from the cis to trans conformation, thereby 
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regulating the activity of the target protein (Butterfield et al., 2006d).  Pin-1‟s functions are 
diverse and include regulation of pathways such as the cell-cycle, transcription, apoptosis, the 
DNA damage response, and even acts as a cytokine [Table 7.3] (Butterfield et al., 2006d).  In the 
last decade, Pin-1 has been heavily implicated in AD pathogenesis via its regulation of the 
phosphorylation state of the microtubule-associated protein tau [see section 2.6] (Lee and Tsai, 
2003; Lu et al., 2003), as well as the production of Aβ through binding APP (Pastorino et al., 
2006).  Pin-1 has been shown to be significantly oxidatively modified and has lowered 
expression and activity in the hippocampus of human AD and MCI brain (Sultana et al., 2006c).  
By contrast, the current study reported that Pin-1 levels were increased and nitration was 
decreased in vivo in the brains of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls; it 
should be noted, however, that in the present study, one-half of the mouse brain was 
homogenized (see section 3.4.2) and thus regional comparison to AD was not possible.  
Increased Pin-1 levels may indicate early response strategies that would maintain low levels of 
Aβ and subsequent SP formation in brain.  Furthermore, increased Pin-1 levels may keep post-
mitotic neurons from entering the cell-cycle, maintain normal transcriptional regulation of key 
proteins, and allow the brain to respond to DNA damage that may be occurring in Tg 
PDAPP(J20) mouse brain as a result of Aβ accumulation and plaque deposition and oxidative 
stress.  
Additionally, the levels of the cell signaling protein,  GDP-dissociation inhibitor 1, were 
found to be increased in brains of Tg PDAPP(J20) mice compared to Non Tg PDAPP controls.  
This inhibitor belongs to the  guanosine triphosphatase (GTPase) family of enzymes, which 
regulate membrane trafficking and recycling of GTPases (Wu et al., 1996), as well as APP 
processing [Table 7.3] (Maillet et al., 2003).  In the brain,  GDP proteins are involved in 
neurotransmitter release (Maillet et al., 2003).  A recent study involving the SN56 line of cells 
showed that exogenous exposure of cells to Aβ(1-42) leads to reduced phosphorylation levels of 
 GDP-dissociation inhibitor (Joerchel et al., 2008).  In studies of concanavalin A-associated 
proteins, the  GDP-dissociation inhibitor is reported as decreased in the hippocampus of 
subjects with AD (Owen et al., 2009).  Thus, increased levels of  GDP-dissociation inhibitor 1 
and Pin-1 in Tg PDAPP(J20) mice suggests that normal neurotransmission may still be occurring 
at 9 months-old in this mouse model of Aβ pathology, despite significant Aβ accumulation and 
plaque deposition. 
7.5.7  Conclusions 
The changes in the levels of and oxidative modification of proteins observed in this 
dissertation study of Tg PDAPP(J20) mouse brain support the notion that biochemical pathways 
are altered in AD and FAD.  Alterations in brain proteins in this mouse model of Aβ pathology 
are consistent with previous reports of AD pathology, involving altered proteins associated with 
calcium signaling and neuritic abnormalities.  Interestingly, it appears that the central nervous 
system of these mice may be responding to increased Aβ accumulation and/or SP deposition in 
an attempt to maintain normal ATP levels, cytoskeletal structural integrity, and cell signaling 
pathways.  Moreover, there also appears to be a possible antioxidant defense response that Tg 
PDAPP(J20) neurons are attempting to up-regulate against ROS and RNS, shown to be 
significantly increased in brain of Tg PDAPP(J20) mice at this age (Chapter 6).  Future studies 
of Tg PDAPP(J20) mice will involve continued investigation of the downstream effects of Aβ(1-
42)-induced oxidative stress, accumulation, and plaque deposition, in an attempt to gain more 
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insight into Aβ(1-42)-associated mechanisms of Met-35-mediated oxidation via genetic 
modification of the Tg PDAPP(J20) in vivo model of Aβ pathology.  
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CHAPTER 8 
IN VIVO EFFECTS ON THE PROTEOME OF AN ALZHEIMER DISEASE HUMAN 
MUTANT TRANSGENIC MOUSE MODEL WITH AN ADDITIONAL MET631LEU 
SUBSTITUTION ON APP
 
 
8.1  Overview 
A single methionine residue at position 35 (Met-35) of the amyloid-β peptide (Aβ) has 
been highly implicated in A-induced oxidative stress and neurotoxicity in Alzheimer disease 
(AD) brain.  Results reported in Chapters 6 and 7 of this dissertation demonstrated elevated 
levels of oxidative stress in vivo in brain of PDAPP transgenic (Tg) mice carrying Swedish and 
Indiana mutations on the human amyloid precursor protein (APP) [Tg PDAPP(J20)].  Chapter 6, 
however, shows that substitution of Met-35 of Aβ with a leucine (Leu; corresponding to residue 
631 of the human amyloid precursor protein [APP]) abrogated all indices of oxidative stress (i.e., 
protein carbonyls, protein-resident 3-nitrotyrosine [3-NT], and protein-bound 4-hydroxy-2-trans-
nonenal [HNE]), thereby supporting the notion that Met-35 mediates the majority of A-induced 
oxidative stress in AD brain.  In the current dissertation study, differential expression proteomics 
analysis of Tg PDAPP(J20) mice relative to PDAPP mice carrying a Met631Leu substitution on 
APP [Tg PDAPP(M631L)] was conducted to gain a better understanding of specific protein 
pathways that may be altered as a result of maintaining low levels of oxidative stress in the 
absence of Met-35 of Aβ.  2D-gel expression studies identified 21 proteins as being significantly 
down-regulated in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  These 
proteins are involved in pathways such as cell signaling, migration, and proliferation, the cell-
cycle, structural integrity, energy and metabolism, antioxidant/detoxification activity, 
proteasomal degradation, and pH regulation.  In addition, three proteins were found to be 
significantly differentially expressed in brain of Tg PDAPP(M631L) mice relative to non-
transgenic (Non Tg) M631L littermate mice.  1D-Western blot analysis used to validate spots 
identified as significantly differentially expressed by SEQUEST and PD-Quest image analyses 
confirmed the significant down-regulation of pyruvate kinase M2 (PK M2) in brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  Overall, these results suggest that in 
addition to the role of Met-35-associated oxidative stress and neurotoxicity, this Aβ residue also 
causes numerous downstream effects, which lead to differential expression of relevant protein 
pathways in AD.   
8.2  Introduction 
Autosomal dominant mutations in APP and presenilins-1 or -2 lead to a familial form of 
AD [FAD] (Citron et al., 1992; Cruts et al., 1998; Goate et al., 1991; Scheuner et al., 1996; 
Sturchler-Pierrat et al., 1997), which is clinically diagnosed by the age-related decline in 
cognition, in the same way as sporadic AD, but at an earlier age of onset [~30 years-old]  (Citron 
et al., 1992; Price et al., 1998; Scheuner et al., 1996; Sturchler-Pierrat et al., 1997; Wisniewski et 
al., 1998).  Major histopathological hallmarks of AD include the accumulation and deposition of 
senile plaques (SPs) and neurofibrillary tangles (NFTs), synapse and neuronal cell loss, and 
oxidative stress (Butterfield and Lauderback, 2002; Good et al., 1996; Markesbery, 1997; 
Mohmmad Abdul et al., 2006; Smith et al., 1997; 1994).  As a major component of SPs, Aβ(1-
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42) is considered to be the more toxic form of Aβ produced in AD brain, especially in its soluble, 
oligomeric form (Boyd-Kimball et al., 2005a; 2005b; 2005c; Demuro et al., 2005; Drake et al., 
2003a; Mohmmad Abdul et al., 2004; 2006; Selkoe, 1996; 2008; Viola et al., 2008).  The 
concept of Aβ-induced oxidative stress in AD has been extensively supported through various 
studies of AD model systems and subjects with AD (Abdul et al., 2008; Ansari et al., 2006; 
Boyd-Kimball et al., 2004; 2005b; Drake et al., 2003a; Mohmmad Abdul et al., 2006; Pappolla et 
al., 1999; Resende et al., 2008; Sultana et al., 2005; Zhu et al., 2008). 
Many of studies suggest the Met-35 residue of Aβ to be the main contributor to Aβ-
induced oxidative stress and damage.  For example, in vitro studies substituting norleucine (Nle) 
for Met (replacing the Met sulfur [S]-atom with a CH2 group; Fig. 2.53) at position 35 in human 
Aβ(1–42) demonstrated an almost complete abrogation of the oxidative and neurotoxic effects of 
the resulting Aβ(1-42) Met35Nle peptide in cultured neurons, while maintaining similar length, 
hydrophobicity, and tendency to aggregate as native human Aβ(1-42) (Butterfield and Boyd-
Kimball, 2005; Varadarajan et al., 2001; Yatin et al., 1999).  In addition, studies of 
Caenorhabditis elegans (C. elegans) demonstrate that substitution of Met-35 with a cysteine 
(Cys) [Fig. 2.53] in DNA encoding human Aβ(1-42) prevents in vivo protein oxidation and 
worm paralysis (Fay et al., 1998; Yatin et al., 1999).  Furthermore, results from Chapter 6 of this 
dissertation show that Tg PDAPP mouse models of Aβ pathology with an A Met35Leu 
substitution [Tg PDAPP(M631L)] have a significant decrease in protein oxidation and lipid 
peroxidation relative to Tg PDAPP(J20) mice carrying the Swedish (K670N and M671L) and 
Indiana (V717F) familial forms of AD (APPSw,In), which are expressed behind a platelet-derived 
growth factor (PDGF) β-chain promoter (Galvan et al., 2006; Mucke et al., 2000).  Additionally, 
the A Met35Leu mutation results in animals with lessened SP formation (Galvan et al., 2006; 
Mucke et al., 2000; Chapter 6).   
It has been proposed by the Butterfield laboratory that oxidative stress associated with 
toxic Aβ(1-42) is dependent on the formation of a S-centered, transient free radical on Met-35 
(Boyd-Kimball et al., 2004; Butterfield and Boyd-Kimball, 2005; Kanski et al., 2002; 
Varadarajan et al., 2001; Yatin et al., 1999).  Free radical initiated one-electron oxidation of the 
Met-35 S-atom makes it more susceptible to attack by reactive oxygen species (ROS), leading to 
sulfuranyl or hydroxysulfuranyl radical cations, which may react with superoxide (O2
.-
) or 
paramagnetic oxygen species.  Thus, Met-35 can undergo a reversible oxidation leading to the 
formation of methionine sulfoxide or it can undergo a two-electron oxidation leading to the 
irreversible formation of methionine sulfone (Fig. 8.1).  When Met-35 is not oxidized, 
hydrophobic A(1-42) can insert into the lipid bilayer and therein form a S-centered, transient 
free radical cation on Met-35 that can remove allylic hydrogen (H)-atoms from the acyl chains of 
membrane lipids, leading to the formation of lipid peroxidation products (Butterfield and Bush, 
2004; Butterfield and Boyd-Kimball, 2005).  The hydrophilicity of Met-35, however, increases 
when it is oxidized to methionine sulfoxide (Chao et al., 1997), making it less likely to insert into 
the lipid bilayer of neurons and lead to further oxidation.   
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Figure 8.1 
 
 
 
Figure 8.1 Reversible oxidation of methionine (Met).  Met can undergo a reversible 
oxidation leading to the formation of methionine sulfoxide or it can undergo a two-
electron oxidation leading to the irreversible formation of methionine sulfone.   
 
 
Other proposed mechanisms of Met-35-associated neurotoxicity of Aβ involve Met being 
a source of electrons for metals such as copper or zinc, which could generate O2
.-
 and highly 
reactive hydroxyl radicals [
.
OH] (i.e., Fenton chemistry; see section 2.4.2.1; reaction 3) and 
increase A deposition (Bush et al., 1994; Pogocki, 2004; Varadarajan et al., 2000; 2001).  Met-
35 is also important in AD pathology because its redox status directly correlates with amyloid 
fibril formation; when Met-35 is oxidized to methionine sulfoxide, the rate of fibril formation 
with A(1-42) is lowered and protofibrils are not formed (Bitan et al., 2003; Hou et al., 2002; 
Johansson et al., 2007a).  Moreover, oxidized Met-35 is reported to be in high abundance in SPs 
analyzed from subjects with AD (Kuo et al., 2001; Naslund et al., 1994).  This accumulation may 
be related to reduced activity of methionine sulfoxide reductase, an enzyme that cycles oxidized 
Met back to its reduced form, in AD brain (Gabbita et al., 1999). 
Met oxidation may be involved in regulatory signaling pathways and in antioxidant 
defense (Butterfield and Kanski, 2002), by becoming oxidized in order to protect amino acids in 
the active sites of various enzymes from oxidative insult (Stadtman, 2004).  Met may also 
influence the activity of repair or chaperone proteins (Bose-Basu et al., 2004) and helps to 
regulate cellular redox state (Schoneich, 2002).  Further insight into the exact mechanisms by 
which Met-35 redox status contributes to or even prevents A-induced oxidative stress and AD 
pathology can be realized by global proteome investigations.  To-date, there are no reports 
involving changes in the proteomes of AD or in vivo models of Aβ pathology as a function of the 
redox state of Met-35.   
The present dissertation study examined the hypothesis that the levels of specific brain 
proteins isolated from Tg PDAPP(M631L) mice may be significantly altered relative to Tg 
PDAPP(J20) mouse models of Aβ pathology, as well as Non Tg M631L mice.  2D-
polyacrylamide gel electrophoresis (2D-PAGE) coupled with mass spectrometry (MS) identified 
alterations in the expression of 21 proteins isolated from brain of Tg PDAPP(M631L) mice in 
comparison to Tg PDAPP(J20) mice, which are known to be involved in cell signaling, 
migration, and proliferation, the cell-cycle, structural integrity, energy and metabolism, 
antioxidant/detoxification activity, proteasomal degradation, and pH regulation.  Additionally, 
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three proteins were found to be significantly differentially expressed in brain of Tg 
PDAPP(M631L) mice relative to Non Tg M631L littermates.  1D-Western blot analysis used to 
validate spots identified as significantly differentially expressed by SEQUEST and PD-Quest 
image analyses confirmed the significant down-regulation of PK M2 in brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  Results reported in this chapter will 
be discussed with regard to the implications of the differentially expressed proteins as a result of 
Met-35 redox state in AD.     
8.3  Experimental Procedures 
All materials and methods used in this study are described in Chapter 3 of this 
dissertation.  Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, 3.7, 3.8.1.2, 3.9.1, 3.10, and 3.11. 
8.3.1  Statistical Analysis 
All data are presented as mean ± standard deviation (S.D.) or mean ± standard error of 
the means (S.E.M.), as noted.  Statistical analyses were performed using a two-tailed Student‟s t-
test, wherein P<0.05 was considered significant for differential expression fold-change values 
and oxidative modification levels.  Protein and peptide identifications obtained with the 
SEQUEST search algorithm with a P-value<0.01 were considered statistically significant.  To 
further validate PD-Quest and SEQUEST identifications of significantly different spots, the 
location of protein spots on 2D-gels were manually checked to ensure they were near the 
expected molecular weight (MW) and isoelectric point (pI) values based on SwissProt database 
information.   
8.4  Results 
PDAPP mice were created in collaboration with Professor Lennart Mucke at the 
University of California (San Francisco, CA), while M631L mice were created by our 
collaborators at the Buck Institute for Age Research (Novato, CA).  Many lines of 
PDAPP(M631L) were produced (>10) to derive two with high-level APP expression similar to 
that of Tg PDAPP(J20) mice, in order to form an accurate comparison.  Therefore, because the 
A1058 line of Tg PDAPP(M631L) mice was closest to Tg PDAPP(J20) mice in APP expression, 
it was used for all studies reported here.  2D-gel-based proteomics analyses were performed on 
proteins extracted from the brains of Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L 
mice, resulting in two comparisons:  Tg PDAPP(M631L) mice relative to Tg PDAPP(J20) mice 
and Tg PDAPP(M631L) mice relative to Non Tg M631L mice.   
8.4.1  Tg PDAPP(M631L) Mice Compared to Non Tg M631L Mice 
Effects inherently present in Tg PDAPP(M631L) mice as a result of the M631L 
transgene can be realized through comparisons with their Non Tg M631L littermates as a 
control.  Three spots were observed to have significant differences in protein levels based on an 
image analysis of spot densities in Tg PDAPP(M631L) mice compared to Non Tg M631L mice. 
Examples of 2D-gel images from these analyses can be found in Figure 8.2.  Table 8.1 lists the 
number of peptide sequences, spectral counts (SC), MW, pI, fold-change levels, and P-values 
associated with each protein identified in Tg PDAPP(M631L) relative to Non Tg M631L mice.  
In order to increase confidence in proteins identified with only a single peptide sequence, more 
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than one SC was observed and/or the protein was identified in other MS/MS experiments of that 
protein spot.  I am confident in the identification of these proteins based on the low P-values 
associated with the SEQUEST identifications (i.e., P3.00e
-04
).  In addition, the location of 
protein spots visually align with their anticipated MW and pI values on the 2D-gels.  It is 
important to note that in some cases, there appears to be a shift in the observed MW and pI from 
the predicted locations, presumably due to factors such as post-translational modification, which 
influences the net charge of proteins and degradation products.  Following MS/MS analysis of 
in-gel tryptic digests, these spots were identified as dynamin-1, heat shock protein 90 B1 (Hsp90 
B1), and proteasome, subunit , Type 2.  As listed in Table 8.1, both dynamin-1 (5.98-fold, 
*P<0.013) and Hsp90 B1 (2.28, *P<0.035) are up-regulated in Tg PDAPP(M631L) brain 
relative to that of Non Tg M631L mice, whereas proteasome, subunit , Type 2 (1.65, 
*P<0.019) is down-regulated. 
 
Figure 8.2 
 
A) Non Tg M631L 
 
 
166 
 
Figure 8.2 (cont.) 
 
B) Tg PDAPP(M631L) 
 
 
Figure 8.2 Representative 2D-gel images of proteins isolated from brain of Tg 
PDAPP(M631L) and Non Tg M631L mice.  Protein spots identified as significantly 
differentially expressed after PD-Quest and SEQUEST analyses of A) Non Tg M631L 
and B) Tg PDAPP (M631L) 2D–gels are labeled.  Hsp90 B1, heat shock protein 90 B1. 
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Table 8.1 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to 
Non Tg M631L controls.  
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
Fold-
Changec 
P-valued 
Dynamin-1 P39053 97.74 7.62 1(3) 6.00e-09 5.99 ↑ 0.013 
Heat-shock protein 90, B1 
(Hsp90 B1) 
P08113 92.42 4.59 4(8) 5.00e-06 2.28 ↑ 0.035 
Proteasome, subunit β, 
Type 2 
Q9R1P3 22.89 6.61 1(2) 3.00e-04 1.65 ↓ 0.019 
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.  The 
total number of MS/MS spectral counts (SC) is indicated in ( ). 
b
The probability of an incorrect identification associated with each protein identification using the 
SEQUEST search alogorithm. 
c
The fold-change in spot density from Tg PDAPP(M631L) mice compared to Non Tg M631L 
controls.  The arrow indicates the direction of change. 
d
The P-value associated with fold-change
c
 calculated using a Student‟s t-test.  n=10 for Tg 
PDAPP(M631L), n=5 for Non Tg M631L. 
pI, isoelectric point; MW, molecular weight. 
 
 
8.4.2  Tg PDAPP(M631L) Mice Compared to Tg PDAPP(J20) Mice 
21 spots were observed to have a significant differential levels based on an image 
analysis of spot densities in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, used 
as a positive control of Aβ-related AD pathology.  Examples of 2D-gel images from these 
analyses can be found in Figure 8.3.  Table 8.2 lists the number of peptide sequences, SC, MW, 
pI, fold-change levels, and P-values associated with each protein identified in Tg 
PDAPP(M631L) relative to Tg PDAPP(J20) mice.  Interestingly, each of these proteins is down-
regulated in brain of Tg PDAPP(M631L) mice.  In order to increase confidence in proteins 
identified with only a single peptide sequence, more than one SC was observed and/or the 
protein was identified in other MS/MS experiments of that protein spot.  I am confident in the 
identification of these proteins based on the low P-values associated with the SEQUEST 
identifications (i.e., P3.00e
-04
).  In addition, the location of protein spots visually align with 
their anticipated MW and pI values on the 2D-gels.  Again, it is important to note that in some 
cases, there appears to be a shift in the observed MW and pI from the predicted locations, 
presumably due to factors such as post-translational modification, which influences the net 
charge of proteins and degradation products.  The proteomic investigation into Tg PDAPP(J20) 
mice relative to Non Tg PDAPP littermates reported in Chapter 7 of this dissertation will also be 
used in this chapter to allow direct proteome comparisons based on the redox status of Met-35.   
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Figure 8.3 
A) Tg PDAPP(M631L) 
 
A) Tg PDAPP(M631L) [cont.] 
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Figure 8.3 (cont.) 
 
B) Tg PDAPP(J20) 
 
B) Tg PDAPP(J20) [cont.] 
 
 
Figure 8.3 Representative 2D-gel images of proteins isolated from brain of Tg 
PDAPP(M631L) and Tg PDAPP(J20) mice.  Protein spots identified as significantly 
differentially expressed after PD-Quest and SEQUEST analyses of A) Tg 
PDAPP(M631L) and B) Tg PDAPP(J20) 2D–gels are labeled.  Drp-2, 
dihydropyrimidinase-related protein 2; FBA-C, fructose bisphosphate aldolase C; MDH, 
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malate dehydrogenase, cytoplasmic; CA-2, carbonic anhydrase 1; TPI, triose phosphate 
isomerase; NADH DH, nicotinamide adenine dinucleotide (NADH) dehydrogenase 
[ubiquinone] flavoprotein 2; PEBP-1, phosphatidylethanolamine-binding protein 1; PRX-
2, peroxiredoxin-2; PRX-1, peroxiredoxin-1; Pin-1, peptidyl-prolyl cis-trans isomerase 1; 
VDAC-1, voltage-dependent anion channel 1; MnSOD, superoxide dismutase [Mn], 
mitochondrial; PK M1/M2, pyruvate kinase M1/M2; PGM 1, phosphoglycerate mutase 1; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
 
 
Table 8.2 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice.  
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
Fold-
Changec 
P-valued 
Acot7, isoform B of cytosolic acyl 
coenzyme A, thioester 7 
Q91V12 42.51 8.77 2(5) 3.00e-07 2.10 ↓ 0.024 
ATP synthase subunit α, 
mitochondrial * 
Q03265 59.72 9.53 5(10) 8.00e-07 4.21 ↓ 2.55e-05 
Q03265 59.72 9.53 11(37) 1.00e-10 2.25 ↓ 0.0001 
Carbonic anhydrase 2 (CA-2) P00920 29.01 6.54 2(6) 1.00e-10 2.08 ↓ 0.0004 
Dihydropyrimidinase-related 
protein 2 (Drp-2) 
O08553 62.24 5.93 3(10) 2.00e-11 3.81 ↓ 0.019 
Fructose bisphosphate aldolase C * 
P05063 39.37 6.74 3 (6) 9.00e-08 3.86 ↓ 0.028 
P05063 39.37 6.74 1(3) 2.00e-08 1.70 ↓ 0.0014 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) * 
P16858 35.81 8.33 4(11) 9.00e-11 3.23 ↓ 0.019 
P16858 35.81 8.33 4(11) 2.00e-07 1.58 ↓ 0.0002 
Malate dehydrogenase, 
cytoplasmic 
P14152 36.49 6.16 2(4) 2.00e-05 2.33 ↓ 0.007 
NADH dehydrogenase 
[ubiquinone] flavoprotein 2 
Q9D6J6 27.27 7.15 3(7) 5.00e-07 2.15 ↓ 0.0097 
Peptidyl-prolyl cis-trans 
isomerase (Pin-1) * 
P17742 18.30 7.97 1(3) 3.00e-05 5.86 ↓ 0.0017 
P17742 18.30 7.97 1(3) 1.00e-05 2.24 ↓ 0.0015 
P17742 18.30 7.97 1(6) 2.00e-04 1.80 ↓ 0.00087 
Peroxiredoxin-1 P35700 22.16 8.2 1(2) 2.00e-04 6.02 ↓ 0.004 
Peroxiredoxin-2 Q61171 21.77 5.08 2(2) 4.00e-09 5.31 ↓ 0.037 
Phosphatidylethanolamine-
binding protein 1 (PEBP-1) 
P70296 20.82 5.07 3(11) 1.00e-07 5.51↓ 0.010 
Phosphoglycerate mutase 1 Q9DBJ1 28.81 6.79 3(7) 4.00e-08 1.81 ↓ 0.00074 
Proteasome, subunit β, Type 3 Q9R1P1 22.95 6.15 1(3) 9.00e-09 2.45 ↓ 0.027 
Pyruvate kinase isozymes M1/M2 
(PK M1/M2) * 
P52480 57.95 6.73 1(2) 3.00e-04 33.3 ↓ 0.0063 
P52480 57.95 6.73 8(25) 1.00e-08 2.53 ↓ 0.0049 
Serum Albumin P07724 68.65 5.69 1(4) 6.00e-09 5.39 ↓ 0.0026 
Superoxide dismutase [Mn], 
mitochondrial (MnSOD) 
P09671 24.59 8.80 1(3) 4.00e-05 2.09 ↓ 0.019 
Transgelin-3 Q9R1Q8 22.46 7.16 1(5) 1.00e-04 2.37 ↓ 0.028 
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Table 8.2 (Cont.) 
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
Fold-
Changec 
P-valued 
Triose phosphate isomerase 
(TPI) * 
P17751 26.69 7.07 1(1) 4.00e-06 4.86 ↓ 0.022 
P17751 26.69 7.07 6(12) 2.00e-07 2.31 ↓ 9.97e-05 
Voltage-dependent anion-
selective channel protein 1 
(VDAC-1) 
Q60932 32.33 8.66 2(3) 3.00e-07 1.56 ↓ 0.029 
V-type proton ATPase, subunit F Q9D1K2 13.36 5.45 1(5) 2.00e-13 2.08 ↓ 0.045 
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.  The total 
number of MS/MS spectral counts (SC) is indicated in ( ). 
b
The probability of an incorrect identification associated with each protein identification using the 
SEQUEST search alogorithm. 
c
The fold-change in spot density from Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  
The arrow indicates the direction of change. 
d
The P-value associated with fold-change
c
 calculated using a Student‟s t-test.  n=10 for Tg 
PDAPP(M631L), n=10 for Tg PDAPP(J20). 
*These proteins were detected at multiple spot locations, as shown in Figure 8.3 
pI, isoelectric point; MW, molecular weight. 
 
 
8.4.3  Pyruvate Kinase M2 (PK M2) Western Blot Spot Validation  
Western blot validation was performed for the PK M2 protein as a representative 
confirmation of those brain proteins identified as significantly differentially expressed by PD-
Quest and SEQUEST analyses.  This data was obtained in collaboration with Dr. Rena Sowell 
Robinson (University of Pittsburgh, Pittsburgh, PA).  Western blot analysis showed that the lanes 
corresponding to PK M2 (~58 kDa) and the loading control, actin (42 kDa; used as a loading 
control to normalize the amount of protein loaded in each well of the gel), levels agree with their 
expected positions based on MW (Fig. 8.4a).  The histogram based on lane intensity shows a 
~30% decrease in the level of PK M2 in the brains of Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice (Fig. 8.4b; P<0.06).  The P-value for this change was near the level of 
significance (i.e., *P<0.05), therefore, these results are in agreement with the down-regulation 
observed in 2D-PAGE expression proteomics analyses described above.   
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Figure 8.4 
 
 
Figure 8.4 Pyruvate kinase M2 (PK M2) levels in brain of Tg PDAPP(M631L) and Tg 
PDAPP(J20) mice.  PK M2 and actin levels were measured by 1D-polyacrylamide gel 
electrophoresis (1D-PAGE; 75 μg/lane) and subsequent Western blot analysis in 9 
month-old Tg PDAPP(M631L) [lanes 2, 4, 6, 8, 10, and 12] and Tg PDAPP(J20) mice 
(lanes 1, 3, 5, 7, 9, and 11).  A)  Increased band intensity after normalization with actin 
represents an increase in the amount of PK M2 present.  n=6 for both Tg 
PDAPP(M631L) and Tg PDAPP(J20) groups.  B) Graphical representation of data shown 
in A) demonstrates a ~30% decrease in the levels of PK M2 in Tg PDAPP(M631L) mice 
compared to Tg PDAPP(J20) mice.  Percent control values are presented as mean ± 
S.E.M.; P<0.06.  Data obtained in collaboration with Dr. Rena Sowell Robinson 
(University of Pittsburgh, Pittsburgh, PA). 
 
 
8.5  Discussion 
Met-35 has been shown to have significant relevance to AD pathology, as evidenced by 
its critical role in A(1-42)-induced oxidative stress.  Changes to the redox status of Met-35 can 
influence levels of oxidative stress and A-associated fibril and aggregate formation (Butterfield 
and Bush, 2004; Butterfield and Boyd-Kimball, 2005).  Supporting this notion are results 
reported in Chapter 6 of this dissertation, where it was shown that the levels of oxidative stress in 
Tg PDAPP(J20) mice increase significantly compared to Non Tg PDAPP littermates, as indexed 
by protein carbonyls, protein-resident 3-NT, and protein-bound HNE.  In vivo substitution of 
Met-35 with Leu in Tg PDAPP(M631L) mice effectively returned oxidative stress levels in brain 
to levels similar to that observed in Non Tg PDAPP and Non Tg M631L littermate control mice.  
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Therefore, in order to gain further insight into the biochemical pathways altered as a result of the 
Met35Leu substitution, differential expression proteomics analyses of Tg PDAPP(M631L), Non 
Tg M631L littermates, and Tg PDAPP(J20) mice were conducted.   
In the current study, 2D-PAGE analyses identified dynamin-1, Hsp90 B1, and 
proteasome subunit , Type 3, to be significantly up-regulated in Tg PDAPP(M631L) mice 
relative to Non Tg M631L mice (Table 8.1).  Previous studies have demonstrated altered levels 
of Hsp90 in AD hippocampus (Owen et al., 2009) and have indicated that both α and β subunits 
of the proteasome are oxidatively modified in a C. elegans model of AD (Boyd-Kimball et al., 
2006).  Moreover, studies have shown an Aβ-induced decrease in dynamin-1, resulting from 
calpain-mediated cleavage of dynamin-1 protein, in addition to potential down-regulation of 
dynamin-1 gene expression (Kelly et al., 2005; Sinjoanu et al., 2008).  The observed alteration in 
these proteins‟ levels in Tg PDAPP(M631L) mice may reflect introduction of the APPSw,In 
transgene with a Met35Leu substitution.  Dynamin-1 is a phosphatidylinositol 3-kinase inhibitor 
and may be associated with synaptic vesicle recycling and endocytosis (Yao et al., 2003).  Thus, 
the up-regulation of dynamin-1 may reflect an increase in synaptic recycling, since synapse loss 
was not shown to be compromised in brain of Tg PDAPP(M631L) mice in Chapter 6.  Similar to 
dynamin-1, up-regulation of the molecular chaperone, Hsp90 B1, suggests that Tg 
PDAPP(M631L) mice have heightened cellular defense responses as compared to Non Tg 
M631L mice.  Down-regulation of proteasome, subunit , Type 2, in brain of Tg 
PDAPP(M631L) mice relative to Non Tg M631L mice may be indicative of alterations in 
proteasomal machinery caused by other pathways not directly related to A(1-42)-induced 
oxidative stress.  Since a decrease in proteasome subunit levels would deter the cells ability to 
remove oxidatively or otherwise damaged proteins, it is reasonable to believe the cell employs an 
equal but opposite response, which causes up-regulation of potentially protective proteins, like 
dynamin-1 and Hsp90 B1, to compensate.    
However, the primary goal of the current research was to determine differences in protein 
levels between Tg PDAPP(M631L) and Tg PDAPP(J20) mice.  In Chapter 7 of this dissertation, 
the alteration of several proteins in brain of Tg PDAPP(J20) mice relative to Non Tg PDAPP 
littermates was reported, possibly as a result of increased A oligomerization, deposition, and 
oxidative stress (Galvan et al., 2006; Mucke et al., 2000).  Moreover, AD pathology, including 
SPs and oxidative stress, were shown to be significantly reduced in brain of Tg PDAPP(M631L) 
mice compared to Tg PDAPP(J20) mice in Chapter 6, supporting the involvement of Met-35 in 
A(1-42)-induced oxidative stress.  In the current study, 21 proteins were identified as being 
significantly down-regulated in Tg PDAPP(M631L) brain relative to that of Tg PDAPP(J20) 
mice; below is a brief discussion of the overall functions associated with these proteins and their 
implications to AD pathology.          
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Table 8.3 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) and Non Tg M631L mice and their cellular functions.  
Current 
Alteration 
Protein Cellular Function(s) 
Tg PDAPP(M631L) vs. Tg PDAPP(J20) 
↓ Expression 
Acot7, isoform B of cytosolic acyl coenzyme 
A, thioester 7 
Energy  Metabolism; Lipid 
Synthesis 
↓ Expression ATP synthase, subunit α, mitochondrial Energy Metabolism 
↓ Expression Fructose bisphosphate aldolase C Energy Metabolism 
↓ Expression 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) 
Energy Metabolism 
↓ Expression Malate dehydrogenase, cytoplasmic Energy Metabolism 
↓ Expression 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2 
Energy Metabolism 
↓ Expression Phosphoglycerate mutase 1 Energy Metabolism 
↓ Expression 
Pyruvate kinase isozymes M1/M2  
(PK M1/M2) 
Energy Metabolism 
↓ Expression Triose phosphate isomerase  (TPI) Energy Metabolism 
↓ Expression V-type proton ATPase, subunit F Energy Metabolism 
↓ Expression 
Voltage-dependent anion-selective channel 
protein 1 (VDAC-1) 
Mitochondrial Permeability 
↓ Expression Peroxiredoxin-1 Antioxidant 
↓ Expression Peroxiredoxin-2 Antioxidant 
↓ Expression 
Superoxide dismutase [Mn], mitochondrial 
(MnSOD) 
Antioxidant 
↓ Expression Transgelin-3 Structural Protein 
↓ Expression Dihydropyrimidinase-related protein 2 (Drp-2) Structural Protein 
↓ Expression Peptidyl-prolyl cis-trans isomerase (Pin-1) Cell Signaling; Cell-Cycle 
↓ Expression 
Phosphatidylethanolamine-binding protein 1  
(PEBP-1) 
Cell Signaling, Proliferation, 
& Migration; Cholinergic 
System 
↓ Expression Carbonic anhydrase 2 (CA-2) pH Regulation 
↓ Expression Proteasome, subunit β, Type 3 Protein Degradation 
↓ Expression Serum Albumin 
Oncotic Pressure; Transport 
Protein 
Tg PDAPP(M631L) vs. Non Tg M631L 
↑ Expression Dynamin-1 
Structural Protein; 
Receptor-Mediated 
Endocytosis 
↑ Expression Heat-shock protein 90, B1 (Hsp90 B1) Molecular Chaperone 
↓ Expression Proteasome, subunit β, Type 2 Protein Degradation 
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8.5.1  Energy Dysfunction, Metabolism, & Mitochondrial Alterations 
Down-regulation of proteins involved in energy metabolism and mitochondrial function 
observed in these studies (Table 8.3) are consistent with known alterations in the brain of 
subjects with AD (Blass et al., 2002; Bubber et al., 2005; Watson and Craft, 2004), especially 
since a majority of the identified proteins have previously been found oxidatively modified in 
subjects with and animal models of AD (reviewed in Sultana et al., 2009).  Cellular metabolism, 
particularly cerebral glucose uptake, is known to be altered in the brains of patients with AD and 
mild cognitive impairment (MCI) [Fig. 7.7] (Watson and Craft, 2004).  Proteins identified to be 
significantly up-regulated in brain of Tg PDAPP(J20) mouse models of Aβ pathology in Chapter 
7, including α-enolase and ATP synthase, subunit α, support this notion.  The significant 
decrease in proteins associated with glucose metabolism in this current study serve to reaffirm 
previous findings, suggesting that glucose metabolism, and hence, adenosine triphosphate 
(ATP)-based energy production is reduced following substitution of Met-35 with Leu.  This 
down-regulation of energy- and metabolic-related proteins suggests that Tg PDAPP(M631L) 
brain is not under a substantial amount of oxidative stress, which would initiate the increased 
production of key glycolytic proteins (Mielke et al., 1996), compared to Tg PDAPP(J20) brain.  
Likewise, down-regulation of voltage-dependent anion channel protein-1(VDAC-1), a major 
component of the mitochondrial permeability transition pore (see section 2.5.1), also suggests 
that Tg PDAPP(M631L) mouse brain is not exposed to a substantial amount of oxidative stress 
relative to brain of Tg PDAPP(J20) mice. 
8.5.2  Antioxidant & Cellular Defense 
Peroxiredoxins-1 and -2 and superoxide dismutase [Mn], mitochondrial (MnSOD or 
SOD2) are antioxidant enzymes (Table 8.3) which help the cell defend itself against ROS and 
reactive nitrogen species (RNS).  Peroxiredoxins catalyze the reduction of peroxynitrite (ONOO-
), hydrogen peroxide (H2O2), and alkyl hydroperoxides (ROOH) [see sections 2.4.2 & 2.4.3] 
(Peshenko and Shichi, 2001).   Peroxiredoxin-1 is up-regulated in the brain of subjects with AD 
(Kim et al., 2001), as well as in brain of Tg PDAPP(J20) mouse models of Aβ pathology 
(Chapter 7).  MnSOD, an antioxidant enzyme that catalyzes the dismutation of O2
.-
 into 
molecular oxygen and H2O2 (see section 2.4.2.1), has previously been found to be oxidatively 
modified in brain of subjects with AD, and is also down-regulated in the current study.  The 
down-regulation of peroxiredoxins-1, -2, and/or MnSOD in brain of Tg PDAPP(M631L) mice is 
consistent with the notion that the Met35Leu substitution substantially reduces the amount of 
ROS and RNS produced in neuronal cells, likely by Aβ, suspending the need for a greater 
surplus of antioxidant enzymes.  This notion is supported by results observed in Chapter 6, in 
which Tg PDAPP(M631L) mice had significantly lower levels of oxidative stress relative to Tg 
PDAPP(J20) mice.     
8.5.3  Neuritic Abnormalities & Structural Integrity 
Cellular structural integrity is another known alteration in AD brain (Mohmmad Abdul et 
al., 2006; Sultana et al., 2009).  Transgelin-3 and dihydropyrimidinase-related protein 2 (Drp-2) 
are two structural proteins found to be down-regulated in the present study (Table 8.3).  
Transgelin-3, also known as neuronal protein 25, is an F-actin binding protein whose cellular 
functions are not completely understood  (Mori et al., 2004).  In brain of Tg PDAPP(J20) mice, 
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an increase in the levels of F-actin capping protein, subunit β, was observed relative to Non Tg 
PDAPP controls (Chapter 7).  Although further investigation into the function(s) of transgelin-3 
are necessary, it can be speculated that current results suggest that the Met35Leu mutation 
reduces the need to maintain structural integrity and locomotion, compared to Tg PDAPP(J20) 
brain.  Likewise, Drp-2 is associated with axonal outgrowth and maintenance of neuronal 
plasticity (Hamajima et al., 1996; Kato et al., 1998).  Although a significant alteration in Drp-2 
levels was not observed in brain of Tg PDAPP(J20) mice, this protein was found to be 
significantly carbonylated in brain of Tg PDAPP(J20) mice (Chapter 7), as well as in brain of 
subjects with AD (Boyd-Kimball et al., 2005c; Casserly and Topol, 2004; Castegna et al., 
2002a).  Therefore, down-regulation of Drp-2 in Tg PDAPP(M631L) mouse brain may signify 
the ability of neurons to maintain structural integrity.   
8.5.4  pH Regulation  
Carbonic anhydrase 2 (CA-2) is involved in the maintenance of cellular pH levels (Table 
8.3) through catalysis of carbon dioxide (CO2) into bicarbonate (HCO3
-
) and protons, as well as 
regulating CO2 and HCO3
-
 transport, and maintaining H2O and electrolyte balance (Sly and Hu, 
1995).  In addition, CA-2 is also involved in the production of cerebral spinal fluid and the 
synthesis of glucose and some lipids (Frey et al., 1998; Markesbery, 1997).  The ability of the 
cell to maintain the proper pH is necessary for optimal efficiency of mitochondrial and glycolytic 
enzymes involved in ATP production, as well as preventing the formation of protein aggregates.  
CA-2 has also previously been found to be oxidatively modified in brain of AD patients (Sultana 
et al., 2006b).  A decrease in CA-2 levels in Tg PDAPP(M631L) brain relative to that of Tg 
PDAPP(J20) mice suggests that pH maintenance is properly regulated in the brains of Tg 
PDAPP(M631L) mice.   
8.5.5  Lipid Abnormalities, Cholinergic Dysfunction, & Proteasome Degradation 
Phosphatidylethanolamine-binding protein 1 (PEBP-1; also known as neuropolypeptide 
h3 and Raf-kinase inhibitor protein [RIP]), a precursor of the hippocampal cholinergic 
neurostimulating peptide (HCNP), is involved in the regulation of choline acetyltransferase 
(ChAT), which influences the levels of the neurotransmitter, acetylcholine [Table 8.3] (Ojika, 
1998).  Elevated levels of PEBP-1 was previously reported in AD brain (Chen et al., 2006) and 
in brain of Tg PDAPP(J20) mice (Chapter 7), as well as oxidatively modified in brain of subjects 
with AD (Castegna et al., 2003; Reed et al., 2008a; 2008b).  Increased PEBP-1 levels would be 
indicative of a disruption in acetylcholine neurotransmission and lipid asymmetry; however, the 
significant decrease in PEBP-1 levels in brain of Tg PDAPP(M631L) mice suggests that 
cholinergic neurotransmission is still quite adequate and, thus, ChAT up-regulation via PEBP-1 
is not necessary.  This notion is, again, consistent with the concept that oxidative stress disrupts 
cholinergic neurotransmission, as Met-35 contributes to reduced acetylcholine levels and poor 
neurotransmission in subjects with AD and Tg PDAPP(J20) mouse models of Aβ pathology.  
Moreover, PEBP-1 is believed to be a potential calpain substrate leading to proteasome 
dysfunction (Chen et al., 2006).  Defects in proteasomal machinery in AD brain would lead to an 
accumulation of oxidatively and otherwise modified proteins that require degradation.  It appears 
intuitive that an increase in the levels of proteasome subunits would suggest that additional 
proteasome machinery is necessary to handle an overabundance of potential degradable proteins 
(i.e., aggregated or oxidized proteins).  In brain of Tg PDAPP(M631L) mice, however, it appears 
177 
 
that the Met35Leu substitution circumvents accumulation of degradation products and 
proteasomal dysfunction; therefore, excess production of proteasome-related proteins, such as 
proteasome subunit β, Type 3, is unnecessary, and subsequently reduced relative to that of Tg 
PDAPP(J20) brain. 
8.5.6  Cell Signaling, the Cell-Cycle, Tau Phosphorylation, & Amyloid-β (Aβ) 
Production 
Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) is a regulatory protein that belongs to the 
family of peptidyl-prolyl isomerase enzymes (PPIases), and acts as a regulatory protein by 
binding to and isomerizing a proline residue on the C-terminal side of a phosphorylated Ser/Thr 
moiety (pSer/pThr) from the cis to trans conformation, thereby regulating the activity of the 
target protein (Butterfield et al., 2006d).  Pin-1‟s functions are associated with cell-cycle 
regulation, transcription, cytokines, apoptosis, and the DNA damage response [Table 8.3] 
(Butterfield et al., 2006d).  Moreover, Pin-1 has been heavily implicated in AD pathogenesis via 
its regulation of the phosphorylation state of the microtubule-associated protein tau [see section 
2.6] (Lee and Tsai, 2003; Lu et al., 2003), as well as the production of Aβ through binding APP 
(Pastorino et al., 2006).  In Chapter 7, a significant increase in Pin-1 levels was observed in Tg 
PDAPP(J20) mice compared to brain of Non Tg PDAPP littermate controls, which may indicate 
an attempt by the brain to reduce Aβ levels and prevent SP formation.  In the current study, a 
significant decrease in the levels of Pin-1 was observed in brain of Tg PDAPP(M631L) mice 
relative to Tg PDAPP(J20) mice.  Thus, taken together, results indicate that involvement of Pin-1 
in AD pathology may be directly related to Met-35 of Aβ.   
8.5.7  Conclusions 
The results from the current dissertation study are rather striking, in that all 21 proteins 
identified as differentially expressed in brain of Tg PDAPP(M631L) mice are down-regulated  
when compared with the brain of Tg PDAPP(J20) mice.  The Met35Leu substitution on Aβ 
appears not only to lead to a reduction in the levels of oxidative stress levels and AD pathology, 
but also lowered levels of proteins involved in energy metabolism and mitochondrial 
maintenance pathways.  Such global changes in the proteome appear to make the brain of Tg 
PDAPP(M631L) mice similar to that of Non Tg M631L controls.  Moreover, other affected 
pathways include proteins involved in maintenance of neuronal structural integrity, antioxidant 
defenses, and cellular signaling likely play key roles in AD pathology as a result of Met-35 redox 
status and the overall redox status of the brain.  Overall, the current results suggest that in 
addition to the role of Met-35-associated oxidative stress and neurotoxicity, this Aβ residue also 
causes numerous downstream effects, which lead to differential expression of relevant protein 
pathways in AD.  Results also suggest that incorporation of Leu at position 35 of Aβ prevents a 
global response to oxidative stress, as evidenced by down-regulation of key proteins.  Future 
studies of Tg PDAPP(M631L) mice (Chapter 9) will involve a continued investigation of the 
downstream effects of Aβ(1-42)-induced oxidative stress, accumulation, and plaque deposition, 
in an attempt to gain more insight into Aβ(1-42)-associated mechanisms of Met-35-mediated 
oxidation via redox proteomics.  
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CHAPTER 9 
REDOX PROTEOMICS ANALYSIS OF AN ALZHEIMER DISEASE TRANSGENIC 
MOUSE MODEL CARRYING A MET631LEU SUBSTITUTION ON APP 
 
9.1  Overview 
Studies conducted in this dissertation, as well as previous literature reports, have shown 
that amyloid-β (Aβ)-induced oxidative stress plays a predominant role in both human and animal 
model Alzheimer disease (AD) pathology.  Results from Chapters 6 and 7 showed elevated 
levels of oxidative stress in vivo in brain of PDAPP transgenic (Tg) mice carrying Swedish and 
Indiana mutations in the human amyloid precursor protein (APP) [Tg PDAPP(J20)], as indexed 
by protein carbonylation, nitration, and protein-bound 4-hydroxy-2-trans-nonenal (HNE), 
compared to non-transgenic (Non Tg PDAPP) littermate controls.  Since this oxidative damage 
was found to be dependent upon a single methionine residue at position 35 (Met-35) of the Aβ 
peptide (residue 631 in human APP numbering) in Chapter 6, the current study compared 
genetically and age-matched PDAPP mice carrying a Met to leucine (Leu) substitution at 
position 35 (Met35Leu) of Aβ [Tg PDAPP(M631L)] to Tg PDAPP(J20) and Non Tg M631L 
littermate mice using a redox proteomics approach.  Based on present redox proteomics analyses, 
a total of 15 proteins were identified with significantly different levels of protein carbonyls or 
protein-resident 3-nitrotyrosine (3-NT), many, of which, have been previously identified as 
differentially expressed and/or oxidatively modified in in vitro and in vivo models of Aβ 
pathology and subjects with AD.  Five proteins were found significantly carbonylated in brain of 
Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, while only one protein had 
significantly decreased levels of carbonylation; no brain proteins were found to be significantly 
carbonylated in Tg PDAPP(M631L) mice relative to Non Tg M631L mice.  Redox proteomics 3-
NT analyses identified three proteins to be significantly nitrated, and two proteins with 
significantly reduced levels of protein-resident 3-NT, in Tg PDAPP(M631L) brain relative to 
that of Tg PDAPP(J20) mice; four proteins were identified as significantly nitrated in brain of Tg 
PDAPP(M631L) mice compared to Non Tg M631L mice.  In addition, immunoprecipitation 
validation of SEQUEST and PD-Quest image analyses spot identification confirmed the 
significant nitration of peptidyl-prolyl cis-trans isomerase 1 (Pin-1) in brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.   
9.2  Introduction 
Oxidative stress and damage is a hallmark of AD pathology, as many differential 
expression and redox proteomics analyses of both human and animal models AD brain have 
identified a number of dysfunctional, oxidatively modified proteins consistent with known 
biochemical, pathological, and clinical alterations in this devastating dementing disorder [see 
section 2.6] (Boyd-Kimball et al., 2005b; Butterfield and Sultana, 2008; Butterfield et al., 2006a; 
Reed et al., 2008b; Sultana et al., 2007b; 2006b; 2006c).  AD is also marked by the pathological 
manifestation of neurofibrillary tangles (NFTs) and senile plaques (SPs), whose main component 
is the Aβ(1-42) peptide.  In AD brain, it is the soluble, oligomeric form of Aβ(1-42) that is 
considered the toxic Aβ species (Demuro et al., 2005; Drake et al., 2003a; Selkoe, 2008; Viola et 
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al., 2008), which serves to exacerbate escalating levels of oxidative stress and damage, leading to 
loss of learning and memory (Selkoe, 2008; Walsh et al., 2002). 
Numerous studies have shown that Aβ(1-42) induces oxidative stress in AD and various 
AD model systems, linked to the Met-35 residue of this particular Aβ peptide (Abdul et al., 
2008; Ansari et al., 2006; Boyd-Kimball et al., 2004; 2005b; Butterfield and Boyd-Kimball, 
2005; Drake et al., 2003a; Kanski et al., 2002; Mohmmad Abdul et al., 2006; Pappolla et al., 
1999; Resende et al., 2008; Varadarajan et al., 2001; Yatin et al., 1999).  It has been proposed 
that the oxidative stress properties of Aβ(1-42) are dependent on the formation of a sulfur (S)-
centered, transient sulfuranyl radical cation on Met-35, that promotes protein oxidation and lipid 
peroxidation events within neurons [Figs. 2.54; 2.55] (Kanski et al., 2002; Varadarajan et al., 
2001; Yatin et al., 1999).  In support of this notion, results reported in Chapter 6 of this 
dissertation demonstrate a significant decrease in three indices of oxidative stress, including 
protein carbonyls, protein-resident 3-NT, and protein-bound HNE, in brain of Tg 
PDAPP(M631L) mice relative to Tg PDAPP(J20) mice, used as a positive control of Aβ-related 
AD pathology.  Moreover, the Met35Leu substitution returned oxidative stress levels back to a 
baseline amount, similar to that measured in Non Tg M631L littermate control mice. 
Therefore, the present dissertation study examined the hypothesis that specific brain 
proteins isolated from Tg PDAPP(M631L) mice may have significant differences in oxidative 
modification relative to Tg PDAPP(J20) mouse models of Aβ pathology, as well as Non Tg 
M631L mice.  Post-translational oxidative modification of proteins isolated from brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) and Non Tg M631L mice were identified 
following a comparative analysis between proteins separated by 2D-polyacrylamide gel 
electrophoresis (2D-PAGE) and identified as oxidatively modified by 2D-Western blotting.  A 
total of 15 proteins were identified with differential levels of protein carbonyls or protein-
resident 3-NT; five proteins were found significantly carbonylated in brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice, while only one protein had 
significantly decreased levels of carbonylation.  No proteins were found to be significantly 
carbonylated in Tg PDAPP(M631L) mice relative to Non Tg M631L mice.  3-NT analyses 
identified three proteins to be significantly nitrated, and two proteins with significantly reduced 
levels of protein-resident 3-NT, in Tg PDAPP(M631L) brain relative to that of Tg PDAPP(J20) 
mice; four proteins were identified as significantly nitrated in brain of Tg PDAPP(M631L) mice 
compared to Non Tg M631L mice.  Results obtained from SEQUEST and PD-Quest image 
analyses were validated by Pin-1 immunoprecipitation, which confirmed the significant nitration 
of Pin-1 in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  Findings from 
this redox proteomics study serve to enhance understanding of altered pathways in AD as they 
pertain to the Aβ peptide and provide potential targets for AD prevention and treatment. 
9.3  Experimental Procedures 
All materials and methods used in this study are described in Chapter 3 of this 
dissertation.  Specifically, sections 3.2.3, 3.3, 3.4.2, 3.5, and 3.7-3.12.  
9.3.1  Statistical Analysis 
All data are presented as mean ± standard error of the means (S.E.M.).  Statistical 
analyses were performed using a two-tailed Student‟s t-test, wherein P<0.05 was considered 
significant for differential expression fold-change values and oxidative modification levels.  
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Protein and peptide identifications obtained with the SEQUEST search algorithm with a P-
value<0.01 were considered statistically significant.  To further validate PD-Quest and 
SEQUEST identifications of significantly different spots, the location of protein spots on the 2D-
gels and 2D-Western blots were manually checked to ensure they were near the expected 
molecular weight (MW) and isoelectric point (pI) values based on SwissProt database 
information.   
9.4  Results 
PDAPP mice were created in collaboration with Professor Lennart Mucke at the 
University of California (San Francisco, CA), while M631L mice were created by our 
collaborators at the Buck Institute for Age Research (Novato, CA).  Many lines of 
PDAPP(M631L) were produced (>10) to derive two with high-level APP expression similar to 
that of Tg PDAPP(J20) mice, in order to form an accurate comparison.  Therefore, because the 
A1058 line of Tg PDAPP(M631L) mice was closest to Tg PDAPP(J20) mice in APP expression, 
it was used for all studies reported here.  Redox proteomics analyses were performed on proteins 
extracted from the brains of Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L mice, 
resulting in two comparisons:  Tg PDAPP(M631L) mice relative to Tg PDAPP(J20) mice and Tg 
PDAPP(M631L) mice relative to Non Tg M631L mice.   
9.4.1  Redox Proteomics 
Tryptic digestion and MS analysis was completed on excised protein spots according to 
PD-Quest analyses of 2D-gels and corresponding 2D-Western blots; Tables 9.1 and 9.2 provide a 
list of corresponding protein spot identifications, the number of peptide sequences and spectral 
counts (SC; the number of MS/MS events observed that meet SEQUEST filter criteria), MW, pI, 
fold-change levels, and P-values associated with each protein identified.  Approximately two-
thirds of proteins listed were identified with more than one single peptide and several SC (Tables 
9.1 & 9.2); for proteins identified with only a single peptide, more than one SC was observed 
and/or the protein was identified in other MS experiments of that protein spot.  I am confident in 
the identification of these proteins based on the low P-values associated with the SEQUEST 
identifications (i.e., P3.00e
-04
; the probability of an incorrect identification based on random 
identification of a protein).  In addition, the location of protein spots visually align with their 
anticipated MW and pI values on the 2D-gels (Fig. 9.1) and 2D-Western blots. 
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Figure 9.1 
 
A) Non Tg M631L 
 
 
B) Tg PDAPP(M631L) 
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Figure 9.1 (cont.) 
 
C) Tg PDAPP(J20) 
 
 
Figure 9.1 Representative 2D-gel images of proteins isolated and transferred to 2D-
Western blots from Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L mouse 
brain.  Protein spots identified as significantly carbonylated or nitrated after PD-Quest 
and SEQUEST analyses of A) Non Tg M631L, B) Tg PDAPP(M631L), and C) Tg 
PDAPP(J20) 2D–Oxyblots are labeled. GFAP, glial fibrillary acidic protein; TCP-1α, T-
complex protein 1 subunit  A; PK M1/M2, pyruvate kinase isoforms M1/M2; Pin-1, 
peptidyl-prolyl cis-trans isomerase 1; AATM, aspartate aminotransferase, mitochondrial; 
TPPP, tubulin polymerization-promoting protein; CK, ubiquitous creatine kinase, 
mitochondrial; GST μ1, glutathione-S-transferase μ 1; PGA mutase, phosphoglycerate 
mutase 1; PEBP-1, phosphatidylethanolamine-binding protein 1. 
 
 
9.4.1.1  Protein Carbonyls 
Utilizing previously established redox proteomics approaches for the detection of protein 
carbonyls (Butterfield and Sultana, 2008), six proteins were identified to be significantly affected 
by protein carbonylation in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) 
mice as a control (Table 9.1), while no proteins were found to be significantly carbonylated in Tg 
PDAPP(M631L) mice relative to Non Tg M631L mice as a control (Table 9.2).  Representative 
examples of 2D-gel images (corresponding to 2D-Western blots) from these analyses can be 
found in Figure 9.1, while two representative examples of carbonyl Western blots can be found 
in Figure 9.2.  A significant increase in carbonylation was found for five proteins: calmodulin, 
isoform 1(*P<0.028), 14-3-3 δ/δ (*P<0.036), phosphatidylethanolamine-binding protein 1 
(PEBP-1; *P<0.033), phosphoglycerate mutase 1 (*P<0.049), and PK M1/M2 (*P<0.032; Fig. 
9.2a), while a significant decrease in carbonylation was found for aspartate aminotransferase, 
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mitochondrial (AATM, *P<0.029; Fig. 9.2b) in brain of Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice as a control. 
 
Table 9.1 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice.  
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
% 
Control 
(J20Tg)c 
P-valued 
Protein Carbonyls:        
Calmodulin, isoform 1 P62204 16.83 3.93 2(11) 3.00e-10 17700 ↑ 0.028 
14-3-3 protein δ/δ P63101 27.75 4.57 2(5) 3.00e-10 219 ↑ 0.036 
Phosphatidylethanolamine- 
binding protein 1 (PEBP-1) 
P70296 20.82 5.07 2(4) 3.00e-07 323 ↑ 0.033 
Phosphoglycerate mutase 1 Q9DBJ1 28.81 6.79 3(7) 4.00e-08 209 ↑ 0.049 
Pyruvate kinase isozymes 
M1/M2 (PK M1/M2) 
P52480 57.95 6.73 11(37) 4.00e-10 3660 ↑  0.032 
Aspartate aminotransferase,  
 mitochondrial (AATM) 
P05202 23.56 9.27 2(3) 5.00e-07 1.33 ↓ 0.029 
3-NT:        
Actin (multiple isoforms)  P60710 41.71 5.18 3(5) 6.00e-07 33200 ↑ 0.033 
T-complex protein 1, 
subunit α A (TCP-1αA) 
P11984 60.30 5.7 1(2) 2.00e-07 350 ↑ 0.027 
Tubulin polymerization- 
promoting protein (TPPP) 
Q7TQD2 23.56 9.87 1(3) 9.00e-13 20.8 ↓ 0.026 
Aspartate aminotransferase,  
mitochondrial (AATM) 
P05202 47.38 9.27 2(3) 5.00e-07 1.83 ↓ 0.015 
Peptidyl-prolyl cis-trans 
isomerase 1 (Pin-1) 
P17742 18.30 7.97 1(6) 3.00e-04 211 ↑ 0.022 
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.  The total 
number of MS/MS spectral counts (SC) is indicated in ( ). 
b
The probability of an incorrect identification associated with each protein identification using the 
SEQUEST search alogorithm. 
c
Percent oxidation in Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice (J20Tg) as a  
control (oxidative level arbitrarily set to 100%). 
d
The P-value associated with % Control (J20Tg)
c
 calculated using a Student‟s t-test.  n=10 for Tg 
PDAPP(M631L); n=10 for Tg PDAPP(J20). 
pI, isoelectric point; MW, molecular weight. 
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Table 9.2 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Non 
Tg M631L controls.  
Protein 
SwissProt 
Accession 
No. 
MW 
(kDa) 
pI 
Peptides 
(SC)a 
pb 
% 
Control 
(NTg)c 
P-valued 
3-NT:        
Secernin-1 Q9CZC8 46.30 4.52 2(6) 3.00e-08 1110 ↑ 0.022 
Glial fibrillary acidic protein 
(GFAP) 
P03995 49.87 5.14 2(5) 3.00e-06 154 ↑ 0.037 
Glutathione-S-transferase μ1 
(GST μ1) 
P10649 25.95 8.11 1(2) 2.00e-07 494 ↑ 0.014 
Creatine kinase, ubiquitous, 
mitrochondrial (CK) 
P30275 46.98 8.13 1(3) 2.00e-09 3160 ↑ 0.038 
a
The number of peptide sequences identified by nanospray ESI-MS/MS of tryptic peptides.  The 
total number of MS/MS spectral counts (SC) is indicated in ( ). 
b
The probability of an incorrect identification associated with each protein identification using the 
SEQUEST search alogorithm. 
c
Percent oxidation in Tg PDAPP(M631L) mice compared to Non Tg M631L (NTg) controls 
(oxidative level arbitrarily set to 100%). 
d
The P-value associated with % Control (NTg)
c
 calculated using a Student‟s t-test.  n=10 for Tg 
PDAPP(M631L); n=5 for Non Tg M631L. 
pI, isoelectric point; MW, molecular weight. 
 
 
Figures 9.2 
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Figure 9.2 Representative 2D-Western blot images corresponding to carbonylated 
pyruvate kinase isoforms M1/M2 (PK M1/M2) and aspartate aminotransferase, 
mitochondrial (AATM).  A)  These images show a clear increase in PK M1/M2 protein 
carbonylation in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  
B)  These images show a clear increase in AATM protein carbonylation in brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice [images have been zoomed in 
to these spots].  Proteins were probed with an anti-dinitrophenylhydrazone (DNP) 
antibody, as described in Chapter 3.   
 
 
9.4.1.2  3-Nitrotyrosine (3-NT) Redox Proteomics 
Utilizing previously established redox proteomics approaches for the detection of protein-
resident 3-NT (Butterfield and Sultana, 2008; Sultana et al., 2006b), five proteins were identified 
to be significantly affected by protein nitration in brain of Tg PDAPP(M631L) mice compared to 
Tg PDAPP(J20) mice as a control (Table 9.1), while four proteins were found to be significantly 
affected by protein nitration in brain of Tg PDAPP(M631L) mice relative to Non Tg M631L 
mice as a control (Table 9.2).  Representative examples of 2D-gel images (corresponding to 2D-
Western blots) from these analyses can be found in Figure 9.1, while representative examples of 
3-NT Western blots are shown in Figures 9.3 and 9.4.  A significant increase in nitration was 
found for three proteins in brain of Tg PDAPP(M631L) mice compared to Tg PDAPP(J20) mice: 
actin (*P<0.033), T-complex protein 1, subunit α A (TCP-1αA; *P<0.027), and peptidyl-prolyl 
cis-trans isomerase 1 (Pin-1; *P<0.022; also Fig. 9.3b).  Two proteins with a significant decrease 
in nitration were the tubulin polymerization-promoting protein (TPPP; *P<0.026), and AATM 
(*P<0.015; also Fig. 9.3a).  All four proteins found to be significantly affected by nitration in 
brain of Tg PDAPP(M631L) mice compared to Non Tg M631L mice as a control showed a 
significant increase in 3-NT levels:  secernin-1 (*P<0.022), glutathione-S-transferase μ1 (GST 
μ1; *P<0.014; also Fig. 9.4a), glial fibrillary acidic protein (GFAP; *P<0.037; also Fig. 9.4b), 
and creatine kinase, ubiquitous, mitochondrial (CK; *P<0.038).  These results, as well as the 
aforementioned protein carbonyl redox proteomics results, will be discussed in detail below 
(section 9.5) with respect to protein function(s) and how the detected changes may be implicated 
in AD etiology.  
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Figure 9.3 
 
 
 
Figure 9.3 Representative 2D-Western blot images corresponding to nitrated aspartate 
aminotransferase, mitochondrial (AATM) and peptidyl-prolyl cis-trans isomerase 1 (Pin-
1). A) These images show a clear decrease in AATM nitration in brain of Tg 
PDAPP(M631L) mice compared to Tg PDAPP(J20) mice.  B)  These images show a 
clear increase in 3-nitrotyrosine (3-NT)-modified Pin-1 in brain of Tg PDAPP(M631L) 
mice compared to Tg PDAPP(J20) mice [images have been zoomed in to these spots].  
Proteins were probed with an anti-3-NT antibody, as described in Chapter 3.   
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Figure 9.4 
 
       
 
Figure 9.4 Representative 2D-Western blot images corresponding to nitrated 
glutathione-S-transferase μ1 (GST μ1) and glial fibrillary acidic protein (GFAP).  A)  
These images show a clear increase in GST μ1 nitration in brain of Tg PDAPP(M631L) 
mice compared to Non Tg M631L mice.  B)  These images show a clear increase in 3-
nitrotyrosine (3-NT)-modified GFAP in brain of Tg PDAPP(M631L) mice compared to 
Non Tg M631L mice [images have been zoomed in to these spots].  Proteins were probed 
with an anti-3-NT antibody, as described in Chapter 3.   
 
 
9.4.2  Peptidyl-Prolyl Cis-Trans Isomerase 1 (Pin-1) Immunoprecipitation  
Immunoprecipitation validation was performed for Pin-1 as a representative confirmation 
of those brain proteins identified as significantly oxidatively modified by SEQUEST and PD-
Quest image analyses.  Western blot analysis shows that lanes corresponding to Pin-1 (18 kDa) 
are indeed nitrated (Fig. 9.5a), while the histogram representing the average lane intensity for 
both Tg PDAPP(M631L) and Tg PDAPP(J20) mice shows a significant increase in the level of 
nitrated Pin-1 in Tg PDAPP(M631L) brain compared to Tg PDAPP(J20) mice as a control 
(*P<0.04; Fig. 9.5b).  These results are consistent with redox proteomics analyses described 
above, in which Pin-1 was identified as being significantly more nitrated in Tg PDAPP(M631L) 
mice relative to Tg PDAPP(J20) mice (211.44%; Table 9.1). 
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Figure 9.5 
 
 
 
Figure 9.5 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) nitration levels in brain of Tg 
PDAPP(M631L) and Tg PDAPP(J20) mice.  Following immunoprecipitation, Pin-1 
nitration was measured by 1D-polyacrylamide gel electrophoresis (1D-PAGE; 75 
μg/lane) and subsequent Western blot analysis of 9 month-old Tg PDAPP(M631L) 
[M35L] and Tg PDAPP(J20) [J20] mice.  A)  Increased band intensity represents an 
increase in the amount of 3-nitrotyrosine (3-NT)-modified Pin-1 present.  n=5 for both 
M35L and J20 groups, however only representative bands from n=3 independent samples 
are shown.  B) Graphical representation of data shown in A) demonstrates a significant 
increase in Pin-1 nitration levels in Tg PDAPP(M631L) mice compared to Tg 
PDAPP(J20) mice as a control.  Percent control values are presented as mean ± S.E.M.; 
*P<0.04. 
 
 
9.5  Discussion  
Indeed, much evidence supports Met-35 as being a major contributor to Aβ(1-42)-
induced oxidative stress and damage in brain of subjects with AD and mouse models thereof 
(Abdul et al., 2008; Ansari et al., 2006; Boyd-Kimball et al., 2004; 2005b; Butterfield and Boyd-
Kimball, 2005; Drake et al., 2003a; Kanski et al., 2002; Mohmmad Abdul et al., 2006; Pappolla 
et al., 1999; Resende et al., 2008; Varadarajan et al., 2001; Yatin et al., 1999).  Results reported 
in Chapters 6-8 of this dissertation also support this notion, as replacement of Met-35 with a Leu 
was shown to effectively abrogate oxidative stress associated with the native human Aβ(1-42) 
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peptide present in Tg PDAPP(J20) mice and down-regulate a number of proteins identified as 
over-expressed in Tg PDAPP(J20) mouse models of Aβ pathology.  In the current study, redox 
proteomics analyses identified secernin-1, GFAP, GST μ1, and ubiquitous, mitochondrial CK as 
being significantly nitrated relative to Non Tg M631L littermate control mice (Table 9.2).  The 
observed increase in protein-resident 3-NT levels for these proteins in brain of Tg 
PDAPP(M631L) mice may reflect a compensatory effect induced by introduction of the APPSw,In 
transgene with a Met35Leu substitution, and/or result from toxicity induced by other APP 
cleavage products, such as Jcasp, sAPPβ, and C31, or other non-amyloidogenic pathways that 
contribute to oxidative stress.  Although the primary goal of the current study was to determine 
differences in oxidative modification between Tg PDAPP(M631L) and Tg PDAPP(J20) mice, 
the effect(s) inherently present in Tg PDAPP(M631L) mice as a result of the M631L transgene 
can only be realized through comparison with their Non Tg M631L littermates.  Therefore, in 
order to gain further insight into the biological pathways altered as a result of the Met35Leu 
substitution in normal mice and mouse models of Aβ pathology, differential expression 
proteomics analyses of Tg PDAPP(M631L) and Non Tg M631L mice was completed, and 
results discussed below with respect to AD pathogenesis.  
9.5.1  Oxidative Modification in Brain of Tg PDAPP(M631L) Mice Compared to Non 
Tg M631L Mice 
GFAP is a glial intermediate filament protein known to maintain the cytoskeletal 
structure of mature reactive astrocytes, and is a well-known marker for inflammation (Table 9.3).  
GFAP levels are known to increase with age and neurodegeneration, especially in AD (Beach et 
al., 1989; Boyd-Kimball et al., 2005c; Eddleston and Mucke, 1993; Gomes et al., 1999; Owen et 
al., 2009).  Although differential expression studies did not show increased expression of GFAP 
in brain of Tg PDAPP(M631L) mice (Chapter 8), the current study identified GFAP to be 
significantly more nitrated in Tg PDAPP(M631L) brain compared to Non Tg M631 littermate 
mice.  This result suggests that the structural integrity of astrocytes may be compromised as a 
down-stream effect of the Met35Leu substitution, thereby hindering astrocytic clearance of 
cellular debris in brain of Tg PDAPP(M631L) mice and indirectly contributing to the extreme 
cognitive deficit of Tg PDAPP(M631L) mice compared to Non Tg M631L and even Tg 
PDAPP(J20) mice (Chapter 6).  Moreover, it is possible that in brain of Tg PDAPP(M631L) 
mice an inflammatory response has been activated, making GFAP more available for oxidative 
modification relative to Non Tg M631L mice.  This notion is supported by immunohistochemical 
results reported in Chapter 6 of this dissertation, where an increase in activated microglia was 
observed in Tg PDAPP(M631L) mice.  An increased inflammatory response in Tg 
PDAPP(M631L) mouse brain could increase the levels and/or activity of  inducible nitric oxide 
synthase (iNOS; see section 2.4.3), which would increase intracellular levels of nitric oxide 
(NO
.
).  Such a cascade of events during inflammation may also explain the increase in nitration 
observed in brain of Tg PDAPP(M631L) mice, in lieu of carbonylation events. 
Like GFAP, the antioxidant defense protein GST μ1was also found to be significantly 
nitrated in brain of Tg PDAPP(M631L) mice relative to Non Tg M631L controls.  GST normally 
catalyzes the S-glutathionylation of reactive oxygen (ROS) and nitrogen species (RNS), as well 
as other nucleophilic compounds, such as HNE, which permits efflux of these destructive 
compounds out of the cell [see section 2.4.6.1] (Renes et al., 1999).  Therefore, S-
glutathionylation by GST enzymes not only scavenges ROS and RNS, but also protects redox 
sensitive proteins from oxidative modification [Fig. 2.38; see section 2.4.6.1] (Chrestensen et al., 
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2000).  Because of its active scavenging role, it is not surprising that GST has previously been 
found oxidatively modified in brain of subjects with AD (Perluigi et al., 2009; Sultana and 
Butterfield, 2004), as well as in canine models of AD (Opii et al., 2008) and C. elegans treated 
with Aβ(1-42) (Boyd-Kimball et al., 2006).  Significant nitration of GST μ1 would suggest that a 
certain level of non-amyloidogenic oxidative stress is still present in brain of Tg 
PDAPP(M631L) mice, albeit significantly less than Tg DAPP(J20) mouse models of Aβ 
pathology, and resultant oxidative species are not being scavenged through this particular 
antioxidant pathway.  This possibility also may indirectly contribute to the significant cognitive 
deficit in Tg PDAPP(M631L) mice relative to Non Tg M631L and equal to that of Tg 
PDAPP(J20) mice observed in Chapter 6 of this dissertation.   
Significant nitration of ubiquitous, mitochondrial CK in this study would seem to imply 
an energy deficit in brain of Tg PDAPP(M631L) mice compared to Non Tg M631L controls that 
is not directly related to glucose metabolism.  CK catalyzes the reversible conversion 
phosphocreatine into creatine, which produces adenosine triphosphate (ATP; i.e., energy).  In 
tissues that rapidly consume ATP, such as skeletal muscle, cardiac smooth muscle, and brain, 
phosphocreatine is a key energy reservoir for the rapid buffering and regeneration of ATP, 
beyond that produced by glycolysis and the electron transport chain (ETC) [see section 2.3] 
(Wallimann and Hemmer, 1994; Wallimann et al., 1992).  Ubiquitous, mitochondrial CK, in 
particular, is present in non-muscle tissues (i.e., brain), and is located in the mitochondrial 
intermembrane space where it produces phosphocreatine from mitochondrially-generated ATP 
and cytosolic creatine (Wallimann and Hemmer, 1994).  Moreover, previous studies have shown 
that CK is oxidatively modified in brain of subjects with AD (Castegna et al., 2002b).  Post-
translational oxidative modification of ubiquitous, mitochondrial CK is indicative of a wide-
spread depletion in readily available ATP stores, which would directly contribute to the lack of 
learning and memory in Tg PDAPP(M631L) mice. 
Interestingly, the cytosolic brain secretory protein, secernin-1, was identified to be 
significantly nitrated in brain of Tg PDAPP(M631L) mice relative to Non Tg M631L controls.  
To-date there are no studies indicating a link between secernin-1 expression or oxidation and AD 
pathology.  In fact, the majority of research on this particular protein is related to its function as a 
tumor-associated antigen.  Secernin-1 typically functions in the regulation of exocytosis in 
permeabilized mast cells (Way et al., 2002), which are secretory cells found on mucosal and 
serosal surfaces of tissues throughout the body that are involved in the allergic response 
(Wedemeyer and Galli, 2000).  Upon activation, mast cells secrete a variety of inflammatory 
mediators, including histamine and secernin-1 (Griffiths, 1996; Way et al., 2002).  Therefore, 
significant nitration of sercernin-1 is likely reflective of an impaired immune response in brain of 
Tg PDAPP(M631L) mice, possibly activated (as evidenced by secernin-1 secretion) by a 
compensatory response induced by the M631L transgene. 
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Table 9.3 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to 
Tg PDAPP(J20) and Non Tg M631L mice and their cellular functions.  
Current 
Alteration 
Protein Cellular Function(s) 
Tg PDAPP(M631L) vs. Tg PDAPP(J20) 
↑ Carbonylation Calmodulin, isoform 1 Ca
2+
 Signaling & Regulation 
↑ Carbonylation 14-3-3 δ/δ 
Cell Signaling; Protein 
trafficking 
↑ Carbonylation 
Phosphatidylethanolamine-binding 
protein 1 (PEBP-1) 
Cell Signaling, Proliferation, 
& Migration; Cholinergic 
System 
↑ Nitration  
Peptidyl-prolyl cis-trans isomerase 1 
(Pin-1) 
Cell Signaling; Cell-Cycle 
↑ Carbonylation Phosphoglycerate mutase 1 Energy Metabolism 
↑ Carbonylation 
Pyruvate kinase isozymes M1/M2  
(PK M1/M2) 
Energy Metabolism 
↓ Carbonylation; 
↓ Nitration 
Aspartate aminotransferase,  
 mitochondrial (AATM) 
Amino Acid Metabolism; 
Malate-Aspartate Shuttle 
Protein 
↑ Nitration Actin (multiple isoforms)  Structural Protein 
↓ Nitration 
Tubulin polymerization-promoting 
protein (TPPP) 
Structural Protein 
↑ Nitration 
T-complex protein 1, subunit α A 
(TCP-1αA) 
Molecular Chaperone; 
Structural Integrity 
↑ Nitration 
Glutathione-S-transferase μ1  
(GST μ1) 
Antioxidant Defense 
Tg PDAPP(M631L) vs. Non Tg M631L 
↑ Nitration 
Creatine kinase, ubiquitous, 
mitrochondrial (CK) 
Energy Metabolism 
↑ Nitration Glial fibrillary acidic protein (GFAP) 
Structural protein; 
Inflammatory Marker 
↑ Nitration 
Glutathione-S-transferase μ1  
(GST μ1) 
Antioxidant Defense 
↑ Nitration Secernin-1 
Secretory System; Tumor-
Associated Antigen 
 
 
9.5.2  Oxidative Modification in Brain of Tg PDAPP(M631L) Mice Compared to Tg 
PDAPP(J20) Mice 
Redox proteomics analyses reported in this study indicate 11 structural, antioxidant, Ca
2+
 
signaling, and energy-related proteins with significant changes in oxidative modifications in Tg 
PDAPP(M631L) mice relative to Tg PDAPP(J20) mice.  Many of these proteins have also been 
previously identified as oxidatively modified in brain of subjects with AD (reviewed in Sultana 
et al., 2009).  Interestingly, introduction of the Met35Leu substitution on Aβ led to increased 
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protein carbonylation and nitration of eight critical glycolytic, cellular signaling, and structural 
proteins compared to Tg PDAPP(J20) mice, suggesting the existence of other non-
amyloidogenic pathways which contribute to oxidative stress and damage that also affect 
learning and memory in these mice.  The significant increase in carbonylation and nitration of 
proteins detected in Tg PDAPP(M631L) brain compared to that of Tg PDAPP(J20) mice could 
be a consequence of proteins produced in low abundance, which might appear to be more 
carbonylated or nitrated simply because there are fewer available to oxidize.  The down-
regulation of Pin-1, PEBP-1, phosphoglycerate mutase 1, and PK M1/M2 in Tg PDAPP(M631L) 
mice compared to Tg PDAPP(J20) mice (Chapter 8) would seem to support this notion.  
However, it seems more likely that other non-amyloidogenic pathways inducing oxidative stress 
and/or other APP cleavage products also may contribute to the oxidative modification of these 
enzymes.   
For example, alternate APP cleavage products, Jcasp, C31, and sAPPβ, have all been 
reported to be cytotoxic, inducing activation of internal apoptotic pathways and forming 
cytotoxic protein complexes with APP and other proteins (Furukawa et al., 1996; Lu et al., 2000; 
Madeira et al., 2005; Park et al., 2009).  Chapter 6 of this dissertation showed that Tg 
PDAPP(M631L) mice express APP in amounts similar to that of Tg PDAPP(J20) mice, ensuring 
the global reduction in indices of oxidative stress in Tg PDAPP(M631L) brain was not a result of 
differential expression or production of APP and/or Aβ.  Considering both Tg PDAPP(J20) and 
Tg PDAPP(M631L) mice express significantly greater amounts of APP than Non Tg mice 
(Chapter 6), they are effectively producing copious amounts of APP cleavage products, including 
Aβ, C31, Jcasp, and sAPPβ.  Although the vast majority of Aβ-related oxidative stress present in 
Tg PDAPP(J20) brain was abrogated by the Met35Leu substitution (Chapter 6), neurotoxicity 
induced by other cleavage products is still quite probable in brain of Tg PDAPP(M631L) mice, 
especially considering the abundance to which they could be produced.  The significant cognitive 
decline, as measured by Morris water-maze testing, in Tg PDAPP(M631L) mice supports this 
possibility (Chapter 6).  Moreover, the significant oxidative modification and deactivation of 
these proteins, as reported in the current study, would also contribute to the decline in learning 
and memory in Tg PDAPP(M631L) mice compared to either Tg PDAPP(J20) or Non Tg M631L 
mice. 
In addition, present redox proteomics analyses also identified a significant decrease in the 
levels of protein carbonyls and protein-resident 3-NT for AATM and a decrease in 3-NT levels 
for TPPP in Tg PDAPP(M631L) brain relative to that of Tg PDAPP(J20) mice.  AATM is 
involved in amino acid metabolism and the malate-aspartate shuttle by catalyzing the reversible 
conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate, key components of 
the tricarboxylic acid cycle and neurotransmission (see sections 2.1.3 & 2.3.3).  TPPP is a brain-
specific protein that interacts with the tubulin/microtubule system, supporting the formation and 
elongation of microtubules by promoting polymerization of tubulin, as the name suggests.  
Considering the oxidative modification of proteins results in either a toxic “gain-of-function”, or 
complete “loss-of-function”, the significant reduction in AATM and TPPP oxidation suggests 
that there are antioxidant defense systems still operational in brain of Tg PDAPP(M631L) mice 
able to protect proteins from oxidative stress and damage elicited by non-Aβ-related pathways. 
193 
 
9.5.3  Conclusions 
The combined efforts from studies reported in Chapters 6-9 of this dissertation have 
provided additional evidence supporting the critical role of Met-35 in Aβ(1-42)-induced 
oxidative stress, as well as specific pathways that are altered in AD and mild cognitive 
impairment (MCI) brain as a result of this oxidative insult.  Although Chapter 6 revealed a 
significant decrease in global levels of oxidative stress, these global indices only represent an 
ambiguous majority of proteins and lipids in brain tissue being analyzed and can mask the redox 
status of individual proteins in a given sample.  Therefore, redox proteomics analyses were 
utilized to complete an in-depth analysis of specific proteins affected in brain of Tg 
PDAPP(J20), Tg PDAPP(M631L), and Non Tg mice.  It appears that although the majority of 
oxidative stress detected in AD brain is likely the result of Met-35 of Aβ, the observed increases 
in protein-resident 3-NT and protein carbonyls in brain of Tg PDAPP(M631L) mice from the 
present study are indicative of potential compensatory responses induced by introduction of the 
APPSw,In transgene with a Met35Leu substitution, and/or result from toxicity induced by other 
APP cleavage products, such as Jcasp, sAPPβ, and C31, or other non-amyloidogenic pathways 
that contribute to oxidative stress.  Studies to test this notion are now underway. 
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CHAPTER 10 
CONCLUSIONS & FUTURE STUDIES 
 
10.1  Conclusions 
Work presented in this dissertation examined the role of lipid peroxidation, apoptotic 
factor expression, and amyloid-β (1-42) [Aβ(1-42)] to the exposure of the aminophospholipid 
phosphatidylserine (PtdSer) to the outer-leaflet of the lipid membrane, as well as the role played 
by methionine-35 (Met-35) of Aβ in oxidative stress and damage in brain of subjects with 
amnestic mild cognitive impairment (aMCI), Alzheimer disease (AD), and mouse models of 
familial AD (FAD) Aβ pathology.  Chapter 4 of this dissertation demonstrated that within the 
inferior parietal lobule (IPL) of subjects with aMCI and AD, a significant collapse in PtdSer 
asymmetry was found in association with increased levels of both pro- and anti-apoptotic 
proteins, Bax, caspase-3, and Bcl-2.  In the same way, results reported in Chapter 5 showed a 
significant age-related collapse in PtdSer asymmetry in whole brain of human double-mutant 
knock-in mouse models of Aβ  pathology (APP/PS-1), together with significantly reduced 
Mg
2+
ATPase activity, representing flippase activity, and increased levels of pro-apoptotic 
caspase-3.  Moreover, significant PtdSer externalization corresponded to the age at which 
significant Aβ(1-42) aggregation occurs in APP/PS-1 mice (9 months), and not of plaque 
deposition (12 months), suggesting that elevated levels of Aβ(1-42), together with increasing 
oxidative stress and apoptotic pathway activation, may contribute to altered PtdSer membrane 
localization.  Thus, Chapters 4 and 5 provide evidence that PtdSer asymmetric collapse is an 
early indicator of neurodegenerative processes already well underway in AD brain, and may 
represent a reliable biomarker of those patients with aMCI that eventually develop full-onset AD.   
Analyses of oxidative stress and damage in half brain of APPSw,In (PDAPP) transgenic 
mice [Tg PDAPP(J20)] and PDAPP mice carrying a Met35Leu substitution on the Aβ peptide 
[Tg PDAPP(M631L)] (i.e., Met-631 in human amyloid precursor protein [APP] numbering) in 
Chapter 6-9 revealed that in vivo Aβ-induced oxidative stress requires the presence of Met-35 of 
Aβ, as all indices of oxidative damage measured in Chapter 6 (i.e., protein carbonylation, 
nitration, and 4-hydroxy-2-trans-nonenal [HNE] modification) in brain of Tg PDAPP(M631L) 
mice were completely prevented.  While these findings were independent of total Aβ(1-42) 
accumulation and deposition, immunohistochemical analyses indicated that the Met35Leu 
mutation influences plaque formation, as a clear reduction in Aβ-immunoreactive plaques and 
punctate deposition of Aβ(1-42) in Tg PDAPP(M631L) mice was found in conjunction with a 
significant increase in microglial activation.  In contrast, however, behavioral analyses suggested 
that spatial learning and memory was independent of Met-35 of Aβ, as Tg PDAPP(M631L) mice 
demonstrated inferior water-maze performance compared to non-transgenic littermates.   
Differential expression and redox proteomics analyses in Chapters 7-9 revealed a number 
of specific proteins that were significantly altered by the APPSw,In and Met35Leu mutations.  
Expression proteomics identified 21 proteins in brain of Tg PDAPP(M631L) mice with 
significantly reduced levels of expression compared to Tg PDAPP(J20) mice, used as a positive 
control of Aβ-related FAD pathology.  In addition, eight proteins were identified with 
significantly increased expression levels in brain of Tg PDAPP(J20) mice compared to brain of 
Non Tg PDAPP mice as a control, while a total of three proteins (one decreased, two increased) 
were found differentially expressed in brain of Tg PDAPP(M631L) mice relative to Non Tg 
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M631L littermates.  Redox proteomics analyses identified a total of six proteins (five increased, 
one decreased) with significantly altered levels of protein carbonylation and a total of five 
proteins (three increased, two decreased) with significantly altered levels of protein-bound 3-
nitrotyrosine (3-NT) in half brain of Tg PDAPP(M631L) mice compared to brain of Tg 
PDAPP(J20) mice as a positive control.  In brain of Tg PDAPP(J20) mice compared to Non Tg 
PDAPP controls only one protein was found significantly carbonylated and two proteins found to 
have significantly reduced 3-NT levels.  Interestingly, there were no proteins identified as being 
significantly carbonylated in brain of Tg PDAPP(M631L) mice compared to Non Tg M631L 
littermate control mice, while a total of five proteins were found to have significantly different 
levels of protein-resident 3-NT (three increased, two decreased).   
Proteins identified as differentially expressed or oxidatively modified as a result of the 
APPSw,In and/or Met35Leu mutations play significant roles in the cell-cycle, signaling, structure, 
proliferation, migration/trafficking/chaperoning, endocytosis, the cholinergic system, energy and 
metabolism of proteins, lipids, and nucleic acids, Ca
2+
 regulation, inflammation, pH regulation, 
detoxification, protein degradation, and mitochondrial permeability.  However, the majority of 
proteins affected by the Met35Leu substitution are normally involved in energy metabolism and 
structural integrity of the cell, suggesting the importance of further investigation into metabolic 
and structural alterations in AD brain.   
 In summary, studies presented in this dissertation demonstrate the considerable toll 
oxidative stress and damage, induced by reactive oxygen (ROS) and nitrogen species (RNS), as 
well as Aβ, can take on brain integrity in this devastating dementing disorder. Furthermore, these 
studies may provide researchers with diagnostic markers of disease pathology and point to 
clinical translational possibilities for therapy to potentially treat, slow progression of, or prevent 
aMCI, AD, and FAD.  Specifically, by blocking oxidative damage dependent on Met-35 of 
Aβ(1-42) in brain of subjects with aMCI and AD offers a highly focused therapeutic approach. 
10.2  Future Studies 
Based on the findings reported in this dissertation, the following are suggested avenues of 
future research which may be pursued: 
 
1. A regional analysis of PtdSer asymmetry should be completed in brain of 
subjects with aMCI and AD to evaluate any differences in regions highly 
implicated in AD pathology (i.e., hippocampus) and those that are not (i.e., 
cerebellum). 
2. Considering PtdSer asymmetry could be congruent with loss of other 
important membrane contents (i.e., cholesterol, other phospholipids, etc.), a 
complete lipid analysis of synaptosomes should be examined.  Any change in 
the membrane lipid profile could be important to interpretation of PtdSer 
asymmetry, especially with age.   
3. Because flippase activity is essential to maintenance of PtdSer asymmetry, 
derivation and/or acquisition of monoclonal antibodies specific for flippase 
should provide researchers with the ability to directly examine its response to 
oxidation phenomena apart from Ptdser and other Mg
2+
ATPases. 
4. Since immunohistochemical analyses indicated a clear reduction in Aβ-
immunoreactive plaques in Tg PDAPP(M631L) mice in conjunction with a 
significant increase in microglial activation, and PtdSer externalization is a 
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crucial signal for phagocytosis by microglia in the brain, PtdSer asymmetry 
studies in tandem with Mg
2+
ATPase activity assays should be completed in 
Tg PDAPP(M631L) mice.  If possible, these studies should be conducted as a 
function of age. 
5. Because behavioral analyses of Tg PDAPP(M631L) mice demonstrated 
inferior performance compared to non-transgenic littermates, an analysis of 
apoptotic factor expression (e.g., Bcl-2, Bax, caspase-3, etc.) should be 
completed in brain of Tg PDAPP(M631L) and Tg PDAPP(J20) mice.  If 
possible, these studies should be completed as a function of age, as well as in 
parallel with PtdSer asymmetry studies.  
6. A redox proteomics investigation of protein-bound HNE modified proteins in 
brain of Tg PDAPP(M631L) and Tg PDAPP(J20) mice should be conducted 
in order to indirectly evaluate lipid peroxidation events in brain of these 
transgenic mice. 
7. Because behavioral analyses of Tg PDAPP(M631L) mice demonstrated 
inferior performance compared to non-transgenic littermates, an analysis of 
the levels and toxicity of other non-Aβ, APP cleavage products (e.g.,  Jcasp, 
sAPPβ, C31, etc.) should be assessed, since all have been implicated in 
different aspects of the AD phenotype (Galvan et al., 2006; Lu et al., 2000; 
Madeira et al., 2005; Nikolaev et al., 2009). 
8. Since Tg PDAPP(M631L) mice have significantly reduced levels of 
oxidative stress and punctate plaque staining, but increased microglial 
activation and inferior learning and memory, an analysis of the ability to and 
properties of the Aβ(1-42)M35L peptide to aggregate should be conducted. 
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APPENDIX A 
OXYBLOT ANALYSIS OF OXIDATIVE STRESS IN BRAIN OF APP
NLh
/APP
NLh
 x PS-
1
P264L
/PS-1
P264L
 HUMAN DOUBLE KNOCK-IN MICE 
 
 
A.1  Overview 
Results provided in this appendix are supplemental to studies reported in Chapter 5 of 
this dissertation.  Although an age-related increase in indices of oxidative stress (i.e., protein 
carbonyls, protein-resident 3-nitrotyrosine [3-NT], and protein-bound 4-hydroxy-2-trans-nonenal 
[HNE]) in brain of APP
NLh
/APP
NLh
 x PS-1
P246L
/PS-1
P246L
 human double knock-in (APP/PS-1) 
mice has previously been described (Abdul et al., 2008), it is possible that a statistically 
significant amount of variation could occur from one sample set to another, which would 
drastically alter interpretation of results obtained in Chapter 5.  Therefore, these same three 
indices of oxidative stress were measured in synaptosomes isolated from whole brain of 1, 6, 9, 
and 12 month-old wild-type (WT) and APP/PS-1 mice. 
 
A.2  Experimental Procedures 
All materials and methods used in this supplemental study are described in Chapter 3 of 
this dissertation.  Specifically, sections 3.2.2, 3.3, 3.4.1, 3.5, and 3.13. 
A.2.1 Statistical Analysis 
All slot-blot (Oxyblot) analyses provided in this supplement are presented as mean ± 
standard error of the means (S.E.M.) and analyzed via GraphPad Prism 5.0 software for 
Windows (San Diego, CA).  In one-variable analyses, one-way ANOVA was used to determine 
the effect of WT mouse age on protein carbonylation, nitration, and HNE-modification, followed 
by Bonferroni‟s post-hoc analysis to evaluate the significance of differences between group 
means.  In two-variable analyses, two-way analysis of the variants (ANOVA) was used to 
determine the effect of age and WT or APP/PS-1 genotype on the levels of protein carbonylation, 
nitration, and HNE-modification, followed by Bonferroni's post-hoc analysis to evaluate the 
significance of differences between group means.  P<0.05 was considered significant for all 
studies. 
A.3 Results 
A.3.1  Protein Carbonyls 
In order to assess the levels of protein oxidation via carbonylation during normal brain 
aging, synaptosomes extracted from whole brain of 1 month-old WT mice were used as a control 
from which to compare synaptosomes isolated from whole brain of 6, 9, and 12 month-old WT 
mice.  Results demonstrated a significant age-related increase in protein carbonylation beginning 
at 9 months-old (Fig. A.1a, ***P<0.001), an increase that remains significant through 12 months 
of age (Fig. A.1a, ***P<0.001).  These results are consistent with previous reports of an age-
related increase in protein carbonylation in brain of WT mice (Abdul et al., 2008), as well as 
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with the well-known increase in human brain oxidative stress with age that leads to neuronal cell 
death (Butterfield and Stadtman, 1997; Harman, 1956). 
To assess effects of normal brain aging and mouse genotype, protein carbonyl levels in 
synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 mice were analyzed relative to 
that of 1 month-old WT mice as a control (Fig. A.1b). Results demonstrated a significant 
increase in protein carbonylation at 9 and 12 months-old in brain of APP/PS-1 mice compared to 
1 month-old WT controls (Fig. A.1b, 9 & 12 months-old, ***P<0.001).  Additionally, there was 
a significant increase in 9 month-old APP/PS-1 protein carbonyl levels compared to respective 9 
month-old, age-matched WT mice (Fig. A.1b, 
§
P<0.05), demonstrating that the APP/PS-1 knock-
in genotype affects levels of oxidative stress, measured by protein carbonylation, significantly 
more than normal aging alone at this particular age.  These results are consistent with previous 
reports of an age-related increase in protein carbonylation in brain of APP/PS-1 mice (Abdul et 
al., 2008).  Interestingly, both WT and APP/PS-1 mice exhibited an age-related increase in 
protein carbonyl levels from 6 to 9 months-old (Fig. A.1a,b, 
§§§
P<0.001), directly correlating 
with significant amyloid-β (1-42) [Aβ(1-42)] aggregation reported to begin at 9 months of age in 
this particular mouse model of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996; 
Siman et al., 2000).   
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Figure A.1 
 
 
 
Figure A.1 Protein carbonyl (PCO) levels in synaptosomes from brain of wild-type (WT) 
and APP/PS-1 mice.  A) Protein carbonylation in each WT age-group is presented as a 
percentage of 1 month-old WT PCO levels.  Results demonstrated a significant increase 
in WT mouse carbonylation beginning at 9 months that continues to increase with age.  
Percent control values are presented as mean ± S.E.M. and significance assessed by one-
way ANOVA followed by Bonferroni‟s post-hoc analysis; 
§§§,
***P<0.001; n=5 for all 
age groups.  B) PCO levels for each WT and APP/PS-1 age-group is presented as a 
percentage of 1 month-old WT PCO levels.  Results demonstrated a dramatic age-
dependent increase in carbonylation in both WT and APP/PS-1 mice from 6 to 9 months 
that continues to increase with age.  However, this increase is more prominent in 
APP/PS-1 mice.  Percent control values are presented as mean ± S.E.M. and significance 
assessed by two-way ANOVA followed by Bonferroni's post-hoc analysis; 
§
P<0.05, 
§§§,
***P<0.001; n=5 for all age groups.  
 
 
200 
 
A.3.2  Protein-Resident 3-Nitrotyrosine (3-NT) 
Assessment of protein oxidation via protein nitration in normal brain aging, was also 
conducted on synaptosomes extracted from whole brain of 6, 9, and 12 month-old WT mice, 
using 1 month-old WT mice as a control.  Results demonstrated a significant age-related increase 
in protein nitration beginning at 6 months-old that remains significantly increased as mice age to 
12 months (Fig. A.2a; 6, 9, & 12 months-old, ***P<0.001).  These results are also consistent 
with previous reports of an age-related increase in protein nitration in brain of WT mice (Abdul 
et al., 2008), as well as with the well-known increase in brain oxidative stress with age that leads 
to neuronal cell death (Butterfield and Stadtman, 1997; Harman, 1956). 
Effects of normal brain aging and mouse genotype were assessed by measuring the levels 
of protein-resident 3-NT in synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 mice 
relative to that of 1 month-old WT mice as a control (Fig. A.2b).  These results demonstrated a 
significant increase in protein nitration beginning at 6 months-old in APP/PS-1 mice  (Fig. A.2b, 
**
P<0.01) that remains significant as APP/PS-1 mice age to 12 months of age (Fig. A.2b, 9 
months-old, **P<0.01; 12 months-old, ***P<0.001) compared to 1 month-old WT controls.  
Additionally, there was a significant increase in 1, 9, and 12 month-old APP/PS-1 3-NT levels 
compared to their respective 1, 9, and 12 month-old, age-matched WT mice (Fig. A.2b, 1 & 12 
months-old, 
§§§
P<0.001; 9 months-old, 
§
P<0.05), demonstrating that the APP/PS-1 knock-in 
genotype affects levels of oxidative stress, as indexed by protein nitration, significantly more 
than normal aging alone, as early as 1 month-old.  These results are consistent with previous 
reports of an age-related increase in protein nitration in brain of APP/PS-1 mice (Abdul et al., 
2008).  Interestingly, APP/PS-1 mice exhibited an age-related increase in 3-NT levels from 6 to 
9 and 9 to 12 months-old (Fig. A.2b, 
§§§
P<0.001), directly correlating with significant Aβ(1-42) 
aggregation reported to begin at 9 months of age in this particular mouse model of Aβ pathology 
(Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).    
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Figure A.2 
 
 
 
Figure A.2 Protein-resident 3-nitrotyrosine (3-NT) levels in synaptosomes from brain of 
wild-type (WT) and APP/PS-1 mice.  A) Protein nitration in each WT age-group is 
presented as a percentage of 1 month-old WT 3-NT levels.  Results demonstrated a 
significant increase in WT mouse protein nitration beginning at 6 months that continues 
to increase with age.  Percent control values are presented as mean ± S.E.M. and 
significance assessed by one-way ANOVA followed by Bonferroni‟s post-hoc analysis; 
***P<0.001; n=5 for all age groups.  B) 3-NT levels for each WT and APP/PS-1 age-
group is presented as a percentage of 1 month-old WT 3-NT levels.  Results 
demonstrated a significant age-dependent increase in protein nitration in both WT and 
APP/PS-1 mice beginning at 6 months that continues to increase with age.  However, this 
increase is more prominent in APP/PS-1 mice.  Percent control values are presented as 
mean ± S.E.M. and significance assessed by two-way ANOVA followed by Bonferroni's 
post-hoc analysis; 
§
P<0.05, **P<0.01, 
§§§,
***P<0.001; n=5 for all age groups.  
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A.3.3  Protein-Bound 4-Hydroxy-2-Trans-Nonenal (HNE) 
Protein oxidation and lipid peroxidation levels due to normal brain aging were measured  
via protein-bound HNE in synaptosomes extracted from whole brain of 6, 9, and 12 month-old 
WT mice compared to 1 month-old WT mice as a control.  Interestingly, although levels of 
protein-bound HNE appear to slightly increase with age, at no age is there a significant increase 
compared to 1 month-old WT controls (Fig. A.3a).  Moreover, it appears that the levels of 
protein-bound HNE drop from 1 to 6 months of age, although not significantly (Fig. A.3a). 
Assessment of normal brain aging and mouse genotype was completed by measuring the 
levels of protein-bound HNE in synaptosomes of 1, 6, 9, and 12 month-old WT and APP/PS-1 
mice relative to that of 1 month-old WT mice as a control (Fig. A.3b).  The results showed a 
significant increase in protein-bound HNE beginning at 9 months-old in APP/PS-1 mice  (Fig. 
A.2b, 
*
P<0.05), directly correlating with significant Aβ(1-42) aggregation reported to begin at 9 
months of age in this particular mouse model of Aβ pathology (Anantharaman et al., 2006; 
Reaume et al., 1996; Siman et al., 2000).  This increase was augmented in brain of 12 month-old 
APP/PS-1 mice (Fig. A.2b, **P<0.01) relative to 1 month-old WT controls.  Additionally, there 
was a significant increase in 6 and 12 month-old APP/PS-1 HNE levels compared to their 
respective 6 and 12 month-old, age-matched WT mice (Fig. A.2b, 6 & 12 months-old, 
§
P<0.05), 
demonstrating that the APP/PS-1 knock-in genotype affects levels of oxidative stress, as indexed 
by protein-bound HNE, significantly more than normal aging alone.  As with protein carbonyls 
and protein-resident 3-NT levels, HNE results are consistent with previous reports of an age-
related increase in protein-bound HNE in brain of APP/PS-1 mice (Abdul et al., 2008).  
Additionally, APP/PS-1 mice exhibited an age-related increase in HNE levels from 6 to 12 
months-old (Fig. A.3b, 
§
P<0.05). 
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Figure A.3  
 
 
 
Figure A.3 Protein-bound 4-hydroxy-2-trans-nonenal (HNE) levels in synaptosomes 
from brain of wild-type (WT) and APP/PS-1 mice.  A) Protein-bound HNE in each WT 
age-group is presented as a percentage of 1 month-old WT HNE.  Results demonstrated a 
slight age-related increase in WT mouse HNE levels that is only significant from 6 to 9 
months-old.  Percent control values are presented as mean ± S.E.M. and significance 
assessed by one-way ANOVA followed by Bonferroni‟s post-hoc analysis; 
§
P<0.05; n=5 
for all age groups.  B) HNE levels for each WT and APP/PS-1 age-group is presented as 
a percentage of 1 month-old WT HNE.  Results demonstrated a significant age-dependent 
increase in protein-bound HNE in APP/PS-1 mice beginning at 9 months that continues 
to increase with age.  However, this increase is more prominent in APP/PS-1 mice.  
Percent control values are presented as mean ± S.E.M. and significance assessed by two-
way ANOVA followed by Bonferroni's post-hoc analysis; 
§,
*P<0.05, 
§§,
**P<0.01; n=5 
for all age groups.  
 
 
204 
 
A.4  Conclusions 
The three indices of oxidative stress measured in synaptosomes of age-matched WT and 
APP/PS-1 mice (i.e., protein carbonyls, protein-resident 3-NT, and protein-bound HNE) confirm 
the previously reported age-related increase in protein oxidation and lipid peroxidation (Abdul et 
al., 2008) and serve to validate results reported in Chapter 5 of this dissertation.  Although both 
WT and APP/PS-1 mice follow a similar age-dependent trend of elevated levels of oxidative 
stress (Figs. A.1-A.3), it is evident that this increase is more severe in brain of APP/PS-1 mice.  
Furthermore, the present results demonstrate a significant increase in oxidative stress from 6 to 9 
months-old in all indices of oxidative stress measured (Figs. A.1b-A.3b), corresponding to the 
age at which significant Aβ(1-42) aggregation is reported to occur in brain of this mouse model 
of Aβ pathology (Anantharaman et al., 2006; Reaume et al., 1996; Siman et al., 2000).  
Therefore, the current results support the notion that elevated levels of sodium dodecyl sulfate 
(SDS)-soluble, oligomeric Aβ(1-42), together with increasing oxidative stress and damage 
(Abdul et al., 2008; Butterfield and Lauderback, 2002; Butterfield et al., 2007a; LaFontaine et 
al., 2002), in APP/PS-1 brain may contribute to the up-regulation and increased activation of 
pro-apoptotic caspase-3, oxidative inactivation of the aminophospholipid translocase flippase, 
and alter phosphatidylserine (PtdSer) plasma membrane localization beyond the effects of 
normal brain aging, as reported in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Miranda Lu Lange, 2010 
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APPENDIX B 
DATA SUPPORTING FIGURES & TABLES 
 
Figure 4.1 NBD-PS assay in inferior parietal lobule (IPL) of subjects with amnestic mild 
cognitive impairment (aMCI) and Alzheimer disease (AD). 
 
MCI: Sample ID Well 1 Well 2 Average 
Control 1092c 346.636 285.231 315.934 
Control 1089c 325.619 316.984 321.302 
Control 1103c 314.122 334.489 324.306 
Control 1106c 304.455 301.798 303.127 
Control 1095c 339.741 320.910 330.326 
MCI 1029m 195.265 227.985 211.625 
MCI 1083m P 196.007 227.673 211.840 
MCI 1065m 200.897 194.976 197.937 
MCI 1077m 196.155 194.126 195.141 
MCI 1087m 213.554 211.565 212.560 
 
 
 
Control MCI 
Avg 319.00 205.82 
% Control -0.961 -33.660 
% Control 0.722 -33.592 
% Control 1.664 -37.951 
% Control -4.976 -38.827 
% Control 3.551 -33.367 
Avg% 0.00 -35.48 
StDev% 3.22 2.68 
   T value 18.93358 
 P-value 6.26E-08 
 DOF 8 
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Figure 4.1 data (cont.) 
 
AD: Sample ID Well 1 Well 2 Average 
Control 1070 234.967 135.567 185.27 
Control 1069 198.260 182.433 190.35 
Control 1063 179.079 150.883 164.98 
Control 1065 178.909 149.138 164.02 
Control 1064 189.724 162.905 176.31 
AD 1062 128.134 127.017 127.58 
AD 1071 145.342 108.232 126.79 
AD 1058 124.739 139.589 132.16 
AD 1073 163.882 155.939 118.82 
AD 1074 146.447 147.934 147.19 
 
 
 
Control AD 
Avg 176.19 130.51 
% Control 5.154 -27.591 
% Control 8.037 -28.038 
% Control -6.360 -24.986 
% Control -6.903 -32.562 
% Control 0.073 -16.458 
Avg % 0.00 -25.93 
StDev % 6.69 5.95 
   T value6.470900 
 P-value 0.000194 
 DOF 8 
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Figure 4.2 Post-mortem interval (PMI) NBD-PS assay in brain of normal FVB/N mice.   
 
Sample ID Well 1 Well 2 Average 
 
0hr & 2.8hr 
 0a 222.863 224.681 223.772 
 
T value -0.50883 
0b 221.716 291.546 256.631 
 
P-value 0.6459 
0c 245.133 287.610 266.372 
 
DOF 3 
  
Avg 248.92 
   
  
StDev 22.32 
   
       Sample ID Well 1 Well 2 Average 
 
0hr & 3.5hr 
 2.8a 278.868 256.937 267.903 
 
T value -0.26979 
2.8b 207.104 289.736 248.420 
 
P-value 0.8007 
  
Avg 258.16  DOF  4 
  
StDev 13.78 
   
       Sample ID Well 1 Well 2 Average 
 
2.8hr & 3.5hr 
 3.5a 227.903 262.894 245.399 
 
T value -0.62675 
3.5b 269.376 236.610 252.993 
 
P-value 0.5753 
3.5c 255.169 263.450 259.310 
 
DOF 3 
  
Avg 252.57 
   
  
StDev 6.97 
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Figure 4.3 Mg
2+
ATPase activity assay in brain of normal FVB/N mice. 
 
 
Column 1 Column 2 Column 3 Column 4 Column 5 
 
(Blank) Prtn + Buffer + Prtn, Buffer Column 4 - 
Sample ID Buffer Only Buffer Ouabain + Ouabain Column 3 
0a 0.131 1.330 0.133 1.098 0.965 
0b 0.135 1.369 0.128 1.221 1.093 
0c 0.134 1.255 0.130 1.074 0.944 
2.8a 0.136 1.139 0.130 0.940 0.810 
2.8b 0.140 1.142 0.142 0.892 0.750 
3.5a 0.132 1.332 0.134 1.150 1.016 
3.5b 0.132 1.141 0.128 0.804 0.676 
3.5c 0.128 1.253 0.125 1.001 0.876 
 
     
0hr & 2.8hr 
 
     
T value 3.4406 
     
P-value 0.0412 
     
DOF 3 
 
0hr 2.8hr 3.5hr 
   
 
0.965 0.810 1.016 
 
0hr & 3.5hr 
 
 
1.093 0.750 0.676 
 
T value 1.32608 
 
0.944 -- 0.876 
 
P-value 0.25547 
Avg 1.001 0.780 0.856 
 
DoF 4 
StDev 0.081 0.042 0.171 
   
     
2.8hr & 3.5hr 
 
     
T value -0.58771 
     
P-value 0.59803 
     
DOF 3 
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Figure 4.4 Bcl-2 levels in brain from subjects with amnestic mild cognitive impairment (aMCI) 
and Alzheimer disease (AD).   
 
Data obtained by my collaborator, visiting Ph.D. student, Giovanna Cenini (University of 
Kentucky, Lexington, KY). 
 
Bcl-2 AD Tubulin-Normalized 
     Sample ID Values 
   
Control Avg AD Avg 
Control 1 134 
  
 170.50 233.00 
Control 2 161 
  
% Control 78.59 124.93 
Control 3 171 
  
% Control 94.43 147.21 
Control 4 216 
  
% Control 100.29 137.83 
AD 1 213 
  
% Control 126.69 -- 
AD 2 251 
  
Avg % 100.00 136.66 
AD 3 235 q-test out 
 
StDev % 20.01 11.19 
AD 4 98 0.75163 
 
P-value 0.0292 
  
 
Bcl-2 MCI Tubulin-Normalized 
    Sample ID Values 
  
Control Avg MCI Avg 
Control 1 200 
 
 181.25 226.50 
Control 2 190 
 
% Control 110.34 134.62 
Control 3 164 
 
% Control 104.83 125.24 
Control 4 171 
 
% Control 90.48 115.86 
MCI 1 244 
 
% Control 94.34 124.14 
MCI 2 227 
 
Avg % 100.00 124.97 
MCI 3 210 
 
StDev % 9.18 7.68 
MCI 4 225 
 
P-value 0.0059 
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Figure 4.5 Bax levels in brain from subjects with amnestic mild cognitive impairment (aMCI) 
and Alzheimer disease (AD). 
 
Data obtained by my collaborator, visiting Ph.D. student, Giovanna Cenini (University of 
Kentucky, Lexington, KY). 
 
Bax AD Tubulin-Normalized 
    Sample ID Values 
  
Control Avg AD Avg 
Control 1 144 
 
 181.33 54.50 
Control 2 163 
 
% Control 79.41 31.99 
Control 3 237 q-test out % Control 89.89 23.16 
Control 4 49 0.50532 % Control 130.70 21.51 
AD 1 58 
 
% Control -- 43.57 
AD 2 42 
 
Avg % 100.00 30.06 
AD 3 39 
 
StDev % 27.10 10.11 
AD 4 79 
 
P-value 0.0361 
  
 
Bax MCI Tubulin-Normalized 
    Sample ID Values 
  
Control Avg MCI Avg 
Control 1 54 
 
 62.25 89.75 
Control 2 58 
 
% Control 86.75 130.12 
Control 3 81 
 
% Control 93.17 162.25 
Control 4 56 
 
% Control 130.12 165.46 
MCI 1 81 
 
% Control 89.96 118.88 
MCI 2 101 
 
Avg % 100.00 144.18 
MCI 3 103 
 
StDev % 20.25 23.22 
MCI 4 74 
 
P-value 0.0285 
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Figure 4.5 Caspase-3 levels in brain from subjects with amnestic mild cognitive impairment 
(aMCI) and Alzheimer disease (AD). 
 
Data obtained by my collaborator, visiting Ph.D. student, Giovanna Cenini (University of 
Kentucky, Lexington, KY). 
 
Caspase-3 AD 
     
 
Tubulin-Normalized 
    Sample ID Values 
  
Control AvgAD Avg 
Control 1 279 
 
 282.50 402.00 
Control 2 322 
 
% Control 98.76 150.44 
Control 3 232 
 
% Control 113.98 176.28 
Control 4 297 
 
% Control 82.12 136.99 
AD 1 425 
 
% Control 105.13 105.49 
AD 2 498 
 
Avg % 100.00 142.30 
AD 3 387 
 
StDev % 13.45 29.46 
AD 4 298 
 
P-value 0.0400 
  
 
Caspase-3 MCI 
     
 
Tubulin-Normalized 
    Sample ID Values 
  
Control Avg MCI Avg 
Control 1 292 
 
 268.50 337.25 
Control 2 239 
 
% Control 108.75 119.18 
Control 3 307 
 
% Control 89.01 121.42 
Control 4 236 
 
% Control 114.34 135.20 
MCI 1 320 
 
% Control 87.90 126.63 
MCI 2 326 
 
Avg % 100.00 125.61 
MCI 3 363 
 
StDev % 13.53 7.11 
MCI 4 340 
 
P-value 0.0154 
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Figure 5.1 Soluble amyloid-β (Aβ) load in sodium dodecyl sulfate (SDS)-fractions of aging 
APP/PS-1 mouse brain.   
 
 
(pmol/g) (pmol/g) 
 
(pmol/g) (pmol/g) 
   
(pmol/g) 
 
(pmol/g) 
Age: Aβ40 Aβ42 Age: Aβ40 Aβ42 
 
Age: 
 
Aβ40 Age: Aβ42 
1mo 1.21537 1.34043 3 mo 6.81 7.18 
 
1 mo mean 1.25 mean 1.72 
 
1.14689 1.35563 
 
4.56 2.36 
  
s.e.m. 0.16 s.e.m. 0.14 
 
2.03523 1.56419 
 
3.38 3.45 
 
3 mo mean 8.77 mean 3.89 
 
2.21973 1.88059 
 
12.91 3.68 
  
s.e.m. 2.48 s.e.m. 0.86 
 
1.91791 2.34759 
 
16.21 2.76 
 
6 mo mean 1.68 mean 2.37 
 
2.10689 1.71798 6 mo 0.72 1.16 
  
s.e.m. 0.91 s.e.m. 0.83 
 
1.22665 1.36168 
 
0.92 1.03 
 
9 mo mean 64.43 mean 69.28 
 
1.13288 1.08830 
 
0.00 2.30 
  
s.e.m. 39.58 s.e.m. 45.59 
 
2.05539 1.46134 
 
5.17 5.58 
 
12 mo mean 636.14 mean 483.50 
 
1.90115 3.12128 
 
1.59 1.77 
  
s.e.m. 367.27 s.e.m. 257.74 
 
1.88439 2.30039 9 mo 21.26 24.96 
      
 
1.97756 1.92594 
 
219.00 248.17 
      
 
1.41427 2.45778 
 
54.97 56.24 
      
 
0.00000 1.10177 
 
25.58 13.49 
      
 
0.92193 1.46763 
 
1.33 3.55 
      
 
0.00000 3.10246 12 mo 195.30 121.16 
      
 
1.29700 2.38094 
 
1951.23 1305.50 
      
 
0.00000 1.23560 
 
932.64 877.93 
      
 
2.02453 1.56273 
 
32.72 30.36 
      
 
0.00000 1.20608 
 
68.83 82.58 
      
 
0.71109 1.70397 
         
 
1.29471 1.79449 
         
 
0.16905 0.13277 
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Figure 5.2 Insoluble amyloid-β (Aβ) load in formic acid (FA)-fractions of aging APP/PS-1 
mouse brain.   
 
 
(pmol/g) (pmol/g) 
 
(pmol/g) (pmol/g) 
   
(pmol/g) 
 
(pmol/g) 
Age: Aβ40 Aβ42 Age: Aβ40 Aβ42 
 
Age: 
 
Aβ40 
 
Aβ42 
1 mo 0 0 3 mo 0.0 0.0 
 
1 mo mean 0 mean 0 
 
0 0 
 
0.0 0.0 
 
  s.e.m. 0 s.e.m. 0 
 
0 0 
 
0.0 3.203 
 
3 mo mean 0 mean 1.096 
 
0 0 
 
0.0 2.279 
 
  s.e.m. 0 s.e.m. 0.687 
 
0 0  0.0 0.0 
 
6 mo mean 0.690 mean 0.362 
 
0 0 6 mo 3.452 0.0 
 
  s.e.m. 0.690 s.e.m. 0.221 
 
0 0 
 
0.0 1.173 
 
9 mo mean 0.592 mean 6.024 
 
0 0 
 
0.0 0.0 
 
  s.e.m. 0.592 s.e.m. 4.253 
 
0 0 
 
0.0 0.481 
 
12 mo mean 31.176 mean 94.891 
 
0 0  0.0 0.159 
  
s.e.m. 28.619 s.e.m. 75.311 
 
0 0 9 mo 0.0 0.113 
      
 
0 0 
 
2.958 22.846 
      
 
0 0 
 
0.0 4.035 
      
 
0 0 
 
0.0 1.864 
      
 
0 0  0.0 1.264 
      
 
0 0 12 mo 5.343 26.028 
      
 
0 0 
 
145.561 394.731 
      
 
0 0 
 
4.976 43.764 
      
 
0 0 
 
0.0 5.425 
      
 
0 0  0.0 4.505 
      
 
0 0 
         
 
0 0 
         
 
0 0 
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Figure 5.3 Annexin V (AV) binding assay in synaptosomes from wild-type (WT) and APP/PS-1 
mice.   
 
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID Well 1 Well 2 Average 
wt 2544 48.879 47.337 48.11 wt 2235 53.135 55.645 54.39 
wt 2546 56.299 51.594 53.95 wt 2236 54.166 55.176 54.67 
wt 2548 52.431 51.106 51.77 wt 2237 56.309 56.849 56.58 
wt 2549 53.750 57.413 55.58 wt 2238 56.731 57.259 57.00 
wt 2550 48.625 50.316 49.47 wt 2292 53.899 56.660 55.28 
HO AP1 56.099 53.664 54.88 wt 1183 49.327 58.352 53.84 
HO AP2 55.571 56.715 56.14 wt 1189 51.094 61.211 56.15 
HO AP3 48.540 47.884 48.21 wt 1218 49.448 57.227 53.34 
HO 2538 57.684 54.835 56.26 HO 2313 50.589 54.281 52.44 
HO 2540 56.868 51.633 54.25 HO 2314 58.240 58.416 58.33 
     
HO 2315 53.907 52.351 53.13 
     
HO 2316 50.735 52.282 51.51 
     
HO 2247 52.544 53.885 53.21 
     
HO 1149 49.528 59.803 54.67 
     
HO 1147 47.782 59.618 53.70 
     
HO 1142 58.795 61.095 59.95 
          9 month Sample ID Well 1 Well 2 Average 12 month Sample ID Well 1 Well 2 Average 
wt 2030 56.006 56.193 56.10 wt 1790 53.952 55.408 54.68 
wt 2032 55.373 62.027 58.70 wt 1793 57.164 56.166 56.67 
wt 2154 59.011 59.622 59.32 wt 1800 57.813 57.507 57.66 
wt 2155 60.249 57.647 58.95 wt 1831 55.463 55.469 55.47 
wt 2156 62.427 61.101 61.76 wt 1852 56.848 57.960 57.40 
HO 2002 63.307 62.647 62.98 HO 1817 63.865 61.693 62.78 
HO 2003 66.495 63.904 65.20 HO 1819 67.703 65.052 66.38 
HO 2195 61.671 62.689 62.18 HO 1821 61.928 62.366 62.15 
HO 2196 66.781 64.269 65.53 HO 1856 64.717 65.355 65.04 
HO 2197 64.721 65.069 64.90 HO 1924 66.897 62.805 64.85 
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Figure 5.3 data (cont.) 
 
1 month Control APP/PS-1 6 month Control APP/PS-1 
% 1mo wt 92.918 106.001 % 1mo wt 105.055 101.275 
% 1mo wt 104.195 108.437 % 1mo wt 105.594 112.659 
% 1mo wt 99.988 93.119 % 1mo wt 109.279 102.616 
% 1mo wt 107.350 108.662 % 1mo wt 110.083 99.486 
% 1mo wt 95.550 104.782 % 1mo wt 106.778 102.781 
% Avg 100.00 103.77 % 1mo wt 103.988 115.780 
StDev % 6.50 6.52 % 1mo wt 108.455 103.717 
   
% 1mo wt 103.018 105.583 
   
% Avg 106.53 105.49 
   
StDev % 2.56 5.73 
      9 month Control APP/PS-1 12 month Control APP/PS-1 
% 1mo wt 108.353 121.637 % 1mo wt 105.602 121.254 
% 1mo wt 113.368 125.929 % 1mo wt 109.445 128.205 
% 1mo wt 114.567 120.093 % 1mo wt 111.367 120.034 
% 1mo wt 113.855 126.558 % 1mo wt 107.130 125.613 
% 1mo wt 119.294 125.341 % 1mo wt 110.873 125.256 
% Avg 113.89 123.91 % Avg 108.88 124.07 
StDev % 3.89 2.87 StDev % 2.46 3.36 
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Figure 5.4 NBD-PS assay in synaptosomes from wild-type (WT) and APP/PS-1 mice.   
 
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID Well 1 Well 2 Average 
wt 2549 1020.544 836.678 928.61 wt 2235 1159.214 1188.223 1173.72 
wt 2546 1082.930 1143.052 1112.99 wt 2236 1150.728 1115.030 1132.88 
wt 2548 1263.832 1045.147 1154.49 wt 2237 1246.071 1100.782 1173.43 
wt 2544 1217.608 1132.651 1175.13 wt 2292 1162.174 1170.201 1166.19 
wt 2550 1262.349 1069.014 1165.68 wt 2238 1291.406 1097.232 1194.32 
HO 2540 1430.835 1278.884 1354.86 wt 1183 1190.820 1189.530 1190.18 
HO 2538 1249.006 1083.442 1166.22 wt 1189 1190.057 1161.649 1175.85 
HO AP3 1315.794 1143.848 1229.82 wt 1218 1203.926 1189.204 1196.57 
HO AP2 1431.897 1331.315 1381.61 HO 2313 1116.062 1279.405 1197.73 
HO AP1 1304.520 1325.176 1314.85 HO 2315 1151.949 1201.425 1176.69 
     
HO 2247 1241.221 1184.663 1212.94 
     
HO 2314 1372.741 1051.178 1211.96 
     
HO 2316 1221.478 1208.621 1215.05 
     
HO 1142 1226.663 1231.111 1228.89 
     
HO 1147 1243.001 1235.577 1239.29 
     
HO 1149 1221.682 1216.698 1219.19 
          9 month Sample ID Well 1 Well 2 Average 12 month Sample ID Well 1 Well 2 Average 
wt 2030 703.268 627.606 665.44 wt 1852 618.798 632.694 625.75 
wt 2032 633.522 661.602 647.56 wt 1790 628.749 611.084 619.92 
wt 2154 651.827 617.525 634.68 wt 1831 684.265 690.266 687.27 
wt 2156 660.770 648.768 654.77 wt 1800 668.327 636.730 652.53 
wt 2155 700.882 645.352 673.12 wt 1793 716.685 636.684 676.68 
HO 2002 598.696 577.096 587.90 HO 1821 585.702 539.576 562.64 
HO 2003 554.645 600.173 577.41 HO 1856 540.114 518.679 529.40 
HO 2196 578.438 581.740 580.09 HO 1817 551.656 539.928 545.79 
HO 2197 617.726 569.970 593.85 HO 1924 537.429 592.824 565.13 
HO 2195 614.251 518.093 566.17 HO 1819 600.517 538.175 569.35 
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Figure 5.4 data (cont.) 
 
1 month Control APP/PS-1 6 month Control APP/PS-1 
% 1mo wt 84.085 122.681 % 1mo wt 106.279 108.454 
% 1mo wt 99.419 105.600 % 1mo wt 102.581 106.548 
% 1mo wt 104.538 107.467 % 1mo wt 106.253 109.831 
% 1mo wt 106.407 125.103 % 1mo wt 105.597 109.742 
% 1mo wt 105.551 119.058 % 1mo wt 108.144 110.022 
% Avg 100.00 116.20 % 1mo wt 107.769 111.274 
StDev % 11.19 10.17 % 1mo wt 106.472 112.216 
   
% 1mo wt 108.348 110.396 
   
% Avg 106.43 109.81 
   
StDev % 1.85 1.72 
      9 month Control APP/PS-1 12 month Control APP/PS-1 
% 1mo wt 60.255 53.233 % 1mo wt 56.661 50.946 
% 1mo wt 58.636 52.284 % 1mo wt 56.133 47.936 
% 1mo wt 57.469 52.526 % 1mo wt 62.231 49.421 
% 1mo wt 59.289 53.772 % 1mo wt 59.086 51.172 
% 1mo wt 60.950 51.266 % 1mo wt 61.273 51.554 
% Avg 59.32 52.62 % Avg 59.08 50.21 
StDev % 1.36 0.96 StDev % 2.71 1.51 
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Figure 5.5 Mg
2+
ATPase activity in synaptosomes from wild-type (WT) and APP/PS-1 mice.   
 
1 month 
 
Column 1 Column 2 Column 3 Column 4 Column 5 
  
(Blank) Prtn + Buffer + Prtn, Buffer Prtn, Buffer 
 
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain 
wt 2235 0.115 3.673 0.115 1.529 1.520 
wt 2236 0.113 3.914 0.116 1.589 1.585 
wt 2237 0.102 3.514 0.101 1.416 1.414 
wt 2238 0.111 3.846 0.113 1.486 1.455 
wt 2292 0.111 3.386 0.115 1.389 1.363 
HO 2247 0.119 2.929 0.114 1.290 1.334 
HO 2313 0.111 3.776 0.112 1.585 1.535 
HO 2314 0.111 3.105 0.112 1.298 1.304 
HO 2315 0.111 3.509 0.111 1.420 1.370 
HO 2316 0.114 3.662 0.114 1.602 1.393 
 
 
  
Avg of 
Avg - Column 3 
 
Sample ID Columns 4 & 5 
wt 2235 1.525 1.410 
wt 2236 1.587 1.471 
wt 2237 1.415 1.314 
wt 2238 1.471 1.358 
wt 2292 1.376 1.261 
HO 2247 1.312 1.198 
HO 2313 1.560 1.448 
HO 2314 1.301 1.189 
HO 2315 1.395 1.284 
HO 2316 1.498 1.384 
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Figure 5.5 data (cont.) 
 
6 month 
 
Column 1 Column 2 Column 3 Column 4 Column 5 
  
(Blank) Prtn + Buffer + Prtn, Buffer Prtn, Buffer 
 
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain 
wt 2544 0.099 3.199 0.101 1.319 1.38 
wt 2546 0.101 3.324 0.101 1.321 1.336 
wt 2548 0.112 3.401 0.101 1.426 1.614 
wt 2549 0.101 3.313 0.101 1.418 1.436 
wt 2550 0.101 3.521 0.102 1.450 1.506 
wt 1183 0.098 3.367 0.103 1.277 1.146 
wt 1189 0.098 3.407 0.099 1.540 1.525 
wt 1218 0.101 3.346 0.099 1.488 1.492 
HO AP1 0.100 3.652 0.102 1.423 1.551 
HO AP2 0.100 3.516 0.101 1.591 1.679 
HO AP3 0.102 3.339 0.102 1.610 1.508 
HO 2538 0.094 2.790 0.095 1.591 1.546 
HO 2540 0.099 3.170 0.099 1.629 1.595 
HO 1142 0.099 3.425 0.100 1.583 1.604 
HO 1147 0.099 3.355 0.111 1.604 1.635 
HO 1149 0.098 3.393 0.100 1.453 1.477 
 
 
  
Avg of 
Avg - Column 3 
 
Sample ID Columns 4 & 5 
wt 2544 1.350 1.249 
wt 2546 1.329 1.228 
wt 2548 1.426 1.325 
wt 2549 1.427 1.326 
wt 2550 1.478 1.376 
wt 1183 1.212 1.109 
wt 1189 1.533 1.434 
wt 1218 1.490 1.391 
HO AP1 1.551 1.449 
HO AP2 1.635 1.534 
HO AP3 1.559 1.457 
HO 2538 1.569 1.474 
HO 2540 1.612 1.513 
HO 1142 1.594 1.494 
HO 1147 1.620 1.509 
HO 1149 1.465 1.365 
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Figure 5.5 data (cont.)  
 
9 month 
 
Column 1 Column 2 Column 3 Column 4 Column 5 
  
(Blank) Prtn + Buffer + Prtn, Buffer Prtn, Buffer 
 
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain 
wt 2030 0.097 3.044 0.097 1.220 1.101 
wt 2032 0.097 3.008 0.096 1.257 1.246 
wt 2154 0.097 3.256 0.096 1.529 1.331 
wt 2155 0.093 2.971 0.095 1.408 1.251 
wt 2156 0.097 2.526 0.097 1.287 1.213 
HO 2002 0.097 3.293 0.098 1.199 1.205 
HO 2003 0.098 3.174 0.096 1.274 1.277 
HO 2195 0.098 3.181 0.098 1.273 1.307 
HO 2196 0.098 3.321 0.100 1.255 1.491 
HO 2197 0.099 3.255 0.098 1.106 1.027 
 
 
  
Avg of 
Avg - Column 3 
 
Sample ID Columns 4 & 5 
wt 2030 1.160 1.063 
wt 2032 1.251 1.155 
wt 2154 1.331 1.235 
wt 2155 1.329 1.234 
wt 2156 1.250 1.153 
HO 2002 1.202 1.104 
HO 2003 1.275 1.179 
HO 2195 1.290 1.192 
HO 2196 1.373 1.273 
HO 2197 1.066 0.968 
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Figure 5.5 data (cont.) 
 
12 month 
 
Column 1 Column 2 Column 3 Column 4 Column 5 
  
(Blank) Prtn + Buffer + Prtn, Buffer Prtn, Buffer 
 
Sample ID Buffer Only Buffer Ouabain + Ouabain + Ouabain 
wt 1793 0.092 2.903 0.090 1.075 1.232 
wt 1800 0.090 2.604 0.091 1.179 1.286 
wt 1831 0.091 2.907 0.094 1.189 1.263 
wt 1852 0.089 2.832 0.090 1.296 1.326 
wt 1790 0.089 2.595 0.090 1.213 1.120 
HO 1924 0.090 2.539 0.090 1.040 0.900 
HO 1817 0.089 2.649 0.090 1.083 0.993 
HO 1819 0.090 2.789 0.090 1.028 0.987 
HO 1821 0.087 2.425 0.088 0.921 1.056 
HO 1856 0.090 2.486 0.088 1.005 0.906 
 
 
  
Avg of 
Avg - Column 3 
 
Sample ID Columns 4 & 5 
wt 1793 1.154 1.064 
wt 1800 1.233 1.142 
wt 1831 1.226 1.132 
wt 1852 1.311 1.221 
wt 1790 1.167 1.077 
HO 1924 0.970 0.880 
HO 1817 1.038 0.948 
HO 1819 1.008 0.918 
HO 1821 0.989 0.901 
HO 1856 0.956 0.868 
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Figure 5.5 data (cont.) 
 
1 month Control APP/PS-1 6 month Control APP/PS-1 
% 1mo wt 103.442 87.920 % 1mo wt 91.626 106.341 
% 1mo wt 107.955 106.231 % 1mo wt 90.085 112.579 
% 1mo wt 96.433 87.260 % 1mo wt 97.241 106.928 
% 1mo wt 99.626 94.232 % 1mo wt 97.314 108.139 
% 1mo wt 92.544 101.534 % 1mo wt 100.983 111.038 
Avg % 100.00 98.23 % 1mo wt 81.352 109.607 
StDev % 8.92 9.83 % 1mo wt 105.203 110.707 
   
% 1mo wt 102.084 100.176 
   
Avg % 95.74 108.19 
   
StDev % 7.73 3.87 
      9 month Control APP/PS-1 12 month Control APP/PS-1 
% 1mo wt 78.049 81.022 % 1mo wt 78.049 64.582 
% 1mo wt 84.801 86.562 % 1mo wt 83.774 69.573 
% 1mo wt 90.636 87.480 % 1mo wt 83.076 67.335 
% 1mo wt 90.599 93.424 % 1mo wt 89.608 66.087 
% 1mo wt 84.618 71.077 % 1mo wt 79.003 63.665 
Avg % 85.74 83.91 Avg % 82.70 66.25 
StDev % 5.22 8.42 StDev % 4.59 2.33 
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Figure 5.6 Procaspase-3 levels in brain from wild-type (WT) and APP/PS-1 mice.   
 
1 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 56691.3 57434.67 52765.60 51031.82 51544.87 
procaspase-3 2214.09 2308.00 2587.28 2242.00 1802.89 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 45803.40 55146.25 58594.57 46800.27 48045.71 
procaspase-3 1940.17 2166.64 2343.00 1543.40 2120.80 
      6 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 60341.08 70099.09 51354.51 62821.66 63782.40 
procaspase-3 1426.94 3837.82 530.54 2626.62 2463.67 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 61394.67 53587.43 72781.78 59212.23 65029.00 
procaspase-3 2683.71 2942.76 2963.96 1251.33 4151.19 
      9 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 71717.71 67338.00 62921.37 69019.17 70733.57 
procaspase-3 1790.00 1893.00 2376.40 2811.40 2979.71 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 73900.78 67295.00 59684.43 72021.35 66393.16 
procaspase-3 2633.50 2761.50 2360.89 2979.06 2106.00 
      12 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 52970.00 56917.20 57777.75 58564.63 52010.50 
procaspase-3 1194.00 1010.40 1043.00 1578.67 898.80 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 55305.13 54603.08 55924.07 55757.79 59621.75 
procaspase-3 1428.82 1133.18 1328.50 1426.67 1312.00 
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Figure 5.6 data (cont.) 
 
1 month 
  
6 month 
  procaspase-3 wt HO procaspase-3 wt HO 
% 1mo wt 94.25 102.22 % 1mo wt 57.07 105.49 
% 1mo wt 96.98 94.82 % 1mo wt 132.13 132.53 
% 1mo wt 118.33 96.50 % 1mo wt 24.93 98.28 
% 1mo wt 106.03 79.59 % 1mo wt 100.90 51.00 
% 1mo wt 84.41 106.53 % 1mo wt 93.22 154.06 
Avg % 100.00 95.93 Avg % 81.65 108.27 
StDev % 12.82 10.25 StDev % 41.45 38.96 
      9 month 
  
12 month 
  procaspase-3 wt HO procaspase-3 wt HO 
% 1mo wt 60.23 86.00 % 1mo wt 54.40 62.35 
% 1mo wt 67.84 99.03 % 1mo wt 42.84 50.08 
% 1mo wt 91.15 95.46 % 1mo wt 43.56 57.33 
% 1mo wt 98.30 99.82 % 1mo wt 65.05 61.75 
% 1mo wt 101.66 76.55 % 1mo wt 41.70 53.11 
Avg % 83.84 91.37 Avg % 49.51 56.92 
StDev % 18.66 9.94 StDev % 10.08 5.34 
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Figure 5.7 Active p18 fragment caspase-3 levels in brain from wild-type (WT) and APP/PS-1 
mice.   
 
1 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 56691.3 57434.67 52765.60 51031.82 51544.87 
caspase-3 (20kDa)  4968.50 5420.21 5184.00 7086.88 6285.95 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 45803.40 55146.25 58594.57 46800.27 48045.71 
caspase-3 (20kDa)  5623.93 5154.89 8578.60 7499.05 6981.23 
      6 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 60341.08 70099.09 51354.51 62821.66 63782.40 
caspase-3 (20kDa)  9651.71 11272.00 6630.85 9868.50 9408.52 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 61394.67 53587.43 72781.78 59212.23 65029.00 
caspase-3 (20kDa)  11448.86 10233.55 11513.34 9944.45 6048.50 
      9 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 71717.71 67338.00 62921.37 69019.17 70733.57 
caspase-3 (20kDa)  13271.76 11158.42 11282.29 10353.69 12288.00 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 73900.78 67295.00 59684.43 72021.35 66393.16 
caspase-3 (20kDa)  14333.38 17220.76 13168.20 15434.25 12838.39 
      12 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 52970.00 56917.20 57777.75 58564.63 52010.50 
caspase-3 (20kDa)  8349.28 8431.57 6822.13 7212.00 10744.79 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 55305.13 54603.08 55924.07 55757.79 59621.75 
caspase-3 (20kDa)  11651.68 10050.16 11242.65 11981.00 11346.67 
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Figure 5.7 data (cont.) 
 
1 month 
  
6 month 
  caspase-3 (20kDa)  wt HO caspase-3 (20kDa)  wt HO 
% 1mo wt 80.99 113.46 % 1mo wt 147.81 172.32 
% 1mo wt 87.21 86.38 % 1mo wt 148.59 176.47 
% 1mo wt 90.79 135.29 % 1mo wt 119.32 146.18 
% 1mo wt 128.33 148.07 % 1mo wt 145.16 155.19 
% 1mo wt 112.69 134.27 % 1mo wt 136.31 85.95 
Avg % 100.00 123.49 Avg % 139.44 147.22 
StDev % 19.83 24.17 StDev % 12.26 36.42 
      9 month 
  
12 month 
  caspase-3 (20kDa)  wt HO caspase-3 (20kDa)  wt HO 
% 1mo wt 171.01 179.23 % 1mo wt 145.66 194.68 
% 1mo wt 153.13 236.47 % 1mo wt 136.89 170.08 
% 1mo wt 165.69 203.88 % 1mo wt 109.11 185.77 
% 1mo wt 138.62 198.03 % 1mo wt 113.80 198.56 
% 1mo wt 160.53 178.69 % 1mo wt 190.90 175.86 
Avg % 157.80 199.26 Avg % 139.27 184.99 
StDev % 12.59 23.62 StDev % 32.68 12.09 
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Figure 5.8 Active p12 fragment caspase-3 levels in brain from wild-type (WT) and APP/PS-1 
mice. 
 
1 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 56691.3 57434.67 52765.60 51031.82 51544.87 
caspase-3 (18kDa)  4139.62 4168.56 6435.76 5357.30 4657.84 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 45803.40 55146.25 58594.57 46800.27 48045.71 
caspase-3 (18kDa)  4766.95 3721.40 5976.60 5331.95 6528.27 
      6 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 60341.08 70099.09 51354.51 62821.66 63782.40 
caspase-3 (18kDa)  3511.82 6865.00 4241.20 6150.73 6363.02 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 61394.67 53587.43 72781.78 59212.23 65029.00 
caspase-3 (18kDa)  4228.00 6930.88 8632.15 5903.60 2729.25 
      9 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 71717.71 67338.00 62921.37 69019.17 70733.57 
caspase-3 (18kDa)  13650.28 9932.25 10181.47 10587.57 9406.75 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 73900.78 67295.00 59684.43 72021.35 66393.16 
caspase-3 (18kDa)  12521.02 12904.67 8979.22 10161.50 6399.26 
      12 month wt - 1 wt - 3 wt - 5 wt - 7 wt - 9 
α-tubulin 52970.00 56917.20 57777.75 58564.63 52010.50 
caspase-3 (18kDa)  2933.10 5713.71 5119.85 4074.15 6031.11 
 
HO - 2 HO - 4 HO - 6 HO - 8 HO - 10 
α-tubulin 55305.13 54603.08 55924.07 55757.79 59621.75 
caspase-3 (18kDa)  4766.13 5036.00 4962.11 4001.67 4835.33 
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Figure 5.8 data (cont.)  
 
1 month 
  
6 month 
  caspase-3 (18kDa) wt HO caspase-3 (18kDa) wt HO 
% 1mo wt 78.87 112.41 % 1mo wt 62.86 74.38 
% 1mo wt 78.39 72.89 % 1mo wt 105.78 139.70 
% 1mo wt 131.74 110.17 % 1mo wt 89.20 128.11 
% 1mo wt 113.39 123.06 % 1mo wt 105.75 107.69 
% 1mo wt 97.60 146.76 % 1mo wt 107.75 45.33 
Avg % 100.00 113.06 Avg % 94.27 99.04 
StDev % 22.94 26.73 StDev % 19.09 38.94 
      9 month 
  
12 month 
  caspase-3 (18kDa) wt HO caspase-3 (18kDa) wt HO 
% 1mo wt 205.58 183.00 % 1mo wt 59.81 93.08 
% 1mo wt 159.32 207.13 % 1mo wt 108.43 99.62 
% 1mo wt 174.78 162.50 % 1mo wt 95.71 95.84 
% 1mo wt 165.69 152.39 % 1mo wt 75.14 77.52 
% 1mo wt 143.64 104.11 % 1mo wt 125.25 87.60 
Avg % 169.80 161.83 Avg % 92.87 90.73 
StDev % 23.00 38.48 StDev % 26.01 8.59 
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Figure 6.1 Oxidative modification of brain in transgenic (Tg) and non-transgenic (Non Tg) 
mice: Role of Met-35 of amyloid-β (Aβ).  A)  Protein oxidation as indexed by protein 
carbonylation.  B) Lipid peroxidation as indexed by protein-bound 2-hydroxy-2-trans-nonenal 
(HNE).  C) Protein oxidation as indexed by protein-resident 3-nitrotyrosine (3-NT).   
 
 
J20 NTg J20 Tg M53L NTg M35L Tg 
 
J20 NTg J20 Tg M35L NTg M35L Tg 
 
184 202 204 151 
 
148 281 321 196 
 
158 242 135 116 
 
75 465 60 219 
 
176 253 116 151 
 
141 724 103 180 
PCO 149 218 143 162 PCO 229 298 219 213 
Run 1 161 252 125 134 Run 2 267 441 135 140 
  
261 
 
123 
  
388 
 
155 
  
234 
 
138 
  
272 
 
247 
  
216 
 
147 
  
478 
 
260 
  
188 
 
154 
  
149 
 
293 
  
263 
 
132 
  
316 
 
217 
Avg 165.60 232.90 144.60 140.80 Avg 172.00 381.20 167.60 212.00 
StDev 14.15 25.88 34.73 14.66 StDev 76.19 157.97 103.67 47.00 
 
 
PCO Combined J20 NTg J20 Tg M53L NTg M35L Tg 
    % Control 111.11 121.98 141.08 104.43 
    % Control 95.41 146.14 93.36 80.22 
    % Control 106.28 152.78 80.22 104.43 
 
 
  % Control 89.98 131.64 98.89 112.03 
    % Control 97.22 152.17 86.45 92.67 
    % Control 86.05 157.61 191.53 85.06 
    % Control 43.60 141.30 35.80 95.44 
    % Control 81.98 130.43 61.46 101.66 
 
J20NTg vs J20Tg P-value  0.00030 
% Control 133.14 113.53 130.67 106.50 
 
M35LNTg vs M35LTg P-value 0.4446 
% Control 155.23 158.82 80.55 91.29 
 
M35LNTg vs J20NTg P-value 1.0000 
% Control 
 
163.37 
 
116.95 
 
M35LTg vs J20Tg P-value 0.0004 
% Control 
 
270.35 
 
130.67 
    % Control 
 
420.93 
 
107.40 
    % Control 
 
173.26 
 
127.09 
    % Control 
 
256.40 
 
83.53 
    % Control 
 
225.58 
 
92.48 
    % Control 
 
158.14 
 
147.37 
    % Control 
 
277.91 
 
155.13 
    % Control 
 
86.63 
 
174.82 
    % Control 
 
183.72 
 
129.47 
    Avg % 100.00 181.13 100.00 111.93 
    StDev % 30.08 76.40 44.24 25.38 
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Figure 6.1 data (cont.) 
 
 J20 NTg J20 Tg M53L NTg M35L Tg 
 
J20 NTg J20 Tg M53L NTg M35L Tg 
 
236 217 196 168 
 
347 651 103 208 
 
201 285 228 209 
 
360 589 75 73 
 
216 271 272 224 
 
280 490 82 141 
HNE 226 258 238 233 HNE 273 463 51 101 
Run 1 203 242 249 194 Run 2 
 
220 
 
165 
  
252 
 
242 
  
173 
 
119 
  
209 
 
292 
  
318 
 
123 
  
170 
 
228 
  
347 
 
185 
  
257 
 
212 
  
379 
 
64 
  
222 
 
238 
  
321 
 
48 
Avg 216.40 238.30 236.60 224.00 Avg 315.00 395.10 77.75 122.70 
StDev 14.94 34.05 27.98 32.74 StDev 44.86 153.01 21.44 52.98 
 
 
HNE Combined J20 NTg J20 Tg M53L NTg M35L Tg 
    % Control 109.06 100.28 82.84 71.01 
    % Control 92.88 131.70 96.37 88.33 
    % Control 99.82 125.23 114.96 94.67 
    % Control 104.44 119.22 100.59 98.48 
    % Control 93.81 111.83 105.24 81.99 
    % Control 110.16 116.45 132.48 102.28 
    % Control 114.29 96.58 96.46 123.42 
    % Control 88.89 78.56 105.47 96.37 
    % Control 86.67 118.76 65.59 89.60 
 
J20NTg vs J20Tg P-value  0.0170 
% Control 
 
102.59 
 
100.59 
 
M35LNTg vs M35LTg P-value   0.9375 
% Control 
 
233.33 
 
181.18 
 
M35LNTg vs J20NTg P-value 1.0000 
% Control 
 
211.11 
 
63.59 
 
M35LTg vs J20Tg P-value 0.0454 
% Control 
 
175.63 
 
122.82 
    % Control 
 
165.95 
 
87.98 
    % Control 
 
78.85 
 
143.73 
    % Control 
 
62.01 
 
103.66 
    % Control 
 
113.98 
 
107.14 
    % Control 
 
124.37 
 
161.15 
    % Control 
 
135.84 
 
55.75 
    % Control 
 
115.05 
 
41.81 
    Avg % 100.00 125.87 100.00 100.78 
    StDev % 10.00 42.46 18.84 33.75 
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Figure 6.1 data (cont.) 
 
 
J20 NTg J20 Tg M35L NTg M35L Tg 
 
J20 NTg J20 Tg M35L NTg M35L Tg 
 
429 567 390 410 
 
374 467 496 268 
 
521 645 385 484 
 
348 457 433 608 
 
492 658 501 438 
 
544 466 388 550 
3-NT 435 642 408 369 3-NT 411 565 400 435 
Run 1 421 463 385 450 Run 2 321 619 424 427 
  
423 
 
432 
  
789 
 
402 
  
531 
 
358 
  
708 
 
429 
  
531 
 
294 
  
471 
 
342 
  
612 
 
309 
  
503 
 
253 
  
578 
 
383 
  
430 
 
587 
Avg 459.60 565.00 413.80 392.70 Avg 399.60 547.50 428.20 430.10 
StDev 44.30 79.05 49.66 61.57 StDev 87.29 121.31 41.98 123.32 
 
 
3-NT Combined J20 NTg J20 Tg M35L NTg M35L Tg 
    % Control 93.34 123.37 94.25 99.08 
    % Control 113.36 140.34 93.04 116.96 
    % Control 107.05 143.17 121.07 105.85 
    % Control 94.65 139.69 98.60 89.17 
    % Control 91.60 100.74 93.04 108.75 
    % Control 93.59 92.04 115.83 104.40 
    % Control 87.09 115.54 101.12 86.52 
    % Control 136.14 115.54 90.61 71.05 
    % Control 102.85 133.16 93.41 74.67 
 
J20NTg vs J20Tg P-value  0.00049 
% Control 80.33 125.76 99.02 92.56 
 
M35LNTg vs M35LTg P-value 0.70085 
% Control 
 
116.87 
 
62.59 
 
M35LNTg vs J20NTg P-value 1.00000 
% Control 
 
114.36 
 
141.99 
 
M35LTg vs J20Tg P-value 0.00012 
% Control 
 
116.62 
 
128.44 
    % Control 
 
141.39 
 
101.59 
 
 
  % Control 
 
154.90 
 
99.72 
 
  
  % Control 
 
197.45 
 
93.88 
    % Control 
 
177.18 
 
100.19 
    % Control 
 
117.87 
 
79.87 
    % Control 
 
125.88 
 
59.08 
    % Control 
 
107.61 
 
137.09  
   Avg % 100.00 129.97 100.00 97.67 
    StDev % 15.92 25.08 10.33 22.49 
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Figure 6.2 Specificity assay for protein carbonyls. 
 
Data obtained by collaborator Dr. Rukhsana Sultana (University of Kentucky, Lexington, KY). 
 
 
 
Figure 6.3 Amyloid precursor protein (APP) expression and amyloid-β (Aβ) production.   
 
Data obtained by our collaborators at the Buck Institute for Age Research (Novato, CA).   
 
 
 
Figure 6.4 Immunohistochemical staining of amyloid plaques and microglia.   
 
Data obtained by our collaborators at the Buck Institute for Age Research (Novato, CA).   
 
 
 
Figure 6.5 Morris water-maze behavioral assessment of PDAPP mice: Effect of the M631L 
mutation.  A) Latency index spatial training.  B) Floating.  C) Probe trial.   
 
Data obtained by our collaborators at the Buck Institute for Age Research (Novato, CA).   
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 Figure 7.1 Representative 2D-gel images of proteins isolated from Tg PDAPP(J20) and Non Tg 
PDAPP mouse brain. 
 
Table 7.1 List of proteins with differential levels in Tg PDAPP(J20) mice relative to Non Tg 
PDAPP controls. 
 
Expression 
SSP# J20NTg_562 J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 
2 558.3 563.5 275.8 1047.4 8.9 
2201 516.1 862.8 1707.2 6.9 8.9 
3303 12.1 12 9.3 6.9 8.9 
4608 803.6 1217.4 1102.9 1756.1 8.9 
4701 12.1 12 9.3 6.9 8.9 
7002 12.1 957.3 1333.2 6.9 803.4 
7710 488.9 12 9.3 6.9 8.9 
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
2 1161.9 2262.9 989.4 1345.7 10.3 
2201 11.6 2399.1 1353.2 2363.1 1016.4 
3303 883.7 634.2 652.7 764.5 10.3 
4608 3191.9 2212.8 1632.5 1926.4 1208.2 
4701 11.6 819.9 520.5 346.2 100.3 
7002 2194.3 2329 1845.6 1047.9 2006.4 
7710 909.5 1606.1 760.5 1493.6 1980.2 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
2 1445.6 1257.4 927.5 1404.9 1329.5 
2201 2011.2 2413.7 1879.9 1280.7 1537.8 
3303 7.3 1045.9 9.4 10.8 864.2 
4608 1870.1 1834.4 1059.2 1357.7 2089.5 
4701 482.6 968.9 501 397 573.5 
7002 1589.8 1965.5 1819.9 2206.1 2243.9 
7710 798 1106.2 1526.2 1354.7 1264.2 
      From Boolean 
    Normalized intensity values shown  
    
 
Expression 
  
Fold Change 
 SSP# Sample ID J20NTg Avg J20Tg Avg Tg/NTg P-value 
2 Calcineurin, subunit B, Type 1 490.78 1213.51 2.47262 0.0135 
2201 ρGDP-dissociation inhibitor 1 620.38 1626.67 2.62205 0.0329 
3303 F-actin-capping protein, subunit β 9.84 488.3 49.62398 0.0064 
4608 α-Enolase 977.78 1838.27 1.88004 0.0386 
4701 T-complex protein 1, subunit α A 9.84 472.15 47.98272 0.0007 
7002 Peptidyl-prolyl cis-trans isomerase 1 622.58 1924.84 3.09172 0.0047 
7710 ATP synthase, subunit α, 105.2 1279.92 12.16654 5.09e-06 
 
mitochondrial 
    
  
J20NTg StDev 591.92 
  
  
J20Tg StDev 502.45 
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Figure 7.2 Peptidyl-proyl cis-trans isomerase (Pin-1) expression levels in brain of transgenic 
(Tg) and non-transgenic (Non Tg) mice. 
 
 
NTg - 1 NTg - 3 NTg - 5 NTg - 7 NTg - 9 
actin 33121.65 40140.69 37954.74 33752.62 34162.42 
Pin-1 12072.42 13714.17 13363.89 13454.18 11022.26 
Normalized 0.36449 0.34165 0.35210 0.39861 0.32264 
 
Tg - 2 Tg - 4 Tg - 6 Tg - 8 Tg - 10 
actin 37612.45 35244.92 33997.29 29574.00 30400.24 
Pin-1 14600.10 16638.49 13458.34 11165.44 12635.53 
Normalized 0.38817 0.47208 0.39587 0.37754 0.41564 
      
  
NTg Tg 
  
 
Tot Avg 0.35590 0.40986 
  
 
% NTg 102.41 109.07 
  
 
% NTg 96.00 132.64 
  
 
% NTg 98.93 111.23 
  
 
% NTg 112.00 106.08 
  
 
% NTg 90.66 116.79 
  
 
Avg % 100.00 115.16 
  
 
StDev % 7.97 10.53 
        
 P-value 0.0332    
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Figure 7.3 Representative 2D-Western blot image corresponding to carbonylated 
dihydropyrimidinase-related protein 2 (Drp-2).   
 
Table 7.2 List of oxidatively modified proteins in Tg PDAPP(J20) mice relative to Non Tg 
PDAPP controls.  
 
From Boolean 
    Normalized intensity values shown 
  
 
GELS 
 
PCO 
  SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
4702 3563.9 6236.7 18167.2 7786.2 4202.3 
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
4702 7555 10721 11211.4 17640.9 6380.4 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
4702 6938.1 7190.3 6029.2 111.8 23470.6 
      
 
BLOTS 
 
PCO 
  SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
4702 8.4 64.8 37.7 30.3 57 
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
4702 3079.4 48.8 17354.9 9.6 39.5 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
4702 8897.8 3531.9 42.9 50.8 27.8 
      
 
FOLD CHANGE PER ANIMAL       PCO 
 
 
J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
4702 0.00236 0.01039 0.00208 0.00389 0.01356 
 
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
4702 0.407598 0.004552 1.547969 0.000544 0.006191 
 
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
4702 1.282455 0.491203 0.007115 0.454383 0.001184 
 
 
 
PCO 
  
Fold Change Actual % 
 SSP# Sample ID J20Tg Avg J20NTg Avg Tg/NTg Tg/NTg P-value 
4702 Dihydropyrimidinase-related 0.420319 0.006456 65.110 6510.97 0.0462 
 
protein 2 
     
  
J20NTg StDev 0.005 
   
  
J20Tg StDev 0.566 
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Figure 7.4 Representative 2D-Western blot image corresponding to nitrated 
phosphatidylethanolamine-binding protein 1 (PEBP-1). 
 
Figure 7.5 Representative 2D-Western blot image corresponding to nitrated peptidyl-prolyl cis-
trans isomerase 1 (Pin-1).   
 
Table 7.2 List of oxidatively modified proteins in Tg PDAPP(J20) mice relative to Non Tg 
PDAPP controls.  
 
From Boolean 
    Normalized intensity values shown 
  
 
GELS 
 
3-NT 
  SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
2101 6747.6 25746.6 27259.1 32305.6 14233.1 
6101 6877.1 23713.3 33630.4 7278.1 7158.7 
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
2101 28859.2 22372.4 31165.8 37589.4 16666.1 
6101 30480 18198.2 20075.4 19543.1 27219.2 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
2101 21655.7 31852 14375.3 32730.5 19637.7 
6101 11188.4 40687.3 31548.5 24249 44754.9 
      
 
BLOTS 
 
3-NT 
  SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
2101 11434.3 20420.3 37713.3 12902.3 15328.2 
6101 9324.7 6166.5 16694.1 4033.9 3849.3 
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
2101 1563.3 17563.6 14003 2531.2 3198.8 
6101 2005.8 4514.4 5331 1795.2 1297.4 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
2101 4679.3 7625.6 4378.3 4225.4 9635.8 
6101 53.3 3577.2 4670.2 5498.2 1628.6 
      
 
FOLD CHANGE PER ANIMAL    3-NT 
 
 
J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2101 1.69457 0.79313 1.38351 0.39938 1.07694 
6101 1.35591 0.26004 0.49640 0.55425 0.53771 
 
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2101 0.05417 0.78506 0.44931 0.06734 0.19193 
6101 0.06581 0.24807 0.26555 0.09186 0.04766 
 
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2101 0.21608 0.23941 0.30457 0.12910 0.49068 
6101 0.00476 0.08792 0.14803 0.22674 0.03639 
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Figures 7.4 & 7.5 & Table 7.2 data (cont.) 
 
 
3-NT J20 J20 Fold Change Actual % 
 
NTg Tg 
SSP# Sample ID Tg Avg NTg Avg Tg/NTg Tg/NTg P-value StDev StDev 
2101 Phosphatidylethanolamine- 0.29276 1.0695 0.27373 27.37 0.0230 0.504 0.226 
 
binding protein 1 
       6101 Peptidyl-prolyl cis-trans 0.12228 0.6409 0.19081 19.08 0.0488 0.417 0.094 
 
isomerase 1 
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Figure 7.6 Peptidyl-prolyl cis-trans isomerase (Pin-1) nitration levels in brain of Tg 
PDAPP(J20) and Non Tg PDAPP mice. 
 
 
Tg - 1 Tg - 3 Tg - 6 NTg - 2 NTg - 4 NTg - 5 
Pin-1 16115.88 12439.5 11229.45 19655.93 18765 19473.19 
       
   
NTg Tg 
  
  
Tot Avg 19298.04 13261.61 
  
  
% NTg 101.85 83.51045 
  
  
% NTg 97.24 64.45991 
  
  
% NTg 100.91 58.18959 
  
  
Avg % 100.00 68.72 
  
  
StDev % 2.44 13.19 
         
  P-value 0.015    
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Figure 8.1 Representative 2D-gel images of proteins isolated from brain of Tg 
PDAPP(M631L) and  Non Tg M631L mice.   
 
Table 8.1 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Non 
Tg M631L controls.  
 
M35L EXPRESSION 
    SSP# M35LNTg 664 M35LNTg 604 M35LNTg 661 M35LNTg 606 M35LNTg 607 
1903 16 547.9 6.1 560.3 408.1 
6201 422 473.4 740 541.1 528.8 
6902 16 259.6 6.1 47.6 12.9 
8002 1812.3 1536.1 1680.8 1187.5 957.9 
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
1903 1295.5 7 848.7 781.9 721.7 
6201 402.9 284.6 347.3 485.8 13.7 
6902 449.8 7 11.6 586.6 1107.4 
8002 1403.7 788 946.7 961.5 1095.7 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
1903 503.9 625.7 643.8 883.8 704.9 
6201 370.4 348.3 493.7 514.2 18 
6902 496.9 532.6 13.6 501.5 388.9 
8002 13.3 13.8 1370.6 12.1 1325.9 
      M35LNTg  
Avg 
M35LNTg 
StDev M35LTg Avg 
M35LTg 
StDev 
Fold Change  
Tg/NTg P-value 
307.68 277.3240 701.69 324.04929 2.28058 0.03579 
541.06 120.9138 327.89 180.11973 0.60601 0.01943 
68.44 108.0478 409.59 338.09943 5.98466 0.01321 
1434.92 354.2156 793.13 573.40273 0.55273 0.02044 
 
From Boolean 
  Normalized intensity values shown 
 
SSP# Sample ID 
1903 Heat shock protein B1 
6201 Proteasome, subunit B, type 1 
6902 Dynamin-1 
8002 Glutathione-S-transferase μ1  
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Figure 8.2 Representative 2D-gel images of proteins isolated from brain of Tg PDAPP(M631L) 
and  Tg PDAPP(J20) mice.   
 
Table 8.2 List of proteins with differential levels in Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice.  
 
From Boolean 
    Normalized intensity values shown 
   M35L GELS 
     SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
1104 268.8 369.2 11.6 6 13.7 
1105 14.5 328.1 11.6 6 13.7 
2008 558.2 409.1 11.6 6 13.7 
3201 663.5 7 331 779 13.7 
4105 14.5 7 352.8 645.4 13.7 
4205 14.5 322.4 11.6 6 13.7 
4402 1474.1 575.1 11.6 1802.2 1853.9 
5203 14.5 7 11.6 6 645.3 
5403 2276.5 1845.8 1919.6 601.4 1096.4 
5506 407.9 324.5 163.2 6 13.7 
5702 507.8 7 11.6 632 13.7 
6101 2028.8 1351.3 1790.2 1696.2 1720.8 
6102 14.5 342.4 585.8 797 530.8 
6103 14.5 456.8 11.6 6 617.8 
6203 1040.9 544.1 568.1 6 657 
6301 14.5 910.1 914.4 1231.7 768.5 
6303 1262.2 680.5 956.7 1158.8 839.8 
6403 1264.4 7 2133.5 1138.9 13.7 
6504 723 428.6 536.5 782.6 756.9 
6704 904.9 580.9 11.6 6 13.7 
7002 14.5 851.3 11.6 6 13.7 
7102 405.2 380.1 366.3 373 406.5 
7402 2028.4 1751.6 2304.7 2051 2624.1 
7710 739.8 954.8 692.8 6 13.7 
8701 14.5 7 11.6 6 13.7 
8709 1997.8 1080.8 1610.5 2026.3 2114.5 
9001 1290.8 616.6 917.2 1127.5 273.5 
9204 14.5 7 11.6 70.8 322.4 
9401 1123.4 681.1 681.7 1271.5 830.9 
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Figure 8.2 & Table 8.2 data (cont.) 
 
M35L GELS Cont. 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
1104 310.8 13.8 13.6 12.1 18 
1105 13.3 13.8 13.6 12.1 18 
2008 662.3 13.8 700.4 639.6 18 
3201 13.3 13.8 489.7 12.1 295.4 
4105 13.3 13.8 13.6 12.1 18 
4205 301.1 455.9 427.8 12.1 18 
4402 456.4 739.7 916.1 12.1 346.7 
5203 13.3 13.8 13.6 12.1 18 
5403 13.3 722.7 13.6 12.1 18 
5506 13.3 13.8 13.6 12.1 18 
5702 337.9 13.8 13.6 162.2 18 
6101 2120.1 1227.2 1311.5 1019.1 1367.3 
6102 13.3 620.8 13.6 12.1 18 
6103 13.3 13.8 13.6 12.1 18 
6203 555.5 630.1 634.6 839.8 18 
6301 314.2 311.8 534 681.8 550.3 
6303 549.8 637 604.2 675 516.6 
6403 13.3 13.8 13.6 825.3 18 
6504 405.3 607.5 658.2 573.8 413.8 
6704 1057.6 274.2 307.1 330.7 349.3 
7002 1943.2 2139.6 1239.1 1036.9 1315 
7102 13.3 13.8 13.6 186.4 18 
7402 772.5 1782.1 1971.6 1859.6 1451.1 
7710 13.3 13.8 13.6 578 18 
8701 13.3 13.8 13.6 12.1 18 
8709 852.4 1448.1 1392.2 1220.6 882.3 
9001 1549.8 1140.9 1160 1009.6 1163.3 
9204 13.3 13.8 13.6 12.1 18 
9401 587.6 947 618.5 990.3 663.4 
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Figure 8.2 & Table 8.2 data (cont.) 
 
J20 GELS 
     SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
1104 740.7 447.7 727.2 452.4 211.5 
1105 430.3 522.1 432.7 614.7 316.3 
2008 584.3 552.6 601.8 806.4 1018.7 
3201 687.5 776.4 459.1 631.7 487.3 
4105 907.7 927.3 874.5 500.5 1134 
4205 551.2 500.1 557.9 465.5 10.3 
4402 1980.4 1009.1 1137.2 1627.3 997.7 
5203 11.6 672.8 652.9 630.2 482.5 
5403 2693.9 2735.9 1893 1828.7 1536.5 
5506 11.6 103.8 704 390.3 462.7 
5702 11.6 10.7 379.7 896.2 10.3 
6101 3059.9 2547 2339.4 1770.2 3513.9 
6102 11.6 804.7 787.9 559.8 10.3 
6103 485.3 978.6 1113.8 730.6 1026 
6203 915.3 1293.4 1283.6 1201.8 819.7 
6301 1583.2 1101 1593.7 1060.1 623.5 
6303 1139.2 1310.2 1284.7 1339 779.3 
6403 2322 2698.7 2177.3 1610.3 2840.7 
6504 1344 738.9 906.5 1172.9 561.6 
6704 1021.9 1242.8 1073.3 1797.7 1013.1 
7002 2194.3 2329 1845.6 1047.9 2006.4 
7102 596.1 484.6 329.5 410.5 404.8 
7402 3543.2 3377.7 2968.7 2661.6 3301.6 
7710 909.5 1606.1 760.5 1493.6 1980.2 
8701 700.7 431.6 355.6 1136.3 10.3 
8709 4130.1 2457.4 2590.1 3705.7 2263.2 
9001 1512.3 1418.6 1358.1 1236.4 2022.7 
9204 346.3 433.1 7.7 384 543 
9401 1273.8 2639.2 967.2 1080 1003.4 
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Figure 8.2 & Table 8.2 data (cont.) 
 
J20 GELS Cont. 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
1104 7.3 413.1 9.4 1113.8 1594.1 
1105 7.3 4.3 9.4 10.8 13.8 
2008 868.2 969.8 881.8 10.8 13.8 
3201 690.2 334.5 408.6 602 551.3 
4105 7.3 397.4 504.6 683.2 13.8 
4205 7.3 257.1 715.3 368.1 449.7 
4402 2389 883.2 2882.1 3270.1 2913.1 
5203 563.8 628.2 9.4 10.8 13.8 
5403 7.3 1144.4 1490.1 2636.4 1976.4 
5506 7.3 710.8 9.4 453.5 947.5 
5702 841.3 1596.7 900.3 684.8 1216.8 
6101 1622.2 3417.2 2770.5 2352.7 4752.9 
6102 922.6 1317.2 1015.9 1071.6 495 
6103 7.3 713.1 540.8 1289.9 13.8 
6203 1166.9 995.1 1680.9 1835.5 1528.1 
6301 1258.5 1014.4 1485.3 1600 1646.2 
6303 1291.3 1242.5 2031 2225.3 1672.8 
6403 7.3 3421 9.4 2470.5 13.8 
6504 809.4 598.3 1167.9 1392.5 1336.3 
6704 697.8 1115.7 898.1 10.8 831 
7002 1589.8 1965.5 1819.9 2206.1 2243.9 
7102 465.6 538.3 390.6 928.7 13.8 
7402 1745.6 2602.4 3013.5 3390.9 2777 
7710 798 1106.2 1526.2 1354.7 1264.2 
8701 578.6 4.3 9.4 875.4 13.8 
8709 2858.1 1728.9 4161.6 5238.6 3819.4 
9001 1554.1 1723.5 1871.8 2351.8 2263.4 
9204 418.9 4.3 266.1 572 13.8 
9401 893.6 1546.8 1612.4 1540.6 532.9 
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Figure 8.2 & Table 8.2 data (cont.) 
 
J20Tg vs M35L Tg Expression 
     
Fold Change 
 SSP# J20Tg Avg J20Tg StDev M35LTg Avg M35LTg StDev M35LTg/J20Tg P-value 
1104 571.72 495.66 103.76 148.59 0.181487 0.01041 
1105 236.17 250.68 44.47 99.70 0.188297 0.03742 
2008 630.82 363.59 303.27 315.94 0.480755 0.04536 
3201 562.86 139.91 261.85 297.92 0.465213 0.00971 
4105 595.03 383.54 110.42 216.17 0.185570 0.00267 
4205 388.25 233.36 158.31 193.18 0.407753 0.02742 
4402 1908.92 907.43 818.79 683.10 0.428928 0.00712 
5203 367.6 311.03 75.52 200.23 0.205441 0.02245 
5403 1794.26 831.59 851.94 888.39 0.474814 0.02480 
5506 380.09 339.45 98.61 149.93 0.259439 0.02750 
5702 654.84 545.37 171.76 236.60 0.262293 0.01929 
6101 2814.59 924.64 1563.25 361.56 0.555409 0.00087 
6102 699.66 434.40 294.83 315.27 0.421390 0.02828 
6103 689.92 437.84 117.75 224.37 0.170672 0.00172 
6203 1272.03 329.20 549.41 321.34 0.431916 0.00010 
6301 1296.59 341.34 623.13 355.62 0.480591 0.00041 
6303 1431.53 429.31 788.06 259.23 0.550502 0.00074 
6403 1757.1 1291.46 544.15 757.84 0.309686 0.01962 
6504 1002.83 318.03 588.62 142.17 0.586959 0.00143 
6704 970.22 449.02 383.6 365.84 0.395374 0.00493 
7002 1924.84 383.51 857.09 821.44 0.445279 0.00155 
7102 456.25 228.83 217.62 185.37 0.476975 0.01958 
7402 2938.22 531.28 1859.67 497.39 0.632924 0.00018 
7710 1279.92 391.35 304.38 386.96 0.237812 0.00003 
8701 411.6 408.55 12.36 3.54 0.030029 0.00631 
8709 3295.31 1084.04 1462.55 467.81 0.443828 0.00011 
9001 1731.27 385.03 1024.92 357.58 0.592005 0.00048 
9204 298.92 218.58 49.71 97.56 0.166299 0.00405 
9401 1308.99 578.36 839.54 234.50 0.641365 0.02865 
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Figure 8.2 & Table 8.2 data (cont.) 
 
J20Tg vs M35L Tg Expression 
SSP# Sample ID 
1104 Phosphatidylethanolamine-binding protein 1 
1105 Peroxiredoxin-2 
2008 V-type proton ATPase, subunit F 
3201 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial 
4105 Serum albumin 
4205 Proteasome subunit β, type 3 
4402 Malate dehydrogenase, cytoplasmic 
5203 Triose phosphate isomerase 
5403 Acot7, isoform B of cytosolic acyl CoA, thioester 7 
5506 Fructose bisphosphate aldolase C 
5702 Dihydropyrimidinase-related protein 2 
6101 Peptidyl-prolyl cis-trans isomerase 1 
6102 Transgelin 3 
6103 Peptidyl-prolyl cis-trans isomerase 1 
6203 Triose phosphate isomerase 
6301 Carbonic anhydrase 2 
6303 Phosphoglycerate mutase 1 
6403 Glyceraldehyde-3-phosphate dehydrogenase 
6504 Fructose bisphosphate aldolase C 
6704 Pyruvate kinase M1/M2 
7002 Peptidyl-prolyl cis-trans isomerase 1 
7102 Superoxide dismutase [Mn], mitochondrial 
7402 Glyceraldehyde-3-phosphate dehydrogenase 
7710 ATP synthase, subunit α, mitochonodrial 
8701 Pyruvate kinase M1/M2 
8709 ATP synthase, subunit α, mitochonodrial 
9001 Pyruvate kinase M1/M2 
9204 Peroxiredoxin-1 
9401 Voltage-dependent anion-selective channel protein 1 
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Figure 8.3 Pyruvate kinase M2 (PK M2) levels in brain of Tg PDAPP(M631L) mice and Tg 
PDAPP(J20) mice.   
 
 
J20Tg - 1 J20Tg - 3 J20Tg - 5 J20Tg - 7 J20Tg - 9 J20Tg - 11 
actin 193182 164524.25 139239.84 178059.63 163689.3 169476 
PK M2 5955.68 8513.4 10941.13 11907.08 13462.77 15742.5 
Normalized  0.03083 0.05175 0.07858 0.06687 0.08225 0.09289 
       
 
M35LTg - 2 M35LTg - 4 M35LTg - 6 M35LTg - 8 M35LTg - 10 M35LTg - 12 
actin 176950.5 157933.05 154947.9 162976.68 182230.8 226463.4 
PK M2 5564 8047.63 7931.52 10506.14 4825.27 9054.75 
Normalized  0.03144 0.05096 0.05119 0.06446 0.02648 0.03998 
       
   
J20Tg M35LTg 
  
  
Tot Avg 0.06719 0.04409 
  
  
% J20Tg 45.88 46.80 
  
  
% J20Tg 77.01 75.84 
  
  
% J20Tg 116.94 76.18 
  
  
% J20Tg 99.52 95.94 
  
  
% J20Tg 122.40 39.41 
  
  
% J20Tg 138.24 59.50 
  
  
Avg % 100.00 65.61 
  
  
StDev % 33.79 21.04 
  
       
  
P-value 0.0604 
    
247 
 
Figure 9.1 Representative 2D-gel images of proteins isolated and transferred to 2D-Western 
blots from Tg PDAPP(M631L), Tg PDAPP(J20), and Non Tg M631L mouse brain. 
 
Figure 9.2 Representative 2D-Western blot images corresponding to carbonylated pyruvate 
kinase isoforms M1/M2 (PK M1/M2) and aspartate aminotransferase, mitochondrial (AATM). 
 
Table 9.1 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice.  
 
From Boolean 
  Normalized intensity values shown 
J20 GELS 
 
PCO 
  SSP# J20NTg_462 J20NTg_463 J20NTg_523 J20NTg_524 J20NTg_562 
0102 26037.7 70814.4 114927.9 52535.9 21585.6 
1301 66 17292.1 65.2 23905.1 95.9 
2101 6747.6 25746.6 27259.1 32305.6 14233.1 
6303 3743.6 10447.4 7455.2 17573 9127.3 
7702 4440.4 19795.3 28569.1 37132.4 12676 
9603 8150.9 97.3 34755.2 109.2 95.9 
SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
0102 81226.6 51230.3 70661.8 55456.2 20471.3 
1301 115.9 76.4 2354.2 10858.9 80 
2101 28859.2 22372.4 31165.8 37589.4 16666.1 
6303 11348 9361.4 11024.4 14781.8 6036.4 
7702 27453.8 10995.2 13778.2 31778.5 10904.8 
9603 44685.8 35828.4 42708.1 48827.2 80 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
0102 45470.3 82733.4 84719.9 37751 42713.9 
1301 27105.8 50.9 41298.5 111.8 130.2 
2101 21655.7 31852 14375.3 32730.5 19637.7 
6303 8906.7 14794.1 23127.7 22936.4 15752 
7702 16264.4 23546.1 34749.5 31395.7 26015.5 
9603 18308.4 50.9 106.9 111.8 130.2 
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Figures 9.1 & 9.2 & Table 9.1 data (cont.) 
 
J20 BLOTS 
 
PCO 
  SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
0102 41.1 48.8 68.7 9.6 39.5 
1301 17341.6 18664.7 3805.4 5488.6 1237.5 
2101 5060 8470.2 2932.8 4050.6 6383.8 
6303 41.1 48.8 68.7 9.6 39.5 
7702 7898.7 48.8 68.7 9.6 39.5 
9603 41.1 48.8 68.7 9.6 39.5 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
0102 42.7 53.1 42.9 50.8 27.8 
1301 7574.7 8096.7 7753.2 41618.2 43553.6 
2101 5703.4 12543 348.6 6184.6 7297.5 
6303 42.7 53.1 42.9 50.8 27.8 
7702 42.7 53.1 42.9 50.8 27.8 
9603 42.7 53.1 42.9 50.8 27.8 
      J20 FOLD CHANGE PER ANIMAL PCO 
 
 
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
0102 0.00051 0.00095 0.00097 0.00017 0.00193 
1301 149.62554 244.30236 1.61643 0.50545 15.46875 
2101 0.17533 0.37860 0.09410 0.10776 0.38304 
6303 0.00362 0.00521 0.00623 0.00065 0.00654 
7702 0.28771 0.00444 0.00499 0.00030 0.00362 
9603 0.00092 0.00136 0.00161 0.00020 0.49375 
 
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
0102 0.00094 0.00064 0.00051 0.00135 0.00065 
1301 0.27945 159.07073 0.18774 372.25581 334.51306 
2101 0.26337 0.39379 0.02425 0.18896 0.37161 
6303 0.00479 0.00359 0.00185 0.00221 0.00176 
7702 0.00263 0.00226 0.00123 0.00162 0.00107 
9603 0.00233 1.04322 0.40131 0.45438 0.21352 
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Figures 9.1 & 9.2 & Table 9.1 data (cont.) 
 
M35L  GELS 
 
PCO 
  SSP# M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664 
0102 21389.8 64614.7 57605.6 6127.5 100.6 
1301 75.1 9063.8 127.2 63.4 100.6 
2101 13621.3 38835.1 29555.6 7047.3 8919.5 
6303 6875.5 11336 8950 12982.1 3108.4 
7702 15915.2 19752.1 17895.4 11590.4 7625.4 
9603 75.1 41446 30145.8 63.4 100.6 
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
0102 58736.2 74459.2 98048.3 31251.3 79448.2 
1301 110.3 110.5 133.4 64.4 89.3 
2101 12545.4 27049 30129.3 35617.9 15809.5 
6303 9613.8 10790.3 11037.9 12375.2 5486.9 
7702 24033.3 18319 11459.9 29741.5 20639.3 
9603 2228.6 35358.8 30128.1 38273.1 36136.9 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
0102 33045.2 92.2 102.6 91 124.6 
1301 86.1 92.2 102.6 91 124.6 
2101 10809.6 10356.4 11348.3 12185.8 10544.6 
6303 3565.9 4268.5 4554.6 5056.6 3570.3 
7702 8503.1 10136.6 8839.8 10446.3 10704.4 
9603 9853.7 8939.6 7655 10110.7 4861.8 
  
M35L BLOTS 
 
PCO 
  SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
0102 0.1 43.9 30.7 50.5 51.5 
1301 17204.2 22055.3 2757 27442.5 40289.4 
2101 3331.7 9557.7 6125.7 6641.5 4857.1 
6303 0.1 43.9 30.7 50.5 51.5 
7702 81017.8 21202.1 32084.8 50.5 72755.8 
9603 0.1 43.9 30.7 50.5 51.5 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
0102 64.5 37.6 42.2 24.4 53.9 
1301 9870 43363.6 27224.8 34926.3 39942.7 
2101 21324.5 21540 10635.4 11447.4 4691.2 
6303 64.5 37.6 42.2 24.4 53.9 
7702 64.5 37.6 4307.6 24.4 53.9 
9603 64.5 37.6 42.2 24.4 53.9 
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Figures 9.1 & 9.2 & Table 9.1 data (cont.) 
 
M35L FOLD CHANGE PER ANIMAL 
 
PCO 
 
 
M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
0102 0.0000017 0.000590 0.000313 0.001616 0.000648 
1301 155.97643 199.59548 20.66717 426.12578 451.16909 
2101 0.265571 0.353348 0.203314 0.186465 0.307227 
6303 0.000010 0.004068 0.002781 0.004081 0.009386 
7702 3.371064 1.157383 2.799745 0.001698 3.525110 
9603 0.000045 0.001242 0.001019 0.001319 0.001425 
 
M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
0102 0.00195 0.40781 0.41131 0.26813 0.43258 
1301 114.6341 470.3210 265.3489 383.8055 320.5674 
2101 1.97274 2.07987 0.93718 0.93940 0.44489 
6303 0.01809 0.00881 0.00927 0.00483 0.01510 
7702 0.00759 0.00371 0.48730 0.00234 0.00504 
9603 0.00655 0.00421 0.00551 0.00241 0.01109 
  
   
PCO 
 
Fold Change 
 SSP# J20Tg Avg J20Tg StDev M35LTg Avg M35LTg StDev M35LTg/J20Tg P-value 
0102 0.00086 0.00050 0.15250 0.20054 176.96600 0.0279 
1301 127.7825 147.1231 280.8211 154.9011 2.197649 0.0360 
2101 0.23808 0.13875 0.76900 0.71713 3.230002 0.0337 
6303 0.00365 0.00202 0.00764 0.00565 2.094753 0.0495 
7702 0.03099 0.09022 1.13610 1.50181 36.66491 0.0321 
9603 0.26126 0.34362 0.00348 0.00341 0.013326 0.0290 
  
SSP# Sample ID 
0102 Calmodulin, isoform 1 
1301 14-3-3 δ/δ 
2101 Phosphatidylethanolamine-binding protein 1 
6303 Phosphoglycerate mutase 1 
7702 Pyruvate kinase M1/M2 
9603 Aspartate aminotransferase, mitochondrial 
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Figure 9.3 Representative 2D-Western blot images corresponding to nitrated aspartate 
aminotransferase, mitochondrial (AATM) and peptidyl-prolyl cis-trans isomerase 1 (Pin-1). 
 
Table 9.1 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Tg 
PDAPP(J20) mice.  
 
From Boolean 
 Normalized intensity values shown 
J20  GELS 
 
3-NT 
  SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
2504 81258.8 82132.9 138412.2 125185.2 54236.2 
4701 115.9 5858.5 4466.4 3822.4 777.1 
6101 30480 18198.2 20075.4 19543.1 27219.2 
9303 23373 19392.5 29294.7 27923.3 80 
9603 44685.8 35828.4 42708.1 48827.2 80 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
2504 67332.3 83971.4 116217.5 71908.2 118488.8 
4701 3328.6 11535.9 5705.2 4092.2 5400.6 
6101 11188.4 40687.3 31548.5 24249 44754.9 
9303 50.3 50.9 106.9 111.8 130.2 
9603 18308.4 50.9 106.9 111.8 130.2 
      J20 BLOTS 
 
3-NT 
  SSP# J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
2504 42 79.5 81.9 73.4 74 
4701 42 79.5 81.9 73.4 859.9 
6101 2005.8 4514.4 5331 1795.2 1297.4 
9303 42 79.5 81.9 73.4 74 
9603 42 79.5 81.9 73.4 74 
SSP# J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
2504 53.3 77.6 64.8 109.7 91.9 
4701 53.3 77.6 64.8 109.7 91.9 
6101 53.3 3577.2 4670.2 5498.2 1628.6 
9303 53.3 77.6 64.8 109.7 91.9 
9603 53.3 77.6 64.8 109.7 91.9 
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Figure 9.3 &Table 9.1 data (cont.) 
 
J20 FOLD CHANGE PER ANIMAL 3-NT 
 
 
J20Tg_454 J20Tg_455 J20Tg_461 J20Tg_465 J20Tg_525 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2504 0.000517 0.000968 0.000592 0.000586 0.001364 
4701 0.362381 0.013570 0.018337 0.019203 1.106550 
6101 0.065807 0.248068 0.265549 0.091859 0.047665 
9303 0.001797 0.004100 0.002796 0.002629 0.925 
9603 0.000940 0.002219 0.001918 0.001503 0.925 
 
J20Tg_530 J20Tg_560 J20Tg_561 J20Tg_565 J20Tg_573 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2504 0.00079 0.00092 0.00056 0.00153 0.00078 
4701 0.01601 0.00673 0.01136 0.02681 0.01702 
6101 0.00476 0.08792 0.14803 0.22674 0.03639 
9303 1.05964 1.52456 0.60617 0.98122 0.70584 
9603 0.00291 1.52456 0.60617 0.98122 0.70584 
  
M35L GELS 
 
3-NT 
  SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
2504 88871.6 135979.1 109628.4 49256.2 69373.7 
4701 110.3 2768.6 133.4 64.4 89.3 
6101 15453.1 21426.1 20654.8 18115.2 11242.7 
9303 110.3 12288.8 17286.8 25551.2 27108.4 
9603 2228.6 35358.8 30128.1 38273.1 36136.9 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
2504 38717.2 41253.1 48746.3 56777.8 54357.7 
4701 2683.3 92.2 5051.5 1493.7 124.6 
6101 13751.3 8223.1 9886.7 7634.8 9448.8 
9303 8286.7 12715.5 102.6 15552.1 7710.3 
9603 9853.7 8939.6 7655 10110.7 4861.8 
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Figure 9.3 &Table 9.1 data (cont.) 
 
M35L BLOTS 
 
3-NT 
  SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
2504 69.4 69574.6 84.2 71.6 37301.4 
4701 69.4 2252.4 84.2 71.6 70.7 
6101 4240 10717.2 2843.4 2340 1774.5 
9303 69.4 88.6 84.2 71.6 70.7 
9603 69.4 88.6 84.2 71.6 70.7 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
2504 38614.7 77.8 54.9 83.2 43698.4 
4701 47.6 77.8 54.9 83.2 86.5 
6101 2060.1 2477.5 1550 3872.2 2562.7 
9303 47.6 77.8 54.9 83.2 86.5 
9603 47.6 77.8 54.9 83.2 86.5 
      M35L FOLD CHANGE PER ANIMAL 3-NT 
 
 
M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2504 0.00078 0.51166 0.00077 0.00145 0.53769 
4701 0.62919 0.81355 0.63118 1.11180 0.79171 
6101 0.27438 0.50019 0.13766 0.12917 0.15784 
9303 0.62919 0.00721 0.00487 0.00280 0.00261 
9603 0.03114 0.00251 0.00279 0.00187 0.00196 
 
M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
2504 0.99735 0.00189 0.00113 0.00147 0.80390 
4701 0.01774 0.84382 0.01087 0.05570 0.69422 
6101 0.14981 0.30129 0.15678 0.50718 0.27122 
9303 0.00574 0.00612 0.53509 0.00535 0.01122 
9603 0.00483 0.00870 0.00717 0.00823 0.01779 
  
   
3-NT 
 
Fold Change 
 SSP# J20Tg Avg J20Tg StDev M35LTg Avg M35LTg StDev M35LTg/J20Tg P-value 
2504 0.00086 0.00035 0.28581 0.39087 332.269 0.0332 
4701 0.15980 0.35004 0.55998 0.39169 3.50433 0.0269 
6101 0.12228 0.09427 0.25855 0.14381 2.11444 0.0220 
9303 0.58137 0.55290 0.12102 0.24405 0.20816 0.0269 
9603 0.47523 0.55277 0.00870 0.00924 0.01831 0.0156 
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Figure 9.3 &Table 9.1 data (cont.) 
 
SSP# Sample ID 
2504 Actin (multiple isoforms) 
4701 T-complex protein 1, subunit α A 
6101 Peptidyl-prolyl cis-trans isomerase 1 
9303 Tubulin polymerization-promoting protein 
9603 Aspartate aminotransferase, mitochondrial 
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Figure 9.4 Representative 2D-Western blot images corresponding to nitrated glutathione-S-
transferase μ 1 (GST μ1) and glial fibrillary acidic protein (GFAP).   
 
Table 9.2 List of oxidatively modified proteins in Tg PDAPP(M631L) mice relative to Non Tg 
M631L controls.  
 
From Boolean 
 Normalized intensity values shown 
M35L GELS 
 
3-NT 
  SSP# M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664 
1601 7088.4 11239.4 12790.5 59187 4551.7 
2603 75.1 129.5 127.2 63.4 100.6 
8202 4904.4 9589.1 8759.1 11020.8 3529.9 
8601 18330.5 26573.5 14701.2 19713.6 7580.8 
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
1601 110.3 110.5 133.4 21845.7 4235.5 
2603 110.3 110.5 133.4 64.4 89.3 
8202 3165.1 7168.8 9004.1 6012.8 5250 
8601 20809.6 26764.8 14041.9 31282.6 10412.9 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
1601 86.1 92.2 8314.3 91 124.6 
2603 86.1 92.2 102.6 91 124.6 
8202 3827.9 2628.9 3984.5 4973 2793.3 
8601 10715.4 7469.3 14990.1 10640.6 7920.9 
      M35L BLOTS 
 
3-NT 
  SSP# M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664 
1601 728.4 1527.1 1273.3 5398 11532.9 
2603 36.9 29.8 58.8 49.3 47.8 
8202 36.9 1091 58.8 1271.3 47.8 
8601 36.9 29.8 58.8 49.3 47.8 
SSP# M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
1601 6964.7 25234.9 8796.3 6292.1 2499.2 
2603 69.4 88.6 84.2 71.6 70.7 
8202 1681.7 3323.9 1032 1041.7 70.7 
8601 4376.4 7944.1 2494.4 71.6 70.7 
SSP# M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
1601 9948.2 1244.3 2163.4 12279.7 4390.2 
2603 47.6 77.8 54.9 83.2 86.5 
8202 47.6 1272.7 1443 1742.9 86.5 
8601 47.6 77.8 54.9 83.2 2278.9 
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Figure 9.4 & Table 9.2 data (cont.) 
 
M35L FOLD CHANGE PER ANIMAL 3-NT 
  
 
M35LNTg 604 M35LNTg 606 M35LNTg 607 M35LNTg 661 M35LNTg 664 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
1601 0.102759 0.135870 0.099550 0.091202 2.533757 
2603 0.491345 0.230116 0.462264 0.777603 0.475149 
8202 0.007524 0.113775 0.006713 0.115355 0.013541 
8601 0.002013 0.001121 0.004000 0.002501 0.006305 
 
M35LTg 591 M35LTg 593 M35LTg 594 M35LTg 595 M35LTg 596 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
1601 63.1432 228.3701 65.9393 0.28802 0.59006 
2603 0.62919 0.80181 0.63118 1.11180 0.79171 
8202 0.53133 0.46366 0.11461 0.17325 0.01347 
8601 0.21031 0.29681 0.17764 0.00229 0.00679 
 
M35LTg 605 M35LTg 608 M35LTg 626 M35LTg 662 M35LTg 663 
SSP# blot/gel blot/gel blot/gel blot/gel blot/gel 
1601 115.5424 13.49566 0.26020 134.94176 35.2343 
2603 0.55285 0.84382 0.53509 0.91429 0.69422 
8202 0.01244 0.48412 0.36215 0.35047 0.03097 
8601 0.00444 0.01042 0.00366 0.00782 0.28771 
 
  
  
3-NT 
  
Fold Change 
 
SSP# 
M35LTg  
Avg 
M35LTg  
StDev 
M35LNTg  
Avg 
M35LNTg  
StDev 
M35LTg/ 
M35LNTg P-value 
1601 65.7805 74.6850 0.59263 1.08526 110.9980 0.0221 
2603 0.75060 0.17888 0.48730 0.19443 1.54033 0.0366 
8202 0.25365 0.20729 0.05138 0.05774 4.93652 0.0147 
8601 0.10079 0.12707 0.00319 0.00203 31.61423 0.0380 
  
SSP# Sample ID 
1601 Secernin 1 
2603 Glial fibrillary acidic protein 
8202 Glutathione-S-transferase μ1 
8601 Creatine kinase, ubiquitous, mitochondrial 
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Figure 9.5 Peptidyl-prolyl cis-trans isomerase 1 (Pin-1) nitration levels in brain of Tg 
PDAPP(M631L) and Tg PDAPP(J20) mice.   
 
 
M35L - 1 M35L - 2 M35L - 3 J20 - 4 J20 - 5 J20 - 6 
Pin-1 21488.81 18205.92 18310.87 15485.83 11374.47 15986.08 
       
   
J20 M35L 
  
  
Tot Avg 14282.13 19335.2 
  
  
% J20Tg 108.43 150.4595 
  
  
% J20Tg 79.64 127.4735 
  
  
% J20Tg 111.93 128.2083 
  
  
Avg % 100.00 135.38 
  
  
StDev % 17.72 13.06 
         
  P-value 0.049    
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Figure A.1 Protein carbonyl (PCO) levels in synaptosomes from brain of wild-type (WT) and 
APP/PS-1 mice.   
 
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID Well 1 Well 2 Average 
wt 2544 479 478 478.5 wt 2235 386.0 378 382.0 
wt 2546 481 488 484.5 wt 2236 449 448 448.5 
wt 2548 455 436 445.5 wt 2237 417 383 400.0 
wt 2549 411 450 430.5 wt 2238 352 355 353.5 
wt 2550 403 429 416.0 wt 2292 424 410 417.0 
HO AP1 440 456 448.0 HO 2247 444 437 440.5 
HO AP2 481 493 487.0 HO 2313 411 441 426.0 
HO AP3 508 507 507.5 HO 2314 463 488 475.5 
HO 2538 522 502 512.0 HO 2315 454 487 470.5 
HO 2540 526 535 530.5 HO 2316 497 505 501.0 
          9 month Sample ID Well 1 Well 2 Average 12 month Sample ID Well 1 Well 2 Average 
wt 2030 1022 1037 1029.5 wt 1852 813 779 796.0 
wt 2032 1006 992 999.0 wt 1790 947 912 929.5 
wt 2154 1000 1053 1026.5 wt 1831 1021 1090 1055.5 
wt 2156 931 964 947.5 wt 1800 968 943 955.5 
wt 2155 889 868 878.5 wt 1793 1021 972 996.5 
HO 2002 992 989 990.5 HO 1821 1166 1202 1184.0 
HO 2003 1192 1207 1199.5 HO 1819 1148 1214 1181.0 
HO 2196 1160 1076 1118.0 HO 1817 1025 1044 1034.5 
HO 2197 1052 1070 1061.0 HO 1924 1095 1130 1112.5 
HO 2195 1047 1043 1045.0   
    
     
HO 1856 NOT 
ENOUGH 
LEFT! 
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Figure A.1 data (cont.) 
 
1 month wt HO 6 month wt HO 
% 1mo wt 106.097 99.3348 % 1mo wt 84.700 97.671 
% 1mo wt 107.427 107.982 % 1mo wt 99.445 94.456 
% 1mo wt 98.7804 112.527 % 1mo wt 88.691 105.434 
% 1mo wt 95.4545 113.525 % 1mo wt 78.381 104.323 
% 1mo wt 92.2394 117.627 % 1mo wt 92.461 111.086 
Avg% 100.00 110.20 Avg% 88.74 102.59 
StDev 6.61 6.98 StDev 7.94 6.59 
      9 month wt HO 12 month wt HO 
% 1mo wt 228.270 219.623 % 1mo wt 176.496 262.527 
% 1mo wt 221.507 265.964 % 1mo wt 206.097 261.862 
% 1mo wt 227.605 247.893 % 1mo wt 234.035 229.379 
% 1mo wt 210.088 235.255 % 1mo wt 211.862 246.674 
% 1mo wt 194.789 231.707 % 1mo wt 220.953  --  
Avg% 216.45 240.09 Avg% 209.89 250.11 
StDev 14.14 17.63 StDev 21.44 15.64 
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Figure A.2 Protein-resident 3-nitrotyrosine (3-NT) levels in synaptosomes from brain of wild-
type (WT) and APP/PS-1 mice.   
 
1 month Sample ID Well 1 Well 2 Average 
 
6 month Sample ID Well 1 Well 2 Average 
wt AP2 367 315 341.0 
 
wt 2235 312 275 293.5 
wt AP3 367 362 364.5 
 
wt 2236 398 323 360.5 
wt 2540 456 403 429.5 
 
wt 2237 314 292 303.0 
wt 2538 284 269 276.5 
 
wt 2238 405 374 389.5 
HO 2550 86 106 96.0 
 
wt 2292 315 431 373.0 
HO 2544 101 102 101.5 
 
HO 2247 362 378 370.0 
HO 2546 98 95 96.5 
 
HO 2313 502 435 468.5 
HO 2548 183 120 151.5 q-test out HO 2314 401 361 381.0 
HO 2549 313 315 314.0 0.74541 HO 2315 525 480 502.5 
      
HO 2316 472 408 440.0 
wt AP1 NOT ENOUGH LEFT! 
 
  
    
           9 month Sample ID Well 1 Well 2 Average 12 month Sample ID Well 1 Well 2 Average 
 wt 2030 251 297 274.0 wt 1852 320 330 325.0 
 wt 2032 296 335 315.5 wt 1790 290 261 275.5 
 wt 2154 223 232 227.5 wt 1800 280 381 330.5 
 wt 2156 267 255 261.0 wt 1793 252 204 228.0 q-test out 
wt 2155 322 301 311.5 wt 1831 574 671 622.5 0.74018 
HO 2002 553 542 547.5 HO 1821 755 982 868.5 
 HO 2003 389 374 381.5 HO 1817 992 1162 1077.0 
 HO 2196 394 489 441.5 HO 1924 1041 1164 1102.5 
 HO 2197 417 374 395.5 HO 1819 651 684 667.5 
 HO 2195 397 364 380.5   
     
     
HO 1856  NOT ENOUGH  LEFT! 
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Figure A.2 data (cont.) 
 
1 month wt HO 6 month wt HO 
% 1mo wt 86.195 306.173 % 1mo wt 263.524 332.211 
% 1mo wt 91.134 327.273 % 1mo wt 323.681 420.651 
% 1mo wt 86.644 385.634 % 1mo wt 272.054 342.088 
% 1mo wt 136.027 248.260 % 1mo wt 349.719 451.178 
% 1mo wt  --   --  % 1mo wt 334.905 395.062 
Avg% 100.00 316.84 Avg% 308.78 388.24 
StDev 24.12 56.74 StDev 38.66 50.81 
      9 month wt HO 12 month wt HO 
% 1mo wt 246.016 491.582 % 1mo wt 291.807 779.798 
% 1mo wt 283.277 342.536 % 1mo wt 247.363 967.003 
% 1mo wt 204.265 396.409 % 1mo wt 279.794 989.899 
% 1mo wt 234.343 355.107 % 1mo wt 296.745 599.327 
% 1mo wt 279.686 341.639 % 1mo wt  --   --  
Avg% 249.52 385.45 Avg% 278.93 834.01 
StDev 32.94 63.38 StDev 22.21 182.58 
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Figure A.3 Protein-bound 4-hydroxy-2-trans-nonenal (HNE) levels in synaptosomes from brain 
of wild-type (WT) and APP/PS-1 mice 
 
1 month Sample ID Well 1 Well 2 Average 6 month Sample ID Well 1 Well 2 Average 
 wt 2544 174 159 166.5 wt 2235 166 131 148.5 
 wt 2546 182 178 180.0 wt 2236 119 100 109.5 
 wt 2548 195 122 158.5 wt 2237 135 76 105.5 
 wt 2549 157 171 164.0 wt 2238 136 90 113.0 
 wt 2550 98 194 146.0 wt 2292 184 130 157.0 
 HO AP1 197 196 196.5 HO 2247 239 132 185.5 
 HO AP2 159 155 157.0 HO 2313 287 158 222.5 
 HO AP3 208 245 226.5 HO 2314 225 69 147.0 
 HO 2538 267 243 255.0 HO 2315 175 255 215.0 
 HO 2540 197 180 188.5 HO 2316 118 186 152.0 
 
           9 month Sample ID Well 1 Well 2 Average 12 month Sample ID Well 1 Well 2 Average 
 wt 2030 237 164 200.5 wt 1852 218 199 208.5 
 wt 2032 179 183 181.0 wt 1790 255 224 239.5 
 wt 2154 163 213 188.0 wt 1831 139 138 138.5 
 wt 2156 180 195 187.5 wt 1800 153 145 149.0 
 wt 2155 221 173 197.0 wt 1793 149 127 138.0 
 HO 2002 241 202 221.5 HO 1821 238 281 259.5 
 HO 2003 242 213 227.5 HO 1856 251 212 231.5 
 HO 2196 215 193 204.0 HO 1817 257 214 235.5 q-test out 
HO 2197 209 199 204.0 HO 1924 125 129 127.0 0.788679 
HO 2195 224 278 251.0 HO 1819 255 250 252.5 
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Figure A.3 data (cont.) 
 
1 month wt HO 6 month wt HO 
% 1mo wt 102.147 120.552 % 1mo wt 91.104 113.804 
% 1mo wt 110.429 96.319 % 1mo wt 67.178 136.503 
% 1mo wt 97.239 138.957 % 1mo wt 64.724 90.184 
% 1mo wt 100.613 156.442 % 1mo wt 69.325 131.902 
% 1mo wt 89.571 115.644 % 1mo wt 96.319 93.252 
Avg% 100.00 125.58 Avg% 77.73 113.13 
StDev 7.59 22.98 StDev 14.80 21.34 
      9 month wt HO 12 month wt HO 
% 1mo wt 123.006 135.890 % 1mo wt 127.914 159.202 
% 1mo wt 111.043 139.571 % 1mo wt 146.933 142.025 
% 1mo wt 115.337 125.153 % 1mo wt 84.969 144.479 
% 1mo wt 115.031 125.153 % 1mo wt 91.411 154.908 
% 1mo wt 120.859 153.988 % 1mo wt 84.663  --  
Avg% 117.06 135.95 Avg% 107.18 150.15 
StDev 4.82 11.95 StDev 28.54 8.22 
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APPENDIX C 
 
LIST OF ABBREVIATIONS 
 
A 
1
o
, primary 
2
o
, secondary 
A=εlc, Beer-Lambert law; A, absorbance; ε, extinction coefficient or molar absorptivity; l, light 
path length; c concentration 
AAALAC, Association for Assessment and Accreditation of Laboratory Animal Care 
AATM, aspartate aminotransferase, mitochondrial  
Aβ, amyloid-β peptide 
ABB, Annexin binding buffer 
AC buffer, antigen coating buffer 
Acetyl CoA, acetyl coenzyme A 
AD, Alzheimer disease 
ADP, adenosine diphosphate 
AIF, apoptosis inducing factor 
Akt, a serine/threonine protein kinase (a.k.a., protein kinase B) 
ALP, alkaline phosphatase enzyme 
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subtype 
ANOVA, analysis of the variants 
ANT, adenine nucleotide translocase 
AOX, antioxidant 
Apaf-1, apoptosis protease activating factor-1 
APOE, apolipoprotein E 
APP, amyloid precursor protein 
sAPPβ, a 593 amino acid soluble amyloid precursor protein (sAPP), carboxy (C)-terminal, β-
secretase cleavage product, corresponding to amino acids 1 to 593 of APP  
APP
NLh
 /APP
NLh
 x PS-1
P264L
/PS-1
P264L
 mice, amyloid precursor protein (APP) gene carrying a 
humanized mouse amyloid-β (Aβ) peptide sequence (NLh), and a presenilin-1 (PS-1) 
gene carrying a proline to leucine mutation on codon 264 (P264L). 
APP/PS-1 mice, APP
NLh
 /APP
NLh
 x PS-1
P264L
/PS-1
P264L
 human double mutant knock-in mice 
APPSw,In, amyloid precursor protein with Swedish and Indiana mutations 
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ATP, adenosine triphosphate 
AV, Annexin V 
B 
BAPTA AM, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) 
acetoxymethyl (AM) ester 
Bax, B-cell lymphoma-2 associated X protein 
BBB, blood-brain barrier 
BCA, Bicinchoninic acid 
BCIP, 5-bromo-4-chloro-3-indolyl phosphate dipotassium  
Bcl-2, B-cell lymphoma-2 protein 
BSA, bovine serum albumin 
C 
C31, a 31 amino acid amyloid precursor protein (APP) carboxy (C)-terminal cleavage product 
corresponding to amino acids 665 to 696 - the last, most C-terminal amino acid of APP 
[Ca
2+
]i, intracellular calcium ion concentration 
CA-2, carbonic anhydrase 2 
Ca
2+
ATPase, calcium adenosine triphosphate (ATP) transporting enzyme 
CA region, cornu ammonis cell region of brain  
Caspase/Cas, aspartate-specific cysteine protease  
CD45/64, cluster of differentiation antigens 
C. elegans, Caenorhabditis elegans 
ChAT, choline acetyltransferase enzyme 
CK, creatine kinase 
CNS, central nervous system 
Complex I, nicotinamide adenine dinucleotide (NADH)-ubiquinone (Q) oxidoreductase 
Complex II, succinate-ubiquinone (Q) reductase 
Complex III, ubiquinone (Q)-cytochrome c oxidoreductase 
Complex IV, cytochrome c oxidase 
Complex V, adenosine triphosphate (ATP) synthase 
COPD, chronic obstructive pulmonary disease 
CoQ10, coenzyme Q10 
COX, cyclooxygenase 
CREB, cyclic adenosine monophosphate (cAMP)-responsive element binding-protein 
266 
 
Cu/ZnSOD, copper/zinc superoxide dismutase 
CytC, cytochrome c 
CypD, cyclophilin D 
D 
D1-5, dopamine receptors 1-5 
DAG, diacyl glycerol 
DEA, diethylamine 
DHAP, dihydroxyacetone phosphate 
DHLA, dihydrolipoic acid 
DNA, deoxyribonucleic acid 
DNP, 2,4-dinitrophenylhydrazone 
DNPH, 2,4-dinitrophenylhydrazine 
1D-/2D-PAGE, 1-/2-dimensional-polyacrylamide gel electrophoresis 
Drp-2, dihydropyrimidinase protein 2 
DTT, dithiothreitol 
E 
e-, electron 
EDTA, ethylenediamine tetraacetic acid 
EGTA, ethyleneglycol tetraacetic acid 
ELISA, enzyme-linked immunosorbant assay 
EndoG, endoprotease G 
EPSPs, excitatory post-synaptic potentials 
ER, endoplasmic reticulum 
ERK 1/2, extracellular signal-regulated kinase 1/2 
ESI, electrospray ionization 
ETC, electron transport chain 
Ex/Em or λex/em, excitation/emission 
F 
FA, formic acid 
FAD, familial Alzheimer disease 
FADD, Fas-associated death domain-containing protein 
FADH2/FAD, flavin adenine dinucleotide 
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FAEE, ferulic acid ethyl ester 
FBA-C, fructose bisphosphate aldolase C 
FITC, fluorescein isothiocyanate 
FT, Fourier transform 
G 
G-6-P DH, glucose-6-phosphate dehydrogenase 
GABA, γ-aminobutyric acid 
GAP, glyceraldehyde-3-phosphate 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 
sGC, soluble guanylate cyclase 
GCEE, γ-glutamylcysteine ethyl ester 
GCL, γ-glutamylcysteine ligase 
GDP, guanosine diphosphate 
GFAP, glial fibrillary acidic protein 
cGMP, cyclic guanosine monophosphate 
β2GPI, β2 glycoprotein I 
GPx, glutathione peroxidase 
GSH, glutathione (reduced) 
GSSG, glutathione (oxidized) 
GST μ1, glutathione-S-transferase μ1 
GTP, guanosine triphosphate 
GTPase, guanosine triphosphate (GTP) utlizing enzyme 
H 
H1-3, histamine receptors 1-3 
5-HTs, 5-hydroxytryptamine receptor subtypes 
HCD, high-energy C-trap dissociation 
HCNP, hippocampal neurostimulating peptide 
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HK, hexokinase 
HLA-DR, human leukocyte antigen-D related 
HNE, 4-hydroxy-2-trans-nonenal 
HO-1, heme oxygenase-1 
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HRP, horseradish peroxidase enzyme 
HSP90 B1, heat shock protein 90 B1 
I 
IA, iodoacetamide 
IACUC, Institutional Animal Care and Use Committee 
IAP, inhibitor of apoptosis protein 
Iba-1, ionized Ca
2+
 binding-protein-1 
IEF, isoelectric focusing 
IgG, immunoglobulin G 
In, Indiana mutation  
V717F, Indiana mutation; valine to phenylalanine substitution on codon 717 of the 
human amyloid precursor (APP) minigene. 
IP3, inositol trisphosphate 
IPG, immobilized pH gradient 
IPI, International Protein Index 
IPL, inferior parietal lobule 
IPSPs, inhibitory post-synaptic potentials 
J 
Jcasp, short, cytoplasmic domain of the amyloid precursor protein (APP) corresponding to the 
16 amino acids most proximal to the membrane, amino acids 649 to 664 of APP695; 
generated by ε-secretase cleavage of APP at position 664 
K 
KD, dissociation constant 
L 
LA, α-lipoic acid 
LOX-1, lectin-like oxidized low-density lipoprotein receptor-1 
M 
aMCI, amnestic mild cognitive impairment 
MDH, malate dehydrogenase 
MES, 2-(N-morpholino)ethanesulfonic acid 
Mg
2+
ATPase, magnesium adenosine triphosphate (ATP) utilizing enzyme 
MHC, major histocompatibility complex 
MMP, mitochondrial membrane permeability 
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MMSE, Mini-Mental State Examination 
MNDA, methyl-D-aspartate receptor subtypes 
MnSOD, manganese superoxide dismutase 
MPTP, mitochondrial permeability transition pore 
mRNA, messenger ribonucleic acid 
MRP-1, multidrug resistance protein-1 
MS, mass spectrometer/spectrometry 
MW, molecular weight 
MWM, molecular weight marker 
N 
n, sample number 
NAC, N-acetyl-L-cysteine 
NADH DH, nicotinamide adenine dinucleotide (NADH) dehydrogenase 
NADH/NAD
+
, nicotinamide adenine dinucleotide 
NADPH/NADP
+
, nicotinamide adenine dinucleotide phosphate 
Na
+
/K
+
ATPase, sodium/potassium adenosine triphosphate (ATP) exchanging enzyme 
NBD-PS, 1-palmitoyl-2-[6(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]caproyl-sn-glycero-3-
phosphoserine 
NBT, Nitrotetrazolium Blue chloride  
NCI, severely aged, but cognitively normal 
ND, not determined 
NFTs, neurofibrillary tangles 
NINCDS-ARDA, National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer Disease and Related Disorders Association (also now known as the 
Alzheimer Association) 
NMDA/NMDAR, N-methyl-D-aspartate receptor subtype 
NMR, nuclear magnetic resonance 
Non Tg/NTg, non-transgenic 
eNOS, endothelial nitric oxide synthase 
iNOS, inducible nitric oxide synthase 
nNOS, neuronal nitric oxide synthase 
Nrf2, NF-E2-related factor-2 
3-NT, 3-nitrotyrosine 
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O 
Omi/HtrA2, Omi stress-regulated endoprotease/high temperature requirement protein A2 
P 
p, the probability of an incorrect identification associated with each protein identification using 
the SEQUEST search alogorithm 
P1, pellet 1 
P2, pellet 2 
p12, 18 kDa active caspase-3 
p18, 20 kDa active caspase-3 
PBR, peripheral-type benzodiazepine receptor 
PBS, phosphate-buffered saline 
PCO, protein carbonyls 
PDAPP, platelet-derived growth factor (PDGF)-amyloid precursor protein (APP) transgene 
PDGF, platelet-derived growth factor 
PEBP-1, phosphatidylethanolamine-binding protein 1 
PEP, phosphoenolpyruvate 
PET, positron emission tomography 
PFK, phosphofructokinase 
PGA mutase, phosphoglycerate mutase 
6-PG DH, 6-phosphogluconate dehydrogenase 
PGI, phosphoglucose isomerase 
PGM 1, phosphoglycerate mutase 1 
pH, hydrogen ion concentration 
Pi, inorganic phosphate 
pI, isoelectric point 
Pin-1, peptidyl-prolyl cis-trans isomerase  
PIP2, phosphoinositil-4,5-bisphosphate 
pKa, -log10 of the acid dissociation constant (Ka) 
PKG, protein kinase G 
PK M1/M2, pyruvate kinase mitochondrial 1/2  
PLA2, phospholipase A2 
PMI, post-mortem interval 
PMSF, phenylmethanesulfonyl fluoride 
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PP2B, protein phosphatase 2B (i.e., calcineurin, subunit B, Type 1) 
PPP, pentose phosphate pathway 
PPIases, peptidyl-prolyl isomoerases 
PPS, pentose phosphate shunt 
PRX-1/-2, peroxiredoxin-1/-2 
PS-1/-2, presenilin-1/-2 
PSR, phosphatidylserine receptor 
PtdEtn, phosphatidylethanolamine 
PtdIns, phosphatidylinositol 
PtdOH, phosphatidic acid 
PtdSer, phosphatidylserine 
PUFAs, polyunsaturated fatty acids 
PVDF, polyvinylidene difluoride 
Q 
Q, coenzyme Q/ubiquinone 
QH
.
, semiquinone 
QH2, ubiquinol 
R 
RBS, reactive bromine species 
RCSB protein data bank, Research Collaboratory for Structural Bioinformatics (RCSB) protein 
data bank is a repository for the 3D-structural data of large biological molecules 
RCS, reactive chlorine species 
RIA buffer, radioimmunoassay buffer 
RIP, Raf-kinase inhibitor protein 
RNS, reactive nitrogen species 
ROS, reactive oxygen species 
Roto-Vap, rotary evaporator 
RT, room temperature 
S 
S1, supernatant 1 
S2, supernatant 2 
SC, spectral counts 
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S.D., standard deviation 
SDS, sodium dodecyl sulfate 
S.E.M., standard error of the means 
SEQUEST, a tandem mass spectrometry data analysis program used for protein identification 
Smac/DIABLO, second mitochondria-derived activator of caspases (Smac)/direct inhibitor of 
apoptosis (IAP) binding protein with low pI (DIABLO) 
SPs, senile plaques 
Sw, Swedish mutation 
K670N and M671L, Swedish mutations; lysine to asparagine substitution on codon 670 
(K670N) and methionine to leucine mutations on codon 671 (M671L) of human amyloid 
precursor (APP) minigene. 
Swiss-PDB viewer, Swiss-Protein Data Bank viewer (a.k.a., DeepView) is an application that 
provides an interface allowing to visualize and analyze proteins in 3D.  
T 
TBST, Tris base-sodium chloride-Tween-20 buffer 
TCA, trichloroacetic acid 
TCA cycle, tricarboxylic acid cycle 
TCP-1αA, T-complex protein 1, subunit α A 
Tg, transgenic 
Tg PDAPP(D664A), platelet-derived growth factor (PDGF)-amyloid precursor protein (APP) 
transgenic (Tg) mice carrying the Swedish and Indiana mutations on APP (APPSw,In) 
along with an additional aspartate to alanine substitution on codon 664 of APP 
Tg PDAPP(J20), platelet-derived growth factor (PDGF)-amyloid precursor protein (APP) 
transgenic (Tg) mice carrying the Swedish and Indiana mutations on APP (APPSw,In), line 
J20 
Tg PDAPP(M631L), platelet-derived growth factor (PDGF)-amyloid precursor protein (APP) 
transgenic (Tg) mice carrying the Swedish and Indiana mutations on APP (APPSw,In) 
along with an additional methionine to leucine substitution on codon 631 of APP 
TGS, Tris/Glycine/Sodium dodecyl sulfate 
TMB, tetramethylbenzidine 
TNF, tumor necrosis factor 
TNFR1, tumor necrosis factor (TNF) receptor 1 
TP buffer, Tris-phosphate buffer 
TPI, triose phosphate isomerase 
TPPP, tubulin polymerization-promoting protein 
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U 
UK ADC, University of Kentucky Rapid Autopsy Program of the Alzheimer Disease Clinical 
Center 
UV, ultraviolet 
V 
VDAC-1, voltage-dependent anion channel-1 
W 
WT, wild-type 
X-Z 
XT, extended time 
 
List of Amino Acids 
Ala/A, alanine 
Arg/R, arginine 
Asn/N, asparagine 
Asp/D, aspartate/aspartic acid 
Cys/C, cysteine 
Gln/Q, glutamine 
Glu/E, glutamate/glutamic acid 
Gly/G, glycine 
His/H, histidine 
Ile/I, isoleucine 
Leu/L, leucine 
Lys/K, lysine 
Met/M, methionine 
Nle, norleucine 
Phe/F, phenylalanine 
Pro/P, proline 
Ser/S, serine 
pSer, phosphorylated serine 
Thr/T, threonine 
pThr, phosphorylated threonine 
Trp/W, tryptophan 
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Tyr/Y, tyrosine 
Val/V, valine 
 
Units of Measure 
Concentration: 
M, molar 
μM, micromolar 
mM, millimolar 
pM, picomolar 
v/v, volume per volume 
w/v, weight per volume 
Mass/Volume: 
g, grams 
kDa, kilodaltons 
μg, micrograms 
mg, milligrams 
μl, microliters 
ml, milliliters 
mol, moles 
ng, nanograms 
pmol, picomoles 
Time: 
h/hr, hours 
min, minutes 
ms, milliseconds 
s, seconds 
Length/Distance: 
cm, centimeters 
μm, micrometers 
nm, nanometers 
Speed: 
rpm, revolutions per minute 
x g, times gravity  
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Temperature: 
o
C, degrees Celcius 
K, degrees Kelvin 
Power: 
C, coulombs 
F, faradays (C/mol) 
J, joules 
mV, millivolts 
V, volts 
W, watts 
 
Chemical Formulas 
CaCl2, calcium chloride 
C-/COOH-, carboxy-group 
-CH2, methyl group 
CO2, carbon dioxide 
CO3
.-
, carbonate/carbonic acid 
H-, hydrogen-atom 
HCl, hydrochloric acid 
HCO3
-
, bicarbonate ion 
H2O, water 
H3O
+
, hydronium 
H2O2, hydrogen peroxide 
HPO3, phosphoric acid 
H2SO4, sulfuric acid 
KCl, potassium chloride 
L
.
, lipid radical 
LOO
.
, lipid peroxyl radical 
LOOH, lipid hydroperoxide 
MgCl2, magnesium chloride 
NaBH4, sodium borohydride 
NaCl, sodium chloride 
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NaHCO3, sodium bicarbonate 
Na2HPO4, sodium phosphate 
NaN3, sodium azide 
Na2S2O4/S2O4
2-
, sodium dithionite/dithionite ion 
NH4HCO3, ammonium bicarbonate 
(NH4)6Mo7O24 ∙ 4 H2O, ammonium molybdate 
N-/NH2-, amino-group 
NO
.
, nitric oxide radical 
NO2
.
, nitrogen dioxide 
N2O3, nitrogen trioxide 
R
.
, alkyl radical 
R1/R2, hydrocarbon chains of ambiguous length 
ROOH, alkyl hydroperoxide 
O2
.-
, superoxide anion 
.
OH, hydroxyl radical 
OH
-
, hydroxide ion 
ONOO
-
, peroxynitrite 
ONOOCOO
-
, nitrosoperoxycarbonate 
S-, sulfur-atom  
X
.
, ambiguous molecule/atom radical 
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